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MObjectives: To address issues about data monitoring
committees (DMCs) for randomised controlled trials
(RCTs).
Data sources: Electronic databases. Handsearching 
of selected books. Personal contacts with experts in
the field.
Review methods: Systematic literature reviews of
DMCs and small group processes in decision-making;
sample surveys of: reports of RCTs, recently completed
and ongoing RCTs and policies of major organisations
involved in RCTs; case studies of four DMCs; and
interviews with experienced DMC members. All
focused on 23 prestated questions.
Results: Although still a minority, RCTs increasingly
have DMCs. There is wide agreement that nearly all
trials need some form of data monitoring. Central to
the role of the DMC is monitoring accumulating
evidence related to benefit and toxicity; variation in
emphasis has been reflected in the plethora of names.
DMCs for trials performed for regulatory purposes
should be aware of any special requirements and
regulatory consequences. Advantages were identified
for both larger and smaller DMCs. There is general
agreement that a DMC should be independent and
multidisciplinary. Consumer and ethicist membership is
controversial. The chair is recognised as being
particularly influential, and likely to be most effective if
he or she is experienced, understands both statistical
and clinical issues, and is facilitating in style and
impartial. There is no evidence available to judge
suggested approaches to training. The review
suggested that costs should be covered, but other
rewards must be so minimal as to not affect decision-
making. It is usual to have a minimum frequency of
DMC meetings, with evidence that face-to-face
meetings are preferable. It is common to have open
sessions and a closed session. A report to a DMC
should cover benefits and risks in a balanced way,
summarised in an accessible style, avoiding excessive
detail, and be as current as possible. Disadvantages of
blinded analyses seem to outweigh advantages.
Information about comparable studies should be
included, although interaction with the DMCs of similar
ongoing trials is controversial. A range of formal
statistical approaches can be used, although this is only
one of a number of considerations. DMCs usually reach
decisions by consensus, but other approaches are
sometimes used. The general, but not unanimous, view
is that DMCs should be advisory rather than executive
on the basis that it is the trial organisers who are
ultimately responsible for the conduct of 
the trial. 
Conclusions: Some form of data monitoring should be
considered for all RCTs, with reasons given where
there is no DMC or when any member is not
independent. An early DMC meeting is helpful,
determining roles and responsibilities; planned
operations can be agreed with investigators and
sponsors/funders. A template for a DMC charter is
suggested. Competing interests should be declared.
DMC size (commonly three to eight people) is chosen
to optimise performance. Members are usually
independent and drawn from appropriate backgrounds,
and some, particularly the chair, are experienced. A
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* Corresponding authorminimum frequency of meetings is usually agreed, with
flexibility for more if needed. The DMC should
understand and agree the statistical approach (and
guidelines) chosen, with both the DMC statistician and
analysis statistician competent to apply the method. A
DMC’s primary purpose is to ensure that continuing a
trial according to its protocol is ethical, taking account
of both individual and collective ethics. A broader remit
in respect of wider ethical issues is controversial;
arguably, these are primarily the responsibility of
research ethics committees, trial steering committees
and investigators. The DMC should know the range of
recommendations or decisions open to it, in advance. A
record should be kept describing the key issues
discussed and the rationale for decisions taken. Errors
are likely to be reduced if a DMC makes a thorough
review of the evidence and has a clear understanding of
how it should function, there is active participation by
all members, differences are resolved through
discussion and there is systematic consideration of the
various decision options. DMCs should be encouraged
to comment on draft final trial reports. These should
include information about the data monitoring process
and detail the DMC membership. It is recommended
that groups responsible for data monitoring be given
the standard name ‘Data Monitoring Committee’
(DMC). Areas for further research include: widening
DMC membership beyond clinicians, trialists and
statisticians; initiatives to train DMC members;
methods of DMC decision-making; ‘open’ data
monitoring; DMCs covering a portfolio of trials rather
than single trials; DMC size and membership,
incorporating issues of group dynamics; empirical 
study of the workings of DMCs and their decision-
making, and which trials should or should not 
have a DMC.
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Glossary and list of abbreviations
Technical terms and abbreviations are used throughout this report. The meaning is usually clear from
the context, but a glossary is provided for the non-specialist reader. In some cases, usage differs in the
literature, but the term has a constant meaning throughout this review.
Glossary
Administrative analysis The evaluation of
factors that could affect the integrity of the
trial but that can be assessed without returning
relative efficacy results.
Bayesian approach An approach to the
design, monitoring, analysis and interpretation
of studies that explicitly uses external evidence.
Blinded analysis The presentation of data
summarised by treatment arm, in which the
treatment arms are not identified.
Choice-dilemma task A decision-making task
with no right answer (see also Judgement task).
Choice shift Psychological phenomenon
describing the shift in people’s decision
preferences after taking part in a group
discussion.
Clinical trial An investigation in human
participants to discover the clinical effects of a
medicinal product or non-medicinal
technology (e.g. surgical procedure).
Closed session (of DMC meeting) The
session of the DMC meeting that is restricted
to the independent members of the DMC –
those who may see unblinded data. The trial
statistician is often invited to attend this session
of the meeting.
Collective ethics The ethical approach of
putting the interests of future patients who may
benefit from the results of a trial before those
of the individual participants within the trial.
Conditional power analysis A statistical
calculation made on the basis of the interim
data available to assess the likelihood, given
the interim data, that a beneficial effect of the
treatment under consideration will be detected
if the trial were to continue as planned.
CONSORT statement An international
statement to help authors to improve the
reporting of randomised controlled trials
through the use of a structured checklist and
flow diagram. (www.consort-statement.org)
Data monitoring committee (DMC) Any
committee set up to assess, at intervals during
the course of a trial, the progress of the trial,
the trial safety data and the trial outcome data
with a view to recommending whether the trial
should continue, be modified or be terminated.
Decision bias Decision-making behaviour
that deviates from what normative decision-
making models would suggest, i.e. when the
decision reached differs from that which should
be reached according to the theory.
Decision errors Decision-making activities
that fail to achieve their intended outcome.
Decision fiasco Known situations where
decision errors occurred.
Defining issues test Psychometric test to
assess the level of reasoning used by an
individual to solve a particular dilemma.
Effectiveness A measure of the benefit
resulting from an intervention for a given
health problem under normal conditions of
clinical care.
Efficacy A measure of the benefit resulting
from an intervention for a given health
problem under ideal conditions.
Equipoise The belief that alternative
treatments being compared within a trial have
the same expected utilities.
continuedx
Glossary and list of abbreviations
Glossary continued
Equivalence trial A trial whose primary aim
is to establish equivalence rather than a
difference (see Superiority trial) between
interventions.
External evidence Results from trials (or
other studies) of similar interventions, external
to the current trial.
Framing The way in which a problem is
presented. This can be either positive (e.g. the
success rate of an intervention) or negative
(e.g. the failure rate of an intervention).
Frequentist approach An approach to the
design, monitoring, analysis and interpretation
of studies that is based on the long-run
frequency properties of statistical procedures
(often known as the ‘classical’ approach to
statistical inference). 
Futility The result in a superiority trial (see
definition below) when there is no longer a
reasonable chance that the null hypothesis can
be disproved.
Group cohesion The strength of group
members’ positive feelings towards one another
and/or the strength of their shared
commitment to group tasks or goals.
Group polarisation The tendency for the
initial position of a group to be exaggerated as
a result of group discussion, e.g. if group
members are initially cautious about a
dilemma, the outcome of the group discussion
will be more cautious than the aggregated
individual opinions.
Groupthink A psychological model of small
group processes describing the decision-
making phenomenon where the people
engaged in the decision-making are so deeply
involved in a cohesive ‘in-group’ that the
members override their motivation realistically
to appraise alternative courses of action to
achieve unanimity.
Heuristics General rules that guide decision-
making.
Independent (committees or committee
members) Committees or committee
members completely uninvolved in the
running of the trial and who cannot be unfairly
influenced (either directly or indirectly) by
people, or institutions, involved in the trial. 
Individual ethics The ethical approach of
putting the interests of individual participants
within a trial before those of future patients
who may benefit from the results of the trial.
Institutional review board See entry for
Research ethics committee. 
Interim analysis Analysis of the trial data,
summarised by treatment arm, undertaken
before the planned formal analysis at the end
of the trial.
Judgement task A decision-making task with
no right answer (see also Choice-dilemma
task).
Majority influence Influence on decision-
making process of those who hold the majority
decision preference.
Members (of DMCs) Individuals serving on
the DMC who have full voting rights.
Minority influence Influence on the
decision-making process of those who hold the
minority decision preference.
Moral reasoning The processes of reasoning
that individuals employ about moral dilemmas.
Non-inferiority trial A trial whose primary
aim is to establish that an intervention being
investigated is not clinically inferior to its
comparator.
Observers (of DMCs) Individuals who may
be invited to attend all (or part) of the DMC
meetings but who do not have decision-making
rights.
Open session (of DMC meeting) The session
of the DMC meeting that is attended by the
independent members of the DMC, trial
investigators, the trial statistician and, on some
occasions, representatives of the sponsor.
Placebo An inert substance designed to look
(and taste, if appropriate) the same as the
active intervention.
Principal investigator(s) The person(s) who
is (are) responsible for the conduct of the trial.
Prospect theory The dependence of risk-
taking behaviour on whether the decision is
positively or negatively framed.
Protocol A document that describes the
objectives, design, methodology, statistical
considerations and organisation of a trial. The
protocol is a complete specification for the
research plan and the treatment of individual
participants.
continuedHealth Technology Assessment 2005; Vol. 9: No. 7
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Glossary continued
Randomised controlled trial A clinical trial
where interventions are assigned by random
allocation rather than by conscious decisions of
clinicians or participants. This study design
avoids problems of bias and confounding
variables by assuring that both known and
unknown determinants of outcome are evenly
distributed between treatment and control
groups.
Research ethics committee An independent
committee whose purpose is to review
proposed studies with regard to protecting the
dignity, rights, safety and well-being of all
actual or potential research participants. All
trials must receive research ethics committee
approval before they can commence. In the UK
there are both multicentre and local research
ethics committees. These committees are
known as institutional review boards in the
USA.
Responsibilities (of DMCs) The relations
with those groups to which the DMC has some
responsibility, whether explicit or implied.
Risky-shift Psychological phenomenon where
people are more likely to advocate risky courses
of action after taking part in a group
discussion.
Roles (of DMCs) The tasks and activities that
DMCs undertake.
Sequential analysis The routine analysis of
trial data as they accumulate.
Serious adverse event Any untoward medical
occurrence that results in either: a hospital
admission; a life-threatening event, persistent
or significant disability or incapacity; or death.
This includes congenital abnormalities or birth
defects.
Small group processes The processes by
which small groups (typically <20 members)
interact and make decisions.
Social loafing The tendency of individuals to
expend less effort when working in a group
compared with working alone.
Sponsor An organisation, institution or
individual that takes overall responsibility for
the initiation, management and/or financing of
a trial.
Standard operating procedures Detailed
written instructions designed to ensure
uniformity in the performance of a specific
trial function.
Statistician, analysis The statistician
responsible for the analysis of the data
presented to the DMC.
Statistician, DMC The (independent)
statistically experienced member(s) of the DMC
who consider and comment on the
accumulated data presented to the DMC.
Statistician, trial A member of the trial
organising body, responsible for overseeing the
statistical issues of the trial, who is often
responsible for the production of the report to
the DMC.
Stopping rule Formal definition of the
circumstances under which a trial would be
stopped depending on the results obtained.
Superiority trial A trial whose primary aim is
to establish a difference in outcome between
the interventions being compared.
Trial investigators The clinicians who are
supporting the trial by entering patients under
their care.
Trial management group Group set up to
provide day-to-day input into the running of a
trial. Usually comprises the principal
investigator(s), other relevant clinicians and
data coordinating centre staff.
Trial steering committee Committee set up
to provide overall supervision of a trial and to
ensure that the trial is conducted to rigorous
standards for good clinical practice.
Type I error The probability of concluding
that one treatment is better than another
when, in truth, no difference exists, i.e. the
chance of a false-positive result.
Type II error The probability of concluding
that there is no difference between treatments
when, in truth, one treatment was better than
the other, i.e. the chance of a false-negative
result.
Unblinded analysis The presentation of trial
data summarised by treatment arm, in which
the treatment arms are identified.xii
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Objectives
To address issues about data monitoring committees
(DMCs) for randomised controlled trials (RCTs):
why and when they are needed, their roles and
responsibilities, their structure and organisation,
what information is required and who owns it, and
decision-making and reporting arrangements.
Methods
The study included systematic literature reviews of
DMCs and small group processes in decision-
making; sample surveys of: reports of RCTs, recently
completed and ongoing RCTs and policies of major
organisations involved in RCTs; case studies of four
DMCs; and interviews with experienced DMC
members. All focused on 23 prestated questions.
Results
Although still a minority, RCTs increasingly have
DMCs. There is wide agreement that nearly all
trials need some form of data monitoring. Criteria
suggested for RCTs not needing an independent
DMC are: where it is not possible for a DMC to
make a contribution, where any observed
differences would not prompt any protocol change
(such as early stopping), and where there is no
reason why a DMC’s decisions would differ from
those after internal monitoring. 
A range of roles has been suggested for DMCs.
Central is monitoring accumulating evidence
related to benefit and toxicity; variation in
emphasis has been reflected in the plethora of
names. DMCs for trials performed for regulatory
purposes should be aware of any special
requirements and regulatory consequences. 
Advantages were identified for both larger and
smaller DMCs. There is general agreement that a
DMC should be independent (no commercial,
clinical or intellectual competing interests) and
multidisciplinary (at least one statistician and one
clinician). Consumer and ethicist membership is
controversial. The chair is recognised as being
particularly influential, and likely to be most
effective if he or she is experienced, understands
both statistical and clinical issues, and is facilitating
in style and impartial. There is no evidence
available to judge suggested approaches to training. 
The review suggested that costs should be covered,
but other rewards must be so minimal as to not
affect decision-making. 
It is usual to have a minimum frequency of DMC
meetings, with the committee able to meet at
shorter notice. There is evidence that face-to-face
meetings are preferable, especially for the first
meeting or when difficult decisions are predicted;
teleconferencing can be used when the discussion
is expected to be straightforward or when there
are practical difficulties convening the committee.
It is common to have open sessions (where general
issues, such as recruitment, are discussed with
investigators) and a closed session (where
confidential information, such as interim analyses,
is discussed by the DMC supported by the analysis
statistician). 
The general view is that a report to a DMC should
cover benefits and risks in a balanced way,
summarised in an accessible style, avoiding
excessive detail, and as current as possible.
Disadvantages of blinded analyses seem to outweigh
advantages. Information about comparable studies
should be included, although interaction with the
DMCs of similar ongoing trials is controversial. 
A range of formal statistical approaches can be
used. However, this is only one of a number of
considerations that a DMC should take into
account. DMCs usually reach decisions by
consensus, but other approaches are sometimes
used. The general, but not unanimous, view is that
DMCs should be advisory rather than executive on
the basis that it is the trial organisers who are
ultimately responsible for the conduct of the trial. 
Conclusions
The conclusions of the study are summarised below.
Some form of data monitoring should be considered
for all RCTs, with reasons given where there is no
DMC or when any member is not independent. 
Executive summaryxiv
An early DMC meeting is helpful. Roles,
responsibilities and planned operations can be
agreed with investigators and sponsors/funders. 
A template for a DMC charter is suggested.
Competing interests should be declared.
DMC size (commonly three to eight people) is
chosen to optimise performance. Members are
usually independent and drawn from appropriate
backgrounds, and some, particularly the chair, are
experienced. Hitherto, members have received
little training. 
A minimum frequency of meetings is usually
agreed, with flexibility for more if needed.
Meetings are best held face-to-face, if practicable.
There are advantages of having both open and
closed sessions. Often, the trial’s statistician
conducts the confidential analyses and attends the
closed sessions (but not as a member). 
The DMC should understand and agree the
statistical approach (and guidelines) chosen, with
both the DMC statistician and analysis statistician
competent to apply the method. 
A DMC’s primary purpose is to ensure that
continuing a trial according to its protocol is ethical,
taking account of both individual and collective
ethics. A broader remit in respect of wider ethical
issues is controversial; arguably, these are primarily
the responsibility of research ethics committees, trial
steering committees and investigators. 
The DMC should know the range of recommenda-
tions or decisions open to it in advance. A record
should be kept describing the key issues discussed
and the rationale for decisions taken. 
Errors are likely to be reduced if a DMC makes a
thorough review of the evidence and has a clear
understanding of how it should function, there 
is active participation by all members, differences
are resolved through discussion and there is
systematic consideration of the various decision
options. 
DMCs should be encouraged to comment on draft
final trial reports. These should include
information about the data monitoring process
and detail the DMC membership.
It is recommended that groups responsible for
data monitoring be given the standard name ‘Data
Monitoring Committee’ (DMC). 
Recommendations for research
Areas that warrant further research include:
  widening DMC membership beyond 
clinicians, trialists and statisticians (e.g. to
include consumer representatives or 
ethicists) 
  initiatives to train DMC members 
  methods of DMC decision-making, such as
voting and formal decision-making tools
  ‘open’ data monitoring
  DMCs covering a portfolio of trials rather than
single trials
  DMC size and membership, incorporating
issues of group dynamics
  empirical study of the workings of DMCs and
their decision-making
  which trials should or should not have 
a DMC.
Executive summaryIntroduction
In July 2002, a large, multicentre randomised
controlled trial (RCT) in the USA was terminated
on the recommendation of its data monitoring
committee (DMC). The trial was testing hormone-
replacement therapy in healthy, postmenopausal
women. The DMC had judged that the evidence
available to it was sufficiently convincing to be
made available to current and future trial
participants to help them to make decisions about
their future use of hormone-replacement therapy.
This decision by a small group of people was
arguably the most important made in the context
of research on this therapy. It would not only
potentially have a dramatic impact on the future
use of hormone-replacement therapy, but also
define the evidence base on which future decisions
would be made. The viability of a parallel UK
Medical Research Council (MRC)-funded trial was
immediately reviewed in the light of the findings
in the US trial. While the MRC trial’s DMC and
steering committee both recommended that the
UK trial should continue as planned – their view
was that there was still significant uncertainty
about many potential risks and benefits of this
therapy and neither committee was convinced that
the results of the the US trial were sufficient to
guide its future use – the MRC eventually decided
that its trial should stop too. By that stage millions
of pounds had been invested in establishing the
UK trial. Closure at this stage, prompted by a
decision taken by a DMC of another trial in
another country, would mean little scientific
payback from this investment.
This example illustrates the heavy responsibility
carried by a trial’s DMC, the difficulty of the
decisions that it sometimes has to make, and the
profound and wide-ranging effects such decisions
may have. The Data Monitoring Committees:
Lessons, Ethics and Statistics (DAMOCLES)
project described in this monograph aimed to
examine the processes of monitoring accumulating
trial data, and to identify ways to maximise the
likelihood that DMCs make the ‘right’ decisions.
The project took a broad perspective
concentrating on behavioural and organisational
aspects of DMCs and procedural issues of interim
analyses. The work was commissioned by the NHS
Health Technology Assessment (HTA) programme
and was performed by a collaborative group, the
majority of whose members had significant
experience of DMCs. The project focused on RCTs
and did not cover Phase I and Phase II trials, or
non-randomised trials or epidemiological studies.
Background
The RCT is now widely accepted as the principal
research methodology for healthcare evaluation
because it minimises the chances of obtaining a
wrong answer due to bias. Random allocation of
participants to one of the forms of care being
compared avoids selection bias and attention can
be given to other sources of potential bias because
all data collection is prospective.
As a general rule, a trial’s sample size is
prespecified before recruitment starts. This is
largely dictated by clinical and statistical
considerations. While the calculation is based on a
‘primary’ measure of outcome, the sizes of effect
that can be identified in relation to other
measures such as possible hazards of the
treatments are also often considered in relation to
the sample size selected.
The sample size chosen can be viewed as a balance
between two considerations. The first is the
interests of trial participants and potential future
participants, and the second the interests of society,
particularly in respect of people who may benefit
from (or be harmed by) the treatment in the future.
The interests of participants should be best served
if recruitment is closed as soon as a clear answer is
available (so that they and/or future patients then
get the best treatment). The interests of society
should be best met if recruitment continues until
there is a clear answer (such that the results are
sufficiently conclusive to lead to changes in the
clinical management of future patients). Often
these coincide, but sometimes there may be a
tension between the two. Although early stopping
may be seen to confer benefits for those allocated
the apparently poorer treatment, the results may be
incorrect owing to random highs and lows with
small sample sizes and be less persuasive than they
would be after continuing the trial. They then may
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Chapter 1
Introduction and backgroundnot be sufficiently convincing to change standard
practice (or if the intervention is unlicensed, to
justify a licence) and hence the wider benefit to
society is reduced. The deliberations of DMCs thus
have a fundamental ethical dimension, which has
been discussed in detail elsewhere.1
These considerations have led to widespread
acceptance of the need to monitor trial data as
they accumulate to check that there is no clear
reason to change a trial’s protocol. Changes in a
protocol could include terminating recruitment
early for some (e.g. a subgroup most likely to
benefit) or all patients, or extending recruitment
to secure a larger sample size. During long-term
follow-up after recruitment has been completed, a
decision may be taken based on monitoring
accumulating data to report results earlier than
planned in the protocol.
The ways in which accumulating data are
monitored vary, however, and have changed over
time. Doll2 described how arrangements for
monitoring interim data developed in the UK as
the methodology of RCTs evolved. Early RCTs
were small and led by single investigators. Because
of their small sizes, they rarely showed differences
at completion and so early stopping was not seen
as an issue. As collaborative groups emerged, more
formal organisational structures developed. The
trials were run by committees, which included a
chairperson, secretary and statistician. Although
there was no formal DMC, the statistician and
secretary “kept an eye on the results and told the
chairman if they thought that there was any reason
for stopping the trial”. Doll2 dates the formal
independent DMC from the late 1970s and early
1980s, coinciding with the start of the era of large
trials. These were exemplified by the series of ISIS
(International Study of Infarct Survival) trials of
interventions3,4 to reduce the risk of death
following myocardial infarction, which were
coordinated from Oxford and for which Doll was
the chairman of the DMC. Because of their larger
sizes, the possibility of interim data analysis
providing the basis for early stopping was greatly
increased. The choice of independent members of
the DMC reflected concern about investigators
being responsible for such decisions, particularly if
made on their own, because of the potential for
conflicts of interest. Investigators may, for
example, be particularly keen to see a very clear
result, which may delay a decision to stop early.
Alternatively, knowledge of trends in accumulating
data may undermine their relationship with other
participating clinicians or jeopardise their ability
to recruit patients under their own care.
Following the example of the ISIS trials,3,4
independent DMCs became increasingly common
in the UK, although the rate of adoption varied
between specialities. Reflecting the change in
attitude to data monitoring that occurred in the
1980s, the UK MRC, in 1998, made the
establishment of an independent DMC mandatory
for all its trials. This was in parallel with the
adoption of the International Conference on
Harmonisation (ICH) Good Clinical Practice
guidelines of 1996, which recommended the
establishment of DMCs in randomised trials.
In the USA, the development of current policies
and practices for DMCs has been linked to a 1967
task force report for the National Heart Institute.
This is commonly called the Greenberg report5
after the chairman of the task force. This
recommended an external and independent ‘Policy
Advisory Board’, whose role was to provide
guidance to the Institute on the conduct and
progress of a trial. The report outlined a
mechanism for interim analysis and data
monitoring of accumulating data. Over time, these
specific functions were taken on by DMCs, and
these are now standard National Institutes of
Health (NIH) policy. As in the UK, the rate of
adoption of data monitoring varied between
speciality types. DMCs were also a relatively late
development in pharmaceutical industry trials.
Interim trial data have only rarely been made
accessible to current or potential trial participants,
on the basis that trends in accumulating data may
lead current participants to withdraw from a trial
and dissuade others from joining. The standard
policy used in the large majority of trials is to keep
accumulating data confidential to the DMC and
the trial statistician who prepares reports, although
this practice has been questioned.1 This is
discussed in more detail in Chapter 2 (Question 8).
The principal role of DMCs, as their name
implies, is to monitor data and alert the organisers
of the trial if they think the pattern of data – on
benefits or hazards, or both – is sufficiently
persuasive to warrant either closing recruitment to
a trial or changing the protocol, such as
terminating recruitment in one or more subgroups
of trial participants. This is the aspect of data
monitoring that has received most attention and
there is a considerable literature on statistical
‘stopping rules’. Rather than review this, as others
have already done, the present study group has
chosen to summarise the broad statistical
principles and this overview is presented in
Appendix 1 of this report. 
Introduction and background
2Although statistical issues are central to the
functions of DMCs, statistical criteria for stopping
are now accepted as providing guidelines rather
than rules that should be considered alongside
other information, which demand an element of
judgement from a DMC. These include external
evidence from other trials and an assessment of
the likelihood that the interim results would
persuade clinicians to change practice. In
addition, some DMCs are taking on a wider range
of roles and responsibilities, such as those related
to ensuring ethical standards and quality
assurance in the conduct of a trial. Practices in
these and other respects vary widely, and there is
no standard approach. Such broader issues in
DMC decision-making and the factors that may
influence the way a DMC performs its functions
are the focus of this report. 
The ways in which the range of issues was
addressed were organised around 23 questions, and
these are listed in Box 1. These were developed by
the DAMOCLES group at the start of the project
building on the original proposal to the HTA
programme. The questions were in four sections
related to: (1) the roles of DMCs; (2) their structure
and organisation; (3) what information should be
available to DMCs; and (4) decision-making and
reporting in DMCs. The project consisted of
discrete components, each performed by a
subgroup from within the collaboration. Chapter 2
describes a systematic review of published literature
on DMCs. Chapter 3 is a systematic analysis of
reviews of small group processes relevant to DMCs.
Chapter 4 describes a cross-sectional survey of the
use of DMCs and of interim analyses based on a
sample of recent reports of trials. Chapter 5
presents the results of surveys of current DMC
policies of key organisations involved in trials, 
and of DMC practices in ongoing and completed
trials. Chapter 6 describes general interviews 
with experienced DMC members, and case 
studies of trials selected because DMC decision-
making was not straightforward. In Chapter 7 
the project is discussed as a whole. Chapter 8 
draws together conclusions, finishing with
recommendations for future DMCs and related
research. The report also includes a template 
for a DMC ‘charter’, the purpose of which is to
provide a structure for detailing in advance 
the operation and procedures of a newly
established DMC.
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BOX 1 Questions addressed in this report
Role of a DMC
1. Which trials need an independent DMC? (And when should there not be a DMC?)
2. Who should decide the details of how a DMC operates?
3. What should the DMC’s terms of reference cover?
4. Does the DMC have a role before the trial recruitment phase?
– Should the DMC have input into the protocol?
– Should the DMC meet before the start of the trial?
5. How should regulatory issues impact on the DMC?
Structure and organisation
6. What should the membership of a DMC be? 
– What size should a DMC be?
– How should the members be chosen?
– What range of expertise is needed?
– Should there be a chair? And a vice-chair? If so, how should they be chosen?
– What should the responsibilities of the chair and DMC statistician be?
– What should the responsibilities of the trial statistician be?
– Should DMCs include consumer/user representatives?
7. How is independence to be maintained?
– What position should the DMC have with respect to sponsor, trialist and participant?
– Should payment go to members as individuals or to their employers?
– Should conflict of interest be explicitly addressed?
– Should DMC members be paid, and by whom? 
8. Should the DMC deliberations be open or closed (confidential or secret as opposed to publicly available)?
– Who outside the committee should see the interim analysis and how is this changed by whether the analyses were
blinded or unblinded?
– Who should be present during discussions?
– Who outside the DMC should see, or be informed about, the decisions that are reached?
– Should the committee destroy their papers after the meeting?
continuedIntroduction and background
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BOX 1 Questions addressed in this report (cont’d)
9. What are the optimal practical arrangements for interim analysis and data monitoring?
– Frequency of meetings
– Timing of meetings relative to the trial
– Who chooses the dates of the meetings?
– Means of communication (e.g. face-to-face, teleconference)
– Who can suggest unplanned analyses?
10. What sort of training or preparation should DMC members have?
– Who should provide it?
– How much experience should they have?
Information available to the DMC
11. What material should be available to a DMC?
– Who produces it: trial statistician/DMC statistician/principal investigator/other?
– What should be produced (e.g. primary and secondary outcomes, by centre, blinded, safety, efficacy, completeness,
compliance)?
– Who sees the interim results?
– Should information be available before the meeting or only during the meeting?
– Should external evidence be included and how (e.g. from other trials/systematic reviews)? Who should be responsible
for identifying and circulating this?
– Are there specific issues related to type of intervention (e.g. surgery)?
– Are there specific issues related to type of outcome (e.g. survival data, surrogate outcomes)?
– Should there be interaction with other DMCs?
– Should trial investigators be available to the DMC?
12. Who should own the interim data and analyses?
– Who has the right to share them with people outside the DMC?
– Should interim data be released externally (e.g. for use in a systematic review)?
13. Should non-comparative analyses (which are administrative and not separated by treatment arm) be carried out?
Decision-making and reporting in the DMC
14. Is the function of the DMC advisory (to make recommendations) or executive (to make decisions)?
15. What decisions and recommendations should be open to the DMC?
– Early stopping due, for example, to positive active finding, positive control finding, safety on secondary outcome,
futility, slow recruitment, external evidence?
– Stopping in subgroups?
– Extending recruitment?
– Stopping single arm?
– Sanctioning and/or proposing protocol changes?
16. How should the decisions or recommendations be reached within the DMC?
– What methods and criteria should be adopted for guiding deliberations?
– What is the process of decision-making?
– What factors may impact on that process?
– Is there a role for formal methods of achieving consensus?
– What is the role of consumer members?
– What should be the role of the chair?
17. What should be the role of formal statistical methods in DMCs?
– Stopping rule versus guidelines?
18. Should specific trial designs influence the proceedings?
– e.g. cluster trials, equivalence trials, multi-arm trials?
19. How should ethical issues be handled in DMCs?
– Should ethical issues be made explicit?
– Who should raise ethical issues?
– How should these issues be handled?
– Should different weights be given to different end-points (e.g. safety, efficacy)?
20. What should DMCs do with their decisions or recommendations?
– Who should the DMC report to?
– Should the DMC be advisory or executive?
– What form should the report take?
– Are minutes of the meetings or notes of decisions made? If so, by whom and how detailed?
21. What should be done in ‘difficult’ situations?
– e.g. unforeseen circumstances?
– Under external pressure?
continuedHealth Technology Assessment 2005; Vol. 9: No. 7
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BOX 1 Questions addressed in this report (cont’d)
22. Should some DMC decisions be considered to be ‘errors’?
– On what grounds?
– If errors can exist, how can they be identified?
– Can they be predicted or prevented?
– Were decisions overruled?
– Liability?
23. What should the DMC’s role be concerning publications?
– What information about the DMC should be included in published trial reports?
– Should the DMC approve publications, especially with respect to reporting of any DMC recommendation regarding
termination of a trial?Background
Although DMCs are becoming increasingly used
within RCTs, it is clear that their composition,
practice and remit vary between countries, disease
areas and work environments. The purpose of this
part of the project was to summarise the
information relating to DMCs on practices and
beliefs. The aim was to be systematic but not
comprehensive or exhaustive: relatively few people
had written on this topic and many of them had
presented their ideas in more than one paper. The
review was structured to address the series of
guiding questions (Box 1) and this literature review
was structured to identify published material
relating to each of these questions.
Identification: methods
Information was sought from several sources:
electronic bibliographic databases, reference lists
of relevant articles, handsearching of selected
books, personal contacts with experts in the field,
Internet searching and library catalogues.
Electronic bibliographic databases
The primary method for the identification of
papers was searching bibliographic databases. In
the first instance, a subgroup responsible for this
part of the project agreed a number of potential
search terms (e.g. that may be appropriate
MEDLINE keywords). Each of these terms was
then iteratively tested in electronic databases using
the first 20–50 abstracts that were identified to
evaluate their potential relevance. Terms that
generated potentially relevant articles at a rate of
at least three per 20 articles from each test set
were retained. The search strategies that evolved
from these are shown in Appendices 2 and 3. No
language or other restrictions were applied.
Titles, abstracts and keywords were searched in the
following databases:
  MEDLINE
  EMBASE
  CINAHL
  HealthSTAR
  Cochrane Library.
The resulting references, including the abstract
where possible, were stored in a Reference
Manager database, Reference Manager 9.5N (ISI
ResearchSoft, Carlsbad, CA, USA). Automated
searching for duplicates was performed and any
duplicate articles were removed. After the removal
of further duplicates by handsearching, the
remaining abstracts were then assessed. All the
available details of each identified article were
read separately by pairs of researchers from the
group of five, including one researcher who
reviewed all of them. Each article was scored by
consensus into one of the following groups:
0: not relevant to the project
1: paper discussing DMCs
2: case study with a DMC mentioned in the
abstract
3: case study with no DMC mentioned in the
abstract
4: statistical or technical paper.
The resulting data were stored in an MS Access
2000 (version 9.0) database. Primarily, the
researchers were interested in group 1 articles as
these were to be considered for the systematic
review that is described in this chapter. However, it
was anticipated that the search strategy used would
also identify articles that would describe examples
of DMCs in practice, or situations where decisions
were made on interim analyses. Therefore, articles
were assigned to groups 2 and 3 if they could be
considered for inclusion as short illustrative case
studies (ten of which appear as boxed case studies
throughout this chapter); and articles assigned to
group 4 were to be considered for inclusion in the
non-systematic review of statistical methods
applicable to DMCs (see Appendix 1).
Articles that were assigned to group 2, 3 or 4 were
also given subjective interest ratings ranging from
1 (not interesting) to 5 (very interesting). In the
case of uncertainty during the assessment phase,
classification into the five groups and the allocation
of interest, ratings erred on the side of inclusion.
All articles classed as group 1 plus those in groups
2, 3 and 4 with high interest ratings (4 or 5)
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Chapter 2
Systematic review of published literature on data 
monitoring committeespassed to a second stage of review. (Each of these
papers is referenced in the reference section of
this report.)
  Group 1: at the second review stage, the
subgroup responsible for this review reached a
consensus about which of the articles in group 1
would be most useful. These were ranked into
‘To acquire’, ‘To consider if time permits’ and
‘Not to acquire’. There was a necessary element
of subjectivity in the selection process.
  Groups 2 and 3: the potential case studies in
groups 2 and 3 that were regarded as
‘interesting’ were also ranked into ‘To acquire’,
‘Consider if needs be or time permits’, ‘Unlikely
to consider’ and ‘Discard’ by consensus. The ‘To
acquire’ articles were collected, and those
considered as interesting and highlighting a
pertinent issue are presented throughout this
chapter in boxes.
  Group 4: those articles classed into group 4 and
rated ‘interesting’ were later considered in the
context of the summary of statistical methods
associated with DMCs and interim analyses
(Appendix 1).
Reference lists of relevant articles
Lists of references from included articles were
searched and those that appeared relevant from
the text of the included article and had not
already been assessed were examined.
Handsearching
The Encyclopedia of Biostatistics was
handsearched.6,7 Additional handsearches were
performed in books pertaining to RCTs in the
personal possession of members of the
DAMOCLES team or in the MRC Clinical Trials
Unit. Only books or book chapters that were
authored by people whose views had not already
been included through other means were
included. Although this method was not
exhaustive, it was presumed that the majority of
the major books covering data monitoring in trials
were handsearched.
Library catalogues
Owing to time and resource constraints only the
University College London (UCL) Cruciform
library was searched for relevant books and book
chapters.
Personal contacts and other experts in the field
The majority of the relevant literature was
expected to be written in the English language.
However, through personal contacts of the group,
the possibility of appropriate additional major
foreign language articles on this topic was
explored, but not in a systematic fashion.
Internet searching
General Internet searching was considered but not
performed because of time and resource
constraints. Only articles, books and book chapters
that would be classed as containing group 1
material were sought using the five methods
described in the above subsections.
Identification: results
The searching of electronic databases was
undertaken in June 2001. It identified 4007
articles after the automated removal of duplicates.
A total of 483 further duplicates were removed 
by hand. The remaining 3524 articles were
classified and rated in the first review stage. 
Table 1 shows the groups and interest ratings of
these articles. With regard to group 1 articles, 
the group reached a consensus to include 11
articles that had initially been categorised as a
grade 1 by one in the pair of reviewers and not
relevant by the other member of the pair. A total
of 301 articles passed to the next stage of review
(those shaded in Table 1).
  Group 1: of the 116 group 1 articles, the
researchers reached a consensus on 84 articles
that were allocated to the ‘To acquire’ category.
Such was the amount of data generated from
these articles that the ‘To consider if time
permits’ articles were not revisited.
  Groups 2 and 3: judgement was exercised by
two subgroup members. Articles from groups 2
and 3 were chosen for further consideration
depending on the publication journal, the
consensus on interest level by the group and
whether other, more informative articles
illustrating the same issues had already been
chosen. Ultimately, ten short summaries from
these published case studies are presented in
boxes throughout this chapter.
  Group 4: articles classed as group 4 were
considered when writing the review of statistical
aspects pertaining to data monitoring in trials
(Appendix 1).
The other methods of searching (described above)
yielded few extra data. The reference lists from
other abstracts provided some extra book
chapters; two sections were used from the
Encyclopedia of Biostatistics,6,7 no additional major
foreign language papers were identified, and
handsearching for book chapters led to the
inclusion of sections of 16 chapters classified as
group 1.
Systematic review of published literature on data monitoring committees
8Thus, a total of 100 publications was finally
accepted for inclusion in the systematic review of
published literature pertaining to DMCs, and
these are considered in the following section.
Figure 1 summarises the identification procedure,
and Appendix 4 is a list of the 100 references.
It should be noted that the majority of literature is
North American and pertains primarily to RCTs of
drug treatments. This is counterbalanced,
somewhat, in the surveys of current practice (see
Chapter 5).
Extraction: methods
Full text copies of all the eligible articles (taking
articles, now, to include book chapters) were
obtained. In each case, electronic versions were
obtained (1) by downloading online text from
appropriate websites, (2) by photocopying and
scanning paper copies and then producing electronic
versions using optical character recognition
software (ABBYY FineReader 5.0 Pro), (3) from
typed electronic versions obtained from translators
of foreign papers, or (4) by requesting the journal’s
current editor to e-mail an electronic copy directly.
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TABLE 1 Grading and interest scores of articles identified by electronic database searching
Interest level Total
Grade NA 12345 U n c e rtain
0: Irrelevant 2684 0000 0 02684
1: Relevant to DMCs 116 0000 0 0 1 1 6
2: Case study (+ DMC in abstract) 0 15 28 29 51 7 0 130
3: Case study (– DMC in abstract) 0 59 80 101 59 3 0 302
4: Technical 0 53 94 69 62 3 3 284
99: Uncertain 8 0000 0 0 8
Total 2808 127 202 199 172 13 3 3524
Shaded cells indicate those articles that passed to the next round (n = 301).
NA, not applicable.
Medical and methodological literature
Search terms agreed
Keyword online search of MEDLINE, PREMEDLINE,
EMBASE, CINAHL and HealthSTAR performed
Removal of duplicates
(automated checks and checks by hand) 
Pairwise review by group
Review and consensus by group
Supplementary sources
(library searches, books, references from other articles)
Potentially relevant articles identified 4007
Non-duplicative set of potentially 
relevant articles 3524
Articles assessed as potentially relevant
(based on title and abstract) 116
Articles graded worthy of first pass retrieval 84
Articles included in review 100
16
FIGURE 1 Flowchart of the identification procedureEach article was saved as a plain text file, with any
picture files saved separately, and uploaded into a
qualitative analysis software package (ATLAS.ti
4.2). Within this software, a series of codes was
defined, each reflecting one of the questions or
subquestions listed in Box 1. Each article was read
by a single researcher, and each section of relevant
text had the appropriate code(s) applied to it.
Subsequently, files were produced from ATLAS.ti
that contained the relevant quotes that had been
linked to each code. Each member of the
subgroup used the data from files allotted to them
to draft a summary of the published data relating
to each of the questions and subquestions listed in
Box 1. These summaries were considered by the
group and the consensus versions follow. 
Drawing conclusions
This review describes the published literature on
DMCs and as a result may be biased towards what
may be considered ‘traditional opinion’.
Systematic reviews of opinions are difficult to
summarise. Simple vote counting is inappropriate,
and there is inevitable authorial subjectivity in
identifying consensus opinion and important
dissenters. (An attempt was made to identify
minority points by presenting them in italics.)
Cited references are generally indicative; 
not every source is cited for every summary of the
literature. 
Question 1: Which trials need an
independent DMC?
It is broadly agreed by most commentators that
the majority of trials should be monitored to some
degree.8,9 DMCs are becoming increasingly
common for RCTs. For example, Morse and
colleagues8 noted that DMCs “have emerged as a
means of assessing appropriateness of continuing
clinical trials based on evolving trial data”. But do
all trials need a DMC? Box 2 summarises the
suggestions presented in the published literature
of which trials need a DMC, and Box 3 summarises
the suggestions for those that may not need a
DMC. 
The widely held opinions are well summarised by
O’Neill:23
“… any clinical trial evaluating a therapy with a
mortality or irreversible morbidity endpoint should
probably use externally independent [DMCs]. This
would include mega-trials, trials with mortality
endpoints, and trials of treatments for life-threatening
diseases with no alternative therapies. Trials which are
exploratory, early phase trials or [trials] which deal
with chronic disease, palliative therapy, or non life-
threatening diseases probably can be monitored by
designated internal bodies who, although not
independent from the sponsor, are insulated from
management in decision making and follow guidelines
as to who has access to their unblinded data.” 
Systematic review of published literature on data monitoring committees
10
BOX 2 Suggestions from the literature for trials that may need a DMC
  Trials likely to have a profound effect on clinical practice; pivotal trials10–12
  “… Trials designed to enable definitive assessments of therapeutic interventions”8
  High-profile trials8
  Trials with vital status as an outcome measure, e.g. “Life-threatening diseases or cause serious morbidity”8,13
  When a clinical trial is large enough to detect important effects on mortality and irreversible morbidity rates13
  Trials where “Serious safety concerns exist”8,14
  When the risk of a treatment (whether experimental or control) is unknown13,15
  When a therapy has a known risk of severe side-effects, special and targeted oversight is needed13
  All studies where outcome is not predictable or where outcome can imply a hazard to the patients should have safety
committees16
  “When independent evaluation is necessary”11
  Trials which have been contracted out14
  Long trial duration11, e.g. longer than 1 year
  Trials in which therapy is masked17
  Trials in which the end-point is masked17
  “When the [DMC] meets other general analysis needs of the study (e.g. is responsible for developing analytic approaches
for dealing with special analytic problems)”18
  “When treatment monitoring activities require frequent meetings and where each meeting requires a half day or more to
carry out the necessary data reviews”18
  “When the trial is investigator-initiated and grant-supported”18
  Trials in vulnerable populations, e.g. where the patient cannot provide consent themselves or where the patient would not
be able to refuse further treatment19Therefore, there are a number of issues to
consider regarding whether or not a clinical trial
may require an independent DMC. The following
points are proposed by Morse and colleagues.8
  How serious are the consequences of the disease
under study?
  What are the potential risks associated with the
treatment being evaluated?
  What is the total length of time planned for the
trial?
  How high a profile does the trial have? (Will
there be pressure for information to be
released?)
  Is the trial intended to provide a definitive
answer to the question regarding which
treatment is superior?
  Do the study investigators or sponsors have
potential conflicts of interest?
  Are the study investigators experienced in the
conduct and monitoring of clinical trials?
  Will an independent [DMC] enhance the
integrity or credibility of the trial?
One may argue like Meier in Yusuf11 that Boxes 2
and 3 describe characteristics of trials that need
some form of monitoring, not trials that need a
DMC per se: “What’s essential is that a trial be
monitored, not necessarily that there be a special
body called the data monitoring committee ….
But all trials should have monitoring and it should
be made explicit who is doing the monitoring ….
It wouldn’t always necessarily be an independent
free-standing data monitoring committee.”
Indeed, Meinert11 agrees, stating “I would not
necessarily be arguing for a formal data
monitoring board for every trial but for a lot more
data monitoring boards than we have …”. 
Indeed, it is impossible to tease apart the need for
a DMC from the role that the DMC would be
expected to play in the trial. The possible
functions that a DMC may assume are addressed
in question 3. Two of the main reasons for the
presence of a DMC are to stop the trial early if
needs be15,24 and to enhance the credibility of the
trial.25,26 The possible recommendations available
to DMCs are considered under question 15.
The support is there for monitoring to be
undertaken and the use of a DMC to be
considered for each trial. A previous HTA report27
noted that “… It has been argued that it is not
feasible for all trials to have a DMC …”. The
response to this is typified by Friedewalde, in
O’Neill:28 “It may not be necessary [to have a
DMC] in each case, but the burden should be on
the trial sponsor to say we don’t need a board for
the following reasons. I personally wouldn’t accept
reasons such as, ‘it was too expensive’, or ‘there
aren’t enough people to serve on the
committees’.”
Ellenberg and colleagues19 describe the potential
use of “internal DMCs” that could “perform many
of the functions” of an independent DMC. In
settings where independent DMCs are not
essential but where some form of structured
monitoring would be desirable it is suggested that
such a committee could “review (blinded) interim
data and formulate recommendations to trial
leadership to help ensure optimal decision-
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BOX 3 Suggestions from the literature for trials that may not need a DMC
  Short trial duration,11 i.e. “When the time required for treatment monitoring is small relative to the time required to
perform more general advisory and review functions”18
  Where events or patients would be accrued before the DMC could provide input, and especially “studies of short duration
involving well-known interventions in non-life-threatening situations”20
  “Small trial with minor hazards”: the trial investigators can be charged with the monitoring role21
  “Trials where the outcomes and side effects are trivial do not need to have a safety committee …”16
  “… studies where the effects (negative or positive) occur some time in the future when the recruitment and follow-up of
patients has been completed”16
  “Behavioral and administrative studies (although some oversight is required)”13
  “Trials aimed at demonstrating a biologic principle might be monitored in a less formal manner“13
  Unblinded trials, e.g. “Some trials, such as those comparing surgery with best supportive care, cannot be blinded. The need for a
[DMC] in such cases is less pronounced, as their function could be subsumed by the Steering Committee”22
  Trials without vital status endpoints: “… trials not directed at survival or irreversible morbidity”11
  When there is little or no need for advice or guidance concerning the analysis procedures used for assessing treatment effects18
  “When the trial is sponsor-initiated”18
  “When the sponsor and/or investigator desire a single combined committee”18
Points in italics are minority opinions.making during the course of the trial”.19 The
internal DMC should have similar multidisciplinary
representation to independent DMCs.
Three main models of DMCs from the literature
are summarised in Table 2. Model 1 is that
favoured by the Food and Drug Administration
(FDA). Model 2, in which all DMC members are
independent and the analyses are performed by
the trial statistician, is the most commonly cited as
appropriate. It allows all parties to express their
feelings about the trial and to bring relevant
information, but retains independence from the
sponsor while allowing the trial statistician to be
involved. A vocal minority supports the third
model on the grounds that “… objectivity should
not be at the expense of competency”.29
Can the DMC role be performed by an
ethics committee?
Pickworth30 noted that “Local research ethics
committees have access to the original research
protocol and are arguably in an ideal position to
increase their monitoring function”, at least in
single-centre trials. In the USA, institutional
review boards (IRBs) often presume the right to
review (at least some of) the interim data
presented to DMCs (see question 19). Cairns and
colleagues13 also considered this issue: “Each
individual IRB monitors the conduct of its own
institution in multi-centre trials.” No data are
given on how this monitoring is performed. They
continue: “The involvement of an IRB alone,
without a [DMC], may be sufficient in a trial that
involves a single institution, especially when a
mechanism is established for the significant
involvement of a subcommittee or a particular
individual. Most local IRBs, however, lack the
expertise to monitor multicentre trials or lack
sufficient time for the intensive work required in
such cases.” 
This is further confounded by practicalities in
multicentre trials, as noted in the UK example:
“… Though progress reports, changes to protocol
and adverse events should be reported to both the
MREC and LREC [multicentre and local research
ethics committees], proactive monitoring could be
an extremely costly and impractical process if
performed by the MREC. For this reason it is
expected that any proactive REC [research ethics
committee] monitoring will be a local rather than
a multicentre activity.”30
Morse and colleagues8 differentiate more clearly
between DMCs and local ethical committees:
“Institutional review boards should not be forced
to function as DMCs, and there should be no
overlap of their functions.” While there seems to
be some potential overlap in function regarding
monitoring, each trial would be best served if the
DMC alone (if one exists) were allowed to be the
sole monitor of trial data.
In summary, the general consensus is that some
trials definitely need monitoring and that a DMC
Systematic review of published literature on data monitoring committees
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TABLE 2 General models proposed in the literature for the independence of a DMC and the role of analysis statistician
Model DMC members Analysis statistician Example
1a Independent Independent All DMC members and the analysis statistician are
independent of the trial, i.e. the analysis statistician is
neither the main trial statistician nor the DMC statistician,
and attends any part of the meeting the DMC wishes
2a Independent Trial statistician The DMC members are independent of the trial. The trial
statistician is responsible for producing the interim analyses
and attends any part of the meeting the DMC wishes
3 Not all independent Trial statistician At least one of the DMC members is not independent
including, e.g. the PI, but there may be some independent
members. The trial statistician is responsible for producing
the interim analyses and attends any part of the meeting the
DMC wishes
Models 1 and 2 present an independent data monitoring committee (IDMC) whereas model 3 presents a non-IDMC which
may be internal or open.
a The DMC members attend all parts of the meeting. However, there may be other non-decision-making (and non-
independent) attendees for open sessions of the meeting. These would include at least the analysis statistician, but also
could include the sponsor and representatives of the investigators who do not attend closed sessions. The trial statistician
is responsible for producing the interim analyses in model 2, but not in model 1.is the most appropriate committee to undertake
this role. Such trials include large, pivotal trials,
trials with vital status end-points, trials with long-
term follow-up, trials where credibility can be
enhanced by having independent review of
accumulating data and trials where early stopping
of the trial owing to benefit or harm is likely.
Question 2: Who should decide
the details of how a DMC
operates?
Several authors have suggested that it is valuable
for the DMC to have a written document
(standard operating procedures or a charter)
outlining its mode of operation and perhaps also
the responsibilities of different parties.31 Detailed
suggestions have been made on the content of
such a charter.31,32 Any variation in understanding
of what the DMC will do can thus be identified
and resolved at an early stage. (See also comments
under questions 3 and 4 regarding a charter.)
Although its initial drafting may be made by any
of the parties, the document should be agreed by
all parties before the trial starts or at least before
the first interim analysis.33 The content of such a
charter could be incorporated in the protocol,16
but in general would be a separate document.
Nonetheless, the wording of a charter is likely to
leave unspecified certain aspects of the DMC
actions, especially with respect to unforeseen
circumstances.17 In addition, it is widely
recognised that much judgement is needed in the
DMC’s deliberations, especially in more complex
trials in which there are both intended and
unintended effects, and there may be other
considerations too (such as accumulating external
data).
Despite the consensus about the desirability of a
charter for the DMC, only a few authors have
detailed what should go in such a charter.19,31,32,34
Further, the extent to which the DMC is
constrained by such a charter was unclear. Thus,
while it is widely noted that the plans for interim
analysis and stopping guidelines would generally
be incorporated in the trial protocol, there is no
comment on the extent to which the DMC is
bound by these. In addition, hardly any discussion
was found in the literature on questions such as
the following: can the DMC request interim
analyses at additional or different times; can it
request additional or alternative analyses; and can
it choose to use different criteria as a basis for
recommendations about stopping or continuing
recruitment? It is, however, implicit in the
designation ‘independent’ that the DMC has some
degree of self-determination.
In summary, the general view is that many of the
details of how a DMC operates can beneficially be
laid down in a document that is agreed by all
parties: DMC, investigators and sponsors or
funders. Nevertheless, it seems implicit that the
DMC has some flexibility in how it actually carries
out its roles. A suggested charter is presented in
Chapter 7.
Question 3: What should the
DMC’s terms of reference 
cover?
Many commentators have addressed what DMCs
do and/or should do. As the duties of a DMC “are
not necessarily obvious”,35 it is surprising that
until recently there have been very few
comprehensive sources of guidance.19,36 There is
no clear agreement on what the roles or
responsibilities of DMCs are, although most
authors state their views with little recognition of
the lack of consensus.
Variation in the suggested functions of DMCs may
partly stem from authors trying to give a brief
summary of a rather complex situation. Thus,
despite the variation between publications there is
little direct disagreement. Rather, different
commentators vary in the roles that they mention.
Some heterogeneity of views may also reflect
context-specific variation in how committees do
and should operate, in relation to the nature of
the funding, the size and duration of trial, type of
outcome, disease, and so on. For example, the
balance of concern for current and future patients
is likely to depend on whether the disease being
studied is rare or very common, whether the
disease or condition is life-threatening or minor,
whether the treatment may have serious adverse
effects, and whether or not the treatment is
already in common use.
The terms ‘roles’ and ‘responsibilities’ are widely
used, but loosely and somewhat interchangeably.
Here, ‘roles’ is used to indicate what DMCs do,
and ‘responsibilities’ to describe the relations with
those groups to which the DMC has some
responsibility, either explicit or implied.
As a general rule, commentators agree that a DMC
has a duty to keep confidential all information
received about the trial (see question 8).
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Many roles have been suggested for DMCs. It is
generally agreed that the DMC’s role is not
limited to statistical monitoring of the
accumulating data, although that is clearly the key
activity.37 A good brief summary is that the DMC
is “… responsible for reviewing accruing data,
monitoring performance of the trial, assuring
safety of the participants in the trial, and assessing
the efficacy of treatment”.17
Table 3 lists the possible roles of a DMC, separated
rather loosely into major and ancillary activities.
Those labelled major could apply to almost all
DMCs, while the ancillary roles may be relevant in
only a minority of cases. It is desirable that the
DMC has an explicit set of operating procedures.
These can be documented in the form of a charter
(see question 2).
Major roles of the DMC
Before the start of the trial the DMC may review
the protocol. This potentially important activity is
discussed in the following section (see question 4).
Most of the main tasks of the DMC take place
while the trial is running and stem from the
interim analysis. This activity encompasses a large
number of different aspects (Table 3a). Non-data-
related issues include assessments of patient
Systematic review of published literature on data monitoring committees
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TABLE 3 Roles suggested in the literature for DMCs
Timing in  Role
relation to 
recruitment
(a) Major roles
Before Review and approval of trial protocol, including logistics (see question 4)
During Interim review of trial progress including updated figures on recruitment, data quality, loss to follow-up,
and primary, secondary and safety outcome data, so as to:
  assess data quality, including completeness (and by so doing encourage collection of high-quality data)
  monitor recruitment
  monitor sample size assumptions
  monitor trial conduct: organisation and implementation of trial protocol
  monitor compliance with the protocol by participants and investigators
  monitor evidence for treatment benefit, and thus decide when/whether the main trial question has
been answered
  monitor evidence for treatment harm (e.g. toxicity data)
  ensure ethical conduct of the trial
  decide whether to recommend changes to the protocol, recruitment procedures, planned sample size,
data collection, etc.
  decide whether to recommend that the trial continues to recruit participants or whether recruitment
should be terminated either for everyone or for some treatment groups and/or some participant
subgroups (see question 15)
  advise PIs about ethical issues
  suggest data analyses
  advise on protocol modifications suggested by investigators or sponsors (e.g. to inclusion criteria, trial
end-points or sample size)
  monitor continuing appropriateness of patient information
  assess the impact and relevance of external evidence 
After   Discuss final data with PIs/sponsors
  Advise PIs and/or writing team about data interpretation
  Ensure that trial results are published in an unbiased, correct and timely manner (see question 23)
(b) Ancillary roles
During   Consider suggested dropping of some centres from a multicentre trial38
  Adjudicate on controversies, e.g. disagreements between/within PIs and steering committee9
  Evaluate and act on special requests from trial investigators or sponsors to provide limited access to
some evolving trial information39
  Determine whether or to whom interim results should be released40,41
  Make recommendations for dissemination of primary results42
  Review/approve auxiliary studies37,43
PI, principal investigator.accrual and data quality (including completeness).
Data-related issues will focus on the assessment of
the accumulating information on the intended
and unintended effects of the treatments. The
possible recommendations (actions) available to
DMCs are considered under question 15.
In addition, the DMC will need to consider
whether any changes to the protocol may be
indicated. They should also consider any external
evidence that has become available (see question
11), including whether patient information sheets
may need to be modified.
All these roles are important and it may not be
sensible to try to identify a single specific main
role. However, several authors have attempted to
suggest what the primary role of a DMC is. These
views vary considerably:
  to review interim analyses of outcome data9,27,40
  to monitor the ongoing trial for safety and for
early convincing evidence of a treatment benefit
from the therapy under investigation44
  to protect the trial subjects from exposure to an
inadequate or a harmful investigational
therapy12
  to ensure that risks to patients in the trial are
reasonable in relation to anticipated
benefit31,45,46
  participant safety and trial integrity35
  to protect patients … included in the trial but
also other patients with the disease in question.47
This variability is reflected in the wide variety of
names for DMCs, in which different aspects are
stressed (see Chapter 4, Table 16). The common
use of the term ‘data’ in the names for DMCs
disguises the wide-ranging nature of their roles.
The role of the DMC at the end of the trial needs
to be considered.48 Whether or not a trial stops
early, the DMC could usefully meet with the PIs
(and sponsors) after the trial has stopped.31 Even
though they will probably not have seen the final
results the DMC may well be much more familiar
with the nature of the data than the PIs (especially
if the trial has stopped after an interim analysis).
They can thus help with the interpretation of the
results, especially in the case where rapid
dissemination is planned. The specific question of
DMC involvement in publication is discussed
under question 23.
Ancillary roles of the DMC
In addition to the primary activities, some other
activities of a DMC are relevant only in a minority
of instances (Table 3b). Several of these possibilities
relate to resolving difficult situations that can
arise.
What the DMC should not do
Activities generally considered to be outside the
remit of the DMC include the specification of the
statistical approach to data analysis, although they
may advise on the analysis plan (see Chapter 5).
The DMC does not have responsibility for
assessing the effects of trial treatments on
individual patients as it cannot ensure that it will
identify adverse effects quickly.32
Integrity of the trial
Amongst the specific roles, it has been noted that
the existence of a DMC implicitly lends additional
integrity and credibility to a clinical trial.49 The
DMC enables the PIs to remain free from
knowledge of the interim data on the effects of
treatment, thus allowing them to deal honestly
with other investigators and trial participants, and
to make judgements on revisions to the trial
protocol or procedures that are not data driven.
Surveys of what DMCs do
The published surveys of what DMCs do are few,
restricted to major grant funders, of small size (ten
to 20), and not recent.37,43,50 (See Chapter 5 for
surveys on DMC function undertaken as part of
this project.)
Responsibilities
The groups to whom the DMC has responsibilities
are listed in Box 4. While it is often pointed out
that there is a need to balance the interests of trial
participants and future patients when monitoring
a trial, it is useful to distinguish further between
patients already enrolled in the trial and those
who would enter the trial if it continues to recruit.
The responsibility to the sponsor is through
helping to ensure that the trial is carried out to a
high standard.
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BOX 4 Groups to whom DMCs have responsibilities
  Patients in the trial
  Future patients to be enrolled in the trial
  Future patients in target population treated after 
the trial
  Society in general
  Principal investigators
  Steering committee
  SponsorQuestion 4: Does the DMC have a
role before the trial recruitment
phase?
Although much has been written about the roles
and responsibilities of DMCs (see question 3), few
authors have considered the specific question of
whether the DMC has a role before the trial starts
(22 of 100 publications). Specific questions to
consider are:
  Should the DMC have input into the protocol?
  Should the DMC meet before the start of the
trial?
The main reasons for the DMC to meet either
before the trial starts or very early after
recruitment (and before many data are available)
are to review the trial protocol and procedures
including stopping rules and analysis plan, to
develop terms of reference and operating
procedures, and to get to know each other.45,51
While most of these activities can be undertaken
early after the start of the trial, there are strong
grounds for suggesting that the first meeting
should take place before the trial starts. Not
appointing the DMC until after the start has been
described as “poor policy”.13
Protocol review
A meeting before the start of the trial gives the
DMC the opportunity to suggest amendments to
the protocol. Presumably most people would not
accept an invitation to join a DMC without seeing
and broadly accepting the protocol (although this
aspect was not mentioned by anyone), but a
detailed discussion can be valuable. As
Whitehead22 explained: “A [DMC] should be
appointed before the trial begins. This allows
them to meet, in person, with representatives of
the Steering Committee and the sponsor to learn
about the trial and to review the protocol while
there remains a chance to make changes. In
reviewing the protocol, the [DMC] needs to be
comfortable about the purpose, methodology and
ethical aspects of the trial, but should accept that
responsibility for detail rests with the Steering
Committee.” Such a meeting gives the DMC
“greater insight into the difficult design issues
[the] investigators [are] confronting”.49 This
meeting could be difficult other than face to face
(see question 9 on practical arrangements).
Review of the protocol can include a variety of
aspects: the objectives, all aspects of the trial
design, including the inclusion criteria and
outcome measures; philosophy and mechanisms
for monitoring the accruing data, including
decision-making criteria and safety monitoring
procedures; whether the anticipated rate of
recruitment to the trial is adequate;45 patient
consent procedures; and quality assurance issues.
Although it is “not unusual for the data
monitoring committee to review and approve the
protocol”11 there is the real possibility of some
protocol modifications as a result of the meeting.
Such changes would rarely be major. For example,
the DMC may discuss with the investigators the
appropriate choice of outcome measure, say,
between clinical end-points and surrogate
markers.49 For an equivalence trial the DMC
would wish to be satisfied that the “standard
treatment was performed as expected from
previous experience”.52
Several authors suggested that DMC input into the
protocol was a good thing, but two publications35,53
suggested that there was a lack of consensus on
this issue; for example, George reported that in
the USA most cancer cooperative groups agree
that DMCs do not review or approve the trial
design.43
Charter and standard operating
procedures
It is desirable that the DMC has terms of reference
and an explicit set of operating procedures,
perhaps in the form of a charter54 (see also
questions 2 and 3). Although a standard format
may not suit all trials55 there is a large degree of
common ground across all trials. Unless these
issues have already been addressed, the first
meeting of the DMC (ideally, before the trial
starts) is the time to agree terms of reference and
to discuss whether there is to be a charter and if so
what it should say. “Topics to be addressed would
normally include a schedule and format for
meetings, format for presentation of data,
specification of who will have access to interim
data and who may attend all or part of DMC
meetings, procedures for assessing conflict of
interest of potential DMC members, and the
method and timing of providing interim reports
to the DMC.”36
None of the articles mentioned the issue of
specification of the format of data at subsequent
meetings (see question 11). Other issues 
addressed later in this chapter could well be
included in a charter, such as voting procedure
(see question 16). Such a charter should be agreed
by the DMC and PIs/steering group. (A charter
developed on the basis of this project is provided
in Chapter 7.)
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One paper reported the discussion of possible
scenarios prior to any data being available. “A
variety of hypothetical scenarios depicting data
sets which lead to continuation or stopping were
presented to the [DMC] prior to the first safety
inspection of this trial. These illustrated in less
mathematical terms under what conditions the
trial would recommend termination.”56 Such dress
rehearsals “increase the likelihood of success”,49
that is, satisfactory decision-making.
Another issue that can be addressed at this time is
what specific information will be provided to the
DMC at its subsequent meetings (see question 11
for data to be presented to the DMC).
Question 5: How should
regulatory issues impact on the
DMC?
Trials of interventions that may provide the basis
for submissions to regulatory bodies are subject to
additional constraints: general guidance
applicable to all regulatory bodies has been issued
by the ICH,57,58 although much of it has also been
adopted by public sponsors such as the MRC59
(see Chapter 5). Additional draft guidance has
been issued by the FDA36 and is discussed below.
Such trials may be sponsored directly by industry
or by public bodies with additional industry
funding, but in both circumstances the FDA
considers it essential that “clinical trials of new
drugs are designed and carried out in a manner
that will insure the integrity and validity of the
study inferences”.38 O’Neill23 and others have
argued that “it is important for those responsible
for trial monitoring and termination to be aware
of the regulatory consequences of their decisions
because of FDA’s view of data monitoring”. 
There are no current special requirements of
DMCs in the context of a regulatory trial (except
in situations where informed consent is
impossible36). The primary differences between
regulatory and non-regulatory trial monitoring
concern justification for a DMC, reporting the
DMC’s deliberations, the risk of releasing interim
data to external bodies, and taking into account
the regulatory consequences of early termination
for a positive result. When it comes to making a
decision whether or not to stop a trial, the draft
guidelines state that the “FDA will rarely, if ever,
tell a sponsor which decision to make. In certain
settings, however, consultation with the FDA
before making a decision may provide the sponsor
with important information regarding the
regulatory and scientific implications of decisions
and may lead to better decisions”.36
Justification for DMCs
Herson60 predicted in 1993 that DMCs “will be
employed even more frequently by pharmaceutical
firms as a source of independent review to increase
the credibility of clinical trials that must be
eventually presented to the FDA”. ICH Efficacy
topic 9 (ICH E9: statistical principles for clinical
trials)57 recommends a DMC “for many clinical
trials of investigational products, especially those
that have major public health significance”, and
states that there should be written operating
procedures and records of meetings (see question
20), and the DMC should be independent of the
sponsor (see question 7). The FDA draft guidance
points out that an independent DMC “promotes
objectivity that benefits not only the participants
and the trial but the sponsor as well, in that the
credibility of the trial’s conclusions is enhanced”.36
In particular, remaining blinded to interim results
“protects the sponsor (and thus the trial) from
pressure towards premature disclosure of results
due to SEC [the Securities and Exchange
Commission] requirements, fiduciary
responsibility, or other business considerations”36
(‘SEC’ refers to obligation to release information
to investment agencies).
Reporting to a regulatory body
For trials of new drugs in the USA, it is standard
that the FDA will have prior review of protocols
with details of proposed data monitoring
procedures.36 Similarly, in Europe, the Medicines
Control Agency (MCA) and the European Agency
for the Evaluation of Medicinal Products (EMEA)
expect to see, in advance, the protocols of any
trials that include unlicensed drugs. A
forthcoming European Union (EU) Directive61
plans to widen this to all trials involving any drug. 
Both ICH E957 and the draft FDA guidance
document36 state that all DMC meeting records,
including confidential reports to the DMC, should
be submitted to the regulatory body. This will
include any recommendations based on safety
considerations.
Serious adverse events or reactions (SAEs) must be
reported to the relevant regulatory body. This
could be via the DMC, but is said to be “an
onerous burden”.32 Data presented to the
regulatory body will generally be blinded;
therefore, it is not able to attribute this to
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comparison anyway.19 Packer and colleagues32
report a compromise whereby the sponsor supplies
blinded reports to the FDA, which can then
contact the DMC directly if concern arises.
Regulatory bodies do not usually want access to
interim data unless the data are known by the
sponsor at time of the interim report.19 “The FDA
should not and does not want to be a routine
observer nor a voting member in a [DMC].”38
However, AIDS trials in the 1990s brought about
the concept of “expedited development” of
therapies for life-threatening diseases, and in this
situation the draft guidance states that the FDA
“may need on occasion to interact with a DMC of
an ongoing trial”,36 with the possibility of sharing
interim data. Ellenberg and colleagues19 point out
that this may suggest a potential conflict with
common DMC policies, and Walters62 argues
strongly against any FDA access to interim data
except in a “bona fide national health emergency”.
Important protocol changes recommended by the
DMC need to be notified to the FDA.36
Risks of exposure of interim data
Trials with potential regulatory impact provoke
particular attention to keeping the sponsor from
knowledge of the interim results. The following
issues arise.
  Unblinding to the sponsor could provoke
further unblinding, which can influence
decisions and can introduce biases.36 ICH E957
says the role of any sponsor representation on
the DMC should be clearly defined and control
of information addressed.
  Sponsor access to interim data for planning
purposes has been explicitly considered and
strongly discouraged, but if necessary could be
carried out under tightly controlled
circumstances36, for example, if production
would need to be scaled up to make a drug
available if a trials stops early (see question 13).
  The FDA should be notified if the sponsor is
going to have access to interim data.38
  An independent statistician is recommended to
act as the analysis statistician and prepare
reports to the DMC.36
Special issues that may arise for a DMC
when stopping early for benefit
The DMC should be aware of regulatory
implications when stopping early for benefit.41
If regulatory requirements are not met (e.g. there
are insufficient cases to assess safety or the final
analysis does not fully confirm the interim
findings), an application for regulatory approval
could fail. This could make any subsequent trial
difficult, jeopardise treatment development and
penalise the sponsor.
Question 6: What should the
membership of a DMC be?
What size should a DMC be?
There is little agreement on the size of a DMC.
Suggestions range from three51 to more than 20,18
although the former just focuses on decision-
making members, while the latter presumably
includes both decision-making and non-decision-
making attendees. However, it is continually
emphasised in the published literature that a large
DMC can be difficult from a number of
perspectives. It may be difficult to find sufficient
individuals suitable and willing to serve (as those
best suited are likely to be in demand); it can be
difficult to arrange dates for meetings; it can be
difficult to arrange meetings at short notice, which
may be needed from time to time, which are
suitable to all members; and it is more difficult to
ensure that leaks are prevented.
One helpful practical suggestion is that, in
anticipating the possible need to resolve difficult
issues by voting, it may be prudent to have an odd
number of members.45
What model is best for a DMC? How
should the members be chosen and
what range of expertise is needed?
There are numerous models for the membership
of the DMC. However, most DMCs fit into three
models that may be considered representative.
These were presented in Table 2. 
  The extreme model is that all members of the
DMC should be completely independent of the
trial being monitored; this includes the analysis
statistician.36 This model is rarely used in the
public sector.
  An alternative, more widely used model is that
the DMC meeting should include both decision-
making and non-decision-making attendees.
The decision-making members should be
independent in that they do not have any actual
or potential conflict of interest (see question 7).
The decision-making members attend all parts
of the meeting. Other attendees, who would not
be involved in decision-making, could include
the sponsor, representatives of the investigators
and the trial statistician. They do not attend all
parts of the meeting. They should not be
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the definitions used in this report. The sponsor
and investigators should attend only any open
parts of each meeting, if at all54 (see question 8).
The analysis statistician, in contrast, may
remain throughout parts of the closed session at
the discretion of the DMC so as to present and
give advice on the interim results. Many feel
that this structure is the most appropriate,
allowing all parties to express their feelings
about the trial and to bring relevant
information to the DMC, but retaining the
independence of the DMC in making
recommendations.17,20,63
  However, a substantial minority of individuals
disagree with the need for independence in
decision-making. This view is best expressed by
Meinert,29 who says: “If the involvement of
study investigators increases collective
competency, then their exclusion [from the
discussion on outcomes] has the potential of
reducing competency and is open to challenge
on that ground. Objectivity should not be at the
expense of competency.” In this model, the
DMC is largely populated with relevant
individuals from the trial who see all the data
from the trial, but this group is often
supplemented by one or two individuals who
are independent of the trial (see question 7).
There is little guidance on how to choose members
for a DMC. When considering individuals the
suggested attributes to be desired include:
  broad knowledge (often of the area being studied)
  good judgement
  experience
  a reputation for objectivity
  being well respected
  impartiality (in particular, no conflict of interest,
professional or financial)
  knowledge of the generally accepted principles
of clinical trials methodology and practical
issues in trial conduct
  knowledge of the statistical issues, in particular
the ability to appraise the play of chance on
trial results
  being supportive of the objectives of the trial
and the design, including any early stopping
guidelines
  the ability to work in a committee format
  the ability to deal with possible pressures, for
example from sponsors or the media.
There is general agreement that DMCs should
have multidisciplinary representation because the
decision to stop a trial involves many non-
statistical considerations and is, in part,
subjective.24 Typically, this will involve at least one
clinician and at least one statistician. There are
different views on whether other specialities, such
as laboratory scientists or, in particular, lay
representation such as consumer representatives,
ethicists or lawyers need to be included. Such
individuals may need more training, as they are
unlikely to have had wide exposure to DMCs (see
question 10, which further considers training.)
Their inclusion may depend on the disease under
consideration. It is generally agreed that members
of regulatory authorities should not be included
on DMCs.13
Who should choose the DMC members?
This varies from proposals that it should be the
sponsor (acting on suggestions from the trials
investigators)13,15 to the investigators,11 and maybe
even the DMC chair being appointed and then
choosing the other members.45 The former
approach is probably most appropriate, as the
sponsor is ultimately responsible for funding and
organising the trial. Whoever formally appoints
the committee, all those with a major involvement
in the trial should have a chance to review and
comment on the membership.18,64
Should there be a chair? And a vice-
chair? If so, how should they be chosen?
It is generally accepted that a chair should be
appointed.43,45 However, there is very little written
about the basis on which the chair should be
chosen. The opinions expressed range from the
committee itself electing the chair,16 to the
organising group18 or sponsor appointing the
chair.45 It is probably unrealistic to expect the
former, and therefore the latter is often used.
Other than a survey reporting the use of vice-
chairs on DMC,18 there was no mention in the
reviewed literature of DMC vice-chairs.
What should the responsibilities of the
chair and DMC statistician be?
The chair of the DMC is seen as responsible for
facilitating and coordinating the DMC. The chair
usually serves as a liaison between the DMC and
trial investigators and sponsors for the trial.52 The
chair is responsible for drafting and agreeing the
agenda for the meeting, and is also responsible for
signing off the minutes of each DMC meeting.16
The chair is usually either a clinician or a
statistician.
The DMC statistician is responsible for guiding
the committee if statistical issues are raised during
the discussions of the accumulating data; this is
Health Technology Assessment 2005; Vol. 9: No. 7
19
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.particularly with regard to advising against
overinterpretation (the most common problem).51
Sometimes it is the DMC statistician who has
performed the analysis of the data (although, as
outlined in question 11, this is rare). The DMC
statistician sometimes takes on the role of secretary
to the DMC if this is not done by a professional
secretary or another DMC member, because issues
and discussions of a technical nature often have to
be documented.22
What should the responsibilities of the
trial statistician be?
The trial statistician will usually be responsible for
drafting and agreeing an analysis plan with the
various groups involved towards the start of the
trial.31 As indicated above, the analysis statistician
(who may be the trial statistician in many cases, as
in model 2 of Table 2) will usually prepare a
written report for the DMC in a digestible and
standard format26,31,45 (which may be sent some
weeks before the DMC meeting; see question 9).
The analysis statistician will also typically present
this report orally at the meeting,55 and answer any
questions that the DMC may have. Some authors
suggest that the analysis statistician should present
recommendations, alongside the analyses,
although this is not universally agreed.40 The
analysis statistician is also usually responsible for
performing any extra analyses agreed and
requested by the DMC. In some models, the DMC
statistician is responsible for ensuring that the
interim analyses are performed, but does not
perform the analyses.33
Should DMCs include consumer/user
representatives?
It is argued that consumer/user representatives
help to ensure that ‘common sense’ prevails and
that consumer issues are always raised.22 There are
mixed views on whether consumer/user
representatives should be included on a DMC,8,40
with an overall tendency to favour their inclusion
among those who have chosen to publish on this
issue.35,46,65
Question 7: How is independence
to be maintained?
Much literature has been published on the
maintenance of a DMC’s independence, and the
arguments have been well rehearsed
elsewhere.13,32,62 This section summarises the main
points.
What is independence?
Independence for DMC members has been
characterised in the many ways. These are shown
in Box 5 and are also summarised by Cairns and
colleagues:13
“An independent [DMC] is free from financial
conflicts, hands-on participation in a study,
involvement with the DCC [data coordinating centre],
and financial involvement with the sponsor. Financial
conflicts may appear in many forms but, at a
minimum, [DMC] members should not have stock
holdings with any entity involved in the study they
oversee, nor should they have ongoing consultancies
or advisory positions with such entities. Because a
[DMC] reviews data as needed during a trial, the
objectivity of a member who knows the trends in the
data could easily be compromised if he or she were to
advise an individual study patient; thus [DMC]
members should be independent of clinical sites. Just
as with financial conflict, direct involvement with the
affairs of a trial sponsor or its coordinating center
could place a [DMC] member in a position in which
his or her recommendations could jeopardise future
relationships.”
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BOX 5 Characteristics for defining independence of DMC members
  No stock ownership in drug company
  No stock transaction in the company (if previously holding stock)
  No large consulting arrangements with the sponsor
  No frequent speaking engagements on behalf of the intervention64
  Career is not tied up in a product or technique
  No hands-on participation in the trial
  No involvement in the running of the trial
  No emotional involvement in the trial
  No intellectual conflict, e.g. prior belief in the trial’s experimental arm32
  No involvement in regulatory issues relevant to the trial procedures
  No investment (financial or intellectual) in competing products
  No involvement in the publication66 (see question 23)
Italics refer to minority opinion.Some argue that these same criteria should be
equally applied to the families of DMC
members.42 “[As far] as possible, [DMC] members
should refrain from involvement in these types of
situations and avoid financial dealing with
companies involved with products being evaluated
or with competing companies.”32 The avoidance
of such conflicts is not written in law (at least in
the USA), but is ethical in nature.32
Although the majority of published literature
pertains to drug trials, in general terms, the issues
are the same for other types of intervention and
medical devices.11,41
Is independence necessary?
The avoidance of any perception that members of
a committee may be biased is important for the
credibility of the decisions made by the committee
and for the integrity of the trial.25,39 Maintaining
credibility requires that the “voting members
should be without actual or potential conflict of
interest”.63
However, Green and Crowley67 noted, “I wouldn’t
want the message to be conveyed that all trials
need an independent committee. I don’t think
that’s always necessary”.11 Each medical speciality
is a relatively small field with a limited number of
experts. So, not infrequently, only individuals with
direct involvement in the field of study have the
expertise required to evaluate the complex data
that a clinical trial will yield. Expertise in medical
statistics is similarly hard to come by. Armitage
noted that “In the few instances I have known
where a small number of investigators were privy
to the full results during the data monitoring
procedure, I did not detect any lack of objectivity
or undue distress on their part. I suggest that a
flexible attitude should be adopted on this
issue”.55
Indeed, many pharmaceutical companies have
formed internal DMCs32 primarily because the
trials were not sufficiently high profile and if an
external DMC were appointed for every trial there
is a belief that there would not be enough
qualified individuals to serve.
The issue of independence may be related to
whether any statistical stopping rules exist for the
trial and whether they are interpreted as rules or
as guidelines (see question 17). Crucially, if the
DMC has some leeway, as is the case with
guidelines, it is necessary that the DMC is
objective: and independence increases objectivity.
Bias caused by subjectivity, both conscious and
unconscious, can affect the rationality of decision-
making (see Chapter 3).11,68,69
Previously, question 6 discussed membership for
DMCs. Table 4 summarises the arguments for and
against many potential people being appointed as
DMC members with regard to independence.
Meinert11 stated that he would argue for including
anyone with knowledge of the trial in the decision-
making process. “I would rather have a slightly
biased committee which is informed, than a clean
committee that does not have all the information
it needs to evaluate the results.”11
However, even if an individual is not a member of
the DMC per se their knowledge should not be
discarded. As stated by Fleming, “A key point is
that if these individuals are not members of the
committee, it does not mean they should not be
involved in the process”11 (see question 8 for the
practicalities of DMC sessions). 
Addressing conflict of interest
A 1993 survey of US cooperative trial groups
showed that seven of 11 groups had formal rules
or criteria that defined potential conflict of
interest.50 Meier has argued that conflict of
interest is an inappropriate term and should be
replaced with related interest, since “not every
related interest should be seen as a conflict”,11 but
his terminology has not been widely accepted.
The generally accepted principle for dealing with
potential conflicts of interest is one of voluntary
disclosure, as adopted by the FDA, so that others
can “make independent assessment about whether
these could have significant impact”.11 The
involvement of people with such conflicts may still
be justified if others with the same knowledge but
without the conflict are not available. “Often,
simple disclosure is sufficient to resolve these …
conflicts.”32
Possible conflicts of interest should be disclosed to
the appointing authority,18 the group chair46 or
whoever appoints the DMC (see question 6 on
who decides membership). There is little
discussion in the literature considered in this
review of what should be done if a member of an
ongoing DMC has conflicts of interest. Where the
DMC is planned to be independent the decision
may be more straightforward: remove the conflict
or stop participating in the DMC.64
Payment to DMC members
It is generally accepted that members of DMCs
should be reimbursed for their travel and
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accepted that private companies should
compensate for time expended at the ‘usual’
rates.34,45 While private company rates tend to be
higher than those paid by public sector employers,
they are usually “modest enough that there would
be little chance that the payment could influence
the objectivity of the DMC members”.60 To put
this another way, there is a broad consensus that
compensation paid at a reasonable rate should not
compromise the independence of the DMC,52 and
should be small enough that members should “not
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TABLE 4 Arguments for and against inclusion of potential members with regard to independence
Position Inclusion Exclusion Majority opinion with regard
to participation
Sponsor  May have knowledge of drug not  Primary aim is profit, therefore  Do not allow drug company 
representative:  available elsewhere clear pro-treatment bias expected.  employees as DMC member, 
drug company Reassures sponsor that the trial  May wish to stop trial for financial  but perhaps invite to present 
is being undertaken well and  reasons. In addition, the DMC  information or answer DMC’s 
monitored adequately members may have funding from  questions
the sponsor and believe that 
criticising this trial may prejudice 
their own funding
Sponsor  Reassures sponsor that the trial  May wish to stop trial for financial  Do not allow publicly funded 
representative:  is being undertaken well and  reasons. The DMC members may  sponsors as DMC member, but 
other funding  monitored adequately have funding from the sponsor and  perhaps invite to present 
(e.g. public,  believe that criticising this trial  information or answer DMC’s 
charity) may prejudice their own funding questions
Principal  May have specific trial knowledge  May later reveal confidential  Do not allow as DMC member, 
investigator or  not available elsewhere accruing data or be taken out of  but invite to present 
study chair equipoise, thereby compromising  information or answer DMC’s 
ability to promote trial questions
Career may be tied up with drug, 
product or technique
Other trial  May have some specific trial  May be taken out of individual  Do not allow on as DMC 
investigators knowledge not available  equipoise, compromising ability  member. Invite as appropriate 
elsewhere to recruit  (e.g. if PI unavailable)
Coordinating  Knowledge of day-to-day running  Invested much time and effort  Exclude as members but report 
centre of trial not available elsewhere;  getting trial to this stage; intimately  to DMC routinely
understanding of data involved with data and with 
promoting trial
Trial statistician Intimately involved with trial Intimately involved with trial. May  FDA would prefer analysis to be 
be under pressure from sponsor performed by independent
statistician in many cases,36 but
this is not widely accepted as
necessary or appropriate.
Sessions attended by the trial
statistician will be at the DMC
chair’s discretion
Regulatory  “Would help regulatory reviewers  The DMC reviews data from one  Exclude from DMC unless 
authorities make better informed decisions  trial, while regulators have to  completely necessary
in a more timely way”62 consider all available data. In a 
position to have greater knowledge 
of any drug information from 
outside the trial. Also have different 
type of relationship with drug 
companies than the general DMC 
members
Members of  Perhaps able to provide a bigger  If on DMC for a similar trial,  (None)
DMCs of similar  picture and may help to protect  because may have pre-existing 
trials against overreacting to random  biases from viewing confidential 
data trends data from other trialsderive any financial support from the trial”70, that
is, service on DMCs should not be their primary
source of income. Bergqvist and colleagues argue
that the compensation should reflect the amount
of time and the amount of expertise made
available by the DMC members.16 They
additionally argue that payment should be made
to the employer (e.g. “research foundation, the
university or health service employer”) rather than
to the individual directly. No mention is explicitly
made of payment to any non-members who report
to the DMC or attend their meeting, but by
extension it would be expected that travel
expenses should be reimbursed, at a minimum.
Question 8: Should the DMC
deliberations be open or closed
(confidential or secret as opposed
to publicly available)?
Many authors have considered the questions of
whether DMC meetings should be open or closed,
and whether anyone other than the DMC
members be allowed to participate, and if so who?
The difficulty to be surmounted is that the
independent members of the DMC may not know
very much about the details of the trial or other
relevant external events, whereas the aim is to
keep those who do know – the trial investigators –
blind to the emerging results.53 There is
considerable agreement that the solution is for
DMC meetings to comprise both open and closed
sessions. The objective can be summarised as “to
preserve confidentiality while maximising the
opportunities for interaction with all individuals
who would have valuable input for the
committee”.26
The open session is attended by DMC members,
trial investigators, the trial/analysis statistician and
possibly also the head of the statistical centre,
members of the trial oversight committee and
perhaps also representatives of the sponsor, funder
or regulator (e.g. the FDA). It should not,
however, be open to the public.71 At this session
the progress of the trial is reviewed, including
participant accrual rates, loss to follow-up, the
timeliness and quality of the data, the
performance of centres in a multicentre trial,
possible modifications to the protocol, and so on.
Toxicity of trial treatments might be discussed in
general terms, but without reference to actual
data. Trial efficacy should not be discussed in the
open session, perhaps not even for the treatment
groups combined as any deviation from the
expected values may be assumed to be the result
of differences between the treatments. For
example, in survival, if the expected 2-year
survival rate is 20% on the control arm and the
combined rate presented is 30% this may be due
to improved survival in the research arm, but it
may also be due to the control arm performing
better than expected (regardless of any differences
in treatment efficacy). There is no consensus as to
whether toxicity data should be presented at the
open session.40,46 Also, at this meeting any
recently available external evidence can be
presented and discussed (see questions 11 and 15).
Some individuals, such as representatives of the
sponsor, may not attend the meeting in person,
but be available to answer questions by
telephone.22 A minority view is that open sessions
are not advisable and that, in particular, there
should be no contact between the sponsor and the
independent DMC (Gent, in Yusuf11). In summary,
it is generally agreed that open sessions in which
any aspects of the trial that do not relate to the
interim findings are discussed are desirable.
Participation in the closed session is restricted to
those who may see the unblinded data from the
trial: almost always this meeting is restricted to the
DMC and trial/analysis statistician. In the closed
session the DMC will see and discuss efficacy and
safety data by treatment group. Care should be
taken that “sloppy management of paper
documents” does not lead to leaks to those
attending only the open meeting.54 Indeed, a
more extreme view, given by Packer,32 is that “Any
breach of confidence may ruin a trial …”.
Most writers explicitly or implicitly assume that
the interim results will be shown to the DMC
unblinded, that is, with the treatment groups
identified. It has occasionally been suggested8 that
the DMC should be blinded to treatment (and
perhaps able to ask to be unblinded at any time).
Ellenberg and colleagues observe that “it is
scientifically and ethically problematic to withhold
from the DMC access to the efficacy and safety
data that are fully unblinded by intervention
group”.19 In practice blinding is often unsuccessful
because of a clear difference in the frequency and
nature of adverse effects. Although this problem
can be surmounted by randomly changing the
labelling for different parts of the trial results, it is
then not possible to consider the linkage between
different outcomes.19 Meinert has written
scathingly about blinding of the DMC as “blind
stupidity”.72
Some commentators have suggested that after the
closed session there should be an executive session
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the attendance of anyone additional to the DMC
members at the closed session is at the discretion
of the DMC. At this session the DMC can discuss
any aspect of the trial conduct as well as the data,
and make decisions about what to recommend (see
question 15). Indeed, the analysis statistician may
be present throughout the discussions and
deliberations of the DMC. In the latter situation,
the analysis statistician “has no vote in the
decision making”.15 An additional open session is
possible between the closed session and the
executive session, at which the DMC can enquire
about issues that have arisen during the closed
session discussion.26 Finally, it is possible to have a
final open session at which the DMC can
summarise its response.
The preceding comments apply to the present
time. As recently as 10 years ago it was not
uncommon for the trial investigators routinely to
see the unblinded outcome data during the trial73
(see question 7 for a discussion on independence;
see question 11 for details of the information
available to DMCs).
There is near unanimity that the interim data and
the deliberations of the DMC should be absolutely
confidential.15,31,40,46,64 At the end of the meeting
the DMC will make a recommendation to the
steering committee, but the DMC will not discuss
the actual data with the steering committee or
anyone else. Breaches of confidence are to be
treated extremely seriously:32,43,45 one group
suggested that “even the smallest breach of
confidentiality by a [DMC] member should
prevent that person from participating as a
member of any future [DMC]”.32
A contrary minority view is that interim data
should be made publicly available74 and that by
keeping data confidential DMCs are acting
unethically.75. Lilford and colleagues74 point out
that a DMC, faced with fairly convincing data, may
be implicitly making a trade-off between the
general patient population that will benefit from a
precise answer, and the patients in the trial, half of
whom are currently receiving an apparently
suboptimal treatment. They claim that DMCs
“make big decisions using opaque (and doubtless
variable) heuristics, while ignorance is perpetuated
to stop potential participants voting with their
feet”. This is an ethical issue, in that data arising
from the trial are kept secret from both clinical
and patient participants, whereas there is an
imperative actively to disseminate similar data
from another published trial. “Withholding,
without debate and endorsement of the policy,
information that patients might find useful, is at
best paternalistic, at worst authoritarian and
arguably unnecessary.”74
From a practical perspective, it may be feared that
making interim data public would undermine
recruitment and promote premature adoption of
the apparently favourable treatment. However,
Lilford and colleagues claim, if there exists a
range of prior opinions then data in favour of one
treatment will serve to bring additional clinicians
into “equipoise” and hence they will be willing to
recommend randomisation.74 The Growth
Restriction Intervention Trial (GRIT)76,77 has
released its interim data to recruiting clinicians
with no reduction in recruitment. It can also be
argued that the media may overinterpret interim
results that would not sway a DMC, but Lilford
and colleagues feel that this “derives from a
culture of scientific materialism and is self-
fulfilling”,74 in that secrecy allows uniformed views
to flourish. Bayesian presentation may also
prevent overinterpretation, as used in GRIT.77
Who outside the committee should see
the interim analysis and how is this
changed by whether the analyses were
blinded or unblinded?
Some have suggested that the trial statistician
should remain blinded and that an independent
unblinded statistician should be employed as the
analysis statistician to carry out interim analysis
and to work with the DMC.31,32 There is concern
that the trial statistician cannot participate
neutrally in steering committee discussions, for
example, relating to changing the primary
outcomes, if seeing the accumulating data.19 A
suggestion in the recent draft FDA guidelines36 to
have an independent statistician has caused
considerable consternation. For example, in a
session of the Society for Clinical Trials annual
meeting in 2002, concern was expressed that while
the trial statistician knows the data set thoroughly,
someone brought in from outside would find it
difficult to produce the necessary analyses and
may miss important information.
The DMC may allow “selected individuals (e.g. the
chair of the executive steering committee) to
become unblinded with respect to certain specific
results if, in the view of the [DMC], the trial – and
particularly, patient safety – would be better served
by such action”.54 It has been suggested that
attendance of the trial sponsor at the closed
session may be appropriate (as an observer) for a
non-commercial sponsor.55 For example, for many
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present during the closed session.64 Not all agree
that this should happen.11
The current prevailing view is that the trial
investigators should not see the unblinded interim
results, and that the argument that releasing
interim results would aid enthusiasm and accrual
is false.78 However, for NIH trials the PI may
attend the closed meetings.54 (See Case Study 1 for
an example of the possible impact of this policy.)
Pocock48 discussed the question of whether the
pooled outcome data from the two arms of a trial
might be released to the trial investigators. “Such
knowledge satisfies curiosity and instils confidence
that the trial is functioning well, but could it
adversely affect continuation? Knowledge that the
total of primary events was well below twice that
expected in the control group might lead to
(possibly false) speculation that the treatment was
effective, in which case such data should not be
released.” He notes, however, that a referee of his
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CASE STUDY 1 Impact on accrual of having no independent DMC and showing interim results to participating clinicians, and impact
of early stopping of a trial for efficacy where the late results were markedly different
Trial
This was a European Organisation for Research and Treatment of Cancer (EORTC) trial79 in locally advanced breast cancer
conducted in centres across western Europe between December 1979 and November 1985. The trial was a 2 × 2 factorial
RCT: all patients were to receive radiotherapy and were randomised between chemotherapy and no chemotherapy and
between hormone therapy and no hormone therapy. The primary outcome measure was overall survival. A total of 410
patients was randomised to an initial recruitment target of 330.
DMC role
The DMC (known as the trial monitoring committee) was planned to monitor the conduct and progress of the trial. The
DMC was not independent. Indeed, the data monitoring was initially performed by the trial statistician on a 6-monthly basis.
If any of these interim looks at the data were statistically significant, they were to be discussed with the study coordinator
and possibly with the main clinicians participating in the trial. The DMC was formed later in the trial.
Data
The following table summarises the accumulating data for the trial.
Survival First progression
Events Hormones Chemotherapy Horm Chemo
Timing Gp Acc Prg Dth p HR 95% CI p HR 95% CI pp
Apr. 1982 All 175 35 10 NS –– ≈ 0.05 –– NS ≈ 0.05
Mar. 1983 All 264 81 39 0.65 0.87 0.46 to 1.62 0.08 0.57 0.31 to 1.08 0.13 0.0002
Oct. 1983 All 319 99 62 0.58 0.87 0.53 to 1.43 0.02 0.56 0.34 to 0.92 0.04 0.0000
Apr. 1984 LA 346 96 57 0.46 0.82 0.49 to 1.38 0.01 0.50 0.30 to 0.85 0.14 0.0001
Apr. 1984 All 346 125 –– – – –– – 0.02 0.0001
Nov. 1984 LA 385 120 72 0.36 0.80 0.51 to 1.28 0.009 0.54 0.34 to 0.86 0.03 0.0000
May 1985 LA 399 138 86 0.16 0.75 0.49 to 1.13 0.004 0.53 0.35 to 0.82 0.04 0.0000
Mar. 1988 All 410 264 202 0.06 0.77 0.58 to 1.02 0.23 0.84 0.64 to 1.12 0.001 0.009
Acc, accrual; Chemo, chemotherapy; CI, confidence interval; Dth, death; Gp, group analysis (All, all patients; LA, locally
advanced patients); Horm, hormone therapy; HR, hazard ratio; ns, not significant; p, p-value; Prg, progression.
Considerations
The summaries of each interim look at the data are as follows:
April 1982: continue recruitment
March 1983: data sent to study coordinator
October 1983: data discussed by DMC – continue recruitment
April 1984: continue (although accrual was by now slower)
November 1984: continue
May 1985: close trial because of slow accrual (except for an apex positive subgroup)
March 1988: final trial results published. The results were much changed in both comparisons: the effect of chemotherapy
was no longer statistically significant; in contrast, the benefit to hormone therapy had become more convincing.
Consequences
Accrual had continued, although at decreasing rates, despite interim results. The final results were quite different to the
immature results.paper disagreed, “arguing that a steering
committee cannot steer appropriately without
access to such information”.
The release of unblinded data to sponsors is
generally precluded by the consensus that they do
not attend the closed session. A DMC may
consider the release of blinded data to sponsors in
rare circumstances.8 By contrast, one group32 has
suggested that “in an industry-sponsored trial, an
employee of the sponsor must have access to
unblinded information so that the sponsor can
report any serious adverse event to authorities”.
Of course, the recommendation to continue a trial
provides some information about what the trial
does not (yet) show.33 (See question 12 about
releasing data for systematic reviews.)
Who outside the DMC should see or be
informed about the decisions that are
reached?
In the UK, the DMC usually makes
recommendations to the trial’s steering
committee. In practice, a recommendation to
cease recruitment is effected by unblinding the
steering committee to the latest efficacy and safety
data on which such a recommendation was based.
In most cases the steering committee will follow
the recommendation of the DMC, but on occasion
they will not (see examples in Chapter 6). Using
this approach, it is for the steering committee, not
the DMC, to decide to whom the trial results
should be released, although the DMC may have a
say (see question 14 for consideration of whether
the DMC is advisory or executive and question 20
for who the DMC reports to).
Should the committee destroy their
papers after the meeting?
Some authors have recommended that, to aid
confidentiality, all confidential material should be
collected (by the analysis statistician, or some
other member of the coordinating centre, if they
are allowed to handle this information) at the end
of the DMC meeting.31,70 However, it is not
uncommon for DMCs to monitor results over time
and this requires access to earlier reports.
Question 9: What are the optimal
practical arrangements for
interim analysis and data
monitoring?
Frequency and timing of DMC meetings
The frequency and timing of monitoring vary
according to context, are guided by the trial
design and should be specified in the protocol.34
The arguments for a first organisational meeting
to review the protocol, establish procedure and
agree terms of reference before starting
enrolment19 or, if not, before the first interim
analyses have been discussed previously (see
question 4). The frequency of subsequent meetings
depends on how quickly information on primary
outcomes accumulates. Some monitoring plans use
‘information time’ (proportion of primary end-
points or observed accrual) rather than calendar
time to define the frequency of meetings.
Although the former may be more efficient for
interim analyses of the primary outcome, the
latter is more practicable as meetings can then be
scheduled well in advance. Earlier DMC meetings
focus on monitoring safety and trial conduct
because information on efficacy usually
accumulates at a slower rate early in the trial.
Many commentators suggest that biannual
meetings appear to be more than adequate for
most trials.31,50,51 Safety concerns or trends in
efficacy data may lead to additional or unplanned
interim analyses.15
Means of communication and other
logistical aspects
The choice of dates and other logistical aspects of
DMC meetings are the responsibility of the
sponsor or the coordinating centre with input
from the DMC, particularly in regard to
scheduling and specific requirements.31 Currently,
DMCs could use three modes of communication:
face-to-face meetings, teleconferences and written
correspondence (by mail or e-mail).
It is generally agreed that face-to-face meetings
are the most effective way for committee members
to communicate, as they facilitate adequate
discussion.19 They are necessary when reviewing
complex data or when data are at a crucial stage
and important decisions are to be made.34 They
have also been recommended for the initial
meeting, particularly when members may not be
familiar with each other.51,54 One would presume
that face-to-face meetings are also easier when the
committee is international and does not share a
first language (an example of this is presented in
Chapter 6 Case Study B, p. 111). However, with the
heavy demand on people with DMC experience,
face-to-face meetings are sometimes difficult to
arrange and are more time consuming.
With regard to time, teleconferences are more
efficient and easier to arrange at short notice, but
they allow less effective interaction between
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particularly useful for shorter meetings of small
committees whose members are already familiar
with one another. Little has been written on these
issues in the published literature, but these topics
are considered further in Chapters 3 and 5.
Written correspondence between members is
considered the least satisfactory mode of
communication and should be limited to
administrative issues (e.g. circulation of minutes).
George43 recommended that “Members who fail to
attend two consecutive meetings (including
conference calls) may be replaced”, but that it
“wouldn’t be at the discretion of other DMC
members”.
Question 10: What sort of training
or preparation should DMC
members have?
Although it is generally accepted that experience
of clinical trials and knowledge of the disease area
of the trial are essential for members18 (see also
question 6), little has been written as to how
individuals should gain suitable experience to
serve as DMC members. Similarly, little has been
published as to whether any formal training is
required.
At present, when novice members are appointed
to a DMC there are two ways in which they may be
trained, which are not mutually exclusive.
Following the first method, they “become
apprentices who rely on the oral tradition to learn
the rituals”, with the more experienced members
acting “… like the caravans of yore, passing
information from one society to another”.17 The
tendency in North American cooperative groups is
to have large committees that monitor a portfolio
of trials. Therefore, when new, inexperienced
people attend they are mixed in with those who
are already experienced; this cannot happen so
easily in smaller committees. Indeed, “It is good
practice to include some experienced members on
every [DMC]. A new committee should not be
constructed entirely from inexperienced members,
even if they are all experts” in their field.80 But
there is disagreement as to how many experienced
members are needed to pass on knowledge and
traditions orally.
There is agreement that the chairperson should be
a more experienced member. “Clinical trial
experience by all members of the [DMC] is highly
desirable, but prior experience of serving on a
[DMC] by the [DMC] Chair is essential.”64
The second training method advocates that
potential or new DMC members turn to published
case studies because these are “our best source of
understanding the strengths and weaknesses of
various monitoring and analysis strategies in
practice and of informing current and potential
data-monitoring committee members about
situations they may face in their evaluations of
trials …”.23 There is no widely available list of case
studies to consider. Ten short case studies from the
published literature are presented in boxes
throughout this chapter; and four detailed case
studies are presented in Chapter 6. However,
interesting though these case studies may be, it is
questionable whether case studies worthy of
publication are truly representative of typical DMC
functioning.
There has been a call for professional certification
for DMC members in the belief that this would
increase the transparency of the decision-making
process,81 but even this paper did not suggest who
would be providing the training leading to
certification.
Perhaps training is needed not just for DMC
members, but also for those who a DMC serves. In
one paper, there was concern “that relatively few
of the investigators are very cognisant of the
board’s activities, and we have discussed the
possibility of ‘educational outreach’. Sessions at
upcoming meetings of the clinical trials groups are
being planned to clarify for investigators the
purpose of a [DMC], to present the operating
procedures, and to permit board members to
respond to any questions the investigators may
have”.8
As discussed in question 6, many committees
appoint a member who already has training in
biomedical ethics,53 but no published opinions
were found as to whether all DMC members
should undergo some training in ethics.
Question 11: What material
should be available to a DMC?
Who produces it?
There are mixed views on whether the trial
statistician or an independent statistician should
act as the analysis statistician and produce the
analyses for the DMC to consider. One article12
implies that the DMC should perform the
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independent statistician are that it retains the
principle of keeping blind all those involved (in
any way) with the trial, and prevents placing the
trial statistician in a difficult position – that of
knowing the current results, and interacting
regularly with the other investigators in the trial.
This is the current view of the FDA: “… the
integrity of the trial is best protected when the
statistician preparing unblinded data for the DMC
is external to the sponsor …”.36 (Further
discussion of this issue is presented by Ellenberg
and colleagues.19)
However, a powerful argument that the trial
statistician should perform the analyses is that to
analyse a dataset requires knowledge of the
disease, the trial and detailed aspects of data
collection.15,55 Without this background it is easy
to make many (and sometimes simple) errors in
the analysis. This holds even if the trial statistician
provides all the data for the analysis to be
performed by the independent statistician,
because discrepancies may only be spotted once
the analysis has been performed. Thus, in most
circumstances, it is the trial statistician who
produces the analysis. Analysis of the data and
preparation of the report are not then the
responsibility of the DMC statistician.48
What should be produced?
Buyse73 presents a basic generic table for possible
evaluations to be made to the DMC. Table 5 is an
amended version of this table, supplemented by
extra aspects that may be useful. This could be
used as a template for producing reports to
DMCs. Many authors emphasise the importance of
providing comprehensive, but digestible
information to the DMC.22,45 This must usually be
done in the form of summary tables and statistics
and, wherever possible and appropriate, by using
graphical summaries. It is unrealistic to expect a
DMC to plough through individual patient
records,42 except perhaps at very early stages for
certain key outcome measures, such as unexpected
SAEs.22 It is often useful to agree the template for
the report at the start or soon after the beginning
of the trial. An argument for waiting until there
are some data is that it can be difficult to make
sense of empty (shell) tables.22
The DMC, after appropriate discussion, should be
able to ask for extra analyses to be performed (at
any time) or further data to be collected during
the course of the trial,64 to enable it to carry out
its primary responsibilities. The analyses should be
based on up-to-date data.42,46
Allied to this framework, it is often useful to set
out an interim analysis plan,31 which will have the
above framework and many of the components of
a final analysis plan. The interim analysis plan
should be seen and agreed by the DMC before the
start of the trial or early on in the trial (see
question 2).
Two reports are often prepared: one for the open
session and one for the closed session.31 The open
session report may be a subset of the closed
session report or entirely separate (see question 8).
The length of reports will depend on the context
of the trial, perhaps between four and 200 pages:
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TABLE 5 Possible evaluations to be made to the DMC (adapted from Buyse73)
General area of evaluation Specific evaluation Session
Evaluation of trial procedures Adequacy of record forms to capture the intended data Open
Procedures and arrangements for data processing and handling Open
Evaluation of trial data General monitoring of the trial Open
Date of freeze of the data set Open
Patient accrual and description Open
Patient exclusions Closed
Quality of data Open
Completeness of follow-up Open
Compliance to treatment Closed
Evaluation of interim statistical analyses Safety analyses Closed
Efficacy analyses Closed
Evaluation of trial context Interpretation of interim results Closed
Results from other individual trials Open
Meta-analyses Closed
Liaison with other groups or DMCs Closedsomewhere between would be “reasonably
satisfactory in context”.55
An important issue is up-to-date information on
the outcome measures. Fleming and DeMets
suggest that, “In order to maximise available
information and reduce the risk that subsequent
data updates would substantively alter analysis
conclusions, nearly current follow-up should be
available on all patients. … Decisions about early
termination should be delayed if available data do
not provide nearly current follow-up on almost all
patients.”39
Should the DMC be masked?
One aspect that has received some attention is
whether the DMC should be masked in the sense
of not knowing which trial group has received
which treatment. In the report the treatments
would just be labelled, for example, with A and B
(see question 8). Some argue that such masking
prevents the DMC from reaching premature
conclusions from early trends.82 Masking also
helps if the report finds its way into the wrong
hands, and offers some protection against leaks.54
In practice, masking data can be difficult because
surrogate markers and adverse events often give
the allocation away, but in these situations
masking can be maintained by having different
treatment codings for different aspects of the
data.54 This may be practically complicated and
open to error. If the DMC is masked then it is
usual to allow them to remove the masking at any
time,72 although the same author feared that once
imposed, the masking tended to become
permanent because “the request [for unblinding]
comes to be seen as heralding recommendations
for changing the protocol”. However, as Pocock
and Furberg54 point out, many experienced DMC
members believe that only the presentation of
unmasked data allows a DMC to consider
risk/benefit issues competently and efficiently and
to integrate the often complex patterns of safety
and efficacy issues more carefully. It has also 
been emphasised that recommendations for a
change to the trial protocol are not usually
independent of the direction of the effect. In such
situations it is unreasonable to ask the DMC to
behave as if it were indifferent to the direction of
any emerging difference.72 In particular, in most
trials, more evidence is required to stop a trial
because of a benefit for new treatment than
because of harm. 
Further, it has been argued that masking
undermines the value of the DMC discussion
because much is conditional on knowing the
allocation. This causes too many ‘what if ’
situations, and complicates the conduct of further
analyses to examine the stability of any result.72
Finally, it has been pointed out29 that it is difficult
to imagine that masking could improve patient
safety. Thus, unblinded data are more commonly
presented to the DMC. Whichever approach is
adopted, the options are best discussed with the
DMC at its first meeting.
Should information be available before
the meeting or only during the
meeting?
Most authors generally agree that DMC members
need some time to consider the information in a
report46 and thus should receive a report at least 
2 weeks before the meeting.70 A secure and
expedited delivery system should be used.31
Should external evidence be included
and how?
There is general agreement that external evidence
should be considered by the DMC.83 It has been
argued that this would be best done in the form of
a systematic review (which may or may not include
a meta-analysis),83 with considerable emphasis on
the need for following the principles of a good
systematic review. This can be a major
undertaking; it is unrealistic to expect the DMC
members to perform this review. The trial team is
likely to be best placed to collect and summarise
this external data for the DMC. Whether the trial
data and external evidence should be formally
combined in some manner depends on many
issues, including the similarity of the trials being
included. Most of the issues are similar to those
faced in any systematic review. The added
difficulty with preliminary data from the ongoing
trials is that it is not clear what point and interval
estimates of effect should be included. As
indicated in the statistics section (see Appendix 1),
for a trial that has stopped early these estimates of
effect are more likely to be overestimates, or
underestimates, depending on the reason for
stopping. It has been suggested that Bayesian
methods may be a solution to this problem.84
Nevertheless, it has been argued that formal
combination of the accumulating results from the
trial and external evidence should not be done, or
done with considerable caution83 (Case Study 2).
Are there specific issues related to type
of outcome?
In some trials outcome measures are reviewed (or
confirmed) independently (often blind to the
treatment assignment) to ensure that they are
assessed objectively and systematically. This may
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assessments and ‘clean’ (confirmed) assessments.
Pocock and Furberg54 noted that: 
“All available data should be included in the interim
report for the [DMC], regardless of what has been
adjudicated to date. This is a fundamental
requirement. The ‘clean’ data should be shown
separately, but possible decisions should inevitably be
based on the totality of information available, whereas
the reduced reliability of unadjudicated events is also
taken into account. When the amount of unclean data
is large, the situation is especially complex. One
successful approach to such a case involves evaluating
the relationship between the unadjudicated, or
unclean, data and the final data for the patients for
whom both types are available. This relationship may
then be used to predict the results that would have
been found had all the data been clean at the time of
presentation.”
Slow reporting and validation of data in a trial
may mean that interim analyses are based on old
data, inhibiting the DMC from performing their
role effectively. A partial solution suggested by
Bolland and Whitehead56 is for data relevant to
formal safety monitoring procedure to be collected
separately from baseline and other trial data,
which may speed the whole process for these data
elements.
Should there be interaction with other
DMCs?
Interaction between DMCs that are monitoring
similar trials is generally regarded as useful, in
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CASE STUDY 2 Impact of external data together with interim data, leading to early stopping for harm
Trial
CARET (Beta-Carotene and Retinol Efficacy Trial).85,86 This was a US-based National Cancer Institute (NCI)-sponsored
double-blind, placebo-controlled, randomised trial for patients who were at risk of lung cancer owing to previous asbestos
exposure or smoking. Patients were randomised between  -carotene plus vitamin A and placebo. The primary outcome
measure was the incidence of lung cancer. The trial was powered to detect a 22% reduction or a 24% increase in the
primary outcome measure with 110,000 person-years of follow-up (approximately 18,000 subjects required). Pilot studies
were run between 1983 and 1988, and the main trial recruited between 1988 and 1995. Overall, 18,314 patients were
accrued. A similar trial, the ATBC (alpha-tocopherol and beta-carotene) Cancer Prevention Trial,87 was run concurrently.
DMC role
The DMC (known as the independent safety and end-points monitoring committee) consisted of five named members with
unspecified positions. Their remit was to review accruing data. “The prespecified monitoring policy for stopping the trial …
was based on O’Brien & Fleming boundaries …” of   = 0.0006 for the first interim analysis and   = 0.007 for the second
interim analysis.
Data
Initially, the data was shown in a blinded fashion, although this was later stopped by the DMC: “When the results of the
ATBC Cancer Prevention Trial became available, the committee reviewed the results of the first interim analysis and
requested that the blinding [of the CARET trial] be ended.” At the second interim analysis (December 1995), 2420 end-
point events had been reported (1446 cancers, 974 deaths). The cumulative incidence of lung cancer was higher in the
active treatment arm than the placebo arm; relative risk = 1.28 (95% CI 1.05 to 1.57, p = 0.02).
Considerations
“The 2nd interim analysis led [the] safety and endpoints monitoring committee and steering committee to recognise the
extremely limited prospect of a favourable overall effect, as well as the possibility of true adverse effects. The decision to
stop the intervention was made by the steering committee on January 11, 1996. It is possible that the excess mortality in
the active-treatment group may have vanished or become statistically insignificant with completion of the intended
intervention period plus several years of follow-up; such reversals of findings have occurred both in the course of a single
large randomised trial and in subsequent randomised trials of the same agent or class of agents. However, it was impossible
to ignore the results of the ATBC Cancer Prevention Study in deciding whether to stop the active-intervention phase.” The
ATBC trial, a prevention study with nearly 30,000 patients, had unexpectedly shown an increase in tumours at several major
sites.
Consequences
The trial was stopped early by the steering committee. There were no systemic toxicities, due in a large part to external
data. A further trial of vitamin A alone was discussed, but it was considered impractical.
Comments
It was a mix of trial data and external data that led to this trial stopping. The format in which the external data were
presented or incorporated is not clear.principle.27,88 However, the practicalities of such
interaction, including timing of reports, meetings
and relevant information is difficult.88 Perhaps
more importantly, this sharing erodes the
independence of each trial, and thus prevents
‘independent confirmation’ of results; such
independence is an important, basic tenet of the
scientific method.83 Other difficulties are that
interaction between the DMC, those preparing the
report and the trial investigators is important in
making any major decisions and this would be
difficult or impossible in a model where DMCs are
sharing confidential data.88 In the absence of such
interaction it is entirely possible that one DMC
may misinterpret or overinterpret a written
report.88 A closely allied difficulty is that it is not
clear what should happen if the DMCs disagree,
especially if the DMCs are representing different
communities (e.g. the trials are in different
countries). It is likely that it would be difficult to
include the trial investigators in any decisions
made. As a consequence, sharing of data is rarely
done in practice. For similar reasons, it is
generally not recommended that the same
individual serves on two parallel DMCs of two
independent similar trials88 (see question 7).
There are some suggestions (e.g. Yusuf11) that
safety data, especially those data relating to
unexpected SAEs, are appropriate exceptions to
the generally held beliefs. The situation may be
slightly different, again, if one or more of the
trials has closed, but is not yet published. These
data may be easier to make available to the DMCs
of other ongoing trials.88
Should trial investigators be available
to the DMC?
It is very useful to have some of the investigators
(including the PI) at the open session of the DMC
meeting in some form45 (see question 8). This
allows both the DMC and trial investigators to ask
questions of each other, which can lead to a very
useful interaction.
Baseline comparability
There is general agreement that the DMC should
establish that any observed differences in
outcomes are not due to imbalances in patient
characteristics before recommending termination
of a clinical trial because of efficacy, futility or
toxicity.80,89 As the DMC will often be considering
a relatively small amount of data, imbalances may
be more likely than in large trials that have
achieved their accrual target. It is, therefore,
important that in such situations analyses are
performed adjusting for possible imbalances. The
adjusted analyses to be performed should be
prespecified in the statistical analysis plan.
Question 12: Who should own the
interim data and analyses?
Little has been written in the published literature
used in this review on ownership of interim
analyses (13 related quotes were identified in ten
of the sources). There are discussions beyond the
scope of this report as to who owns the trial data
overall. Indeed, it has been written that
“pharmaceutical companies and some other
sponsors of clinical research tend to think that
because they have paid for a piece of work they
own the data and are entitled to decide what
should be published and in what form. This view
ignores the rights of the participants in the study,
the investigators and the organisations or
institutions in which the work has been done”.90
It may be fair to assume that whoever owns the
overall dataset (whoever that may be, in reality)
and therefore the interim data, owns the interim
analyses. However, it is accepted, in principle, that
it is the DMC that is responsible for the
interpretation of the interim data and for
providing guidance based upon these data.
Therefore, some may argue that it is the DMC’s
position to decide and guide on (see question 14
on whether the DMC should be advisory or
executive) who else should see the interim results.
There is some suggestion that the choice as to
whether interim analyses are released to a trial
committee for the purposes of planning a new
trial should be made by the DMC.45 Furthermore,
these authors encourage sharing only if the trial is
closed to new accrual and all patients have
completed protocol therapy.
Contrary to this, in many cases the DMC are not
allowed to keep the reports beyond the timeframe
of the DMC meeting31,70 (see question 8): if they
are not sufficiently in control of the data to keep it
beyond the meeting, how can they be best placed to
make conclusions on who else should see the data?
This responsibility may then fall to the steering
committee, if such an independent body exists,
which would pass judgement without ever being
made privy to the interim results. Similarly, “the
responsibility for publishing findings is considered
to belong to the study sponsor, the study’s
Executive Committee or publication committee,
and the principal investigators”.41 Therefore, the
responsibility as to where interim data should go
may not fall under the remit of the DMC.
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the release of unblinded comparative data on
primary end-points from trials involving
unlicensed products, it may be the FDA (or
appropriate national equivalent) that assumes
responsibility at the interim data stage.91
Question 11 deals further with the incorporation
of data from more than one trial. A meta-analysis
may be the more efficient way to combine such
information, but the practicalities are likely to
prove difficult.88
Question 13: Should non-
comparative analyses (which are
‘administrative’ and not separated
by treatment arm) be carried out?
Little discussion of this topic has been revealed in
the articles identified for this review. There is some
debate about the actual nature of ‘administrative’
analyses. The most widely accepted definition of
such analyses would be the evaluation of “factors
that could affect the integrity of the trial but that
can be assessed without revealing relative efficacy
[or safety] results”.39 However, the purposes of the
administrative analysis may be wider than this and
beyond the immediacy of the trial per se (e.g.
planning for future trials).
There are four main ways in the literature in which
the data could be presented without comparing
primary outcomes:
  control arm data only
  active arm data only
  pooled overall trial data
  data by trial arm on non-outcome variables only
(including baseline characteristics).
The ‘control arm only’ form may be considered for
a number of reasons. By viewing ‘control arm only’
data, it is possible to check whether the accruing
data are broadly in line with the anticipated data
with regard to event rates or proportions of event-
free subjects at a given time. The initial sample
size calculation should have been designed based
on historical (trial or non-trial) data on similar
patients receiving the control arm treatment.
Administrative interim analyses of this nature
allow one to check whether the accruing control
arm data deviate from these original assumptions;
since any deviation would affect the power and the
necessary sample size of the trial. This is
commonly accepted as permissible.45
Control arm only and active arm only data may be
used separately for planning purposes of further
drug development trials. However, these data
generally “must be interpreted cautiously due to
small sample sizes”.20 Using the interim data on
the experimental treatment to plan a new efficacy
trial may be seen as rather presumptuous, but may
be appropriate for safety trials.
As with control arm only data, pooled overall data
may be presented to the wider community (or at
least the participating clinicians) to keep interest
in the trial: such data show participants that a trial
is moving towards its goals.54 However, while they
may be easier to prepare, pooled data may be
overly interpreted by participants. For example, a
low overall event rate could be due to a less
beneficial treatment, a lower risk population than
anticipated, poor estimations of control arm data
at the planning stage or chance, but may be
interrupted as showing benefit of the intervention.
Administrative analyses may be defined as ones
that rarely concern early termination.42 During
trials with late-occurring or slow-accruing events
or slow trial accrual it is still useful to convene the
DMC since there is more to monitoring a trial
than just monitoring the accumulating outcome
data (see question 3 for further discussion of the
responsibilities of the DMC). 
One may wish to compare baseline characteristics
between treatment groups to ensure that they are
balanced. One may also check compliance with
treatment.39 A minority view is that administrative
analyses should show data by treatment (e.g.
survival curves), but not perform any formal test
(discussed by Freidlin and colleagues24).
Administrative analyses may consider other factors
than the accruing trial data:12
  cost of the trial
  accrual (e.g. if lower than anticipated)
  trial design (e.g. if faulty or obsolete)
  quality of data collection
  loss to follow-up.
This information is similar to that which may be
presented to a steering committee, should one
exist, as such matters are likely to fall under its
responsibility.
Although administrative analyses need “not affect
the type I or II errors regarding the primary
hypotheses”,39 there is a need to document that
the analyses were performed. “The need to
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resulting from interim analyses performed for
administrative reasons is as necessary as information
obtained from formal interim analyses.”20
Question 14: Is the DMC advisory
(to make recommendations) or
executive (to make decisions)?
There is general agreement among commentators,
which is also reflected in practice, that regardless
of trial context, the DMC role should be advisory
to the steering committee, lead investigators,
sponsors or sponsor’s representative: whoever
would be ultimately responsible for all aspects of
the design, conduct and reporting of the
trial.13,37,40,50 “As the trial is not organised by the
data monitoring committee, its responsibility
should be confined to recommendations to the
organisers rather than decisions.”48
A rather exceptional view that the DMC should
have more than an advisory role is expressed by
Korn and Simon: “Although the study
investigators have the primary responsibility to
suggest and make changes …, we believe that the
DMC should have a voice in any major change to
the trial design. … Although the DMC should
make the decision, the input of the study
investigators is obviously crucial.”78 One of the
arguments put forward for this view is that the
trial organisers may have a real or apparent
conflict of interest when considering a major
change in the design or conduct of the trial, such
as early termination.
Although the accepted wisdom is that the role of
the DMC is advisory, its recommendations
concerning certain types of decisions will generally
prevail (Brown92). For example, if a DMC
recommends early termination of the trial on
grounds of efficacy or safety, it would be unusual,
although not impossible, for the organisers not to
accept such a recommendation; for example, the
Alpha trial93 (see question 22).
Question 15: What decisions and
recommendations should be open
to the DMC?
This section considers the actual
recommendations that may be made by a DMC.
These may be formally agreed and presented in
the DMC charter (see question 3). Some of the
recommendations will be guided by formal
statistical analysis, which is briefly considered in
question 17 and in further detail in Appendix 1.
Possible recommendations open to the DMC will
vary according to the timing of a given meeting,
that is, whether the meeting is taking place before,
during or after the recruitment phase of the trial.
Below are described the possible recommendations
proposed as appropriate to a meeting at each of
these times.
Meetings before the trial
In view of the DMC’s role to ensure that the trial
comes to a valid conclusion, recommendations can
include:
  improving design following review of the
protocol19,31
  improving procedures for quality assurance.19
Meetings while the trial is in progress
In trials with prolonged treatment and follow-up,
meetings can be separated into three stages:24
A: while patients are still being randomised:
stopping accrual does not necessarily mean release
of data, but in practice they will often go
together.40
B: after randomisation is closed, but while
treatment is continuing
C: during the follow-up phase: where the
recommendation is for release of trial data.
Freidlin and colleagues24 emphasise that in
situations A and B potential data will be lost, and
there will be a concomitant decision whether to
recommend release of data or await further follow-
up. In situation C, and sometimes in situations A
and B, there is an opportunity for additional
analyses following further follow-up.
In each of situations A–C, three major
recommendations are open to the DMC.15,22,31
These are detailed below.
The trial should stop completely or
partially
To ensure the safety of trial participants, the DMC
may recommend the trial stop because of safety
concerns. The following reasons have been
suggested by many sources8,19,73 (Case Study 3).
  Apparent benefit of active treatment on primary
outcome: “A DMC, guided by a pre-specified
statistical monitoring plan, will be charged with
recommending early termination on the basis of
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compelling and the risk of a false positive
conclusion is low.”36
  Apparent benefit of control on primary
outcome: a particularly difficult situation arises
when the active treatment appears inferior to
the control. DeMets and colleagues34 describe
the difficulties in dealing with this “agonising
negative trend” (Case Study 4).
  Concerns with safety outcomes (primary or
secondary): monitoring adverse events is usually
not based on a formal statistical procedure, and
is particularly important when the events may
arise from the disease being treated rather than
from the treatment itself; in this case, precise
attribution of cause is difficult and monitoring
must necessarily involve unblinded
comparisons.36,41
Further reasons for stopping arise primarily for
reasons of efficacy rather than safety, although it
could be considered that continuing a trial for no
good reason was itself an unethical, if not an
actively unsafe, activity. Reasons can include the
following.
  Small chance of eventually showing benefit:
“‘Futility’ is the term used to describe the result
in a superiority trial when there is no longer a
reasonable chance that the null hypothesis can
be disproved.”8
  Convincing evidence of equivalence or non-
inferiority, in a trial with this objective: in this
situation the objective of the trial has been
achieved and, although no harm may come to
participants in continuing, it may be considered
inappropriate to expend resources and subject
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CASE STUDY 3 Early stopping for efficacy in a prognostically stratified protocol for leukaemia with no DMC credited
Trial
CLL 80:94 this was a Phase III RCT in chronic lymphocytic leukaemia (CLL) conducted in France and sponsored by Société
Francaise d’Hématologie. Four treatment arms were compared using a risk-stratified approach to treatment, i.e. each
patient was randomised between two treatments, but specifically which two treatments depended on their prognostic
score: 
  comparison X: a watching policy versus one cycle of chlorambucil
  comparison Y: one cycle of chlorambucil versus 12 cycles of COP (vincristine, prednisolone and cyclophosphamide)
  comparison Z: 12 cycles of COP versus 12 cycles of CHOP (COP + adriamycin). 
Between May 1982 and May 1985 the trial recruited 850 patients to a 985 patient target (which was to include 282 patients
in comparison Y and 89 patients in comparison Z). The primary end-point was overall survival.
DMC role
No DMC is named or credited in the paper. However, the trial followed a group sequential design (DeMets and Ware)95
with five interim analyses of   = 0.017.
Data
Trial accrual was quicker than anticipated. In the first year, 180 patients were recruited, whereas only 100 had been
expected. Therefore, the sample size was revised upwards to 1170 and the first interim analysis was deferred until the
original sample size had been met. Interim analyses appeared to have only included patients randomised 9 months before
the interim analysis data (reference date).
Meeting Time Comparison X Comparison Y Comparison Z
First analysis Feb. 1985 (ref. May 1984) n = 445,  2 = 0.58 n = 219,  2 = 0.92 n = 58,  2 = 9.56
Second analysis Sept. 1985 (ref. Jan. 1984) n = 453,  2 = 0.86 n = 223,  2 = 0.11 n = 59,  2 = 9.14
Considerations
At the meeting in February 1985, the interim results of comparison Z were considered conclusive and the comparison was
closed. All patients in comparison Z were then to be given CHOP . Based on this information, a new trial was designed for all
patient groups, a date was set for the second interim analysis (January 1986) and the trial was closed to patient entry in May
1985 (n = 985).
Consequences
The trial closed early, clinical practice was changed and a new trial of CHOP was initiated for comparison Y patients.
Comments
The entire trial closed to recruitment early following the results of the interim analyses of one of the three trial
comparisons. There is no mention of either a DMC or who took responsibility for trial closure.patients to the uncertainty of an experiment. A
superiority trial may also conclude
‘equivalence’, but generally one would expect
the issue of futility to have already been
addressed (Case Study 5).
  Lack of feasibility of trial coming to a sound
conclusion: this could be due, for example, to
quality considerations of the trial, lack of trial
support, slow recruitment, drug supply
problems (e.g. drug supplies run out).
Termination of the trial for these practical
issues is an important possible decision of the
DMC.8,13,71,80
The DMC may also recommend that only a part of
the trial should be stopped for the following
reasons.
  Stopping randomisation in a subgroup for one
of the reasons given above: particular care must
be taken over the multiple testing of hypothesis
in many subsets, and the resulting possibility of
a type I error.
  Stopping randomisation in one arm of the trial
for one of the reasons given above: this may be
particularly appropriate in factorial designs73
(Case Study 6), but again statistical issues of
multiple comparisons need to be carefully
addressed. 
All these decisions may not be based solely on the
trial data:
  External evidence convincing: strong evidence
from other trials may lead to termination in
spite of equivocal results from the trial itself.
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CASE STUDY 4 Independent DMC stopping recruitment leading to early reporting of trial due to harm
Trial
MRC LU16:96 this was a randomised controlled trial of chemotherapy for small cell lung cancer (SCLC) requiring palliation.
The trial treatments were four cycles of either (a) a standard intravenous (IV) regimens (etoposide + vincristine or
cyclophosphamide + doxorubicin + vincristine) or (b) oral etoposide (50 mg, twice daily for 10 days). The trial was UK
based and sponsored by the UK MRC with support from Bristol-Myers-Squibb. The primary outcome was the palliation of
major symptoms 3 months after randomisation. “In this trial, equivalence in the primary endpoint between treatment
groups was considered acceptable, provided that it was achieved without increased risk of toxicity of a clinically important
survival penalty, because oral etoposide is so much easier to administer than IV chemotherapy.” Between September 1992
and September 1995 the trial recruited 339 patients towards a target of 450 patients.
DMC role
The DMC (known as the data monitoring committee) was planned to review the trial’s progress. No details on DMC
membership are given in the publication. The DMC had no formal rules for stopping the trial.
Data
The published paper96 focuses on the data shown to DMC:
Data Oral etoposide Standard IV
Tumour response  Complete response 12/119 (10%) 24/133 (18%)
(first 3 months) Partial response 43/119 (34%) 44/133 (33%)
Survival Deaths 111/171 (65%) 95/168 (56%)
Median survival 130 days 183 days
Hazard ratio 1.35 (95% CI 1.03 to 1.79)
Alive at 6 months 35% 49%
Alive at 1 year 11% 13%
Considerations
The DMC “recommended that intake be stopped, because the interim analysis showed that although the palliative effects of
treatment were similar in the treatment groups, there was increased haematological toxicity and significantly worse survival
in the oral etoposide group”. They also recommended “publication of the interim findings because of the widespread use of
single-drug oral etoposide in the treatment of SCLC”.
Consequences
“Intake was closed in September, 1995, as soon as the DMC recommendation had been received” and the interim results
were submitted for publication soon after wards.
Comments
Based on the interim analyses the DMC recommended action to prevent further harm to patients both within and outside
the trial.In all decisions to stop, the DMC will generally be
expected to make recommendations concerning
the release or reporting of the data. It has been
emphasised that the potential impact of
publication should be taken into account.31,88
The trial should continue with
modifications
As described in question 3, the DMC’s duties can
include monitoring data quality, accrual, protocol
compliance, patient evaluability and
representativeness of trial to target
population.11,13,15,19,37 This can involve a
substantial administrative responsibility.11 To
improve the quality of the trial and the safety of
participants the DMC may make a wide range of
recommendations,19 which may include one or
more of the following.
  Protocol changes: this could involve
adjustments in treatments, changing eligibility
criteria, and so on, to improve the quality of the
trial.73
  Terminate a particular clinic/centre: this will
generally be due to suspected quality problems
or low recruitment.11
  Increased surveillance of specific adverse
events: this would arise if suspicion arises that a
certain type of adverse event is not being
adequately detected.9,13,22
  Additional interim analyses: if the interim data
are suggestive of a trend, the DMC may
recommend additional meetings and analyses.
However, Matthews98 points out that this can
cause problems with certain types of statistical
stopping procedures that are based around
analyses at fixed points.
  Extending recruitment or follow-up time: 
a recommendation for ‘late continuation’ may
arise through initial underestimation of the
necessary sample size, or “for any sensible
reason other than the results observed so
far”.73,78 However, some, for example
Whitehead,51 have claimed that since a sample
size review does not involve treatment
comparison it “does not relate to the activities
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CASE STUDY 5 Early stopping in an equivalence trial based on a secondary outcome measure
Trial
This trial was a randomised comparison of pumactant and poractant alfa for treatment of respiratory distress syndrome in
neonates born at 25–29 weeks of gestation.97 The trial was UK based and funded/sponsored by Britannia Pharmaceuticals,
Serono Laboratories (UK) Ltd, the Community Foundation, Tiny Lives Fund and the Liverpool Newborn appeal. Between
May 1998 and December 1999, 207 patients (target 482 patients) were randomised between two UK standard surfactant
treatments: (a) pumactant, a synthetic surfactant, and (b) poractant alfa, a porcine-derived surfactant. The primary outcome
measure was the cost consequences of treatment based on the number of days spent in high-dependency care.
DMC role
The DMC (known as the data safety and monitoring committee) was to “meet after about half of the neonates had been
recruited”. No details are given about the membership of the DMC. There were “no formal rules for stopping the trial
because the decision would depend on outcomes relating to safety and deaths, as well as clinical efficacy”.
Data
The DMC met in December 1999. “The committee, unaware of treatment assignment, noted an unexpected and highly
significant difference in predischarge mortality that was not explained by differences in gestational age or sex ….”
Outcome measure Poractant alfa Pumactant OR (95%CI) p-Value
Neonatal mortality 11/99 (11%) 25/100 (25%) 0.38 (0.17 to 0.81) 0.011
Predischarge mortality 14/99 (14%) 31/100 (31%) 0.37 (0.18 to 0.74) 0.004
OR, odds ratio.
Consideration
The DMC, which was blinded to the treatment allocation, “recommended that the trial be stopped” based on the
secondary outcome measure.
Consequence
Following the DMC recommendation, “the trial coordinators stopped recruitment”.
Comment
Based on a secondary outcome measure, the DMC acted to prevent further patients receiving an inferior treatment.of the [DMC]”. Ellenberg and colleagues19
suggest pre-establishing a criterion for
triggering sample size revision that is not based
on comparative data.
  Amendment of the alternative hypothesis due
to high accrual rates: Korn and Simon78 suggest
that changing the alternative hypothesis (e.g. to
detect more reliably a smaller difference in
efficacy) may be reasonable provided that the
new alternative is still of interest and unblinded
data will not have influenced the decision. The
trial would still have to be monitored
appropriately.
  Current and future participants should be
informed of newly identified risks: this
possibility is mentioned by the FDA’s draft
guidance.36
  Additional data analyses to be presented to
DMC: it is plausible that the DMC will require
additional information in view of indicative
data.25
The trial should continue without
modification
The DMC will often issue a short report simply
stating that the trial should continue as planned.
However, it may still be asked to make
recommendations concerning additional aspects of
the trial, which may include the following.
  Approve ancillary studies: for example, assess
the need for ancillary studies or additional
secondary questions.80
  Deal with requests for data:80 however, it has
been stated that “members should avoid any
temptation to create problems and issues which
are unimportant for the sake of being seen to
be doing something”.22
Meetings after the end of the trial
The DMC can contribute to determining when the
data may be released37,40 (Case Study 7). However,
Korn and Simon78 say that “the decision on when
the final analysis should be performed is best left
to the study investigators” (see question 23 for
consideration of the DMC’s involvement in
publications).
General recommendations from 
DMCs
DMCs are trying to deal with the triple aims of
safeguarding participant safety, preserving the
trial’s integrity and ensuring reliable results for
the wider clinical community.19 Therefore, it seems
reasonable that “the committee will feel free to
recommend any course of action that enhances the
safety and quality of the trial”.80
Question 16: How should the
decisions or recommendations be
reached within the DMC?
As discussed above, question 15 about the DMC’s
decisions and recommendations can range from
continuation of the trial as designed to early
termination. These decisions are based on the
monitoring plan and are taken after discussion of
a detailed report on the progress of the trial,
including interim analysis of available data. The
meetings should be conducted in such a way as to
facilitate effective discussion of the progress report
and any other issues raised by the investigators
and/or the sponsor.26
A useful approach adopted by many DMCs is to
divide the meeting into sessions including at least
one open and one closed session (see question 8
for the practicalities of DMC meetings). The open
session provides a forum of interaction between
the DMC and the trial leadership where issues of
concern to the investigators can be brought to
light. It is also an opportunity for the DMC
members to question the investigators about any
general issues that merit clarification. The closed
session is restricted to the DMC members and
others whom the DMC chooses to invite (e.g. the
analysis statistician).
The DMCs of some large trialist groups review
several trials during each meeting. Therefore, to
facilitate discussion, they assign two designated
members (a clinician and a statistician) as 
primary reviewers for each trial that the DMC is
monitoring.19 The primary reviewers introduce
the trial report during the closed session and 
lead the discussion of important issues raised 
by the report during both closed and open
sessions.
Process of decision-making
It has been suggested that, ideally all important
DMC decisions should be reached by consensus
rather than by majority vote.13,16 However, on
occasions, arriving at a resolution of a difficult
issue may require a vote, and so it is
recommended by some that the DMC should 
have an odd number of members.13 Some DMCs
allow the chair a casting vote to cover the
eventuality of equal votes.15 It has been
recommended that the process of decision-making
should be laid out in advance (e.g. DMC charter),
including, for example, when a DMC is quorate
for decision-making19 (see question 3 and 
Table 33).
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role of formal statistical methods
in DMCs?
It is widely accepted that because the results of
comparative analyses of efficacy and safety
outcomes based on early interim data are
inherently unstable, early termination of the trial
based on these data requires much stronger
evidence than the usual 5% significance level.
Various methods of monitoring accumulating data,
including sequential and group sequential
boundaries, have been developed. However, 
there is almost unanimous agreement among
experts that these boundaries should be
considered as guidelines for considering early
stopping, rather than as rules.34,39,71,78,101
(Case Studies 8 and 9).
Before recommending termination of a clinical
trial because of efficacy, futility or toxicity, the
DMC should establish that any observed
differences in outcomes are not due to imbalances
in patient characteristics.7 Large imbalances can
occur when small numbers of individuals have
been entered into the trial.
Further issues beyond any formal statistics that
have been identified for taking into consideration
include:
  overall balance between risk and benefit
  internal consistency of the results (for several
outcomes and within subgroups)
  external consistency with what is already 
known about the disease and the treatment in
question
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CASE STUDY 6 Partial early stopping of a factorial trial with formal monitoring of an adverse outcome measure and use of a
combined measure
Trial
Women’s Health Initiative (WHI) Clinical Trial.99,100 This is a large, double-blind, placebo-controlled trial with additional
factorial randomisations and is sponsored by the US National Institutes of Health (NIH). The trial considers postmenopausal
health with a primary outcome measure of coronary heart disease (CHD) incidence, with primary breast cancer as the
primary adverse outcome measure. Women with a previous history of hysterectomy were randomised between oestrogen
and placebo; and women with no history of hysterectomy were randomised between oestrogen plus progestin and placebo.
Additional factorial randomisations of diet-control versus no intervention (for women aged 50–79 years only) and
calcium+vitamin D versus no intervention were also included. From 1993 onwards the trial recruited over 16,600 women
towards a 27,500 target (recruitment to the trial was ongoing at time of this report in 2002). 
DMC role
The DMC (known as the WHI data and safety monitoring board) was to “ensure study subjects’ safety and to make
provision for timely trial termination and reporting”. Formal monitoring began in autumn 1997 using O’Brien–Fleming
boundaries (1979). Adverse effects boundaries were “further adjusted with a Bonferroni correction for the 7 major
outcomes other than breast cancer that were specifically monitored …”. With regard to membership, the “Board includes
twelve outstanding medical researchers with expertise in aging, behavioral science, cancer, cardiology, ethics, gynecology,
nutrition, osteoporosis, statistics, and women’s health” (data from www.whi.org).
Data
Five interim analyses had been completed by late 1999 and “… the [DMC] observed small but consistent early adverse
effects in cardiovascular outcomes and in the global index. None of the disease-specific boundaries had been crossed. In the
spring of 2000 and again in the spring of 2001, at the direction of the [DMC], hormonal trial participants were given
information indicating that increases in MI [myocardial infarction], stroke, and PE/DVT [pulmonary embolism/deep vein
thrombosis] had been observed and that the trial continued because the balance of risks and benefits remained uncertain. 
“In reviewing the data for the 10th interim analyses on 31st May 2002, the [DMC] found that the adverse effects in
cardiovascular diseases persisted, although these results were still within the monitoring boundaries. However, the design-
specified weighted log-rank test statistic for breast cancer (z = –3.19) crossed the designated boundary (z = –2.32) and the
global index was supportive of a finding of overall harm.”
Considerations
“On the basis of these data [31 May 2002], the [DMC] concluded that the evidence for breast cancer harm, along with
evidence for some increase in CHD, stroke, and PE, outweighed the evidence of benefit for fractures and possible benefit
for colon cancer over the average 5.2-year follow-up period. Therefore, the [DMC] recommended early stopping of the
estrogen plus progestin component of the trial.”
Consequences
An attempt was made to develop feasible stopping rules for use on secondary outcome measures.
Comments
This is an example where the DMC recommended partial closure of a trial on the basis of harm.  the impact of early stopping, including whether
and how the results would influence clinical
practice.
Thus, the decision of early stopping is partly
subjective and is based on both statistical and non-
statistical considerations.
Another statistical method used to guide decision-
making by some DMCs involves the notion of
conditional power, that is, the likelihood, given
current interim data, that a beneficial effect of the
treatment under consideration would be detected
if the trial were to continue as planned. However,
the wisdom of stopping a trial based on futility
(low conditional power) is open to debate.55
Although some extreme views question the 
wisdom of making public any stopping boundaries
at the outset of the trial,55 it is generally agreed
that specification and publication of guidelines 
for early termination provide a necessary
framework from which the DMC can make
informed decisions. (Further discussion of the
statistical issues relating to DMCs is presented in
Appendix 1.)
Question 18: Should specific trial
designs influence the proceedings?
Different trial designs will have an effect on the
statistical monitoring procedure and the range of
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CASE STUDY 7 Early reporting of a trial showing benefit after accrual was completed
Trial
BHAT (Beta-blocker Heart Attack Trial): 102 This was a four-arm, double-blind, placebo-controlled trial conducted in the
USA and sponsored by the National Heart, Lung and Blood Institute. The trial compared a  -blocker, propanolol, with
placebo in patients with previous MI. The primary outcome measure was survival. Between June 1978 and October 1980
the trial recruited 3837 patients towards an unspecified target, with follow-up due until a common date of June 1982.
DMC role
The DMC (known as the [independent] policy and data monitoring board) received trial results semi-annually “during [the]
trial for evidence of potential harm or early benefit of propanolol with the aim of terminating the study if the data so
warranted”. The DMC had 14 members comprised of physicians, biostatisticians and an ethicist, of whom seven were full
voting members.
Data
The DMC reviewed data during and after the accrual period. 
Timing Normalised log-rank statistic (mortality)
May 1979 1.68
October 1979 2.24
March 1980 2.37
October 1980 2.30
April 1981 2.34
October 1981 2.82a
a O’Brien and Fleming boundary would have been crossed here.
Considerations
At the October 1981 review the mortality was 9.5% (183 deaths) in the placebo group, and 7% (135) in the propanolol
group, which would have met the stopping rule. “After a thorough evaluation of the issues … the Board recommended that
the BHAT be terminated and the results disseminated promptly.”
Consequences
The trial was terminated 9 months early because “(1) the two groups were considered comparable; (2) the patients
complied reasonably well with the protocol; (3) no unanticipated side effects were observed; (4) the observed treatment
benefit was judged significant and likely to remain so during the 9 months remaining in the trial; (5) little additional
information would be gained from continued follow-up; (6) results were consistent over subgroups and by cause-specific
mortality”. 
Comments
“… the BHAT results were statistically ‘significant,’ and not likely to change during an additional 9 months of follow-up …”.
The results were “quite consistent with those of two other recently reported large-scale clinical trials …”. Therefore, the
DMC allowed the trials results to be disseminated earlier than expected.options open to the DMC. Some specific examples
cited in the literature are listed below:
  New treatment versus established treatment or
placebo: it has been suggested that “Asymmetric
boundaries should be used, because one is only
interested in establishing superiority of the
experimental arm”,24 leading to “less stringent
statistical criteria for negative trends”.34
  One treatment is more “toxic, invasive,
protracted, or much more expensive”: again, it
is argued that asymmetric boundaries may be
more appropriate.24
  Outcome measures: care must be taken over
early stopping owing to the doubts about 
non-proportionality of hazard rates of the
outcome measures with increased data: “early
experience with little follow-up may not be
reflective of the complete survival curves”.24
Examples provided by Ellenberg and
colleagues19 show that the focus of attention
may depend on context: sometimes the 
interest is in short-term outcomes, such as 
after a myocardial infarction, and sometimes 
in long-term outcomes, such as in arthritis
studies.19
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CASE STUDY 8 DMC recommended continuation, aided by a stopping boundary; results changed over time
Trial
CPCRA ddI/ddC trial:103 This RCT was sponsored by Terry Beirn Community Programs for Clinical Research on AIDS
(CPCRA). It was a US-based RCT of dideoxyinosine (ddI) and dideoxycytidine (ddC) in AIDS patients who were intolerant
to, or had failed, zidovudine. Neither treatment could be considered as standard. It was initially designed to check for major
differences between the research arms. However, one of the treatments (ddI) was changed to being considered as the
standard treatment by the DMC after the drug received a monotherapy licence from the FDA while the trial was ongoing.
The primary outcome measure was first disease progression or death. Between December 1990 and September 1991 the
trial recruited successfully to its 467 patient target (set so as to observe 243 primary outcome events). 
DMC role
The DMC (known as the data and safety monitoring board [of the National Institute of Allergy and Infectious Diseases]) was
to monitor “… randomised clinical trials in the context of life-threatening diseases … on an ongoing basis …. If early data
provide convincing evidence of a superior efficacy/safety profile for one of the treatment, then early trial termination would
satisfy important ethical requirements and save valuable resource and time”. The DMC was to monitor the trial using Lan
and DeMets’104 implementation of O’Brien and Fleming’s guidelines.105
Data
Prg or death Death
Analysis Date ddI ddC ddI ddC RR (Prg or death)
Meeting 1  02 May 1991 Administrative meeting only, no data shown
Meeting 2  29 Aug. 1991 19 39 6 12 2.1, p = 0.009
Meeting 3  08 Nov. 1991 50 66 18 22 NA
Meeting 4  13 Feb. 1992 77 91 28 34 NA
Meeting 5  21 Aug. 1992 130 130 73 66 NA
Final results  20 Sept. 1992 157 152 100 88 0.93 (95% CI 0.74 to 1.18)
RR, relative risk; NA, not applicable.
Considerations
In each of the first four meetings the DMC recommended continuation of the trial. This was despite the interim results
presented at the second meeting. “Aided by the conservative O’Brien–Fleming guideline [0.001] and by careful consideration
of all available information, the [DMC] judged these early results to be inconclusive and recommended continuation of the
trial.” At the final meeting the DMC concluded that the trial should “end as planned on September 20, 1992, since the
planned number of events (243) has been achieved”.
Consequences
The DMC did not stop the trial in the early stages, despite the small p-value. “If the trial results from the August, 1991,
interim analysis had been broadly disseminated, it is quite likely that widespread prejudgment about the superiority of ddI
would have occurred, preventing continuation of the trial and eliminating the opportunity to obtain the much more reliable
and strikingly different assessments about the relative efficacy ….”
Comments
The guidance of DMC was beneficial to the trial in preventing a premature end to the trial due to a random high. Indeed,
eventually the trial results did not demonstrate a difference between the trial arms.  Equivalence studies: active control equivalence
Studies require particular care, as poor
compliance in such trials may lead to
misleading claims of equivalence. It is suggested
that a particularly high-quality ‘blue-ribbon’
DMC is required in this context.60 “Monitoring
for non-compliance or sloppiness is perhaps
even more important in equivalence trials than
in superiority [non-inferiority] trials.”8
  Multiple arms: this has been discussed in the
context of factorial studies73 and multiple
experimental arms that may be dropped in
turn.106
  Multiple outcomes: alternative trial designs and
consideration by the DMC of composite
measures may be appropriate.107
  Cluster RCTs: “The broad issues … also apply
generally to cluster randomised trials. Efficacy
monitoring in accordance with a predetermined
plan, however, does not seem to be a common
feature of most cluster randomisation trials.
This is at least partly because the theoretical
underpinnings of standard data-dependent
stopping plans invariably assume individual
randomisation, while methods applicable to
cluster randomisation trials have yet to be
widely adopted ….”108
Question 19: How should ethical
issues be handled in DMCs?
Ethical issues are at the heart of the DMC’s
existence and operations.41,55 However, the way in
which these issues are handled should also reflect
the perspectives of the trial investigators. “The
DMC should therefore not approach the ethical
problems solely from their own personal
perspectives, but rather should try to envisage the
attitude that the investigators would adopt if they
were fully informed about the data.”55
Unlike ethics committees (LRECs and MRECs in
the UK, or IRBs in North America), whose remit is
aimed almost exclusively towards the protection of
the interests of the trial participants (individual
ethics), DMCs also have ethical responsibilities to
future patients (collective ethics). However, most
commentators agree that the DMC’s primary
responsibility is to protect the rights and safety of
patients in the trial. “The fundamental charges to
those responsible for trial monitoring should have
the following prioritisation: a) to safeguard the
interests of the study participant; b) to preserve
the trial’s integrity and credibility; and c) to
facilitate the availability of timely as well as reliable
findings to the broader clinical community.”19
Ethical issues and interim monitoring
The degree to which individual ethics should
override considerations of collective ethics
continues to be a subject of debate. This varies
between committees and is generally reflected in
the DMC terms of reference and detailed
monitoring plans (see question 3). Various
elements of monitoring plans work in favour of
one or the other of these two ethical perspectives.
Thus, close monitoring of adverse events and
guidelines that allow stopping of the trial on less
conclusive evidence of harm than of benefit
favours individual ethics, possibly at the expense
of collective ethics. However, it is commonly
argued that a decision to stop the trial should be
taken as soon as there is sufficient evidence of a
difference in efficacy between the randomised
arms, so as to minimise the number of individuals
who would otherwise be exposed to an inferior
treatment. This can be argued in terms of either
individual or collective ethics, but conservatism in
the stopping rule would tend to favour collective
ethics.
Armitage, in Parmar109 argues that this view may
be too simplistic: 
“I don’t think it’s necessary to see this conflict
between conservatism or radicalism in stopping as an
issue of collective versus individual ethics. The
collective/individual business is whether one regards
the interest of the immediate individual patient as
paramount or whether one thinks the general
population’s interest is paramount. You can take an
individual ethics point of view and still be quite
reluctant to stop merely because a particular
difference is significant at a certain level. The reasons
for that are that there are very many aspects to a
clinical trial, rather than just the significance of one
particular outcome variable, very many outcome
variables, the future progress of the disease as well as
the immediate situation, and so on. I think it’s
entirely consistent with the individual ethics point of
view, for instance, as held by Bradford Hill, to say,
‘Let’s just hold our horses and see what’s going to
happen in the future’, before we decide what is really
in the interest of this individual patient.”
Many authors have strongly emphasised the
importance of taking into account the extent to
which a trial’s results will influence clinical
opinion.8,24,34 This is made explicit in stopping
guidelines for, say ISIS-4, which state that the trial
should only stop if there is both proof of benefit
beyond reasonable doubt and “evidence that
might reasonably be expected to influence
materially the patient management of the many
clinicians who are already aware of the results of
the other main trials”.73 Such a perspective
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duty to future patients.48 The overall view appears
to be that DMCs certainly should be fully aware of
the consequences of their deliberations and their
duty to both the participants and future patients
to ensure the trial’s conclusions are as valuable as
possible.
An extreme view that can be argued for in terms
of individual ethics is to make the results of
interim analyses publicly available to patients and
investigators. However, most authors strongly
recommend that interim findings should not be
released, since such practice may undermine the
integrity of the trial88,110 and prevent its
completion.
Relationship between DMCs and 
IRBs
In the USA, IRBs are responsible for reviewing the
trial protocol, patient information, informed
consent and trial procedures from the perspective
of safeguarding the interests of the trial
participants. During the conduct of the trial, they
receive reports of unexpected SAEs, but they do
not review unblinded interim data. “The
involvement of an IRB alone, without a DSMC
[DMC], may be sufficient in a trial that involves a
single institution, especially when a mechanism is
established for the significant involvement of a
subcommittee or a particular individual. Most
local IRBs, however, lack the expertise to monitor
multicenter trials or lack sufficient time for the
intensive work required in such cases.”13
Little is written on how IRBs relate to the DMC,
and, in practice, there is usually no direct
communication between IRBs and the DMC.
However, some IRBs regularly receive interim
DMC reports (as presented at open sessions)
through the sponsor.
Question 20: What should DMCs
do with their decisions or
recommendations?
It is generally agreed that the recommendations
or decisions should be transmitted efficiently,
accurately and responsibly to the appropriate
bodies (e.g. the sponsor, a steering committee or
the investigators).13,32
Who should the DMC report to?
Models where the DMC reports to the sponsors
and to the investigators (in the form of a
representative committee, such as an executive or
a steering committee) have both been used.32
However, if the DMC is advisory (rather than
executive) then to ensure that conflicts of interest
do not dominate, it has been suggested that the
DMC should report to the sponsor and trial
investigators simultaneously.29 In the lead-up to a
final decision there would be a discussion
including both the investigators and sponsors, or
their representatives. One model is that it is the
sponsor who takes the final decision, because the
legal obligation for safety of the participants falls
to them.11 Another is that it is a joint decision
through a formal committee containing both the
sponsor and investigators which is formed to
receive such reports.113
It has been suggested that relevant regulatory
authorities and appropriate ethics committees
should be kept informed of progress of a trial, but
that such authorities should not be involved in any
decision for early termination.8,38
Should the DMC be advisory or
executive?
Most authors propose that the DMC should be
advisory rather than executive, especially as the
trial is not organised and coordinated by the
DMC.48,73 (For further discussion, see 
question 14.)
What form should the report take?
It is generally agreed that unless there are
concerns about the conduct of the trial, a carefully
worded, brief, written statement from the DMC
chair about the importance of continuing the trial,
avoiding any indication of evolving treatment
differences, provides the best communication.31,45
This may be supplemented by oral communication
to the PI.54
If the DMC is advisory, any report recommending
a change or amendment to the trial should
contain sufficient information for the investigators
and sponsors to consider the basis for the
recommendation for themselves. In contrast, if the
DMC is executive, then the data supporting any
recommended change may best not be released.
This is because there may be advantages for the
closing stages of the trial to be conducted without
knowledge of what the outcome of the interim
analyses had been, beyond that the plan for the
trial has been changed.22
The DMC should also feel free to formally
comment on other ‘open’ aspects of the trial, such
as recruitment and data quality, in its report.
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of decisions made? If so, by whom and
how detailed?
There is almost unanimous agreement that formal
minutes of both open and closed sessions of the
DMC are important for both documenting
decisions and actions, and also for documenting
the major points in discussion, reasons for
decisions and information required for the next
meeting.70 Packer and colleagues provide a useful
checklist suggesting that any minutes should at
least follow minimal principles.32 The checklist is
adapted here.
  Who attended the meeting and was the meeting
quorate? (Note that no definitions for a quorate
DMC were found in the included articles.)
  Who knew what and when? It is important to
know, for example, whether any changes to the
trial are being recommended in light of, or
blind to, the current results.
  The records should include copies of all analyses
that have been used to support the committee’s
decisions; and also include all material reviewed
by the DMC. In particular, clear documentation
of the events leading to a recommendation by
the DMC may be critical to the acceptance of
the recommendations.
  A general sense of the DMC’s discussions, along
with careful discussion of its decisions, should be
documented. There should be limited attribution
of statements to specific individuals, but if a DMC
member has a specific expertise or a unique view
the minutes should reflect this contribution.
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CASE STUDY 9 DMC not following guidance of a stopping rule
Trial
This was an RCT in pressure sore prevention111 sponsored by Northern & Yorkshire Regional Research Committee. The
trial, run in the UK, followed a double triangular sequential design.112 Between 1994 and 1996 patients hospitalised for
surgery were randomised between a standard mattress and a gel bed during their operation. The trial recruited 446
patients. No recruitment target was reported, owing to the sequential design, but it is stated that a fixed sample size design
would have required 1085 patients.
DMC role
The DMC (known as the data monitoring committee) was “to oversee the monitoring of the trial”. The analyses were
planned at approximately 200 patients then every 100 patients (at 6 months, then 3 monthly). The DMC was comprised of
“a statistician, a representative of the NHS purchasing organisation who was also a member of the funding committee, and a
nurse researcher”. The member of the funding committee was present because the funding committee was uneasy about
the flexible nature of the sample size.
Data
The data shown to the DMC was as follows:
Analysis Date Accrual Variance Z-value Comment
Interim analysis 1 27 June 1995 181 6.6 7.6 Outside boundary
Interim analysis 2 22 Jan. 1996 293 8.1 6.7 Inside boundary
Interim analysis 3 30 May 1996 399 11.6 9.9 Outside boundary
Final analysis 05 June 1996 446 12.9 10.2 Outside boundary
Considerations
At the first interim analyses the DMC recommended continuation of the trial despite the statistic being outside the stopping
boundary. “Contrary to initial beliefs of the trial investigators and the data monitoring committee when designing the study,
members felt there was an overwhelming need for a larger definitive trial …” plus there were additional concerns over the
end-point’s subjectivity and differences in pressure sore rate between participating centres.
Indeed, by the second interim analysis the sore rate had dropped and the statistic was back inside the boundary.
Continuation was recommended. By the third interim analysis there was judged to be a sufficiently large number of patients.
“The DMC decided that patient randomisation should be suspended and the data for all patients should be analysed.” 
Consequences
The trial was therefore stopped after 446 patients had been randomised when the result was judged to be clear. The final
results were consistent with this interim result.
Comments
The DMC guided the trial past the stopping rule to enable the trial to become sufficiently large to be more convincing to
the clinical community. In addition, the sequential design was shown to be practicable.  The DMC should make the minutes of any
open session available to the trial leadership as
soon as possible, whereas the minutes from the
closed session should be kept archived until the
end of the trial.
It should be remembered that any documents
prepared for or by the DMC may be scrutinised
subsequently by relevant interested parties.
The drafting of any minutes can involve a
considerable amount of work, and the individual(s)
appointed for this task should be identified at the
time the DMC is formed. To ensure that a single
individual is not overburdened, it is helpful if the
minute-drafters are not heavily involved in the
detailed deliberations of the DMC, and thus it has
been suggested that members of the statistical
coordinating centre fulfil this role, with the
members of the DMC commenting on and signing
off the minutes of the meeting.70 However, if the
statistical coordinating centre is not party to all
discussions, for example closed/executive sessions,
then other models will have to be adopted,
perhaps with a member of the statistical centre
minuting those sections of the meeting that they
attend (see question 8) and a member of the DMC
(such as the chair or an appointed executive
secretary) being responsible for the minutes of the
other sessions. This may be a considerable burden
for these individuals, and thought should be given
as to whether it is feasible; it may be appropriate
to provide some support for this activity.54
Sometimes it may be feasible to tape meetings,54
although it is not easy to access these records if
needed later.
Whichever model is adopted, it is important that
the approach to minute-taking and individuals
involved should be specified at the start of the
trial. Further, all individuals involved should know
and agree with the role set out for them.
Question 21: What should be
done in ‘difficult’ situations?
Although the DMC will have a set of regular
prespecified meetings, there needs to be an option
for the DMC to meet at relatively short notice, for
example if information emerges from other
trials.16 Those outside the DMC can review
external information as well as the DMC, but only
the DMC can assess the external information in
the light of the information from the trial. In
these situations the DMC may need to provide
more detailed comments on the issues raised.88
There may sometimes be considerable external
pressure on a DMC, usually to stop a trial. One
may envisage occasions in which a sponsor may
pressure DMC members to reveal interim results.
In these and similar situations, an independent
DMC is important. Hampton47 insists that, in
connection with drug company sponsorship, the
DMC should be comprised of “strong individuals
who insist on meeting regularly and who will not
bow to company pressures”. He goes on to state
that “only a strong [DMC] can protect [the
sponsor from stock market forces] by allowing
them honestly to claim that they do not know trial
results”.
It has been suggested that information regarding
the DMC members should remain confidential
during the trial.52 Although this may be helpful
when there is external pressure, this approach may
be counterproductive in most circumstances. Also,
in many cases, it is the sponsor that nominates
DMC members (see question 6) and this approach
would have to be reconsidered if the DMC
members were to be unknown to the sponsor.
Subtle pressures from sponsors during meetings
can be relieved by the use of closed sessions (see
question 8).
Pressure may also arise from the media. For
example, Packer and colleagues32 describe 
“a particularly troublesome example, [where]
members of the press frequented the venue of
[DMC] meetings of the Global Utilisation of
Streptokinase and Tissue Plasminogen Activator
for Occluded Coronary Arteries (GUSTO-1)
trial114 in an attempt to acquire some preview of
the results of the study”. The sensationalism
surrounding the trial led to DMC members and
their families being at risk of harassment and
intrusive public scrutiny. Conflict may arise with
the steering committee on occasion if a DMC
recommendation is not followed. Further details of
such circumstances are given in question 22.
Indeed, circumstances can be made more difficult
if disagreements are made public. For example,
Packer and colleagues32 describe the Platelet
Receptor Inhibition for Ischemic Syndrome
Management in Patients Limited to Very Unstable
Signs and Symptoms (PRISM-PLUS) trial.115 The
DMC recommended stopping one of the three
study arms when it observed a high relative risk of
death among individuals in one of the treated
groups. Despite agreement from the sponsor, the
PI disagreed and publicly expressed the opinion
that the arm in question had been stopped
inappropriately.
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decisions be considered to be
‘errors’?
“If a trial is erroneously stopped early, the
reputation of a promising new treatment may
forever be tarnished. If a premature claim of
treatment superiority is not subsequently accepted
as convincing, then another trial may be required.
Even worse, no further trials may be done, leaving
a potentially valuable treatment in limbo.
However, a [DMC] cannot wait until trends
become so convincing that no-one would ever
challenge them.”34 It is clear that decisions are
generally difficult to make and there are rarely
second chances to make or even reverse a
decision. It is further recognised that “less
experienced [DMC]s may sometimes overreact to
favourable as well as unfavourable data trends”.54
“Legitimate differences of opinion can and often
do occur regarding the interpretation of trial data
[amongst DMC members], and the criteria that
should be used to approve, alter, or terminate a
study sometimes require considerable
discussion.”13 But differences of opinion need not
be problematic providing there is adequate group
discussion and that the DMC reaches a considered
conclusion.
It is difficult to judge whether DMCs have made
good or poor decisions, since these decisions are,
by their nature, subjective. Determining whether a
DMC’s recommendation was erroneous may be
possible in hindsight in some situations by
comparing later (final, published) data with the
data presented to the DMC. For example, the
Physician’s Health Study116 was stopped by the
DMC with a relative risk reduction for myocardial
infarction of 45%. The final, clean data
demonstrated a 30% relative risk reduction; this is
still a substantial improvement, but not quite of
the same magnitude.
The DMC may be considered to have made an
erroneous recommendation if, as a result:12,34,89
  the trial is stopped early for a benefit which
subsequently disappears
  the trial is stopped early for a benefit which
subsequently diminishes so that the results are
not sufficiently compelling to the regulatory 
or licensing bodies or to the clinical 
community
  the trial continues in an attempt to demonstrate
a potential benefit despite a serious toxicity
trend; if the benefit does not materialise,
further patients would have been exposed to a
serious risk of harm.
Yusuf11 suggested systematic documentation of
every controversial decision, and suggests that
when there are difficulties, all the criteria for the
decisions, together with the names of the
members of the DMC, should be published.
However, such an approach may be
counterproductive in the long term, as it may
deter individuals from joining DMCs.
DMCs generally make recommendations rather
than decisions (see question 14). In these
circumstances, the body to which the DMC reports
(see question 20) would make decisions based on
the DMC recommendations. It is theoretically
possible then that erroneous decisions may be
made by the decision-making body despite non-
erroneous recommendations from the DMC. But
are DMC recommendations ever overruled? 
Not very often, it would seem (although see 
Case Study 10 for an example). George43 reported
a survey of North American cooperative trials
groups and only one of 11 responding groups
knew of any trial where a DMC’s decision to
terminate or modify a trial had been overruled.
The DMC is usually in a unique position with
regard to data: anyone who challenges their
recommendations would, at least initially, have to
do so without being privy to the interim data.
Indeed, if the trial steering committee (TSC) or
sponsor disagrees with the committee then “In the
absence of ethical issues the sponsor might freely
override a [DMC] decision for early
termination”.52 Where the investigators do not
choose to follow the course of action suggested by
the DMC it can lead to a great deal of friction,
and sometimes the resignation of DMC
members.19,80 It has been suggested that “a [DMC]
charter should contain an ‘escalation clause’ for
resolving differences of opinion”.32
If the TSC, sponsor or coordinators were seriously
concerned about a recommendation of the DMC
they could instead “convene another
committee”.119 For example, Packer and
colleagues32 suggest that “an ad-hoc Executive
Committee with an odd number of participants
should be charged with resolving the dispute. In
recent industry-sponsored trials, the Executive
Committee has consisted of two sponsor
representatives, two Steering Committee
representatives, and an independent third party
agreed by both groups”. Such independent
resolution is helpful and can prevent conflicts
escalating. A more general approach for
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for the DMC to routinely report to a committee
with a degree of independence (see question 7). In
practice such independent resolution has
produced conclusions both supporting and
contradicting the original DMC position.
According to some commentators DMC
recommendations are less likely to be interpreted
as contentious (and, therefore, less likely to be
overruled) if some of the trial staff are present at
the meeting. This way the “advice or
recommendation takes into account the concerns
of the people who have to accept the advice …”.
This is a “consensus building process rather than a
totally independent decision”.120 This consensus
decreases tension between groups and allows them
to reach the best possible decision. “It may be that
completion of data collection reveals that the
stopping criteria had not been reached.
Sometimes, re-opening the trial may be an option.
More usually it will be too late.”22
Practically, the sponsor may be less likely to overturn
a recommendation to stop the trial rather than
one to continue: a recommendation of continuation
is subject to further administrative considerations
by the steering committee or sponsor; for
example, if the DMC recommends continuation
based on clinical data, the sponsor may choose to
stop the trial because of practical issues such as
accrual rates or funding (see question 13).
The participating clinicians may also effectively
overturn a recommendation by the DMC to
continue by refusing to randomise further patients
into the trial. This is only likely if, for some
reason, unblinded interim data had been released
to the participants. This has been a more common
occurrence in the past89 (see Case Study 1).
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CASE STUDY 10 DMC’s recommendation to continue a trial overruled by the steering committee
Trial
Department of Veteran’s Affairs Cooperative Study of Steroid Therapy for Systemic Sepsis117
This was a US based, double-blind, randomised, placebo-controlled, trial that was sponsored by the Department of
Veterans Affairs. Patients with systemic sepsis were randomised between steroids and placebo. The primary outcome
measure was mortality. Between 1983 and 1986 the trial recruited 223 patients towards a 276 patient target.
DMC role
The DMC (known as the data monitoring board) was to monitor the progress of the study annually. It was formed from
“outside experts not involved in the conduct of the study”. For monitoring purposes, the DMC accepted the recommended
closed sequential plan based on Armitage.118
Data
The DMC met twice. No efficacy data were presented at the first meeting. At the second meeting in 1985 the sequential
boundary of no difference in mortality between the two treatment groups was reached for all patients. Contrasting with
this, “a 75% reduction in mortality with steroid therapy was observed in the small subgroup of 51 patients with gram-
negative bacteremia”.
Considerations
At the first meeting “71 patients had been enrolled and of these 60% had gram-negative sepsis and only 23% had gram-
negative septicemia. Therefore, the [DMC] recommended that the study be modified to assess the effect of therapy in all
patients with sepsis and in those with gram-negative infections. The [DMC] made this decision without knowledge of the
observed effect of treatment.” At the second meeting the DMC again “recommended that the trial be continued to evaluate
the emerging trend”.
Consequences
Contrary to the DMC’s recommendations the trial was halted by the responsible committee: “… at the scheduled midpoint
review of the trial by the Cooperative Studies Evaluation Committee [CSEC], the Committee opted to terminate the trial
because steroid therapy did not reduce mortality in all patients with sepsis. The CSEC also viewed the gram-negative trend
as more apparent than real because it was based on a total of only 8 deaths …”.
The DMC was not invited to the CSEC meeting at which study representatives had presented the accumulating data to the
CSEC. The DMC appealed and met with the CSEC. To prevent an escalation of the conflict between the two committees,
two anonymous independent reviewers passed verdict and agreed with the CSEC that the trial should close because the
stated objective had been met.
Comments
The DMC recommendation was overruled because the clinicians were sufficiently convinced by the data. It is unclear why
the clinicians and CSEC were reviewing trial data at this stage. Independent adjudication was used to resolve the conflict.So, who is liable for the recommendations?
According to Herson,60
“In terms of liability insurance coverage, [DMC]
members lie in a ‘no man’s land’ between the
sponsor’s liability insurance and the liability insurance
from the institutions/firms where the [DMC] members
are employed. It is doubtful that [DMC] members
could be protected by the insurance policies at their
home institutions for these extramural activities, but
sponsors are reluctant to include [DMC] members on
their policies because it could compromise the
independence of these boards. At the moment [1993],
this issue is being avoided through ‘hold harmless’
clauses in the agreements between sponsors and
[DMC] members. [DMC] members are, however, not
protected from direct lawsuits from patients and their
families. … more work must be done in this area if
pharmaceutical firms expect qualified people to serve
on their [DMC]s.”
As serving on DMCs is largely a voluntary activity,
this approach could lead to large numbers of
individuals refusing to accept invitations to sit on
DMCs. Indeed, Meier in Yusuf had disagreed on
the DMC’s liability: “It is the people who are
responsible for the trial who ultimately will make
the decision” and it is they who are legally
responsible.11
Question 23: What should the
DMC’s role be concerning
publications?
Few authors have addressed the question of the
DMC’s role concerning publication of the trial
results (32 quotes from 19 sources).
The DMC should have developed a deep
understanding of the data from several discussions
over a period of time, and will generally have had
more time to think about the results than the
investigators.54 As noted under question 3, 
a meeting at the end of the trial offers a valuable
opportunity for members of the DMC to share
their thoughts with the investigators (and/or
sponsor, as appropriate). The data may have
changed since they were last seen by the DMC,
especially if recruitment was terminated with many
enrolled patients still waiting for outcome
assessment. Such discussions would naturally focus
on the interpretation of the data and thus may
lead to some input into the development of a
manuscript for publication. However, members of
a DMC should not be co-authors of the primary
trial publications, which would conflict with their
independent status.19 Involvement of the DMC in
post-trial discussions would help to avoid the rare
situation of DMC members publicising their
disagreement with the published interpretation.54
Several authors have commented on the ethical
principle that the results of the trial should be
published whatever they are.41,54,92 Some have
suggested that ensuring publication is one role of
the DMC.54 Further, Pocock and Furberg54
suggested that as “the conscience of the trial, the
[DMC] should assume the responsibility for
publication of trial results if the trial mechanism
fails”.54 It is unclear whether and how this could
be achieved in practice. In the UK MRC model,
this role is assumed by the steering committee.59
A minority view is that the DMC should decide
when the trial results should be published,35
although in effect the DMC may make this
decision during the course of the trial if and when
they recommend that the trial stops recruiting.
Regardless of the involvement of the DMC in
developing the manuscript, a particular issue is
the way in which the activities of the DMC are
described in the publication.17 As well as
mentioning that there was a DMC (and naming
the individuals), it is desirable that the publication
includes a summary of the process of data
monitoring39 (Chapters 4 and 5 present more
detailed surveys on this issue). The DMC should
approve the wording of such text, and should have
the opportunity to ensure that their views “are not
misrepresented to the public”.54 More generally,
some authors suggest that the DMC should review
the whole manuscript,16,54 to “ensure that
publication is … unbiased and correct”.121
Subsequent literature
Important publications appeared after the formal
interactive searches had been undertaken for this
systematic review. A recent book19 on DMCs covers
a wide range of issues illustrated by numerous
examples, and in particular sets out the need for a
charter to describe the roles and responsibilities of
a DMC. An issue of Controlled Clinical Trials in
February 2003 featured a number of case studies
and commentaries on DMCs. These included a
number of ‘difficult decisions’ (see question 21).
First, where a DMC was unable to reach a decision
and an NCI committee stepped in to recommend
stopping the trial;122 second, where a DMC
wanted to continue but was overruled by a sponsor
who stopped the trial;123 and third, where there
was a large commercial impact of stopping a
trial:124 “With the benefit of hindsight, there are
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would have been better to resolve early on, such as
rules regarding absentee voting in the [DMC], to
which body the [DMC] should report officially,
which body had the power to accept or reject the
[DMC]’s recommendation, and the timing and
general content of dissemination of different kinds
of results.” With increased use of DMCs in
industry trials, it is vital that a DMC charter
should address such issues before the trial
commences. 
A final example concerns the dangers of stopping
early following an early positive finding that
eventually evaporated:125 “It is important that
[DMC]s hold their nerve and consider all aspects
thoroughly and, if they do not consider the
interim analysis provides ‘proof beyond reasonable
doubt’, then they should recommend that the trial
continue.”
Conclusions
This chapter provided a summary of the published
literature on many aspects of DMCs that serve
RCTs. The systematic review was, by nature, a
systematic collection of data pertaining to DMCs.
The a priori formulation of 23 key questions (and
associated subquestions) provided a valuable
framework around which to extract data, and
synthesise summaries of the key topics. This
methodology was useful and is recommended to
others undertaking similar reviews. The
structuring allowed information to be assimilated
on many aspects of DMCs. It demonstrated a
paucity of writing, and perhaps therefore of
thought, in many of these areas.
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Background
The decision that a DMC reaches can have major
implications for the trial participants and for
current and future patients, as well as for the
researchers and sponsors of the trial. Hence, the
quality of the decision reached by a DMC is
crucial. Concern has been raised in the literature
that a DMC may make a ‘mistaken’ decision
because of the ways in which the decision is
reached, rather than any deficit in formal terms 
of reference. 
Decision-making can be a complex process and is
considered to be one of the most important tasks
undertaken by groups. However, groups do not
always make ‘good’ decisions and the current
literature is not conclusive on how best to improve
performance. Most of what we do know is based
on studies within cognitive, social and
organisational psychology, sociology and
management sciences. 
Aim
The aim of this chapter is to review systematically
the social scientific literature to achieve three
objectives:
  to identify factors that make errors more or less
likely in small (less than 20 members), 
task-orientated, decision-making groups
  to consider the implications of these factors for
data monitoring committees
  to make recommendations for the construction
and process of future DMCs and to 
identify areas in which further work is 
needed.
Methods
Scope of material used
The empirical literature on small group processes
is extensive and has been regularly reviewed.126,127
The aim of this review was to identify factors 
that make errors more or less likely in small
decision-making groups (similar to DMCs), and
not to review systematically all of the literature 
on small group processes. To ensure that the
factors we identified were based on robust
evidence, the literature search focused primarily
on high-quality reviews of empirical studies. This
had implications for the search and ascertainment
of the literature, and the final inclusion criteria
were reached in an iterative manner as the search
progressed. 
The review drew on a similar body of
psychological literature to that which informed 
an issue of Health Technology Assessment128 on 
the use of consensus methods in the development
of clinical guidelines. Using comparable 
methods a search strategy was developed to
include issues that were not addressed in that
report or that were of specific relevance 
to DMCs. 
Selection of databases
It was initially decided to search 12 relevant
bibliographic databases. However, a pilot search
found that ABI Inform, IBSS and Westlaw
(databases covering business and law studies) 
did not yield sufficient numbers of relevant
articles. 
Details of the nine electronic databases that were
searched and the periods covered are summarised
in Appendix 5. A full description of the 
keywords and terms searched is presented in
Appendix 6.
Other methods of identifying articles
As each section of this review chapter was written,
further relevant articles were found by reviewing
the bibliographies of included articles and from
the personal knowledge of the authors and
external advisors.
The study excluded reviews of group dynamics or
group processes in small groups other than task-
orientated, decision-making groups (e.g.
psychotherapy groups, focus groups), animal
studies and reviews published in languages other
than English (owing to time and translation
restrictions).
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Chapter 3
Review of small group processes relevant to data 
monitoring committeesSearch strategy
The review strategy focused primarily on:
  reviews of empirical studies of small group
processes and decision errors in small, task-
orientated decision-making groups in laboratory
settings, published between 1950 and 2001
  reviews of empirical studies of small group
processes and decision errors in naturally
occurring groups (e.g. juries, committees),
published between 1950 and 2001.
A secondary search of the same databases was
undertaken to identify any key empirical papers in
areas not covered by reviews or that may have
been published too recently to be included in
reviews. This search aimed to identify empirical
studies of the relationship between group
processes and decision-making in small, task-
orientated groups in laboratory settings, published
between 1990 and 2001, and empirical studies of
group processes and decision-making in naturally
occurring groups (e.g. juries, committees),
published between 1990 and 2001.
A total of 3194 review articles was identified. The
abstracts of all of these articles were obtained and
assessed by two reviewers as ‘possibly relevant’,
‘uncertain’ and ‘not relevant’. In total, 57 review
articles were assessed as relevant and included in
the review (see Appendix 7). Only four of these
were included in the review undertaken by
Murphy and colleagues.128
A total of 1277 ‘possible relevant’ empirical
abstracts was identified, of which 224 reported
findings of interest. The majority of these studies
reported material that had already been included
in reviews. After further assessment, none of these
articles was considered to be of good quality, or
relevant to DMCs and therefore not included
(Figure 2).
Handling of references
A total of 3194 review article references was
retrieved electronically from the electronic
databases, and downloaded into the bibliographic
software, Reference Manager (Reference Manager
9.5N; ISI ResearchSoft, Carlsbad, CA, USA).
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Articles identified from keyword online search 
n = 3187
Articles identified from expert sources 
n = 7
                           Total: 3194 Excluded: duplicates, animal studies, groups 
>20 members, not decision-making, 
intergroup behaviour, therapeutic groups, 
focus groups, problem-solving groups, 
empirical papers 
n = 2974
Abstracts assessed as potentially relevant 
n = 220
Full papers retrieved 
n = 133
Papers included in overview 
n = 57
Excluded: not in English, not available within 
project time-frame, not related to 
task-orientated groups, not decision-making 
n = 87
Excluded: not a review of empirical studies 
(i.e. think pieces and discussion papers), 
not decision-making and small task-orientated 
groups 
n = 76
FIGURE 2 Exclusions at each stage of the small group processes reviewAssessment of references
After downloading into Reference Manager, an
initial screening of references was undertaken by
one researcher. Titles, keywords and abstracts of all
references were assessed and classified into
‘possibly relevant’, ‘uncertain’ or ‘not relevant’.
Thereafter, two researchers fully assessed all the
abstracts to ensure consistency and agreement of
categorisation.
For all the 133 ‘possibly relevant’ references,
copies of the original articles were sought so they
could be read in full. Some articles were
unavailable within the time-frame of the project,
and owing to the cost of interlibrary loans, some
articles were not requested if the abstract indicated
that it would provide, at best, low-level evidence
about a topic already covered. On this basis it was
also decided to exclude one non-English article as
translation would have been costly. Therefore,
seven ‘possibly relevant’ articles were not obtained.
Of the remaining 126 ‘possibly relevant’ reviews,
each full article was initially assessed for its
relevance by one reviewer. Some articles, despite
having promising titles and abstracts, turned out
to be of poor content and/or quality and were
disregarded as irrelevant. Both reviewers read and
assessed any articles that were ‘uncertain’. This
procedure ensured that no ‘possibly relevant’
articles were disregarded without double-checking.
Samples of ‘not relevant’ reviews were checked by
a second reviewer to ensure that no ‘possibly
relevant’ article was disregarded. In addition,
certain articles thought to be particularly
important were tagged ‘key article’. A total of 57
reviews was finally agreed for inclusion in the
review (see Appendix 8).
Each full article accepted for inclusion in the
review was fully assessed by two reviewers and the
relevant information extracted onto a data
extraction form (see Appendix 9); this summarised
the research question, type of review,
methodology, decision-making activities, and
structural and psychological processes.
Synthesis
The synthesis strategy for structuring the review
was guided by a heuristic input–process–output
model of small group behaviour and decision-
making, as shown in Figure 3. This was not an
exhaustive model, but provided a useful structure
of the key variables emerging from the literature.
Once specific group processes had been identified,
the extracted data were coded and analysed using
NVivo, a qualitative software package, to assist
with analysis. Two reviewers assessed the coded
extracts to ensure that all relevant data were
appropriately and consistently coded. Following
this, extracts were imported to NVivo software,
where each data set was coded. Coded data sets
were then subjected to a process of critical,
iterative analysis by two reviewers, in which an
interpretation was evaluated against the data and
discarded or modified until a consistent
interpretation was reached. 
Results: error and bias in 
decision-making
Overview of the literature
Small groups can be involved in a wide range of
decision-making tasks, and evidence indicates that
both the process of decision-making and its
outcome are influenced by the type of task a
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Task characteristics
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Group satisfaction
FIGURE 3 A heuristic input–process–output model of small group decision-making129group is working on.127 The majority of the
literature on small groups is concerned with four
types of decision-making task. These are
generating plans, solving problems with correct
answers (intellective tasks or problem-solving
tasks), deciding issues with no right answers
(judgemental tasks or choice-dilemma tasks) and
resolving conflicts of viewpoint.130 Perhaps
unsurprisingly, the largest body of research is
concerned with experimental studies of artificially
created groups (usually comprised of students)
engaged in intellective tasks. A DMC can be
considered a small group of individuals with
varying expertise charged with the task of
considering the interim data from a trial and
deciding whether or not it should continue. 
This is a task that does not have a demonstrably
correct answer, but which requires consideration 
of evidence, assessment of risk and the
achievement of a consensus view to make a 
group decision. In McGrath’s schema, it equates
most closely to a judgemental or choice-dilemma
task. 
To identify factors that may influence the quality
of the decision made by a DMC, this chapter will
give greatest weight to findings from studies of
groups engaged in judgemental and choice-
dilemma tasks. In particular, studies of real-life
groups, such as juries or political decision-making
groups, will be considered. Evidence from studies
of groups engaged in other types of decision-
making task will be considered, but accorded less
weight in making recommendations for DMC
procedures. 
Error and bias in small group 
decision-making
The key concern for this review is identification of
factors that make errors in decision-making more
likely. How have decision errors been defined in
the literature on small groups? Jones and
Roelofsma131 draw on Reason’s132 definition of
error to make a clear distinction between errors
and biases in small group (or team) decision-
making. They propose that a decision error refers
to ‘those occasions when the team’s decision-
making activities fail to achieve its intended
outcome’.131 From this perspective, a DMC
decision would be considered to be an error 
either if current trial participants were exposed 
to harm from the experimental drug or
procedure, or if future patients were unable to
benefit from it. 
A decision bias is defined as “a team decision-
making behaviour that deviates from what
normative decision-making models imply”.131
Normative decision-making models (e.g.
Subjectively Expected Utility theory)133 allow a
mathematical calculation of the ‘correct’ decision
for an individual (or group) based on a knowledge
of their pre-existing values (or utilities) and the
likelihood that particular choices will satisfy these
preferences. A bias is said to occur when the
decision reached in reality differs from that which
should be reached according to the theory. Several
common biases have been identified in group
decision-making.134 A bias may not necessarily
result in the failure to achieve an intended
outcome; hence it is not in itself an error, but it
may be responsible for one. 
Measuring error and bias in small group decision-
making research
The majority of research on errors and biases in
decision-making is concerned with intellective (or
problem-solving) tasks, in which small groups are
asked to reach a decision about the solution to a
problem with a known answer. A typical example is
the horse-trading task.135 In this task, groups are
told that a man has bought a horse for $60 and
sold it for $70. Then he bought it back for $80
and again sold it for $90. They are then asked to
decide how much money the man made in the
horse-trading business ($20). Typically,
experimental studies systematically investigate 
the effect of structural factors, leadership style,
and so on, on the proportion of occasions on
which groups solve these types of problem
correctly. In addition, some studies consider 
the impact of manipulated variables on features 
of the decision-making process using these 
tasks, for example, the time taken to reach a
decision or the number of alternative solutions
considered. 
Errors and biases are more difficult to quantify in
studies of judgemental tasks or dilemmas. In these
studies, four broad approaches can be identified:
assessment of the process of decision-making,
comparison of group decisions with aggregated
individual decisions, post hoc assessment of the
decision by the group members, and post hoc
assessment of the decision by ‘expert’ panels or
public opinion.136
Errors and biases in the process of decision-
making are usually assessed by reference to the
classical assumption that decision-making should
proceed through a series of stages.137,138 The
detailed description of these stages varies between
authors, but there are generally assumed to be
three or four basic stages. In the simplest version,
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identification, alternative generation, and
evaluation and choice.127 Matsatsinis and
Samaras139 describe four stages of initialisation,
preference elicitation, group preference
aggregation and conflict resolution. In the
initialisation stage, the group’s objectives are
established and decision alternatives are
determined. Individuals then state their
preferences on the decision alternatives. In the
third stage, some sort of synthesising mechanism
(formal or informal) is used to reach a tentative
collective decision. Finally, in the conflict-
resolution stage, this collective decision is
evaluated and an effort is made to reach consensus
or reduce the degree of conflict between opinions,
through information exchange or problem
reconsideration. The preferred and rejected
alternatives are re-examined and a final decision is
reached. From this perspective, the quality of the
output that a group produces is influenced
predominantly by the extent to which all of these
stages are successfully achieved. A group may
make a poor decision because it failed to
conceptualise the problem properly, because it
failed to identify or consider all of the decision
alternatives, because it failed to synthesise all of
the preferences into a collective decision, or
because it failed to consider the implications of
the initial decision or re-examine the alternatives.
The most complete summary of potential defects
in the decision-making process is found in Irving
Janis’s work on real-life decision fiascos (see next
section). Janis identified seven symptoms of a
defective decision-making process in judgemental-
type tasks: incomplete survey of alternatives,
incomplete survey of objectives, failure to re-
examine preferred choice, failure to re-examine
rejected alternatives, poor information search,
selective bias in processing information, and
failure to develop contingency plans. The
existence of one or more of these symptoms is
assumed to increase the likelihood that a decision
will fail to achieve the objective that the group
intended. 
It is rare that an opportunity emerges to
determine the ‘correct’ verdict in actual jury trials.
For this reason, field studies of actual juries 
usually focus on procedural criteria that should
theoretically be related to the accuracy of the
verdict. These include: thorough review of the
facts in evidence, accurate jury-level
comprehension of the judge’s instructions, active
participation by all jurors, resolution of 
differences through discussion, and systematic
matching of case facts to the criteria for various
verdict options.140 The absence of any of these
characteristics is assumed to increase the
likelihood of an inaccurate or erroneous 
decision. 
Results: factors associated with
error or bias in decision-making
on judgemental tasks
This section will consider evidence relating to
factors that may influence the quality of the
decision made by a DMC. A high-quality decision
is one in which all of the stages of decision-making
have been satisfied (see previous section), and the
chance of error or bias is low. A poor quality
decision is one in which one or more of the stages
has not been successfully achieved, or one which
shows symptoms of defective decision-making as
defined by Janis (see above). As noted earlier,
greatest weight will be given to findings from
studies of groups engaged in judgemental and
choice-dilemma tasks. In particular, studies of real-
life groups, such as juries or political decision-
making groups, will be considered. Evidence from
studies of groups engaged in other types of
decision-making tasks will be considered, but
accorded less weight in making recommendations
for DMC procedures. To reflect this weighting, this
section will consider experimental studies of
choice-dilemma tasks, studies of decision fiascos
and jury decision-making, before summarising
findings from studies in other areas of decision-
making. 
Experimental studies of choice-dilemma
tasks
Choice shift and group polarisation
Stoner first described the phenomenon of group
polarisation in 1961. He observed that people
were more willing to advocate risky courses of
action after taking part in a group discussion, and
referred to this effect as the risky shift.141–145 For
example, on average, individuals may decide that
someone should have heart surgery if the chances
of an adverse outcome are 1 in 10. After group
discussion the same individuals may decide that
the operation should go ahead if the chance of an
adverse outcome is 2 in 10. Subsequent research,
largely in experimental settings using a series of
12 standard dilemmas known as the Choice-
Dilemma Questionnaire (Box 6), has demonstrated
that groups do not always shift towards risk. In
some studies, groups were seen to shift towards
caution. In other words, the phenomenon is one
of a choice shift, and not necessarily a risky shift.
The term group polarisation arose from the
Health Technology Assessment 2005; Vol. 9: No. 7
53
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.assumption that direction of the shift would always
reflect the initial opinions of the group
members.141 That is, if group members are
initially tending to be cautious about a dilemma,
then the outcome of the group discussion will be
more cautious than the aggregated individual
opinion. However, the direction of change is not
always related to initial opinions in empirical
studies, and choice shift has become the preferred
description for the phenomenon.141,144 Choice
shift following group discussion is a robust
phenomenon, and research over the past 20 years
has focused predominantly on the development
and evaluation of theoretical explanations for it.
Accounts of this literature can be found within the
included reviews,127,142,144,145 but will not be
discussed here.
In a meta-analysis of 14 articles (121 hypothesis
tests) published between 1962 and 1992, BarNir141
reports a moderate to high choice shift effect size
across a range of choice-dilemma questionnaire
items. Several group characteristics that may
moderate choice shift were considered, including
group size, composition, individual differences,
leadership style, discussion content and degree of
prior acquaintance. BarNir draws the following
conclusions. 
  Larger groups and less well acquainted groups
are more likely to shift to risk (conversely,
smaller and well-acquainted groups are more
likely to shift to caution).
  If risky behaviour is considered socially
desirable, then the motivation to create a good
impression in the presence of unfamiliar others
may lead to a shift to risk in some groups.
  Expert groups (high knowledge) are more likely
to shift to risk. Introducing intervention
techniques that emphasise uncertainty or high
stakes of consequences (e.g. devil’s advocacy)
may be a feasible technique for attenuating
these effects. 
  The same group may not display a consistent
decision pattern over time, because choice shifts
are moderated by the type of decision and by
factors that change over time (knowledge and
familiarity). 
One of the factors that may influence the degree
of choice shift in groups is the framing of the
original problem.143 Framing effects were first
studied by Kahneman and Tversky.147,148 They
presented people with dilemmas such as the
following.
“Imagine that the US is preparing for the outbreak of
an unusual disease, which is expected to kill 600
people. Two alternative programmes to combat the
disease have been proposed. Assume that the exact
scientific estimates of the consequences of the
programmes are as follows:
  If programme A is adopted, 200 people will be saved.
  If programme B is adopted, there is a 1/3
probability that 600 people will be saved, and a 2/3
probability that no people will be saved.”
When presented with this problem, the majority 
of people (72%) choose the risk averse option –
they prefer to save 200 lives for sure than 
gamble on saving more lives. However, when they
changed the framing of the problem, different
results occurred. People were presented with the
same situation, but given the following 
choices.
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BOX 6 An item from the Choice-Dilemma Questionnaire, developed by Kogan and Wallach (1964)146
Mr B, a 45-year-old accountant, has recently been informed by his doctor that he has developed a serious heart ailment. The
disease would be sufficiently serious to force Mr B to change many of his strongest life habits – reducing his workload,
drastically changing his diet, giving up favourite leisure-time pursuits. The physician suggests that a delicate medical operation
could be attempted which, if successful, would completely relieve the heart condition. But its success could not be assured,
and in fact the operation might prove fatal. 
Imagine that you are advising Mr B. Listed below are several probabilities or odds that the operation will be successful.
Please check the lowest probability that you would consider acceptable for the operation to be performed.
Place a check here if you think Mr B should not have the operation no matter what the probabilities.
The chances are 9 in 10 that the operation will be a success
The chances are 7 in 10 that the operation will be a success
The chances are 5 in 10 that the operation will be a success
The chances are 3 in 10 that the operation will be a success
The chances are 1 in 10 that the operation will be a success  If programme C is adopted, 400 people will die.
  If programme D is adopted there is a 1/3
probability that nobody will die and a 2/3
probability that all 600 people will die. 
These options are numerically identical to the
previous ones, but framed in terms of lives lost
rather than lives saved. When presented in this
way, the majority of people (78%) choose the
riskier option – they prefer to gamble on saving
all 600 lives rather than be certain that 400 lives
will be lost. 
The evidence that framing affects individual
decision-making is robust, and although relatively
few studies have considered this possibility in group
decision-making, those that have demonstrate the
same effects.143 That is, when a problem is
presented in a positive frame (e.g. a new drug has a
50% success rate), the majority of groups will
choose to avoid risks in deciding how to resolve the
problem. In contrast, when a problem is presented
in a negative frame (e.g. a new drug has a 50%
failure rate), groups tend to choose a riskier
solution to the problem. Despite the clear
implications of framing, it has proved more difficult
to identify circumstances that trigger groups to see
their decision as a choice between losses (negative
frame) or a choice between gains (positive frame).
The extent to which groups have been historically
involved with the problem and the degree of
escalation of commitment to the decision have both
been shown to be associated with negative framing
(and riskier decision-making),143 but there may be
other important factors, as yet unidentified. 
Majority and minority influence
We are all exposed to numerous attempts to
influence our opinions every day. An extensive
body of research considers the relationship
between the number of people expressing a view
or opinion and the level of attitude
change.127,144,149,150 Do we always conform to a
majority view, or can a minority be persuasive? 
Empirical studies in this area began in the 1950s,
with classic experiments in which naive
participants were asked to make objective
judgements (e.g. about the relative lengths of a
pair of parallel lines).149 The naive participants
joined a group containing five other members
(confederates of the experimenter) and were asked
to make their judgements in public after hearing
all of the other members express their view. In
experiments such as these naive participants
generally conform to the majority view expressed,
even when that view is objectively incorrect.
Studies within this paradigm have demonstrated
that the degree of conformity increases with the
size, status and power of the majority.127 Later
research initiated by Moscovici and his colleagues
using a similar paradigm has shown that
minorities can be influential if they express a
stable view and are consistent among
themselves.149,150 Most of the studies conducted
within this paradigm have investigated the
influence of minority and majority opinions in
non-interacting groups, and hence have limited
direct relevance for DMCs. Findings from studies
of majority and minority influence in groups that
do interact are summarised below.
  When the majority of group members initially
favour a particular position, this position is
likely to determine the group’s final decision. In
addition, the size of the majority affects its
ability to prevail.127
  Although strong evidence for majority influence
is found in decision-making groups, majorities
do not always prevail. Majorities are more
important on judgemental tasks, which lack
demonstrably right answers, than on intellective
tasks, which have such answers.127 However, this
pattern is modified for some choice tasks,
especially in juries. In juries, acquittal requires
less initial support than conviction to prevail.144
  When a group is working on a judgemental task
and status differences are large, the group
decision rule changes from ‘majority wins’ to
‘power wins’.127
  Minorities have been shown to be influential in
jury decision-making and group discussion of
social problems.150 There is strong support for
the notion that a minority needs to be
consistent to be influential.150
  Double minorities, who differ from the majority
in terms of both their expressed views and their
ascribed category membership (e.g. gender,
religion, skin colour), tend to be less
influential.150
  A majority has more direct and public influence
than a minority (minorities tend to influence
private judgements).149
Experimental studies of moral reasoning
The majority of research on reasoning about
moral dilemmas has been conducted by
developmental psychologists, and has focused on
understanding the processes of reasoning that
individuals use as they progress through childhood
and adolescence and into adulthood. There is
relatively little research that investigates moral
reasoning in groups, and only one of the
identified articles reviewed experimental studies in
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work of DMCs, the findings of this review will be
described here in some detail. 
Research on moral reasoning in psychology draws
heavily on the work of Piaget152 and Kohlberg,153
and has identified a sequence of developmental
stages of moral reasoning (see Box 7). An
individual progresses through these stages as his
or her reasoning processes become more
sophisticated. However, not all individuals
progress through all of the stages, and even
among those who do, adults do not always resolve
moral dilemmas using the highest levels of
reasoning. The level of reasoning used by an
individual to solve a particular dilemma can be
assessed using a standard psychometric instrument
called the Defining Issues Test (DIT), which
produces a score on a continuous scale of
‘principled moral reasoning’. The higher the score
on this instrument, the more likely that the
individual is using principled or postconventional
morality in Kohlberg’s scheme (Box 7). 
Dukerich and colleagues151 review existing research
using the DIT to investigate moral reasoning by
groups, and present two experimental studies of
their own. In these studies, participants (university
students) were pretested using the DIT and then
assigned to four-member groups. Each of the
groups contained members with initial DIT scores
in each of the four quartiles of the range of scores.
One to two weeks after the pretesting, the groups
were brought together and asked to discuss and
resolve the three dilemmas presented in the DIT as
a group. Following the tape-recorded group task,
each participant completed another copy of the
DIT (composed of different dilemmas) individually.
The researchers conducted studies in which the
groups were simply observed and manipulated a
range of factors to investigate whether leadership
style and the level of moral reasoning used by the
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BOX 7 Kohlberg’s stages of moral development
Level 1 Stage 1: Punishment and obedience  The child decides what is wrong on the basis of being 
Preconventional  orientation punished. Obedience is valued for its own sake, but the child 
morality obeys because adults have superior power
Stage 2: Individualism, instrumental  The child follows rules when it is in his/her immediate 
purpose and exchange interest. What is good is what brings pleasant results. Right is
also what is fair, what is an equal exchange, a deal, an
agreement
Level 2 Stage 3: Mutual interpersonal  The family or small group to which the child belongs 
Conventional morality expectations, relationships and  becomes important. Moral actions are those that live up to 
interpersonal conformity others’ expectations. ‘Being good’ becomes important for its
own sake, and the child generally values trust, loyalty,
respect, gratitude and keeping mutual relationships
Stage 4: Social system and  A shift in focus from the young person’s family and close 
conscience (law and order) groups to the larger society. Good is fulfilling duties one has
agreed to. Laws are to be upheld except in extreme
circumstances. Contributing to society is also seen as good
Level 3 Stage 5: Social contract or utility and  Acting so as to achieve the ‘greatest good for the greatest 
Principled or  individual rights number’. The person is aware that there are different views 
postconventional  and values, that values are relative. Laws and rules should be 
morality upheld in order to preserve the social order, but they can be
changed. Still, there are some basic non-relative values, such
as the importance of each person’s life and liberty that
should be upheld no matter what
Stage 6: Universal ethical principles The person develops and follows self-chosen ethical
principles in determining what is right. Since laws usually
conform to these principles, laws should be obeyed; but
when there is a difference between law and conscience,
conscience dominates. At this stage, the ethical principles
followed are part of an articulated, integrated, carefully
thought out and consistently followed system of values and
principlesa
Adapted from Kohlberg (1976).153
a Kohlberg (1978)154 concedes that stage 6, if it exists at all, is extremely rare, and should perhaps only be applied to
exceptional individuals, e.g. Martin Luther King and Mother Theresa. leader have an effect on group performance. Their
findings, based on their own studies and previous
research, are summarised below. 
  Task leadership is a dominant variable in this
type of group decision-making task, regardless
of how task leadership was operationalised. The
reasoning level of the individuals who took on
the leadership role had a major impact on the
subsequent performance of the group and the
individual members. Specifically, group
performance suffered when the task leaders
were less principled reasoning individuals (as
measured by the DIT). Groups with more
principled reasoning leaders either improved or
stayed the same. 
  Individual reasoning skills tend to increase after
involvement in group discussion. However, the
more principled reasoners appeared to
experience a setback in reasoning skill after
group discussion (possibly a transitory effect). 
  Emergent leaders are just as likely to be low on
reasoning skill as high. It cannot be assumed
that more principled reasoning individuals will
automatically assume leadership. Organisations
may want to select leaders who are more
principled reasoners, or to train influential
members in moral reasoning. 
Decision fiascos and groupthink
Background and history
Folk wisdom argues that ‘two heads are better than
one’ when it comes to making decisions in complex
situations. If that is so, then a group composed of
particularly intelligent and knowledgeable people
might be expected to make even better decisions.
As Raven155 puts it: “How then could one account
for John F Kennedy’s presidential advisory group,
composed of the ‘best and brightest’, developing
plans for the Bay of Pigs invasion of Cuba,
frequently characterised as one of the most
militarily disastrous and morally disgraceful
ventures in American history?” This puzzle
intrigued Janis and led him to apply his knowledge
of the social psychology of groups to case studies of
political decision fiascos (Table 6). On the basis of
his analysis, he argued that the processes that
generally make groups more effective (e.g. high
morale, high cohesiveness, good leadership,
excellent knowledge and experience) can in some
circumstances lead to disastrous results. In some
cases, he argued, a high level of morale and
commitment to the group can result in a sense of
moral superiority and a stronger tendency to
conform to the majority within the group. He
called this phenomenon groupthink, which
proposes that this high cohesiveness and desire for
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TABLE 6 Some case studies of groupthink
Study Description Summary of results
Janis (1972, 1982) Bay of Pigs invasion of Cuba Identified antecedent conditions and symptoms of 
Invasion of North Korea groupthink and defects of decision-making. Five cases 
Pearl Harbor show evidence of groupthink, two do not (Cuban missile 
Escalation of war in Vietnam crisis, Marshall plan)
Cuban missile crisis
Making of the Marshall Plan
Watergate crisis and cover-up
Raven (1974, 1998)  Advisory groups associated with  Sociometric analysis suggests evidence of groupthink 
President Nixon involved in the  with modified antecedents. The team lacked mutual 
planning that resulted in the Watergate  respect, but consisted of two strongly competing 
fiasco and the cover-up afterwards factions, held together by loyalty to the President and a
desire to be group members. Two antecedents
(cohesiveness and insulation) and six symptoms present
Tetlock (1979) Further analysis of Janis’s original six  Content analysis of public statements of key decision-
case studies makers. Found differences between decision-makers in
groupthink and non-groupthink cases
Huseman and Drive  Decisions of professional investors in  Decision-making groups in industry show signs of 
(1979) the stock market groupthink in decision fiasco situations. Two antecedents 
Decision by the Ford Motor Company  (cohesiveness and insulation) and five symptoms present
to produce the Edsel
Price-fixing conspiracy in the electrical 
industry during the 1950s
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TABLE 6 Some case studies of groupthink
Study Description Summary of results
Smith (1984) US mission to rescue hostages in Iran  Showed all groupthink symptoms and four decision-
making defects present. Antecedent conditions not
examined
Hensley and Griffin  Decision in 1977 to build an addition to  Showed all antecedent conditions, seven out of eight 
(1986) the Kent State University gymnasium on  groupthink symptoms (exception ‘illusion of unanimity’) 
part of the area where students and  and majority of defective decision symptoms present
Ohio National Guard members 
confronted each other before a fatal 
shooting in May 1970
Herek, Janis and Huth  19 US policy decisions about  Examined relationship between symptoms and decision 
(1987) international crises, 1947–1973 outcomes. Concluded that when more symptoms are
present, decisions are more likely to have adverse
effects on US interests and to increase international
conflict
McCauley (1989) Reanalysis of cases described by Janis  Failed to find support for hypothesis that cohesion 
(1982) predicts occurrence of groupthink. Cohesion present in
two out of six groupthink cases. Antecedents present in
both groupthink and non-groupthink cases
Esser and Lindoerfer  Decision to launch the space shuttle  Quantitative analysis using coded statements from 
(1989) Challenger in 1986. Challenger exploded  investigative report. Conclude that the decision to 
73 seconds after launch, killing all seven  launch involved groupthink
astronauts on board, and becoming the 
worst spaceflight disaster in US history
Hart (1990) Iran Contra affair Three antecedents present (cohesiveness, insulation,
leadership) and all eight symptoms
Moorhead,  Challenger disaster Analysed the level 1 Flight Readiness Review meetings 
Ference and Neck  over 2 days before the decision to launch. Three 
(1991) antecedents (cohesiveness, leadership, insulation), eight
groupthink symptoms and a majority of defective
decision symptoms were present
Neck and Moorhead  Jury deliberations in the trial of USA vs  Five antecedents present, but groupthink did not occur 
(1992) John DeLorean owing to the moderating impact of methodical decision-
making procedures
Tetlock, Peterson,  Janis’s seven cases Confirmed Janis’s five groupthink cases. Classified Nazi 
McGuire,  Decision to rescue the crew of the  appeasement as groupthink, but not Mayaguez or Iran 
Chang and Feld (1992) Mayaguez hostage rescue
Iran hostage rescue
Nazi appeasement decision of  Found strong link between symptoms and defective 
Chamberlain cabinet decision-making. Weak links between cohesiveness and
symptoms
Esser (1995)  Challenger  Six antecedents, five symptoms and seven defects in
decision-making present
This table is an adaptation of tables within Raven 1998,155 Neck 1995,156 Esser 1998,157 Moorhead 1991,158 Park 1990,159
and Wekselberg 1996.160unanimity can override the group’s ability to
appraise alternative courses of action and result in
poor-quality decision-making and decision
errors.160 He then went on to develop a model
describing the antecedents, symptoms and
consequences of groupthink (summarised in 
Figure 4). 
The concept of groupthink has a strong intuitive
appeal and has triggered a substantial body of
empirical research, including both case studies of
decision fiascos and empirical studies of
groupthink hypotheses.155–157,162,163 Case-analytical
research includes studies that aim to describe
groupthink and identify situations in which it has
occurred or may be likely to occur. These studies
involve the retrospective application of groupthink
hypotheses to reported decision fiascos (usually
based on content analysis of archival data and
press reports), and tend to consider all aspects of
the model. They have largely been used to
develop the theory and generate hypotheses,
rather than to test relationships between
components of the theory.157 However, some
studies do investigate whether the hypothesised
antecedents of groupthink are present in groups
showing symptoms of groupthink, or broadly to
test the relationship between symptoms of
groupthink and defects in decision quality (see
Table 6 for details). 
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Antecedents
•  High cohesiveness                            
•  Insulation of group 
•  Lack of impartial leadership
•  Lack of procedural norms   
•  Member homogeneity          
•  High stress from external threat and task complexity
•  Moral reasoning
•  Low self-esteem induced by recent failures
Symptoms
•  Illusion of invulnerability
•  Belief in the group’s morality
•  Collective rationalisation
•  Stereotypes of outsiders
•  Self-censorship
•  Illusion of unanimity
•  Pressure on dissenters
•  Self-appointed mind guards 
Decision-making defects
•  Incomplete survey of alternatives
•  Incomplete survey of objectives
•  Failure to re-examine preferred choice
•  Failure to re-examine rejected alternatives
•  Poor information search
•  Selective bias in processing information
•  Failure to develop contingency plans
Concurrence seeking tendency
FIGURE 4 The groupthink model (adapted from Janis and Mann, 1977161)Empirical studies deal with experimental tests of
specific groupthink hypotheses in a laboratory
setting using groups constructed for the purpose
of the study (usually composed of undergraduate
students). While case studies tend to provide
evidence for the existence of groupthink and some
support for the hypothesised links between
antecedents, symptoms and decision quality,
experimental studies generally fail to, and
empirical support for the full groupthink model is
weak.156,157,159,160,163,164 Indeed, some authors
argue that the concept of groupthink is weak both
theoretically and empirically and should be
abandoned, despite its popular appeal.160 Others
feel that the model continues to have a heuristic
value and merits further research,157 or use it as a
basis for more comprehensive models of group
decision-making.163,164 The model serves a useful
function for this chapter in identifying variables
that may impair the quality of decision-making
(the hypothesised antecedents of groupthink). The
evidence relating to each of these is summarised
here. 
Antecedents of groupthink
High cohesiveness
Group cohesion is the central variable in the
groupthink model and is the most widely studied
variable in experimental studies. Cohesiveness is
generally thought of in terms of group members
having strong positive feelings towards one another
(or the group). However, research suggests that
cohesiveness is a multifaceted construct that has both
task and interpersonal dimensions.155,165 Task-based
cohesion occurs when there is a shared commitment
to goals or tasks of the group. Interpersonal
cohesion is based on personal relationships, the
prestige associated with membership of the group
itself, and regard for and dependence on the leader
of the group. Some case studies have suggested that
aspects of cohesiveness that are unrelated to the
personal relationships of group members can be
more important in determining cohesiveness in
some settings (e.g. in the Nixon group associated
with the Watergate fiasco).155
A meta-analysis of nine experimental studies 
(17 hypothesis tests, involving 1382 participants),
found a small and non-significant effect of
cohesiveness on decision quality overall.162
However, relationships were found between
cohesiveness and decision quality in certain
circumstances. When other antecedent conditions
are set up to promote groupthink, high
cohesiveness impairs decision quality (small but
significant effect, three hypothesis tests). When
conditions are set up to thwart groupthink, high
cohesiveness enhances decision-making (six
hypothesis tests, significant but small effect). When
other antecedent conditions are not explicitly
eliminated or exaggerated, decision quality
increases as a function of cohesiveness when
cohesiveness involves more ‘commitment to task’.
Decision quality decreases as a function of
cohesiveness when cohesiveness involves more
‘interpersonal attraction’. In addition, there is a
significant effect of group size on the relationship
between cohesiveness and decision quality.
Cohesiveness tends to impair decision quality as
group size increases.162
Overall, reviews summarising both case studies
and experimental research conclude that group
cohesiveness, either alone or in combination with
other factors, has little effect on groupthink or
decision quality.157,159,160,163,164
Insulation of group
The problems that may occur when a group is
insulated from expert information and external
scrutiny were highlighted by Janis, and insulation
has emerged as a key antecedent of groupthink in
several case studies.157 The reviews included in
this chapter only identify one experimental study
of insulation,157,159 which found partial support
for the theory. Insulated groups generated fewer
alternative decisions (a decision-making defect),
but contrary to the theory, they felt more
vulnerable and were more likely to seek expert
advice than non-insulated groups. In summary, it
is currently unclear whether group insulation is an
important factor in determining decision quality. 
Lack of impartial leadership
An overly directive leadership style is hypothesised
to be another key antecedent of defective decision-
making, and has been investigated in several
empirical studies. Overall, laboratory studies tend
to support this hypothesis,157 with a few
exceptions.159 Groups with directive leaders (who
state their preferred decision early) tend to
suggest fewer alternatives and report more self-
censorship, and are more likely to acquiesce to the
leader’s preferred decision.157,159
Lack of methodical decision-making procedures
Four studies have examined the effect of adopting
clear methodical procedures of information search
and appraisal on decision quality. Three provide
some support for the hypothesis, while one found
that the presence or absence of these procedures
has no effect on decision quality.157,159 The effect
of these procedures seems to be particularly
important in cohesive groups. Highly cohesive
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less likely to agree and make poorer decisions than
similar groups that take a more methodical
approach.157
Other factors
Janis describes four other potential antecedents of
groupthink: high stress from external threat or
task complexity, member homogeneity, moral
reasoning ability and low self-esteem induced by
recent failures. These have received less empirical
attention than other factors, possibly because they
have been less apparent in case studies. Threat, as
operationalised in laboratory experiments, has
rarely had any consequences for group decision-
making outcomes or processes.166 However,
studies that manipulate the degree of
accountability that group members have for the
decision suggest that accountable groups tend to
share influence in the decision-making process
more evenly and are more likely to question
procedures and objectives throughout the process,
but have more difficulty in reaching agreement.157
Studies have investigated the effects of member
homogeneity and moral reasoning ability on
decision quality, but not in relation to groupthink
hypotheses, and these studies are discussed
elsewhere (experimental studies of choice-dilemma
tasks, above; findings from studies of decision-
making on non-judgement tasks). 
Studies of jury decision-making 
Background to and history of jury decision-
making research
Systematic research on juries began with the
Chicago Jury Project, initiated in 1953. This was a
large field study involving 3500 civil and criminal
jury trials. One arm of the study collected survey
data from judges, lawyers and ex-jurors. The other
arm involved audiotaping real jury deliberations
and experimental studies with mock juries. The
invasion of jury privacy by audiotaping their
deliberations raised a storm of protest about the
ethics of the study, and ultimately led the US
Congress to stop the project in 1955. Following
this decision, federal government and most states
banned access to the jury room, limiting the range
of research that could be conducted with real
juries.140,167 Since that time, research on jury
decision-making has largely been confined to
experimental studies of mock juries, interviews or
surveys of real jurors after their deliberations and
archival studies of real jury verdicts. In the 1990s,
two large field studies of juries were initiated in
the USA. The Capital Jury Project investigates jury
decision-making in cases involving a possible
death sentence across 15 states in the USA. 
The Arizona Jury Reform study is a randomised
controlled field trial to evaluate the effect of a
decision by the Arizona Supreme Court to allow
jurors to discuss evidence while a trial is still in
progress. Preliminary findings from these studies
are included in one of the reviews informing this
chapter.140 A systematic review of jury decision-
making from 1955 to 1999140 identified 206
empirical studies, 136 of which involved mock
juries, 40 involved analysis of archival data from
real juries, 14 described surveys of ex-jurors, 13
used field experiments or studies and three used 
a combination of methods. 
Jury decision-making research is directly pertinent
to DMCs because it is concerned primarily with
identifying factors that may result in a miscarriage
of justice. However, as noted earlier (see section
‘Error and bias in small group decision-making’,
p. 52), it is rare that an opportunity emerges to
determine the ‘correct’ verdict in jury research.
Rather than attempt to identify factors that make
errors more or less likely in jury decision-making,
the majority of this research considers the effect of
various factors on the likelihood of a particular
verdict (usually a decision to convict in criminal
cases or find a defendant liable in civil cases). A
large number of such factors has been studied and
reviewed.140,145,167,168 From these, 12 have been
shown to have sizeable effects on jury decision
outcomes: definitions of key legal terms,
verdict/sentence options, trial structure,
juror–defendant demographic similarity, jury
personality composition, jury attitude composition,
defendant criminal history, strength of evidence,
pretrial publicity, inadmissible evidence, case type
(for civil trials) and initial juror verdict preference
distribution. Some topics not included in this list
are associated with small yet reliable effects (e.g.
jury size), mixed results suggestive of higher order
interactions (e.g. juror experience, decision rule,
expert testimony) or potential effects that require
more research to draw firm conclusions (e.g. juror
note-taking, juror question-asking, defendant
appearance, plaintiff characteristics, deliberation
style, foreperson effects on damage awards).140
Many of these factors are unlikely to be pertinent
in DMCs. In the following sections, evidence
relating to those factors that do appear relevant
will be summarised. This evidence has been
divided into two categories: factors relating to the
deliberation process and non-deliberation factors. 
The deliberation process
Foreperson effects
Choosing a foreperson is an initial task for most
juries, and one that tends to be achieved quickly
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tends to be the person who happens (or has
chosen) to be seated at the head of the table and is
more likely to be male, better educated and an
experienced juror. The person selected as
foreperson is usually one of the first people to
speak and often the first member to mention the
need for a foreperson. Once selected, forepersons
speak more during the deliberation (around
25–30% of the time on average) and influence the
speaking time and order in which other members
speak. Hence, forepersons are in a position to
influence the quality of the decision-making
process. The influence of forepersons has only
been studied in civil cases. In these cases they are
disproportionately influential in determining the
size of financial damages awarded, but do not
appear to unduly influence the verdict about
liability.140
Deliberation content
Several studies have examined the content of jury
deliberations through video- or audio-taping mock
jury discussions or through postdeliberation
interviews with real jurors. Findings from these
studies are difficult to synthesise because they have
tended to use study-specific coding schemes.
However, these studies do demonstrate that juries
spend most of their time talking about the facts of
the case and the expressed preferences of
members. Several studies have demonstrated that
deliberation variables can help to explain why jury
verdicts do not always match the initial
preferences of jurors. In particular, these studies
suggest that the content of discussion is
particularly important early in the deliberation
process and before any votes or straw polls have
been taken. Once a vote has been taken and
members are aware of the relative sizes (and
characteristics) of pro-conviction and pro-acquittal
factions, the content of discussion appears to be
less influential than pressures to conform.140
Deliberation style
Observations of jury discussions have identified
two main types of approach that juries can take in
reaching their verdict. These have been called the
verdict-driven style and the evidence-driven style.
Juries adopting a verdict-driven style take a vote
(or straw poll) early in the proceedings and then
focus their discussion around the verdict options.
Evidence-driven juries postpone the first vote until
after extensive discussion of the evidence and
structure their discussion around a systematic
evaluation of the evidence. These two styles occur
equally often in studies of real juries. One study of
mock juries manipulated this variable by asking
jurors to adopt a particular style of deliberation
and found that deliberation style can affect jury
verdicts. Juries using a verdict-driven style were
more likely to find a defendant liable in a civil
case in which liability depended on meeting both
of two legal criteria, but less likely to return a
verdict of liability when either of the two criteria
was sufficient. The opposite was found in juries
using an evidence-driven style.140
Straw polls
Most juries undertake repeated straw polls or votes
during the deliberation process. These are usually
public expressions of the current verdict
preference of individual jurors, but some juries
undertake private votes. The frequency and format
of straw polls affect the deliberation process and
are key factors in changing the verdict preferences
of individual jurors. Juries that undertake frequent
and regular polls take longer over their
deliberations, but are more likely to reach a
decision. Secret votes are associated with rapid
changes of juror opinion in the early stages of
deliberation, but less opinion change in the later
stages. Public votes show the opposite effect: jurors
are less likely to change their expressed opinion
early in the discussion, but more likely to change
their minds later. The format of voting makes little
difference to the final verdict if the evidence in the
case is clear. When cases are close, however, six-
person juries are more likely to reach a decision if
they vote in public, with the opposite being true of
12-person juries. 
Non-deliberation factors
Jury size
In the 1970s, some relaxation of the traditional
requirement for a 12-member jury led to large
body of research on effects of jury size. Most of
these studies compared six-member with 12-
member juries, although some included eight-
member juries. A meta-analysis of these studies
shows that jury size has little if any effect on the
nature of the verdict reached or on the likelihood
that juries will reach a ‘correct’ verdict (i.e. one
that matches the verdict chosen by the majority of
the population).140,165 Smaller juries are less likely
to include members of minority groups, recall less
evidence, deliberate more quickly and less
thoroughly, and less likely to reach a
verdict.140,167,168 Six-member juries award larger
damages in civil cases.140,168
Decision rule
Juries may be asked to return a verdict on the
basis of either a unanimous or a majority decision
(usually a two-thirds majority). These different
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mock jury experiments.140,167,168 Some studies
show that a unanimous decision rule results in
‘hung juries’ more often than a majority decision
rule. Juries operating under a unanimity rule
deliberate for longer and spend more time
discussing legal definitions of verdict categories.168
Juries operating under a majority decision rule
tend to stop deliberating once a quorum is
reached and use fewer straw polls of opinion. As a
consequence, they tend to reach a verdict more
often and more quickly.140
Standard of proof
The prosecution may be required to demonstrate
the guilt of the defendant (or case of the plaintiff)
beyond a reasonable doubt (the strictest standard
of proof), on the basis of clear and convincing
evidence, or on the basis of the preponderance of
evidence. In experimental studies, the proportion
of verdicts favouring the plaintiff decreases
significantly as the standard of proof becomes
stricter.140,160 In addition, the wording used to
convey the standard of proof has a substantial
effect on jury verdicts. For example, higher
acquittal rates are found when reasonable doubt is
defined broadly as any conceivable doubt.140
Demographic characteristics
A considerable body of research has examined the
possibility that social and demographic
characteristics of jurors can predict their verdict
preferences. Much of this work has evaluated the
effects of selecting jury members on the basis of
personal characteristics (‘scientific jury selection’
procedure) on jury verdicts. These studies show
that few if any juror characteristics can predict
individual juror verdict preferences.140,168
However, jury demographic factors interact with
defendant characteristics and the strength of
evidence presented to produce a bias in favour or
against defendants who are similar to jury members
in some salient respect (e.g. gender, age, ethnicity).
When the evidence against a defendant is weak or
ambiguous, juries that are demographically similar
tend to be lenient. When the evidence against a
defendant is clear, however, demographically
similar juries tend to be harsher.140 Jurors who have
prior experience of jury service tend to be more
pro-conviction and influential than novice jurors.
They also appear to evaluate the evidence in the
light of their previous experience, which may bias
their views towards the current defendant.140
Personality and attitudes
Juror attitudes do not predict jury verdicts.
However, juries that contain a high proportion of
members who obtain high scores on measures of
authoritarian or dogmatic personality traits are
more likely to convict a defendant and tend to
impose longer sentences. It should be borne in
mind that these findings are based on studies of
mock juries. The effect of authoritarian
personality on real jury verdicts has not yet been
examined.140 There is some evidence (two studies)
to suggest that the level of jurors’ moral reasoning
(defined according to Kohlberg’s theory, see Box 7)
influences jury verdicts. Juries composed of
members with higher levels of moral reasoning are
more likely to find a defendant non-liable in a civil
case. Mixed juries or juries consisting of more
members with a lower level of moral reasoning are
more likely to fail to reach a decision or award
damages to the plaintiff. This may occur because
jurors with higher levels of moral reasoning are
more dominant during discussion.140
Strength of evidence
The strength of evidence presented is one of the
primary determinants of jury verdicts. Strength of
evidence refers to the quantity and quality of
evidence presented by the prosecution (or
plaintiff) during a trial. In experimental studies it
is manipulated in a variety of ways, e.g. by varying
eyewitness identification of the defendant, the
number of testifying witnesses and the presence of
additional evidence such as polygraph data. Juries
that hear evidence that is strong, either in quality
or in quantity, are more likely to return a guilty
verdict and are more likely to convict in error.
Across studies, conviction rates range from 24%
when the evidence presented is weak to 70% when
the evidence presented is strong. Overall, the
effects of strength of evidence are large and
robust, but the extent to which these effects
interact with (or are moderated by) other biasing
factors is not yet known.140
Pretrial publicity
Folk wisdom suggests that negative pretrial
publicity may bias jury members, and
experimental studies support this. A meta-analysis
of 44 studies found an average correlation of 
r = 0.16 between negative pretrial publicity and
judgements of guilt among non-deliberating mock
jury members.169 Only five studies have
investigated the effect of pretrial publicity on
juries (rather than jurors), but their findings
suggest a consistent bias. Four of the studies
suggest a consistent impact of negative pretrial
publicity, while one found that the impact is
moderated by the strength of evidence presented.
When the prosecution’s case was weak, the bias
associated with negative pretrial publicity
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prosecution case was stronger, jury deliberation
increased the likelihood that a guilty verdict would
be returned. Hence, it seems that in the presence
of strong evidence, the bias that jurors feel towards
a guilty verdict is not reduced by the deliberation
of the jury, and may even be enhanced by it.140
Inadmissible evidence
Jury verdicts are strongly influenced by
inadmissible evidence. Even when judges give
clear instructions to ignore this type of evidence,
jurors do consider information that appears to be
relevant. This effect is particularly strong when the
inadmissible evidence supports the defendant’s
case. The effect of inadmissible evidence is
reduced for more serious charges and if jurors are
presented with information challenging the
credibility of the inadmissible material. The
impact of inadmissible evidence on jury verdicts is
less than the effect on juror preferences, and jury
deliberation can ameliorate its effects; but
majority processes can also increase the effects
(depending on the predeliberation juror verdict
preference distribution, see below).140,168
Initial juror verdict preference distribution
Jurors develop their own verdict preferences as
they hear the trial evidence and before they enter
into discussion with the other jurors. The
judgement they reach is best explained by a ‘story’
model of decision-making, rather than models
that imply a mathematical weighting and
integration of information.140,168 That is, jurors
appear to organise trial evidence into a plausible
story about the defendant. They then attempt to
match the story to the possible verdicts until they
find a verdict that provides the best fit. They then
enter into jury deliberations with an initial verdict
preference in mind. 
Findings from the Chicago Jury Project and from
numerous mock jury studies provide compelling
evidence that the verdict favoured by the majority
of jurors before deliberation will be the final
verdict in 90% of cases. In other words, the
majority view tends to prevail in jury decision-
making. Juries in which opinions are evenly split
before deliberations begin tend to acquit a
defendant or fail to reach a decision. Meta-
analytical reviews support a strong majority effect,
but also show an asymmetrical leniency bias
favouring acquittal. So, for example, a two-thirds
majority favouring guilt will result in a guilty
verdict in 67% of cases, but a two-thirds majority
supporting acquittal will result in a not guilty
verdict in 94% of cases. In a 12-member jury, if
seven or fewer jurors initially favour conviction,
the jury will probably acquit. If ten or more jurors
favour conviction, the jury will probably convict. If
eight or nine jurors favour conviction, the result is
unpredictable.140,167,168
Findings from studies of decision-
making on non-judgement tasks
The general literature on group performance and
decision-making is extensive and has been
reviewed regularly (e.g. Levine and Moreland126,127).
In this section, key factors that are associated with
group performance or decision quality are
described. However, it should be borne in mind
that the studies reviewed here are concerned with
tasks that do not necessarily resemble those
undertaken by DMCs. 
Group composition
Heterogeneity within groups (in terms of
demographics, education, personality or initial
opinion) has a generally negative effect on group
dynamics.127,170 This seems to be due to an
increase in miscommunications and
misunderstandings resulting in greater potential
for interpersonal conflict and feelings of isolation
and alienation. Findings are mixed with regard to
whether the overall effects of heterogeneity on
performance are positive or negative, however.170
Indeed, a few recent studies focus on the
paradoxical effects of heterogeneity, noting the
occurrence of both positive and negative effects.170
There is a consensus that the relationship between
composition and performance is a complex one,
precluding the identification of broad and stable
generalisations.170
Heterogeneity often increases conflict in groups,
which might be presumed to have a negative
impact on performance. This is not the case,
however, and several researchers have found that
conflict and argument can actually improve
decision-making and problem-solving
effectiveness.170 One reason for this may be that
conflict increases the likelihood that a range of
alternatives will be proposed and discussed,
improving the decision-making process. It is also
the case that groups can learn to manage the
effects of having a diverse membership. Two sets
of tactics are generally effective. Negative effects
can be managed by controlling conflicts between
members; for example, by educating them about
their similarities and differences, encouraging
tolerance and improving social skills. In addition,
positive effects can be created by making
structural changes to simulate diversity (of
opinions); for example, by assigning members to
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making norms or introducing occasional
consultants.127
Group size
Having more members increases the reliability of
group judgement, but may cause coordination
problems. The effects of group size on decision-
making are subtle and difficult to detect. It seems
likely that below six participants, reliability will
decline quite rapidly, while above 12 improvements
in reliability will be subject to diminishing
returns.127,128
Leadership
Many reviews have found that the role of the
leader can be a crucial variable in a group context,
which may have important consequences for group
decision processes and outcomes.127,158,163,171
Overall, empirical studies have yielded relatively
consistent evidence that groups with directive
leaders use less of the available information,
suggest fewer solutions and rate their leaders as
more influential in the decision process than
groups with non-directive leaders.129,157,171 A
directive style leader who states his or her opinion
in a forceful way is less likely to foster the
discussion of divergent opinions and hence may
reduce the likelihood of reaching a good
decision.128 It is important to note, however, that
most of the research in this area is concerned with
the type of leader who must lead a group, in the
sense of being ‘the boss’, and not with the type of
leader who is chairing or facilitating a meeting.
Very little is known about the effects of facilitation
or chairing on group decision-making, or which
aspects of these roles are important.128 However,
as Murphy and colleagues conclude, it seems likely
that this key role will influence group decision-
making and the quality of the decision made.128
Incentives
Research into the effect of incentives has been
concerned overwhelmingly with the relationship
between different ‘pay-for-performance’ systems
and either productivity or employee satisfaction.172
Empirical research into group incentive schemes
has focused largely on the effects of distributing
rewards equally or differentially among the group
members. Findings in this area are complex and
appear to be influenced strongly by the nature of
the task and the details of the incentive scheme.
Broadly speaking, differentially divided rewards
appear to be as effective as or occasionally more
effective than equally divided rewards.172 However,
differential division of rewards can cause
individuals to block other members of the group
(e.g. by not sharing important information) rather
than help other members on some types of task. If
blocking is a possibility, then equal division of
rewards leads to better performance.173
In DMCs, sharing of information and generation
of alternative decisions would be considered to be
signs of a better decision process, and might be
associated with higher quality decisions. Applying
these findings would imply that an equal division
of rewards within the group should result in better
decision processes (because it may avoid blocking). 
Presence of others
It is well established that the mere presence of
other people may either facilitate or inhibit
individual performance, depending on the nature
of the task and the degree of expertise that the
individual has.174 Reviews of the social facilitation
literature are inconsistent, however, as to the effect
of the presence of others on performance within
groups.129 However, effects thought to occur in the
presence of other people include apprehension
due to group judgement or evaluation, cognitive
or physical conflict as a result of being distracted
by other group members, increased effort to make
a good impression and an increase in conforming
to group norms.174 One phenomenon that affects
group performance is known as ‘social loafing’.
This describes the tendency of individuals to
expend less effort when working in a group
context compared with working alone. Although a
robust phenomenon, it is not always inevitable.127
It has been suggested that increasing the visibility
and attractiveness of the task and value of
members’ contributions may go some way to
reducing social loafing.126,127,129 In addition, an
individual’s attitude towards the group and task is
considered to predispose their motivation in the
decision situation.175
Communication
Although the study of communication in decision-
making groups has grown considerably over the
past 70 years, it would appear there is not enough
clear evidence of how communication affects
group decision-making.176 Further, there have
been no studies on how communication processes
serve to detract from or enhance the quality of
decisions that should be reached with a group’s
potential.177 However, it is suggested that groups
are more efficient if there is active communication
between members, preferably face-to-face so that
they can communicate directly with everyone in
the group.178 Although there may be a lack of
strong evidence of the impact of communication,
it would appear communication is an important
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and provide cognitive stimulation.177
Participation
Member participation is an important part of the
decision-making process, with much known about
its potential consequences.175,176 Empirical results
consistently support the notion that participation
and influence are highly associated and that a
group’s decision is more likely to reflect the
opinion of those members who have participated
more.128,180,181 In a new group, inequalities in
participation evolve quickly, with members
perceived as having higher task ability being
encouraged to participate more.182 As a result of
their additional contributions and perceived task
performance, they are more influential towards
the group decision.181 Gill and colleagues, in their
review of antecedents to member participation
within small groups, suggest that participation is
influenced by factors such as self-esteem, attitudes
towards the tasks, perceived attitudes of other
group members and group atmosphere.175
However, more research is needed to understand
how other more complex variables may interact on
the decision-making process. 
The size of the group has been shown to affect
disparities in participation. Larger groups tend to
result in less participation from group members,
with disparities being minimised in smaller
groups.162,180 However, it is not clear which
behaviours increase the quantity or quality of
participation in groups.175 In terms of gender role
effects on group participation, it has been
reported that males tend to be much more
verbally active, dominating discussions.129
Although equality of participation is expected to
lead to higher member satisfaction and improved
decision quality, it is likely to result in increased
time needed to reach a decision and possibly create
greater conflict within the group.179 However, as
already stated, although it is commonly assumed
that conflict has a negative effect on decision-
making, several studies have revealed that certain
types of conflict may improve the decision-
making.170,183 Conflict is a common part of the
group experience, and may serve different
functions depending on the stage of group
development. In particular, task-related conflict
has been demonstrated to have a positive effect,
especially in groups that encourage openness.183
Presentation of information
The way in which information is presented to a
group may influence individuals’ judgement in a
variety of ways that are important when reaching a
decision.128,164 Central to this notion is the prospect
theory, which describes how the risk-taking
behaviour is dependent on whether the decision is
positively or negatively framed (see section ‘Choice
shift and group polarisation’, p. 53). Related to this
point, Whyte164 suggests that framing may have
been an important contributing factor in
groupthink. He argues that in the fiascos studied by
Janis the decision-making group framed its
decision as a choice between definite loss and
potentially greater loss. The framing of the decision
in such a negative domain consequently influenced
and contributed to a risk-seeking tendency by the
decision group. As to what type of information is
influential, the few studies that have been reported
suggest that novel information may have the most
impact on influencing opinions.128,142
Efforts to understand the impact of information
on decision-making groups often highlight the
role of information exchange among members.127
Good information exchange combined with careful
consideration of all the information can potentially
lead to better decisions by a group.180,181 The
failure of group members to exchange information
has been a major component of the groupthink
phenomenon on defective decision-making.126 In
addition, the possibility of a faulty or inaccurate
information base has negative consequences for
the decision outcome.126
Results: effects of formal and
informal decision-making
procedures on decision process
and quality
Various formal and informal strategies have been
suggested for helping groups to reach consensus
and improve their decision-making performance.
Examples include informal strategies such as
brainstorming and devil’s advocacy, as well as
more formal strategies, such as computational
schemes or electronic decision support systems.
The effectiveness of these approaches is
thoroughly reviewed in the recent HTA report on
consensus methods in guideline development
groups,128 and hence this literature will not be
discussed in detail here. This review concluded
that formal methods of developing consensus (e.g.
Delphi technique, nominal group technique)
perform at least as well as, and often better than
informal methods. There is insufficient evidence
to know whether any one formal method is better
than any other.128
Review of small group processes relevant to data monitoring committees
66Informal decision-making procedures
Informal decision support procedures are
generally intended to improve the process of
decision-making, either by increasing the number
of alternative decisions that are considered or by
enhancing the evaluation of different options. 
Two commonly recommended techniques are
brainstorming and devil’s advocacy. 
Brainstorming is a popular technique that
encourages members to suggest large numbers of
ideas without evaluation or judgement from other
group members.126,127 Despite its popularity,
empirical data reveal that brainstorming is not
particularly productive, and may in fact be
harmful.127 Brainstorming groups consistently
produce fewer ideas and poorer quality ideas than
either individuals working alone or groups
engaged in free discussion.127,184
Devil’s advocacy is a technique whereby one of the
group members deliberately criticises and attempts
to question all that is wrong with a plan or decision,
expounding the reasons as to why the plan should
be rejected.183 Research suggests that devil’s
advocacy may reduce the quality of performance
in circumstances where tasks are well understood
and non-complex. However, when the devil’s
advocate questions valid assumptions, it may lead
to these assumptions being rejected and thus lead
to defective decision-making.183 It is considered
that devil’s advocacy is most beneficial in group
decision-making when the decision involves high
uncertainty but enough information.185
Electronic group decision support
systems 
Electronic group decision support systems (GDSSs)
act as a facilitation technique that can influence
group structure and procedures. According to the
literature, there is evidence that groups using
GDSS technologies make higher quality decision;
however, decisions will take longer to reach and it
is unclear as to what effect these technologies have
on members’ satisfaction.179 GDSS provides
groups with varying levels of technological support
depending on the group and task type. Its use
facilitates anonymous exchange, which supports
an open discussion, thus making it easier for
group members to present their ideas or solutions
to the group.171 Simultaneously being able to
input ideas and opinions is a creative process
leading to a rich source of ideas, which should
encourage broader, more active participation.171
In GDSS, anonymity is regarded as a tool to
reduce the impact of the group over its members
and this is a key factor to improved decision-
making.186 Although anonymity has frequently
been isolated as an important variable in
determining the effects of GDSS, there has been
no systematic review to date.186 The results on the
impact of computer-mediated communication on
group performance are inconclusive.186 However,
it is suggested that compared with males, females
are more likely to be affected by the absence or
lack of non-verbal communication during
computer-mediated groups.187
Traditionally, research has focused on comparing
electronically mediated groups with face-to-face
groups. However, it has been shown that
electronically supported groups processes are
different from non-computer-assisted groups and
these differences interact with other factors such as
the task and its impact on group effectiveness.188
Overall, the weight of evidence suggests that
GDSS increases equalisation of participation and
decreases domination by some individuals. The
equalising effects of GDSS are attributable to
simultaneous participation and anonymity.171,179
Implications and
recommendations for DMCs
This section will consider the implications of the
evidence described in this chapter by summarising
the findings in relation to ten of the 23 questions
about DMCs outlined in Chapter 1 (see Box 1).
The greatest weight will be given to evidence
drawn from studies of groups engaged in
judgemental and choice-dilemma tasks, especially
juries and political decision-making groups.
Throughout this section, reference will be made to
effects on the outcome of the decision-making
process (decision outcome) and effects on the
process of decision-making (decision quality). 
What should the membership of a 
DMC be? (Question 6)
Size
The relationship between group size and both
decision quality and decision outcome has been
widely researched. This research suggests that size
has very little impact on the decision made, but
may affect the quality of the decision-making
process. For example, jury sizes ranging between
six and 12 members have little effect on the
verdict itself, but larger juries are more likely to
include a wider range of opinions, which tends to
improve the process of decision-making. However,
there is a point at which size may begin to have a
negative impact on the process of decision-making
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express their views in a larger group or because
conflicts occur between the opinions expressed. A
bias towards riskier decision-making may also
occur in larger expert groups, such as DMCs.
Murphy and colleagues128 recommend an
optimum size of six to 12 members for guideline
development groups, and this also seems
appropriate for DMCs. 
Membership
There is a limited pool of potential DMC
membership because members are generally
expected to have a good understanding (and
experience) of trial design and statistics. The
mechanisms by which members are selected from
this pool for a particular DMC are obscure (see
Chapter 2); however, there is very little available
research to guide decisions about how DMC
members should be chosen or selected. It is clear
that groups that include members with a range of
opinions tend to make better quality decisions,
provided that all members have a chance to
participate in the discussion, and that any conflicts
that arise are handled appropriately. Hence,
selection methods that encourage a degree of
diversity within the group should probably be
recommended. Studies of jury selection suggest
that formal methods of selection based on
psychometric assessment of demographic
characteristics and attitudes have few advantages.
It seems unlikely that such methods would have a
role in DMC member selection. Although none of
the reviews included in this chapter considered the
role or effects of consumer representatives in
expert groups, it seems likely that if they add a
different point of view and are able to participate
fully in the discussion, they may improve the
quality of the decision made. 
Chair
Studies of juries and other small decision-making
groups indicate that the person who chairs or
leads the group can have important effects on
both decision outcome and decision quality.
Directive leaders who limit the range of views
expressed can steer the discussion and hence the
decision made. If there are large status differences
among group members, then the decision tends to
be the one preferred by the more powerful
members (which generally includes the leader)
rather than the majority. Defects in decision-
making are more frequently observed if the group
has partial and directive leadership. In addition,
groups led by leaders with more experience (or
expertise) in discussing ethical problems tend to
make better quality decisions. All of these findings
suggest that DMCs should be chaired by
experienced members, who have the skills to be
impartial and can facilitate a full discussion of the
issues.
How is independence to be maintained?
(Question 7)
There is very little research concerned with the
effects of the independence of groups (or group
members) on decision outcome or quality. Jury
research indicates that jurors tend to evaluate the
evidence they hear in the light of their experience.
If this is also the case in DMCs, then conflicts of
interest may occur. None of these reviews
considered the effects of declaring conflicts of
interest on decision quality or outcome. 
Studies of decision fiascos suggest that groups 
that are accountable for their decisions tend to
make better quality decisions. The effects of
payment on groups have largely been studied in
relation to productivity rather than decision-
making, and their implications for DMCs are
unclear. 
Should the DMC deliberations be open
or closed? (Question 8)
The presence of other people can have a
significant effect on how we act, either improving
our performance or inhibiting it. However, it is
not clear what the implications of this are for
whether DMC deliberations should be open or
closed. DMC members whose deliberations are
observed in an open meeting may be inhibited
from expressing their views and more inclined to
agree with the majority, as were the participants in
Asch’s conformity experiments.189 This would
clearly have a detrimental effect on decision
quality. Alternatively, the presence of observers
may serve to increase feelings of accountability
and enhance decision quality. Further empirical
work is required before clear recommendations
can be made on this point. 
What are the optimal practical
arrangements for interim analysis and
data monitoring? (Question 9)
Practical aspects such as the frequency and timing
of meetings have not been studied in relation to
decision quality or outcome. Communication has
been studied more extensively, and findings in this
area suggest that groups are more efficient if there
is active communication between members,
preferably face-to-face. The effects of telephone
conferences on decision quality or outcome are not
clear, but if they inhibit members from expressing
their views then they may impair decision 
quality. 
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largely been considered in the context of
electronic decision support systems. In this
situation, members’ contributions are anonymous,
which supports an open discussion and may
enhance decision quality. However, the effects of
this form of communication on decision quality or
outcome are currently unclear. 
What sort of training or preparation
should DMC members have? 
(Question 10)
Decision quality is generally enhanced if group
leaders have the skills to facilitate a discussion, can
manage conflict effectively and can be impartial.
DMC chairs who do not already possess these skills
may benefit from training. Similarly, an opportunity
to participate in discussions of ethical dilemmas
may be useful for some relatively inexperienced
DMC chairs. All members of DMCs will require
training if formal or methodical approaches to
decision-making are adopted (e.g. GDSS).
What material should be available to a
DMC? (Question 11)
Substantial empirical evidence supports the view
that the way in which information is framed can
have a significant impact on decision outcomes.
Extrapolating from this evidence, it might be
expected that DMCs will tend to avoid risks if they
are only presented with information about the
benefits of treatments, but will have a greater
tolerance for risk if they are only given
information about the costs or harms associated
with different treatments. To avoid these biases,
the material available to DMCs should contain full
information about the benefits and harms of all
the treatments under consideration. 
Studies of juries have shown that the strength of
evidence presented in terms of both quantity and
quality is a major determinant of decision
outcome. Juries that are presented with strong
evidence are more likely to convict a defendant in
error than juries that hear weaker evidence. For
example, juries presented with statements from
several witnesses are more likely to convict than
juries that only hear evidence from one or two
witnesses. If this applies equally to DMCs, then it
might be expected that providing large quantities
of detailed information (e.g. about secondary
outcomes) would increase the chances of making a
mistaken decision. In addition to this, jury
decisions are clearly influenced by all of the
information they are given, and not just the
evidence that is directly relevant to the case.
Again, if this occurs in DMCs, biases may occur if
too much information is provided about secondary
outcomes or subsidiary hypotheses. Guidance
about ‘standard’ data sets to be presented to
DMCs, or restriction of DMC discussions to
primary outcome data may help to reduce the
risks of error associated with strong evidence or
excess information. 
Prior publicity about criminal or civil cases has a
strong effect on juries and can cause significant
bias. It is unlikely that most DMCs will have been
exposed to media publicity about the trials they
consider, although this may occur in some
circumstances. However, care should be taken to
avoid excessive publicity around trials that will be
considered by DMCs. 
How should the decisions or
recommendations be reached within
the DMC? (Question 16)
Criteria for guiding deliberations
It is not currently clear whether DMCs use legally
defined standards of proof to guide their
deliberations; that is, whether DMCs are 
required to decide that a trial should stop or
continue beyond a reasonable doubt, or on the
basis of clear and convincing evidence or on the
basis of a preponderance of evidence. These
differing legal standards of proof are associated
with different decision outcomes in studies of
juries. If different DMCs (or members within a
DMC) use different standards (implicitly or
explicitly) then significant inconsistencies and
apparent biases may occur. To avoid this, guidance
should be provided to DMCs about standards of
proof, and the standard being used should be
made explicit. 
Process of decision-making
As already discussed (section ‘What should the
membership of a DMC be?’, p. 67), the quality of
decision-making is improved if a range of
opinions is expressed and all members have an
opportunity to participate in the discussion.
Following discussion, a decision may be made on
the basis of either a unanimous or a majority view.
Jury studies indicate that the choice of decision
rule (majority or unanimous) has little effect on
the decision outcome, but does influence decision
quality. Juries that are required to reach a
unanimous decision discuss the case for longer
and make greater efforts to resolve conflicting
views. As a consequence, unanimous decisions are
generally of a better quality. However, a
unanimous decision rule is also more likely to
result in a hung jury that is unable to reach a
decision. 
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polls to gauge the range of views and/or to achieve
a final decision. Jury studies indicate that the
timing of these votes can alter both decision
quality and decision outcomes. An early vote (or
public expression of opinion) tends to limit the
amount of discussion and increase the tendency of
group members to conform to the majority view. A
quick decision is generally achieved, but is of
relatively poor quality. Frequent and regular votes
during the deliberations prolong the proceedings,
but increase the chances that the group will
ultimately reach a unanimous verdict. Secret votes
are useful early in the deliberations because they
reduce the pressure to conform before a full
discussion has been held. Later in the
proceedings, public votes are more useful because
they maximise the likelihood that individuals will
consider changing their opinion. Overall, the use
of voting is to be recommended so long as it
follows a full discussion of all views. 
Formal methods of achieving consensus in groups
are generally as good as or better than informal
methods, and may be useful in some DMCs. The
technique of devil’s advocacy, in which one or
more members deliberately present a contradictory
view to promote discussion, can be useful in
improving decision quality if the decision involves
a high degree of uncertainty or complex
information, or if the group is homogeneous.
GDSSs using electronic forms of communication
increase participation by all members and reduce
the risk that any one member will dominate the
discussion. It is not currently clear whether these
effects translate into benefits for decision quality
or outcome. 
How should ethical issues be handled in
DMCs? (Question 19)
Discussion of ethical issues is the main business of
DMCs. Evidence from these reviews suggests that
DMC members (and especially the chair) should
have some experience of discussing this type of
issue (see Case Study A in Chapter 6). 
What should be done in ‘difficult’
situations? (Question 21)
‘Difficult’ situations may occur because of
unforeseen circumstances or external pressures.
The limited available evidence suggests that these
situations may have less impact on decision quality
and outcome than might be expected. Difficult
situations are likely to increase the likelihood of
conflict between group members, which tends to
improve the quality of decisions, providing that all
opposing views are expressed and considered.
Circumstances that limit the available time for
discussion or make it more difficult for all
members to participate (e.g. the need for
meetings at short notice) could have a deleterious
effect. In these circumstances, formal decision
support techniques may be helpful. This may also
be the case if unforeseen circumstances increase
the complexity of the information that a DMC has
to consider. 
Should some DMC decisions be
considered to be ‘errors’? (Question 22)
Group decision errors can be defined as ‘those
occasions when the team’s decision-making
activities fail to achieve its intended outcome’.131
From this perspective, a DMC decision would be
considered to be an error either if current trial
participants were exposed to harm from the
experimental drug or procedure, or if future
patients were unable to benefit from it. It is rare
that an opportunity emerges to determine the
‘correct’ decision in real-life decision-making
groups. For this reason, field studies usually focus
on procedural criteria that should theoretically be
related to the accuracy of the decision. These
include thorough review of the evidence, accurate
comprehension of the instructions, active
participation by all group members, resolution of
differences through discussion and systematic
matching of case facts to the criteria for various
decision options.140 The absence of any of these
characteristics is assumed to increase the
likelihood of an inaccurate or erroneous 
decision. 
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Introduction
This chapter reviews the information provided on
DMCs in main published articles of a sample of
RCTs in order to describe their use and reporting.
Selected general and specialist medical journals
were handsearched for the year 2000 to provide a
cross-sectional picture. In addition, the general
medical journals were handsearched for 1990 to
allow a comparison across time for these journals.
Methods
Choice of journals for inclusion
The aim of this review was to be systematic but not
exhaustive. A sample of RCTs was identified by
searching selected general medical journals and
specialist medical journals covering four disease
areas in which many RCTs have been conducted:
cardiology, infection and immunity, oncology and
psychiatry. The higher impact journals relating to
the chosen disease areas were identified from the
1999 Journal Citation Report (Science Edition).190 At
least four journals that stated that their remit
included reporting RCTs were selected for each
disease area. Journals within each speciality,
ranked by citation impact factor, were examined
from the top of the list until the sample number of
journals had been selected from each list (see
below). Journals were excluded if the journal’s
remit did not include the publication of RCTs or
the journal was US based and three higher ranked
US-based journals had already been selected. This
was to ensure that some non-US journals were
included for each speciality.
For both oncology and psychiatry five journals
were selected; although Leukemia (oncology) and
Neuropsychopharmacology (psychiatry) aim to publish
RCTs, in practice, they publish very few. The
number of general medical journals was also
increased to include the top six journals so that at
least two were non-US based. Table 7 shows the
included journals and their 1999 impact factor
scores. 
Handsearching methods
Journals were handsearched to identify the main
published report of RCTs in human subjects that
intended to evaluate therapeutic or preventive
healthcare interventions. The reported use of
DMCs was estimated from the proportion of
identified RCTs that explicitly mentioned the use
of a DMC, although inevitably this is likely to be
an underestimate of actual use. 
A single researcher handsearched hard copies of
each included journal for the year 2000 for
reports of RCTs. The one exception was Infection
and Immunity. After an unproductive and time-
consuming search of the first two volumes of this
journal, online searches were used to identify the
few RCTs published in 2000. All sections of each
identified article were searched for relevant
information, including the Acknowledgements.
After searching was completed, the same
researcher checked a 20% random sample,
stratified by year and journal category (general
versus specific), for quality-control purposes. 
Details for extraction
Details on the disease, trial treatments, planned
and actual sample size, recruitment time and
general design were collected (see Appendix 10).
Information on the existence of a DMC and
performing of interim analyses was collected
separately; that is, it was not assumed that interim
analyses were planned just because use of a DMC
was reported or vice versa. If any details were not
included in the main trial report earlier published
papers on the trial referred to in the main report
(e.g. papers on methodology and/or preliminary
results) were examined, wherever possible. 
Scope of searching
Although all selected journals were handsearched
for eligible RCTs published in 2000, only the
selected general medical journals were
handsearched for 1990. Therefore, the RCTs
identified in 2000 give a broad contemporary
cross-section of the reported use of DMCs,
whereas the comparison of 1990 and 2000 gives
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TABLE 7 Details of included journals and reported DMC use in 2000
Journal category Journal Impact factora Trials with  Total trials
DMC reported
General New England Journal of Medicine 28.86 22 (35%) 62
Journal of the American Medical Association 11.45 12 (24%) 49
Lancet 10.20 28 (32%) 88
Annals of Internal Medicine 10.10 5 (24%) 21
Archives of Internal Medicine 6.71 3 (11%) 28
British Medical Journal 5.14 0 (0%) 34
General total 70 (25%) 282
Cardiology Circulation 9.90 14 (23%) 60
Journal of the American College of Cardiology 7.37 5 (12%) 41
Stroke 5.54 7 (30%) 23
European Heart Journal 3.21 6 (29%) 21
Cardiology total 31 (21%) 145
Infection and Immunity AIDS 6.93 5 (21%) 24
Journal of Infectious Diseases 4.84 4 (19%) 21
Infection and Immunity 4.18 1 (33%) 3
Journal of Antimicrobial Chemotherapy 3.30 0 (0%) 8
Infection total 10 (18%) 56
Oncology Journal of the National Cancer Institute 12.95 0 (0%) 12
Journal of Clinical Oncology 7.96 5 (8%) 60
Cancer 3.63 1 (6%) 18
Leukemia 3.56 1 (50%) 2
British Journal of Cancer 3.28 1 (9%) 11
Oncology total 8 (8%) 103
Psychiatry Archives of General Psychiatry 10.95 0 (0%) 20
American Journal of Psychiatry 6.34 0 (0%) 20
Neuropsychopharmacology 4.86 0 (0%) 4
Journal of Clinical Psychiatry 4.17 0 (0%) 21
British Journal of Psychiatry 4.09 0 (0%) 11
Psychiatry total 0 (0%) 76
General medical journals  70 (25%) 282
Specialist medical journals  50 (13%) 380
Overall total 120 (18%) 662
a According to the 1999 Science Citation Index.190
Publication year
1990 2000
Collected Collected Comparison 2
Not collected Collected
Comparison 1
General
Specialist
Medical journal
category
FIGURE 5 Study design: depiction of data collection cells. Comparison 1: cross-sectional review of reported DMC use in trials
published in 2000 in general and specialist medical journals; comparison 2: repeated cross-sectional review of reported DMC use in
trials published in 1990 and 2000 in general medical journals. an indication of changes in conduct and/or
reporting over a 10-year period in the general
medical journals (Figure 5).
Analyses and categorisation
Data were collected and stored in a specially
created database (MS Access 2000, version 9.0)
with analyses performed using Stata (version 8.0,
TX) and MS Excel (2000, version 9.0). To perform
analyses on the continuous variables collected,
such as the intended size of the trial,
categorisation was performed. Category
boundaries were chosen after data collection was
complete to produce approximately evenly sized
groups. Data categories were collapsed for
inclusion in univariate and multivariate logistic
regression models where the reported use of a
DMC was the independent variable. Separate
analyses were performed for the data relating to
trials published in 2000 and for the data relating
to trials published in the general medical journals.
Variables were excluded from these two
multivariate analyses if they greatly decreased the
available sample size for the model.
Results
After approximately 150 hours of handsearching,
866 trials that met the inclusion criteria were
identified. For 2000, 662 trials were identified and
are included in the cross-sectional analysis (282 in
general medical journals and 380 in specialist
journals). For the comparison by year of
publication in the general medical journals, 486
trials were identified, 204 in 1990 and 282 in
2000; these latter 282 articles appear in both of
the comparisons reported (Figure 5). 
Most articles did not report at least one item of
data sought for this review. Indeed, the reports of
only five (<1%) trials overall provided a complete
set of the data, including details of interim
analyses and the DMC (e.g. number of members,
any formal stopping guideline).
Cross-sectional review of trials
published in general and specialist
medical journals in 2000
Trials and reporting
Of the 662 eligible trials identified in 2000, 120
(18%) explicitly reported the use of a DMC.
Planned interim analyses were reported for 107
(16%) trials, and 77 (12%) reported use of both a
DMC and planned interim analyses. Planned
interim analyses were reported in 30/107 (28%)
trials, but these made no explicit mention of a
DMC, and 41/120 (34%) of trials explicitly
mentioned a DMC but made no explicit mention
of planned interim analyses. In total, 156 (24%)
trials mentioned either the use of a DMC or
interim analyses (planned or unplanned) or both.
In nine trials it was apparent that no DMC was
involved in the trial and eight reported that
interim analyses were neither planned nor
performed.
In 2000, a DMC was reported more often in the
general medical journals than in the specialist
journals (Table 7): 70/282 (25%) versus 50/380
(13%). Excluding the journals with fewer than ten
published trials, the journals with the highest
proportion of trials reporting DMCs were New
England Journal of Medicine, The Lancet and Stroke,
in which DMCs were reported for approximately
one-third of trials. None of the 76 trials published
in psychiatry journals reported the use of a DMC. 
Cardiology, oncology and psychiatry were the
disease areas most commonly covered by the
included trials (Table 8). Excluding the disease
areas with fewer than ten published trials, the use
of a DMC was reported most often in cardiology
and HIV/AIDS trials. Only one of 29 psychiatry
trials published in the general medical journals
reported a DMC.
None of 21 trials of educational interventions
reported the use of a DMC. The reported use of a
DMC was higher in trials that had at least one arm
using drug, placebo, vaccination or surgery 
(Table 9). Reporting of DMC use was more
common for double-blind trials [73/296 (25%) if
double-blind versus 47/363 (13%) if not; three
unclear]. The reported use of DMCs was higher if
a pharmaceutical company was involved in the
trial in some way than if there was no involvement
[74/305 (24%) versus 35/250 (14%)]. The levels of
reported DMC use were similar (23–25%) over
various levels of pharmaceutical company input:
pharmaceutical company trial, full pharmaceutical
company funding, partial pharmaceutical
company funding and free/discounted drug
supplies. No information regarding funding
sources was given in 107 (16%) of the reports.
No evidence was found that the reported use of a
DMC was related to the number of treatment arms
(18%, 16% and 15% for two, three and more than
three arms, respectively), but DMCs were more
often reported for factorial trials than for non-
factorial trials [8/18 (44%) versus 106/644 (16%)],
although the factorial trials were generally larger.
Of 15 trials identified as cluster-randomised, none
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TABLE 8 Reported DMC use in trials published during 2000 by disease areaa
General Specialist
Disease area Total DMC reported Totalb DMC reported
Accident and Emergency 1 0 (0%) NAb ––
AIDS/HIV 13 6 (46%) 33 6 (18%)
Arthritis 9 3 (33%) NAb ––
Asthma 7 2 (29%) NAb ––
Cardiology 52 23 (44%) 141 32 (23%)
Diabetes 5 0 (0%) 1b 0 (0%)
Elderly 1 0 (0%) NAb ––
Endocrine 3 0 (0%) NAb ––
Gastroenterology 15 2 (13%) NAb ––
Haemaotology 2 0 (0%) NAb ––
Infection 29 6 (21%) 12 2 (17%)
Miscellaneous 6 1 (17%) NAb ––
Neonatal 4 1 (25%) NAb ––
Nephrology 6 0 (0%) NAb ––
Neurology 10 2 (20%) NAb ––
Nutrition 9 0 (0%) NAb ––
Obstetrics and Gynaecology 6 2 (33%) NAb ––
Oncology 22 6 (27%) 104 8 (8%)
Orthopaedics 5 2 (40%) NAb ––
Osteoporosis 2 1 (50%) NAb ––
Palliative 1 0 (0%) NAb ––
Patient care 2 0 (0%) NAb ––
Primary care 4 1 (25%) NAb ––
Psychiatry 29 1 (3%) 77b 0 (0%)
Respiration 21 7 (33%) 2b 0 (0%)
Sexual health 2 0 (0%) 1b 0 (0%)
Surgery 8 1 (13%) NAb ––
Transplantation 3 2 (67%) NAb ––
Vaccination 5 1 (20%) 8 2 (25%)
Total 282 70 (25%) 380 50 (13%)
a It is intended that comparisons be made down columns or across rows, but not diagonally.
b Many categories are not applicable (NA) and others have small numbers; the specialist journals selected were not
expected to cover these areas in great depth, e.g. some trials published in the cardiology journals were classified under
diabetes, nephrology and psychiatry.
TABLE 9 Reported DMC use by intervention evaluated in trials published during 2000
At least one arm containing: Totala DMC reported
Drug 447 99 (22%)
Placebo 241 61 (25%)
No treatment  127 14 (11%)
Surgery 37 9 (24%)
Education 21 0 (0%)
Image/scan 7 1 (14%)
Radiotherapy 13 1 (8%)
Vaccination 14 3 (21%)
Otherb 165 15 (9%)
a Categories are not mutually exclusive.
b For example, follow-up scheduling, choice of carer, hormone therapy (separated here from drug treatment) and nutrition
(including vitamin supplementation).explicitly reported use of a DMC. For only one 
of 37 cross-over trials was a DMC reported,
perhaps reflecting their shorter duration and
smaller size.
The trial size bore some relation to whether the
trial would report a DMC. Both the intended and
actual size of the trial were collected, where
available. Almost half of the reports did not state
the intended sample size [324/662 (49%)]. Only 
51 trials intended to recruit at least 1000
participants, 24 of which were in cardiology. 
Table 10 (rightmost column) shows that, as the
intended size of a trial increased, so did the
likelihood that it reports a DMC. A similar trend
was seen when looking at the actual size of the
trial (Table 10, bottom row). However, the actual
number recruited may not reflect the number
initially intended at the design stage, as trials may
be stopped early or have their targets revised
upwards during the accrual phase. 
Multicentre trials were defined as having more
than two participating sites. The use of a DMC was
more frequently reported for multicentre trials
than for single- or two-centre trials [106/401 (26%)
versus 11/233 (5%); the number of centres was not
reported in 28 trials], although this may be a
reflection of the larger size of multicentre trials
(median=315 participants, where known) over
single- and two-centre trials (median=80
participants) and their longer duration.
Some commentators have suggested that DMCs
are only required where survival is a primary end-
point of the trial.13,23 A DMC was reported more
often for those with survival end-points [15/49
(31%)] and event-free survival primary end-points
[22/62 (35%)] than for trials where the primary
end-point was not survival based [83/551 (15%)].
There is likely to be confounding here by the
intended sample size: there was a trend towards
larger intended sample size in trials with a
survival-based end-point ( 2
(3) = 13.44, p = 0.004).
The majority of these trials with survival-based
primary end-points were conducted in cancer
[60/111 (54%)] and cardiology [34/111 (31%)]. 
Approximately half of the included trials recruited
some or all participants from the USA; 232 (35%)
trials from the USA only and 74 (11%) from the
USA plus at least one other country. There was a
higher rate of reporting of DMC use in trials
involving the USA and at least one other country.
However, trials involving the USA and other
countries’ trials tended to be larger, regardless of
whether a DMC was reported (median 1685
patients with DMC reported and 353 if no DMC
reported for trials with recruitment from the USA
and other countries, versus 480 with a DMC
reported and 150 if no DMC reported for other
recruitment combinations).
Logistic regression models were constructed to
look at the relative importance of 14 of the
variables discussed above in predicting the
reported use of a DMC. Table 11 presents a
summary of 14 univariate analyses and one
multivariate analysis including the ten variables
with adequate data. The more important
explanatory variables in the multivariate analysis
(p < 0.1) were increasing number of patients
actually recruited, at least one arm involving a
placebo, factorial design, survival-based primary
end-point, multicentre trial, publication in a
general medical journal and US involvement in
the trial. The multivariate analysis was based on
519/662 (79%) articles where all of these variables
were available. Those with full data were more
often published in the general medical journals,
were larger, contained a placebo arm, had
multicentre recruitment and involved the USA
than did trials that were excluded from the model
because of missing values. 
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TABLE 10 Reported DMC use by size of trial in those published during 2000a
Intended no. of
Actual no. of participants
participants <100 100 to <500 500 to <1000 ≥ 1000 Total
<100 54 (7%) 9 (0%) 0 (0%) 0 (0%) 63 (6%)
100 to <500 5 (0%) 164 (16%) 7 (14%) 0 (0%) 176 (16%)
500 to <1000 0 (0%) 4 (50%) 38 (21%) 5 (20%) 47 (23%)
1000 0 (0%) 1 (100%) 4 (25%) 47 (74%) 52 (71%)
Missing 137 (5%) 131 (11%) 23 (17%) 33 (45%) 324 (12%)
Total 196 (6%) 309 (14%) 72 (19%) 85 (60%) 662 (18%)
a Number of trials reporting DMC use/number of trials (% trials reporting DMC use).Details of DMCs and interim analyses
Where interim analyses or DMC use were reported
further details were extracted from the paper. For
2000, some data could be obtained for 150/156
trials reporting a DMC and/or interim analyses.
Considering here the trials published in 2000 (see
2000 data in Table 12), the most commonly
reported methods were from the frequentist
‘group sequential’ class of rules (e.g. O’Brien &
Fleming) in both general medical and specialist
journals. (For further details of these rules, see
Appendix 1). For 92/150 trials (61%), these details
were not provided.
Of these 150 trials, the planned number of
analyses was reported explicitly for 51 (34%) trials
and deduced in a further 29 (19%) trials (e.g.
reported as ‘6-monthly’ or ‘at least five analyses’).
The actual number of analyses was reported for 
63 (42%) trials, with an indication of this number
given in a further 22 (15%) trials. Where the
planned and actual number of analyses were
reported or indicated, these matched in 25/54
(46%) cases. Where the number of analyses did not
match, 18/29 (62%) stopped early, whereas 11/25
(44%) stopped early where the numbers matched.
In the 120 trials where a DMC was reported, the
size of the DMC was explicitly described in 72
(60%) trials. The number of members ranged
from one to ten with a median of 4 overall (4 in
specialist journals, 4.5 in general journals). In 43
cases (36%), the DMC was explicitly reported as
being ‘independent’, although a definition of
independence was rarely given (see Chapter 2,
question 7).
Repeated cross-sectional review of
trials published in general medical
journals in 1990 and 2000
Trials and reporting
In total, 204 eligible trials were identified from
1990 and 282 from 2000, an increase of 38%
(Table 13). Much of the overall increase was
accounted for by The Lancet and Journal of the
American Medical Association. The number of trials
Cross-sectional review of the reported use of data monitoring committees
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TABLE 11 Results from univariate and multivariate logistic regression models for trials published in general and specialist medical
journals in 2000
Factorsa, b Univariate analyses Multivariate analysis
n OR 95% CI p-Valuec n OR 95% CI p-Valuec
Year 2000 data
Actual sample size 662 2.811 2.262 to 3.494 <0.001 519 2.368 1.779 to 3.151 <0.001
Placebo involved 662 2.079 1.394 to 3.102 <0.001 519 2.246 1.286 to 3.924 0.004
Factorial design 662 3.800 1.467 to 9.843 0.006 519 5.780 1.680 to 19.889 0.005
Primary end-point 662 2.819 1.782 to 4.459 <0.001 519 2.391 1.245 to 4.591 0.009
Centres 604 6.272 3.284 to 11.977 <0.001 519 2.487 1.112 to 5.565 0.027
Journal category 662 0.459 0.307 to 0.686 <0.001 519 0.608 0.357 to 1.037 0.068
USA involvement 662 2.019 1.350 to 3.022 0.001 519 1.617 0.965 to 2.710 0.068
Drugs involved 662 2.628 1.590 to 4.344 <0.001 519 1.801 0.861 to 3.769 0.118
Cross-over design 660 0.121 0.016 to 0.894 0.038 519 0.317 0.038 to 2.676 0.291
Pharma involvement 555 1.968 1.264 to 3.064 0.003 519 0.906 0.487 to1.687 0.756
Planned sample size 338 3.237 2.381 to 4.400 <0.001 NAd
Recruitment length 381 0.929 0.661 to 1.307  0.672 NAd
Follow-up length 405 1.833 1.300 to 2.584 0.001 NAd
Primary analysis time 436 1.559 1.191 to 2.040 0.001 NAd
a Separate models were constructed for the year 2000 data and the general medical journals.
b Planned and actual sample size: <100 (ref.), 100–499, 500–999, ≥ 1000 patients; Placebo involved: no placebo-based arm
(ref.) versus at least one placebo-based arm; Factorial design: no (ref.) versus yes; Primary end-point: survival-based versus
non-survival based (ref.); Centres: single centre (ref.) versus multicentre; Journal category: general medical (ref.) versus
specialist medical; USA involvement: no involvement (ref.) versus some involvement (ref.); Drugs involved: no drug-based
arm (ref.) versus at least one drug-based arm; Cross-over design: no (ref.) versus yes; Pharmaceutical company
involvement: no involvement (ref.) versus some involvement; Recruitment length: <12 months (ref.), 12–60 months, 
>60 months; Follow-up length: <3 months (ref.), 3 months to 1 year, 1–5 years, >5 years; Primary analysis time: 
<3 months, 3 months to 1 year, 1–5 years, >5 years.
c p-Value for test for interaction.
d Not included in multivariate analysis owing to quantity of missing data.
n, number of trials with available data; OR, odds ratio; 95% CI, 95% confidence interval for odds ratio; 
Pharma, pharmaceutical company; ref., reference category.reporting the use of a DMC increased from 21/204
(10%) in 1990 to 70/282 (25%) in 2000 (relative
increase=141%, 95% CI 53 to 279%). Similarly,
the reporting of planned interim analyses
increased from 21 (10%) to 59 (21%). An increased
proportion of trials reporting DMC use was seen
in all journals, with the exception of the British
Medical Journal, where no trials with DMCs were
detected in either period (Table 13). 
Differences between the type of trial published in
1990 and 2000 were investigated to see whether
this could explain any of the increase in reporting:
as noted, for year 2000 trials, longer follow-up and
time to analysis were each associated with increased
reporting of DMC use. Although the analysis times
and follow-up lengths of the identified trials in the
general medical journals in 1990 and 2000 were
very similar, the relation to reported DMC use was
only seen in the 2000 data. With regard to other
factors that could affect reporting, the proportion
of double-blind trials [114/204 (56%) versus
135/282 (48%)], placebo-controlled trials [107/204
(52%) versus 130/282 (46%)] and cross-over trials
[28/204 (14%) versus 13/282 (5%)] each decreased
from 1990 to 2000, although the explicit reporting
of the double-dummy approach increased [2/204
(1%) versus 13/282 (5%)]. Other than a slight
decrease in placebo-controlled trials, the type of
treatment comparison changed little over time,
although the proportion of trials with three or
more arms increased [45/204 (22%) versus 80/282
(28%)]. There was a small decrease [30/204 (15%)
versus 21/282 (7%)] in the proportion of drug
trials for which the nature of any pharmaceutical
industry involvement was unclear. 
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TABLE 12 Form of interim analyses guidelines reported by year of publication and by journal type
1990 2000 2000
Methodology for interim analysesa, b General General Specialist Total
Frequentist (group sequential) 5 (31%)c 13 (35%) 7 (33%) 25 (34%)
Frequentist (continuous) 5 (31%) 7 (19%) 6 (29%) 18 (24%)
Frequentist (informal) 4 (25%) 10 (27%) 3 (14%) 17 (23%)
Frequentist (group sequential) and  0 (0%) 1 (3%) 0 (0%) 1 (1%)
decision theory
Bayesian 0 (0%) 0 (0%) 1 (5%) 1 (1%)
Other 1 (6%) 2 (5%) 1 (5%) 4 (5%)
None 1 (6%) 4 (11%) 3 (14%) 8 (11%)
Subtotal 16 – 37 – 21 – 74 –
Missing 13 (45%) 47 (56%) 45 (68%) 105 (59%)
Total 29 (100%) 84 (100%) 66 (100%) 179 (100%)
a Further details on these categories can be found in Appendix 1.
b The second and third columns report general medical journal data for 1990 and 2000 and the third and fourth columns
compare the data for trials published in 2000 in the general and specialist journals.
c Percentages are on subtotal of trials with non-missing data.
TABLE 13 Change between 1990 and 2000 in the total number of trials published in the general medical journals and the number of
trials reporting DMC use
Total trials reported Trials reporting DMC use
Journal 1990 2000 % Changea 1990 2000 Change in %b
Ann Intern Med 33 21 –36% 1 (3%) 5 (24%) 21%
Archives Intern Med 22 28 27% 0 (0%) 3 (11%) 11%
BMJ 25 34 36% 0 (0%) 0 (0%) 0%
JAMA 19 49 158% 1 (5%) 12 (24%) 19%
Lancet 40 88 120% 6 (15%) 28 (32%) 17%
N Engl J Med 65 62 –5% 13 (20%) 22 (35%) 12%
Total 204 282 38% 21 (10%) 70 (25%) 15%
a Change in trials published between 1990 and 2000 as a percentage of trials published in 1990.
b Change in percentage of trials reporting use of a DMC between 1990 and 2000.As discussed previously, for all journals in 2000
trial size was associated with the reporting of
DMC. There were changes in factors related to
trial size between 1990 and 2000 that may explain
the increase in reported use of DMCs. For
instance, the proportion of multicentre trials
increased from 84/204 (41%) to 185/282 (66%).
The intended number of participants was more
frequently reported [62/204 (30%) versus 179/282
(63%)]; where this information was available it was
not apparent that the planned trial size had
greatly increased, with the median planned size
only increasing from 225 to 300 (data from 62 and
179 trials, respectively). The actual sample size was
available for all trials. There was a larger increase
in the median actual trial size from 1990 to 2000
(204 and 282 trials, respectively) (Table 14).
Logistic regression models were constructed to
explore the relative importance of 15 variables
listed above in predicting the reported use of a
DMC. Table 15 presents a summary of 15
univariate analyses and one multivariate analysis
including the ten variables with adequate data.
The more important explanatory variables 
(p < 0.1) in the multivariate analysis were survival-
based end-point, increasing number of patients
actually recruited, multicentre trial, at least one
arm involving a drug, at least one arm involving a
placebo, US involvement in the trial and year of
publication. The multivariate analysis was based
on 413/486 (85%) articles where all of the
variables were available. However, the multivariate
analysis model included proportionately more
trials that were published in 2000 and involved
the USA than did trials that were excluded from
the model because of missing values.
Details of DMCs and interim analyses
In total, 113 trials in the general medical journals
reported the use of a DMC, planned interim
analyses or both; 29/204 (14%) trials from 1990
and 84/282 (30%) trials from 2000. Details of
statistical stopping rules for interim analysis were
less clearly reported in 2000 than in 1990 (Table 12,
first and second data columns). The planned
number of analyses was reported explicitly for five
(17%) and 32 (38%) trials in 1990 and 2000,
respectively, and deduced for a further six (21%)
and 13 (15%) trials. Where the planned and actual
number of analyses matched, 1/2 (50%) trials from
1990 and 8/15 (53%) trials from 2000 were
stopped early.
In the 91 cases where a DMC was reported (21
from 1990, 70 from 2000) the size of the DMC was
explicitly reported in 16 (76%) and 48 (69%) trials.
The median number of DMC members was 3.5
(range one to ten) in 1990, and 4.5 (range one to
ten) in 2000. The proportion of DMCs explicitly
reported as independent increased from 5 (24%)
in 1990 to 27 (39%) in 2000.
Nomenclature
The DMCs identified during this review had a
variety of names (Table 16). The most common
were data and safety monitoring board and data
and safety monitoring committee. This may reflect
the preponderance of USA-based trials. None of
the reported DMCs used the UK MRC’s current
preferred choice of name, data monitoring and
ethics committee,59 although the naming policy
was probably introduced too recently to have yet
permeated into any published reports. Similarly,
the names treatment effects monitoring committee
(TEMC), the favoured name of some
commentators18 and independent data monitoring
committee (IDMC), as used by the ICH E9
guidelines,57 were not detected.
Table 17 reports the frequency of keywords used in
the names of the reported DMCs. Apart from
board or committee, the most common words were
monitoring, safety and data. Nineteen different
names using only combinations of these words
were found, representing 113/141 (80%) of the
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TABLE 14 Number of trial participants by journal and year of publication in general medical journals
1990 2000
Journal Median Interquartile range Median Interquartile range
Ann Intern Med 50 (24–160) 194 (72–320)
Arch Intern Med 135 (60–303) 340.5 (138–791.5)
BMJ 97 (40–257) 134.5 (360–614)
JAMA 99 (18–229) 219 (138–1062)
Lancet 93 (60–484) 350.5 (125–837)
N Engl J Med 146 (60–404) 281 (100–683)
Overall 101.5 (41.5–315) 307 (120–751)reported DMCs, and only 28 (20%) DMCs used a
word in the name other than these five words.
Five further trials reported the presence of some
external monitoring: an independent safety
monitor (two trials), an independent safety
reviewer, a medical monitor and a study statistical
consultant.
Discussion
Principal findings
DMCs were explicitly mentioned in a minority of
main published reports of RCTs. Reported use of
DMCs varied considerably by medical speciality
and certain design features, aspects that are not
independent. There were no reports of DMC use
in psychiatry trials; this may reflect a judgement
that DMCs are not necessary because such trials
are typically small and short, and do not have
survival-based primary end-points. There was a
relationship between trial size and reported DMC
use, with larger trials more likely to report DMCs.
However, this does not necessarily mean that
larger trials use a DMC more often than smaller
trials, but could indicate that they were more likely
to report the use of a DMC when there was one;
this would be possible if, for example, they tend to
be awarded greater reporting space by journals. 
The increased proportion of trials reporting DMC
over the decade 1990 to 2000 probably reflects
greater use of DMCs, although it may also be due
to better reporting, or perhaps reflect a change in
the nature of the trials being reported. Some
improved reporting in 2000 may be due to the
application of the Consolidated Standards of
Reporting Trials (CONSORT) statement,191 which
aims to improve the reporting of clinical trials in
general, including the reporting of stopping rules.
However, there remains considerable scope for
better reporting of the way in which accumulating
data in trials are monitored. This is reflected by
Health Technology Assessment 2005; Vol. 9: No. 7
79
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.
TABLE 15 Results from univariate and multivariate logistic regression models for trials published in general medical journals in 1990
and 2000
Factorsa, b Univariate analyses Multivariate analysis
n OR 95% CI p-Valuec n OR 95% CI p-Valuec
General medical journals
Primary end-point 486 8.772 4.804 to 16.017 <0.001 410 9.893 3.953 to 24.755 <0.001
Actual sample size 486 3.099 2.420 to 3.970 <0.001 410 2.468 1.757 to 3.467 <0.001
Centres 461 12.000 5.405 to 26.640 <0.001 410 3.538 1.361 to 9.196 0.010
Drugs involved 486 2.637 1.498 to 4.639 0.001 410 3.218 1.252 to 8.273 0.015
Placebo involved 486 1.769 1.118 to 2.798 0.015 410 2.080 1.038 to 4.169 0.039
USA involvement 486 2.128 1.317 to 3.438 0.002 410 1.996 1.034 to 3.852 0.039
Publication year 486 2.877 1.700 to 4.870 <0.001 410 1.972 0.940 to 4.140 0.073
Pharma involvement 435 1.887 1.151 to 3.096 0.012 410 0.615 0.276 to 1.372 0.235
Factorial design 486 2.718 0.962 to 7.681 0.059 410 1.347 0.211 to 8.605 0.753
Cross-over design 481 0.202 0.048 to 0.854 0.030 410 1.031 0.198 to 5.372 0.971
Planned sample size 241 2.860 2.056 to 3.979 <0.001 NAd
Follow-up length 325 2.397 1.546 to 3.717 <0.001 NAd
Primary analysis time 306 1.955 1.376 to 2.779 <0.001 NAd
Recruitment length 286 1.279 0.841 to 1.943 0.250 NAd
Cluster design 486 0.428 0.054 to 3.385 0.421 NAe
a Separate models were constructed for the year 2000 data and the general medical journals.
b Primary end-point: survival-based versus non-survival based (ref.); Planned and actual sample size: <100 (ref.), 100–499,
500–999, ≥ 1000 patients; Centres: single centre (ref.) versus multicentre; Drugs involved: no drug-based arm (ref.) versus
at least one drug-based arm; Placebo involved: no placebo-based arm (ref.) versus at least one placebo-based arm; 
USA involvement: no involvement (ref.) versus some involvement (ref.); Publication year: 1990 (ref.) versus 2000;
Pharmaceutical company involvement: no involvement (ref.) versus some involvement; Factorial design: no (ref.) versus
yes; Cross-over design: no (ref.) versus yes; Follow-up length: <3 months (ref.), 3 months to 1 year, 1–5 years, >5 years;
Primary analysis time: <3 months, 3 months to 1 year, 1–5 years, >5 years; Recruitment length: <12 months (ref.), 
12–60 months, >60 months; Cluster design: not cluster RCT (ref.), cluster RCT.
c p-Value for test for interaction.
d Not included in multivariate analysis owing to quantity of missing data.
e Not included in multivariate analysis because no cluster randomised trials with reported DMC use in year 2000 data.
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TABLE 16 Reporting names for DMC in review of trials
Reported DMC name 1990  2000  2000  Combined
General medical General medical Specialist
Data and safety monitoring board 2 (10%) 21 (30%) 7 (14%) 30 (21%)
Data and safety monitoring committee 0 (0%) 7 (10%) 8 (16%) 15 (11%)
Data monitoring committee 3 (14%) 6 (9%) 3 (6%) 12 (9%)
Data safety and monitoring board 0 (0%) 5 (7%) 5 (10%) 10 (7%)
Data safety monitoring board 0 (0%) 6 (9%) 3 (6%) 9 (6%)
Data-monitoring committee 2 (10%) 4 (6%) 0 (0%) 6 (4%)
Safety committee 1 (5%) 1 (1%) 4 (8%) 6 (4%)
Data safety monitoring committee 0 (0%) 1 (1%) 3 (6%) 4 (3%)
Safety monitoring committee 0 (0%) 3 (4%) 1 (2%) 4 (3%)
Data monitoring and safety committee 1 (5%) 0 (0%) 1 (2%) 2 (1%)
Data monitoring board 1 (5%) 1 (1%) 0 (0%) 2 (1%)
Data safety and monitoring committee 0 (0%) 2 (3%) 0 (0%) 2 (1%)
Drug safety monitoring board 0 (0%) 2 (3%) 0 (0%) 2 (1%)
External safety and efficacy monitoring  0 (0%) 1 (1%) 1 (2%) 2 (1%)
committee
Monitoring committee 1 (5%) 1 (1%) 0 (0%) 2 (1%)
Safety and data monitoring committee 2 (10%) 0 (0%) 0 (0%) 2 (1%)
Safety monitoring board 0 (0%) 1 (1%) 1 (2%) 2 (1%)
Ad hoc safety committee 1 (5%) 0 (0%) 0 (0%) 1 (1%)
Data efficacy and safety monitoring committee 0 (0%) 0 (0%) 1 (2%) 1 (1%)
Data safety and advisory board 0 (0%) 0 (0%) 1 (2%) 1 (1%)
Data-monitoring board 0 (0%) 0 (0%) 1 (2%) 1 (1%)
Ethical review committee 1 (5%) 0 (0%) 0 (0%) 1 (1%)
Ethics committee 1 (5%) 0 (0%) 0 (0%) 1 (1%)
External data and safety monitoring board 0 (0%) 1 (1%) 0 (0%) 1 (1%)
External data and safety-monitoring board 0 (0%) 0 (0%) 1 (2%) 1 (1%)
External data-monitoring committee 0 (0%) 1 (1%) 0 (0%) 1 (1%)
External monitoring and safety committee 0 (0%) 0 (0%) 1 (2%) 1 (1%)
External safety and efficacy and  0 (0%) 0 (0%) 1 (2%) 1 (1%)
monitoring committee
External safety monitoring board 0 (0%) 0 (0%) 1 (2%) 1 (1%)
Independent safety and data monitoring  0 (0%) 0 (0%) 1 (2%) 1 (1%)
advisory committee
Independent safety committee 0 (0%) 1 (1%) 0 (0%) 1 (1%)
Internal monitoring board 0 (0%) 1 (1%) 0 (0%) 1 (1%)
International review advisory board 0 (0%) 0 (0%) 1 (2%) 1 (1%)
Medical monitoring committee 0 (0%) 1 (1%) 0 (0%) 1 (1%)
Performance and safety monitoring committee 1 (5%) 0 (0%) 0 (0%) 1 (1%)
Policy and data monitoring board 0 (0%) 0 (0%) 1 (2%) 1 (1%)
Protocol-monitoring committee 1 (5%) 0 (0%) 0 (0%) 1 (1%)
Response evaluation committee 0 (0%) 0 (0%) 1 (2%) 1 (1%)
Safety and efficacy data monitoring committee 0 (0%) 1 (1%) 0 (0%) 1 (1%)
Safety and monitoring board 0 (0%) 0 (0%) 1 (2%) 1 (1%)
Safety monitora 1 (5%) 0 (0%) 0 (0%) 1 (1%)
Safety review board 0 (0%) 1 (1%) 0 (0%) 1 (1%)
Safety review committee 0 (0%) 0 (0%) 1 (2%) 1 (1%)
Safety-data monitoring committee 1 (5%) 0 (0%) 0 (0%) 1 (1%)
Safety-monitoring committee 1 (5%) 0 (0%) 0 (0%) 1 (1%)
Trial monitoring board 0 (0%) 1 (1%) 0 (0%) 1 (1%)
Total 21 (100%) 70 (100%) 50 (100%) 141 (100%)
Name are listed in descending order of overall frequency.
Percentage columns may not sum to 100% owing to rounding.
a Blinded, non-participating observer who periodically reviewed coded clinical and laboratory.the lack of detail that could be extracted for this
project; for example, it is unclear who was
monitoring the trials that report planned interim
analyses and whether there was an uncredited
DMC. Certainly, from the authors’ experience they
know this to be the case for some of these trials. 
Possible reasons for not reporting whether a DMC
was used include not wishing to reveal the DMC
membership, the publication policy of the chosen
journal (e.g. inadequate space with word limits)
and the authors not believing it to be important
for their readers. 
Discussion of strengths and weaknesses
This study had a mixed cross-sectional and
longitudinal design; data were collected to cover
1990 and 2000, and general and specialist medical
journals. Owing to resource constraints data from
1990 specialist medical journals were not
collected. This limits the comparisons that can be
made, for example regarding temporal change in
specialist medical journals. 
Journals with higher impact factors were chosen.
If the impact factor is taken as a measure of trial
quality, it is likely that the trials sampled will have
DMCs more often than those in the wider
published literature. However, the length of a
report may be more limited in a high-impact
journal and this could lead to more under-
reporting of DMCs in these journals. However,
while for these reasons the wider
representativeness of the sample is uncertain for
the reporting of DMC use, the factors identified as
associated with the existence of a DMC for a given
trial should be relevant beyond this sample. The
project was adequately sized to comment on the
major issues associated with reporting DMC use
and present plausible results.
A single researcher collected all of the data. There
was no independent searching or double data
entry. A 20% random sample of data was
monitored by checking the source data against
those recorded in the project database by the same
researcher who collected the data originally. Some
changes were made as a result of the sampling, but
the number of changes required did not meet the
specified criteria for checking all of the records.
This method of monitoring checked only those
trials that had already been found; therefore, the
number of RCTs included could not be increased,
but the number of trials with DMCs could be.
The main published reports of trials failed to
present many of the data that were being collected
for this project and this is likely to apply to the
existence of DMCs. Thus, the estimated
proportion of trials using a DMC is likely to be an
underestimate. This issue was explored further in
an in-depth survey of a subsample of the trials
considered here. The authors of the subsample
were contacted to find out more details. The
findings are reported fully in Chapter 5. In brief,
one of 24 trials for which there was no mention of
a DMC was found to have had a DMC, whereas
one of seven trials considered to have had a DMC
based on the report, did not have one. These
findings do not therefore suggest that any
underestimate in the survey reported in this
chapter is large.
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TABLE 17 Most commonly used words in defining DMC name in all trials reporting DMC use
Naming 1990  2000  2000  Total
elements General medical journals General medical journals Specialist journals
Monitoring 16 (76%) 67 (96%) 42 (84%) 125 (89%)
Safety 11 (52%) 54 (77%) 43 (86%) 108 (77%)
Data 12 (57%) 56 (80%) 36 (71%) 104 (74%)
Committee 17 (81%) 30 (43%) 27 (55%) 74 (52%)
Board 3 (14%) 40 (57%) 23 (46%) 66 (47%)
External 0 (0%) 3 (4%) 5 (10%) 8 (6%)
Efficacy 0 (0%) 2 (3%) 3 (6%) 5 (4%)
Review 2 (10%) 1 (1%) 2 (4%) 5 (4%)
Advisory 0 (0%) 0 (0%) 3 (6%) 3 (2%)
Drug 0 (0%) 2 (3%) 0 (0%) 2 (1%)
Independent 0 (0%) 1 (1%) 1 (2%) 2 (1%)
Ethics 2 (10%) 0 (0%) 0 (0%) 2 (1%)
Total 21 (100%) 70 (100%) 50 (100%) 141 (100%)
Words are listed in descending order of overall frequency.Introduction
Background
This chapter describes three interlinked surveys of
practices relating to DMCs in recently completed
RCTs, practices relating to DMCs in ongoing
RCTs, and policies about DMCs from major
agencies involved with RCTs. The three surveys
allowed the authors to consider the practice in
trials conducted in the 1990s (and published in
2000), as well as current trials, and to relate these
to current policies. The rationale for the surveys of
practices was to identify a range of trials with
information to address the 23 questions, while the
policies survey examined relevant data monitoring
policies of a range of organisations. 
The main focus was to identify policies and
practice that may be particularly relevant to trials
with public funding in England. It was also felt
that it was important to extend this to obtain
information both from different funding sources
and from different geographical bases. A further
aim was to include single-centre as well as
multicentre trials, and trials in major disease
areas. It was for these reasons that plans for the
survey of ongoing trials were changed from those
outlined in the application for funding. In the
original proposal, it was planned to limit the
survey to trials funded by the NHS R&D HTA
programme and the MRC. It was decided to
broaden the range of trials considered to industry-
funded trials and publicly funded trials other than
those funded by the HTA programme and MRC.
This did indeed provide a wider based survey,
potentially enhancing its generalisability. This
meant, however, that only a sample of HTA
programme and MRC trials could be considered,
rather than all of them, as originally planned.
Survey of DMC practices 
in recent trials
Aims
This part of the project aimed to determine the
data monitoring practices in a sample of trials
whose reports were published in 2000. It should
be recognised that sampling trials by the year of
their publication is likely to identify trials that ran
throughout the 1990s, and therefore the sample is
more likely to give an indication of practice over
that time than at a defined time-point.
Methods
The sampling frame was the primary reports of
RCTs published in 2000, as identified and
classified in Chapter 4. 
Forty-five trials were selected from the database,
stratified by whether the trial was single or
multicentre, by disease area (cancer;
cardiovascular, vascular or respiratory; and all
others) and by whether or not a DMC was
mentioned in the paper. The sampling strategy is
shown in Appendix 11; it reflects the distribution
of trials published in 2000 with respect to number
of centres, disease area and mention of DMC in
the published report. Trials were randomly
sampled within each stratum. In addition, the
sample was chosen such that for 15 of the trials
the country of the first author was the UK, for 15
it was North America and for 15 another country.
The sample did not take account of funding
source (industry/public) as this information was
not collected at the time of the trial identification.
In recognition of the possibility that trial reports
might not mention a DMC unless the trial was
stopped early at the DMC’s recommendation, the
PIs identified in the selected papers were
contacted whether or not a DMC was mentioned
(see Appendix 12). Copies of the trial protocol
were requested. The information of relevance was
extracted using a standard questionnaire (shown in
Appendix 13). The content of this questionnaire
was based on the global list of the 23 questions
(Box 1). A telephone interview or e-mail followed
where possible to complete data extraction. In
some cases, it was not possible to make contact
with the lead investigator named in the paper. For
these trials, other investigators and/or sponsors
were contacted for information about the trial.
Personal contacts of the DAMOCLES team were
used to make the first contact, whenever possible.
Results
Data monitoring information was gained from
28/45 potential respondents. A further three
responded but did not agree to take part. Some
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Chapter 5
Surveys of policies and practiceinformation about the trial’s data monitoring
procedures was available from the study report of
another three trials, giving information on 31/45
trials (69%) in all (Figure 6).
The categories are not mutually exclusive in the
following tables, as some of the respondents gave
more than one answer to each question.
Higher response rates were obtained for
multicentre trials and for trials dealing with
cardiovascular or respiratory conditions (Table 18).
There was some data monitoring information
available for all trials coded as having a DMC in
the original database. However, in one of these
trials, when contact was made with the trial’s PI, it
transpired that the ‘external safety and efficacy
monitoring committee’ was a monitoring body
rather than a formal DMC operating to
prespecified guidelines. This committee could
have requested unblinding of the trial if it was
thought that this was critical to patient
management; however, there were no guidelines
describing circumstances in which it might do this.
This committee is not included in the discussion
of DMCs. Therefore, six of the seven trials with
DMCs identified in the survey had formal DMCs.
One additional trial with a formal DMC was
identified, although it had not mentioned a DMC
in the trial report. This brought the total number
of trials with a formal DMC to seven, including
the three non-respondents for which data
monitoring information was obtained from the
trial report. Of the seven trials with DMCs, three
were UK based, two were based in North America
and the remaining two in other parts of Europe.
Five were concerned with cardiovascular, vascular
or respiratory pathology, one with cancer and one
with other pathologies. One was a single-centre
trial and the remaining six were multicentre trials. 
Reasons for not having a DMC
Reasons given by respondents for not having a
DMC are summarised in Table 19.
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Sampled
n = 45
No reply but
information
available from
trial report
n = 3
Investigator
replied
n = 31
Investigator
did not agree
to take part
n = 3
Investigator
agreed to
take part
n = 28
Study had
a formal DMC
n = 3
Study had
no formal DMC
n = 24
Study had
a formal DMC
n = 4
No reply and
no information
available
n = 11
FIGURE 6 Responses received from trials sampledThe most common reasons for not having a DMC
were that the trial was not blinded (on the basis
that informal monitoring of adverse events could
be carried out during the course of the trial), or
that the intervention was of a nature that made it
seem unlikely to the investigators that there was a
high risk of SAEs. 
These reasons relate more to the safety aspect of
data monitoring than efficacy. In addition, three
trials performed ongoing safety monitoring,
although not using interim analysis. 
Of the seven trials with a DMC, three DMCs had
recommended that all or part of the trial in
question be stopped, one on grounds of safety, one
on grounds of efficacy and one on grounds of
futility. A fourth DMC had recommended that the
trial continue, but that the increased risk
associated with the trial intervention be explained
to patients before they entered the trial.
One of the respondents whose trial did not have a
DMC added that if the trial were to be repeated
now, updated good practice guidelines would
require a formal DMC. This also applied, but was
not stated explicitly, to another of the
respondents, whose trial would now require the
funder’s standing DMC to oversee trial progress
under its new data monitoring policy. None of the
trials that did not have DMCs stopped early.
Timing and frequency of meetings
Of the four trials for which fuller DMC
information was available, one DMC met seven
times, one met six times, one met five times
(which led to the trial stopping) and one met
twice. The frequency of meetings ranged from
every 4 months to annually.
Guidelines used to draft DMC procedures
Two trials used the MRC guidelines to draft their
data monitoring procedures, and the other two
did not use formal guidelines in setting up and
defining the role of the DMC.
Time-point when the DMC was formed
One of the DMCs was a standing committee; two
were formed before finalisation of the protocol
(one of which suggested some changes to the
protocol which were implemented), and the fourth
was to have been formed before finalising the
protocol, but in the event was formed after the
trial had started.
Choosing the DMC membership
All four DMCs had clinicians experienced in the
relevant fields; three had at least one statistician
and two had epidemiologists (one of whom was a
member of a DMC that did not have a statistician).
Position of the DMC with respect to the sponsor,
trialists and participants
All DMC members were required to be
independent of the trial, but in no case were there
formal procedures to ensure this independence.
For the trial with a standing DMC, the investigator
commented that as the membership rotated, it
sometimes became difficult to choose DMC
members because clinicians could not become
members while recruiting people into the trial.
This was identified as a difficulty for large
multicentre trials in clinical areas that have small
numbers of specialist clinicians.
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TABLE 18 Details of trials for which data monitoring
information was available, either because the investigator agreed
to take part or because mention was made of data monitoring
provisions in the trial report
Details of trials Responses/target
Mention of DMC in the article
Yes 7/7
No 24/38
Centres
Single-centre 8/15
Multicentre 23/30
Disease area
Cancer 6/9
Cardiovascular/respiratory 13/15
Other 12/21
Country of first author
UK 11/15
North America 11/15
Rest of world 9/15
Total 31/45
TABLE 19 Reasons given by respondents for not having a DMC
Reason for not having a DMC Number of 
trials (n = 23)
Trial was not blinded, investigators  6
were monitoring outcomes
Risk of adverse events judged to be low 6
Safety monitoring only by investigators  3
Small number of patients in trial 3
Healthcare professionals involved in  3
the intervention were in a position 
to raise safety concerns
Short duration of trial 1
Trial did not use investigational drugs 1
No reason given 6Conduct of meetings and means of
communication used
For two of the trials, the PI or trial coordinator
attended the first part of the meeting to answer
questions. For the third, the investigator could
attend but this was not routine and for the fourth
the meetings were explicitly closed with no
investigators participating. All of the trials had
face-to-face DMC meetings, except for the trial
with the standing DMC where it was stated that
meetings would be face-to-face wherever possible,
although occasionally they needed to be held by
teleconference.
Training the DMC members for their role
One respondent did not discuss training the DMC
members. For another, all the members had
experience of DMCs so training was not felt to be
an issue. Another investigator said that in the
event the members had served on DMCs
previously; however, they would still have been
invited to serve on the DMC even if they had had
no previous experience. One respondent said the
DMC had inexperienced members but was not
aware of any special requirements regarding
training. 
Who prepared the analysis, and what information
was provided to the DMC?
In three cases the trial statistician performed the
interim analysis; in the fourth, this was done by
the epidemiologist member of the DMC. All
DMCs considered recruitment rates to the trial.
Two considered unblinded outcome data, with one
specifying that anything of interest to the DMC
would be included in the analysis. The last
respondent, speaking of the standing DMC, said
that recruitment rates and baseline data would be
considered at each meeting until a prespecified
number of events had occurred, and then an
unblinded outcome analysis would be performed.
One of the DMCs did not consider interim
outcome data, but rather monitored recruitment
rates and other relevant information.
Should information presented to the DMC be
shared?
Views on sharing the interim information with
other DMCs were consistent; the investigators were
not enthusiastic about the DMC consulting others.
Scope of DMC recommendations and the
decision-making process within the DMC
The four investigators gave an indication of the
scope of the DMC’s recommendations. For two,
the DMC could advise stopping the trial if
necessary, two said that it could suggest alterations
to the protocol, and two that it could suggest
extension of patient recruitment. One investigator
said that the DMC could make any
recommendation regarding the conduct of the
trial. Two investigators reported that DMC
decisions were reached by consensus, whereas the
other two gave no information on this point.
Advisory or executive role
The investigators all reported that the DMC’s
recommendations were advisory to the trial
executive rather than being binding. In two cases,
the DMC reported to the TSC, in one case to the
trial funding body and in the last case to the trial
PI.
Statistical stopping rules
Very little information was available on the use of
statistical rules or guidelines. One investigator
stated that a stopping rule was used to guide the
DMC, but gave no further details. Two
investigators added that in addition to using a
stopping guideline, the DMC must take into
account other information, which may include
relevant information external to the trial. The
fourth DMC did not use a stopping rule because
there was no formal interim analysis.
Discussion of ethical issues
Three investigators felt that the DMC was free to
discuss ethical issues specifically should it wish to
do so; the other did not address this point. 
The investigators all stated that they regarded the
use of a DMC as valuable to ensure the
appropriate running of the trial and independent
oversight.
Discussion of survey of recent DMC
practice
There was information available for 69% of the
sample (31/45 trials). The missing data were due
to refusal to take part in the study (n = 3) and
inability to make contact with investigators 
(n = 11). Perhaps the most obvious explanation
for this missing information may be that although
the trials were published in 2000, in some cases
they had been set up in the late 1980s. This lapse
of time made investigators difficult to contact. It is
possible that in some cases they were unwilling to
revisit a former trial or viewed a survey of data
monitoring practice as an implicit criticism of
their trial (although assured that this was not the
case). 
There is also the possibility that amongst the
researchers contacted there was a degree of self-
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interested in data monitoring may be more likely
to respond to the survey. Thus, the real proportion
of trials with DMCs at this period might be even
lower. 
However, clearly, the main limitation of this survey
is the small number of trials identified with a
DMC. Some information about conduct and
operation of DMCs was available for seven trials,
with fuller details from only four. 
Survey of current data monitoring
practices
Aim
The aim of this part of the project was to describe
current research practice in data monitoring in a
sample of ongoing trials. The survey focused
mainly on publicly funded trials being performed
in the UK. However, some information was
available from other trials.
Methods
As there was no formal register including all
publicly and privately funded ongoing clinical
trials in the UK, a random sample could not be
selected.
The plan was to survey a total of 40 trials, of
which 12 were to be funded by the NHS R&D
HTA programme and 12 by the MRC to assess
practice in trials funded by large government-
supported research organisations. The remaining
16 were selected by contacting RECs; in the case
of multicentre trials this was an MREC, and for
trials with fewer than five centres this was an
LREC. The aim of approaching RECs in this way
was to broaden the range of trials considered to
include projects conducted by individual
researchers and industry-sponsored projects. The
aim was to include ten industry-sponsored trials,
six from the MREC and four from the LREC. 
The sampling strategy is shown in Appendix 14.
Trials were randomly sampled from a list of 
54 RCTs sponsored by the HTA programme 
and a list of 79 RCTs sponsored by the MRC. 
The HTA programme list was made available to
use in January 2002 by staff at the National
Coordinating Centre of that programme, and
MRC trials (described as current in November
2001) were identified using the MetaRegister
available at http://www.controlled-trials.com/. It
was felt that this strategy, in the absence of a
complete register of publicly funded ongoing
trials, would provide a good range of trials in
terms of size, scope and funding. The RECs were
identified and approached through personal
contacts.
For each trial, the PI was identified and contacted
directly for the HTA and MRC trials, requesting
copies of the protocol and where necessary a
follow-up interview to clarify data monitoring
practices (see Appendix 15). For the REC-
approved trials, initial contact was made by the
RECs, and the DAMOCLES team completed the
follow-up. The information requested from the
investigators followed the questionnaire given in
Appendix 16, which was based on the 23 questions
shown in Box 1.
Results
Complete information was obtained for 32 of the
40 selected trials and partial information was
available for another four trials. Information was
obtained for all 12 MRC-funded trials and all 12
HTA programme-funded trials.
In practice, gaining access to information from the
relevant PIs identified from REC applications
proved problematic. This was partly due to delays.
One source of delay was in identifying an LREC
with sufficient number of trials (more than six)
from appropriate specified disease areas with a
mixture of industry and non-industry trials. In
addition, once a suitable MREC and LREC had
been identified and confirmed their support, the
researchers needed to go through a two-stage
process, with an initial letter being sent by the
REC before they were able to make direct contact
with the PIs. The most important source of delay
was that several of the PIs referred the authors to
the pharmaceutical company that supported the
trial. Occasionally the company was then helpful,
but more often they either refused outright, or
agreed, but then did not provide the information.
Where appropriate, the original request was
followed up by e-mail, several telephone calls,
repeat letters and using personal contacts. It is
possible that with more time the response rate
could have been improved. 
Information was available for only two of the six
LREC-approved trials, while there was some
information available for all ten MREC-approved
trials (and complete information for six of them).
Of the 36 trials for which at least some
information was available, seven were conducted at
a single centre and 29 were multicentre trials
(involving more than one centre, and in the case
of MREC-approved trials involving at least five
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industry, while the remaining 29 were publicly
funded; the four trials for which information was
incomplete were all funded by industry. Eight of
the trials investigated some aspect of cancer
treatment, while another eight dealt with
cardiovascular, other vascular or respiratory
diseases. The other 20 considered other types of
disease or pathology, including topics as diverse as
back pain, prevention of HIV infection and
treatment of head injuries.
Not all of the respondents answered all the
questions, and some of the respondents gave more
than one response to each question. The totals in
the text and tables therefore do not necessarily
sum to 36. The MREC and LREC trials are
presented together.
Existence of a DMC
Twenty of the 36 trials had a DMC: 11 of the 12
MRC-funded trials, five of the 12 HTA
programme-funded trials and four of the 12 REC-
approved trials. Reasons for not having a DMC
included:
  the TSC having discussed the issue and decided
that there was no need for a DMC, for example
owing to the nature of the intervention, which
might be minor or involve minimal risk to
patients
  the nature of the trial, which might compare
the efficacy of two well-known and relatively
safe interventions.
Of the 20 trials with a DMC, 14 had met at least
once by the time of the survey. The guidelines on
which the DMC procedures in these trials were
based are summarised in Table 20.
The MRC Good Clinical Practice (GCP) guidelines
were most commonly referred to, in relation not
only to trials funded by the MRC, but also to those
funded by the HTA programme (Table 20). This
reflects the fact that the HTA programme now
recommends that its investigators abide by the
MRC guidelines.
Reasons for having a DMC
The reasons given by respondents for having a
DMC are outlined in Table 21. It is noteworthy that
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TABLE 20 Guidelines relevant to DMCs followed by investigators
Guideline Source
MRC-funded (n = 11) HTA-funded (n = 5) REC-identified (n = 4)
MRC GCP guidelines 11 2 0
Advice from experienced DMC members 1 0 0
Modified MRC GCP 0 2 0
Past experience of investigators 0 1 0
Company-specific data monitoring rules 0 0 3
Old EORTC guidelinesa 001
a The current EORTC guidelines did not exist when the protocol for this trial was drafted.
TABLE 21 Summary of investigator reasons why a DMC was used (not mutually exclusive)
Reason Source
MRC-funded (n = 11) HTA-funded (n = 5) REC-identified (n = 4)
To review interim analyses for efficacy 3 1 2
To perform safety monitoring (including  6 1 4
assessing rates of adverse events)
To advise the TSC about possible protocol  1 0 0
changes
Standard practice 3 1 0
To advise on stopping the trial 1 1 0
To give an overview of the protocol 0 1 0
To confirm recruitment targets and check  0 1 0
the balance between groupsthe reasons given by REC-approved trials, of
which three of the four trials were sponsored by
industry, cover a much narrower spectrum.
Terms of reference for the DMC
The trials could be broadly classified into three
groups in respect of terms of reference for DMCs.
The first group (n = 11) had formal written terms
of reference clearly identifying the DMC’s
mandate; for example: “To inform the steering
committee if 1) there is proof beyond reasonable
doubt that [treatment] is indicated or
contraindicated to an extent that would influence
patient management; 2) it is evident that no clear
outcome will be obtained. The DMC may also
suggest protocol changes.” The second group 
(n = 4) had less formally defined terms of
reference, for example stating that the DMCs were
to monitor adverse events and advise the steering
committee if there was a need to stop the trial.
The third group (n = 5) had no information about
terms of reference available. Some of the DMCs
had input into their own terms of reference, and
therefore it was not always possible for the
protocol to define terms of reference if the DMC
had not approved them. 
Time-point when the DMC was formed and input
into the trial protocol
Table 22 indicates the time when DMCs were
formed; this information was not supplied for two
trials.
Ten of the trials included in Table 22 specified that
the DMC had had an opportunity to make an
input to the protocol. This applied to seven of the
ten funded by the MRC and two funded by the
HTA programme; one was among the trials
identified through RECs. Input to the protocol
included writing or contributing to the DMC’s
own terms of reference in all ten trials.
For the MRC-funded trials, some DMCs had input
into the trial protocol, despite being formed after
the final protocol had been drafted. In most cases
this extended only to their own terms of reference
and stopping guidelines. In one case a standing
DMC had input into the draft trial protocol, which
ensured that there was independent advice from a
group that had good knowledge of clinical trials in
the subject area.
Choosing the DMC membership
Of the 20 trials with DMCs, information on how
the committee was chosen was available for 18. In
11, the PI or TSC nominated the members subject
to funder approval; in three (of which two were
pharmaceutical industry trials) the trial sponsor
chose the DMC membership. In the remaining
four trials the DMC was a standing entity 
and the investigators had no input into the
members. Membership of DMCs is outlined in
Table 23.
All of the nine MRC-funded trials that gave
information on DMC membership included at
least one relevant clinician and in many cases
more than one, and seven included a statistician.
In one of the two MRC trials whose DMC had
neither a statistician nor an epidemiologist, the
investigator explicitly stated that all the DMC
members were well-versed in statistics. In the
other, the membership was composed exclusively
of clinicians and no mention was made of
statistical abilities.
None of the trials in this sample had an ethicist as
a DMC member. In addition, no trials included a
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TABLE 22 Time-point at which the DMC was formed
Time point Source
MRC-funded (n = 11) HTA-funded (n = 5) REC-identified (n = 4)
Before final protocol drafta 321
Before pilot phase of trial 1 0 0
Before trial commenced 4 1 0
After trial commenced 1 2 0
There was a standing DMC for all trials  2 0 1b
in this clinical area
Information not provided 0 0 2
a In one case this referred to the DMC chair who alone had input into the trial protocol.
b Data monitoring for this study was carried out by a group including investigators from other trials; protocol review was
performed by a separate committee. Part of the way through the study the data monitoring arrangements were changed
as the funder altered its DMC provisions.consumer representative, although one had a
nurse to act as patient advocate. 
Role of the chair
Two HTA-funded trials and eight MRC-funded
trials gave some information about the role of the
chair in DMC meetings, although this information
was not very detailed. The role of the chair in the
DMC was interpreted differently between the
trials. In some cases, it was confined to chairing
the DMC meetings. In other cases, the chair’s
responsibility was wider and could include
deciding on the frequency and timing of the
meetings, checking the data, passing queries to
the PI, drafting the DMC report or circulating
information to the other DMC members. The
chair might also help with deciding the members
of the DMC, especially if he or she had previously
been on the DMC of a similar trial. In only one
trial was it explicitly stated that the DMC had no
fixed chair.
Position of the DMC with respect to the sponsor,
trialists and participants
Members of the MRC-funded trial DMCs were all
considered to be independent (see Table 24);
however, none of the respondents described a
formal policy for ensuring that conflicts of interest
were addressed. (Where the respondents have not
stated that there was a formal policy for dealing
with conflicts of interest, it is assumed that there
was no policy.) One MRC-funded investigator
described an informal situation where the TSC
monitored the DMC for possible conflicts of
interest, which were to be dealt with as they arose.
In one case, one potential member of the DMC
was omitted from the final committee because he
worked at the same place as one of the trial
investigators and it was thought that this might
lead to difficulties in serving on the DMC. The
consensus on a definition of independence among
the MRC investigators seemed to be that the
‘members should not be recruiting patients to the
trial’; this definition was used by four of the 11
investigators who specified that the DMC
members must be independent. No other
interpretation of the requirement for
independence was given by any of the MRC
investigators.
For two of the five HTA programme trials it was
explicitly stated that the DMC members were
personal contacts of the PI who were not involved
with, or recruiting to, the trial. This raises the
issue of whether recruiting personal contacts of
the PI to the DMC jeopardises independence and,
if so, how members are to be recruited given that
the pool of experts who are suitable potential
DMC members is small.
One of the REC-identified trials’ respondents
whose DMC members were not independent of
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TABLE 23 Composition of the DMC
Expertise of member Source
MRC-funded (n = 11) HTA-funded (n = 5) REC-identified (n = 4)
Statistician 7 4 2
≥ 1 Clinician(s) in relevant fields 9 4 2
Epidemiologist 2 1 0
Other profession Biochemist Nutritionist 0
Nurse
Clinical trials expert
Information not provided 2 1 1
TABLE 24 Position of DMC members and managing conflicts of interest
Independence of members Source
MRC-funded (n = 11) HTA-funded (n = 5) REC-identified (n = 4)
Members are independent and there is a  0 1 0
formal conflict of interest policy
Members are independent and there is no  11 4 2
formal conflict of interest policy
Members are not independent 0 0 2the trial was a pharmaceutical company where the
DMC members were employees of the company,
although not directly involved in the trial in
question. They were not allowed to reveal the
results of interim analysis to other employees. 
Open, closed or mixed meetings?
The information about who should attend DMC
meetings is summarised in Table 25.
The preference among the MRC and HTA
programme trials seemed to be to have the PI
present for the first part of the meeting to 
answer any questions that may have arisen 
about the conduct of the trial, and in some 
cases to review the recruitment or aggregated
event data. Thereafter, the PI would leave the
meeting. The interim results were often 
presented by the statistician responsible for
carrying out the analysis; in the trials in this
survey, this was always the trial statistician (see
below). 
Timing and frequency of the DMC meetings
All 20 trials with DMCs gave a response to the
question of timing and frequency of meetings.
Practical arrangements for DMC meetings varied
and often depended on the nature of the trial.
Some DMCs met regularly every 6 months or
annually, whereas others planned analyses after a
given number of events. For some DMCs the
timing of the meetings was fixed in the protocol,
whereas for others the members decided, or the
chair suggested, how often meetings should take
place. In some trials there was a nominal time
interval, but this could be altered by the DMC
according to the progress of the trial, for example
if fewer events occurred than anticipated.
Means of communication used
Most respondents thought that it was desirable to
meet face-to-face rather than having
teleconferences. One investigator suggested that it
was beneficial to have the first meeting face-to-face
even if the remainder were by teleconference, so
that the members could get to know each other.
However, the eight investigators who had had at
least one meeting by teleconference agreed that
sometimes they were necessary for the meeting to
go ahead at all, especially when DMC members
lived in different countries.
Experience of DMC members
All of the 20 respondents with DMCs had
members with experience in data monitoring.
Eight of the investigators commented that it was
not necessary for all the members to be
experienced, although the committee should
contain some members who had served on
previous DMCs. The consensus was that if a
member had not been on a previous DMC, that
member should at least understand the rationale
for DMCs, and preferably have some background
in clinical trials. One investigator recommended
that a training programme be implemented for
clinical experts in the field willing to serve on
DMCs to increase the pool of possible DMC
members.
Who prepared the data considered by the DMC?
For 17 of the 18 trials for which there were
responses to this question, the trial statistician
prepared the interim analysis, in two cases with
input from the data manager. For the remaining
trial, the analysis was prepared by the PI in blinded
format, while the DMC held the randomisation
codes to unblind the results if required.
Information provided to the DMC
Aspects of interim analysis that the investigators
judged to be most important are described in 
Table 26.
Three of the five HTA-funded trials explicitly
stated that any other trial information requested
by the DMC would be provided.
Health Technology Assessment 2005; Vol. 9: No. 7
91
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.
TABLE 25 Non-DMC members present at some part of meeting
Present in addition to DMC Source
MRC-funded (n = 11) HTA-funded (n = 5) REC-identified (n = 4)
PI 8 4 0
Trial statistician 5 2 0
Other Data manager (1) 0 Pharmaceutical 
company representatives (1)
Closed to non-DMC members 0 0 1
No information 0 0 2Among the four trials identified through RECs,
the main observation is that the pharmaceutical
companies placed emphasis on consideration of
safety data. One company presented figures
blinded by treatment group; the other company
presented the information partially or completely
unblinded.
Should information presented to the DMC 
be shared?
There was considerable variation in the
investigators’ opinions of whether a DMC should
share information with other bodies, for example
with the DMC of a similar trial, if the results of
interim analysis were to give cause for concern.
Ten investigators would agree to the DMC sharing
information with others if it thought this necessary;
four felt that results should be kept confidential
and six had no provision for this possibility.
Among those who felt that the DMC could share
information if required, many investigators
specified that this should only be done if the DMC
were concerned for the safety of trial subjects; one
felt that it would be acceptable to share safety but
not efficacy data. Another two suggested that any
request for the DMC to share information should
be passed on to the TSC, which would make a
decision based on the individual case. Of those
investigators who thought that the DMC should
not share information, one investigator specified
that the DMC should be at liberty to seek external
advice, although not to divulge the results of
interim analysis. The lead investigator on one of
the trials, which had no clear provision for this
possibility, said that any such situation would be
dealt with by the TSC on an ad hoc basis.
Scope of DMC recommendations
For all 11 of the MRC-funded trials with DMCs
there was information on the scope of
recommendations of the DMC. Five replied that
the DMC would advise if stopping the trial were
necessary, and two that the DMC would advise
protocol changes if necessary. Seven investigators
added that the DMC was free to make any
recommendation. Of these seven, there was some
difference in emphasis, with some investigators
claiming that the DMC was free to make any
recommendation it felt necessary, and others
saying that although any recommendation could
be made in principle, they would normally expect
the DMC to confine itself to recommending that
the trial be stopped if necessary. 
Investigators in all five HTA-funded trials with
DMCs gave information on this; three said that
the DMC would advise if stopping the trial were
necessary, two that the DMC would give advice on
protocol changes, one that general advice about
the running of the trial would be given, and one
that advice about what information to release to
the other investigators would be given by the
DMC. A further two stated that in addition to
these, the DMC could make any recommendation
it felt necessary.
The four trials with DMCs identified through the
RECs gave very little information on the type of
decision open to DMCs, with one stating that the
DMC would advise on stopping the trial, and the
others giving no information on this point. One
respondent in this category had their DMC
provisions changed during the trial when the
sponsoring body’s new regulations came into
force. Throughout the trial, however, the functions
of protocol review and data monitoring were
separate from each other, with a protocol review
committee responsible for suggesting any changes
to the trial design or conduct.
Surveys of policies and practice
92
TABLE 26 Information provided to the DMC
Information provided Source
MRC-funded (n = 11) HTA-funded (n = 5) REC-identified (n = 4)
Baseline demographics 5 5 0
Recruitment rates 4 3 0
Outcome measures (for efficacy) 6 3 1
Proxy outcome measures  1 0 0
(e.g. markers for the primary outcome)
Adverse event rates (for safety analysis)  5 1 3
Dropout data  3 0 0
Other Compliance with  Differences between  0
treatment (1) groups at baseline (1)
No response given 0 0 1The decision-making process within the DMC
Responses to the question of what form the
decision-making process takes within each DMC
are shown in Table 27. The most commonly
reported approach was consensus, but two trials
used a voting procedure. No information was
provided for three of the four REC-identified
trials.
Use of statistical stopping rules
Three of the 20 respondents whose trials had
DMCs gave no information about whether or not
the DMC used statistical stopping rules. In one
trial no provision was made for this because there
was no formal interim efficacy analysis. Fourteen
had statistical guidelines. Respondents said that
these were not to be used rigidly, but rather
interpreted together with other information, such
as new external information provided by the PI. A
further trial used a more rigid statistical stopping
rule; another, in contrast, had no formal stopping
rule because the trial had multiple end-points and
the PI considered that the decision to continue or
stop the trial should be made by balancing the
risks and benefits of the treatments. 
Discussion of ethical issues
The consideration of ethical issues by the DMC
was addressed in varying ways by the 16
investigators who answered this question. Two felt
that in addressing the question of whether the
trial should be allowed to continue, the DMC was
examining a question that was primarily ethical in
nature. Four investigators felt that the ethics of the
trial did not really fall within the DMC’s remit;
one of this group felt that ethics were an issue for
the REC to consider. Ten investigators felt that
there was no reason why DMCs should not
comment on ethical issues. The approach of this
last group ranged from enthusiastic, where the
DMC had specified that it wanted to be able to
consider ethical issues or where the investigator
was quite happy for the DMC to discuss any aspect
of the trial, to more cautious, where the
investigators felt that ethical issues were not really
entirely within the DMC’s scope, but were willing
for the DMC to identify any problems for the
TSC. There was no information on this issue for
four of the respondents.
Advisory or executive role of the DMC
The DMC was considered by 18 respondents to be
advisory to the TSC of the trial; two respondents
(both pharmaceutical companies) did not address
the question of whether the DMC’s output was
advisory to, or binding upon, the trial executive.
Who received the report from the DMC?
The reporting system depended on the
management of the trial. In 16 cases, the DMC
submitted reports to the PI. In one case, the
report was also submitted to a separate executive
committee. In six cases the report was circulated
to the PI or to a group of collaborators. No
information was provided for one trial.
Discussion of survey of current DMC
practice
Very little information was available on industry-
sponsored trials as details of data monitoring were
available for only seven; of these, four had
provision for data monitoring although only two
had formal DMCs.
Most of the investigators were satisfied with the
data monitoring provisions of their trial. Two
investigators suggested that it would have been
helpful to have had a DMC meeting before the
start of the trial for the members to familiarise
themselves with the study and the form of the
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TABLE 27 Decision-making within the DMC
Process Source
MRC-funded (n = 11) HTA-funded (n = 5) REC-identified (n = 1)
Consensusa 631
Votea 200
Chair to define 2 0 0
Investigator unaware 1 1 0
Other 0 DMC to decide how 
decisions will be made (1) 0
No information provided 0 0 3
a One investigator, for example, stated that a consensus would usually be reached; however, if there were great difficulty in
doing so a vote would be taken.interim analysis. One investigator commented that
the statistician presenting the data did not appear
to be entirely familiar with the data; it is not clear
whether this was the trial statistician.
One investigator commented that the DMC was
valuable, not only from an ethical and practical
point of view (in ensuring that the trial was up to
date with data entry and checking), but also to
provide the statistician with a point of reference if
he or she noticed any worrying trends while
carrying out the analyses.
The formality with which the terms of reference
were defined varied somewhat. A formal definition
of the DMC’s responsibilities may help a DMC,
particularly if it has inexperienced members, to
direct its discussions. In contrast, for DMCs with
experienced members there may well be benefit in
allowing the DMC to draft its own terms of
reference and standard operating procedures, a
course favoured by some of the investigators.
The choice of DMC members may be difficult if it
were deemed necessary that members have
previous experience and do not have a personal
connection with investigators, particularly in
clinical areas where there may be only a small
potential pool of expertise to draw upon. Some
respondents identified the need for some form of
training programme or informal apprenticeship
for novice DMC members. If there is a move
towards including consumer representatives on
DMCs, as some people have advocated, such a
training programme would need to be flexible
enough to cover the requirements of lay members
who have had little or no previous experience of
clinical trials, as well as experienced clinicians or
statisticians who have not served on a DMC before.
There was also some disagreement about whether
a DMC should share information. Many
investigators were content to leave this to the
DMC’s discretion. However, some investigators
seemed puzzled as to why or how this sort of
situation may arise.
Finally, the question of whether a DMC should
consider ethical issues elicited mixed responses.
Although many of the respondents were willing for
the DMC to make any recommendation it felt
necessary, there was little common ground about
whether ethical issues should be a subject for
discussion in the DMC. The overlap of the RECs
and DMCs in considering these issues seemed
unclear to some investigators. None of the DMCs
had a bioethicist, despite the fact that a bioethicist
is mandatory for some US trial DMCs (see next
section). In addition, the investigators defined
‘ethical issues’ in different ways, adding further to
the differences in approach. 
Survey of DMC policies of key
organisations involved with 
RCTs
Aims
The aim of this part of the project was to ascertain
the current policies on DMCs of major funders of
trials, regulatory agencies and other relevant
organisations. It was felt that information about
the policies of some influential organisations could
usefully be compared and contrasted with the
findings in the other two surveys described in this
chapter.
Methods
A questionnaire was developed (Appendix 17) with
a series of questions about data monitoring policy.
The questions were drawn from the global list of
23 questions (Box 1). Questions of particular
relevance to organisations funding, conducting or
overseeing RCTs were chosen from the list by
members of the DAMOCLES team to form the
basis of the questionnaire. Organisations were also
asked how long their policies had been in place,
and whether any changes were to be made. 
Given the source of funding for this project, it was
decided to focus on UK-based organisations in the
public sector, but also to investigate policies of
some relevant overseas organisations and of the
private sector. Collectively, the DAMOCLES group
drew on its own experience to identify the most
important funding organisations for trials within
the UK, and supplemented this with information
from key funders of trials in North America, South
Africa and Australia. They also sought information
from key organisations in industry and the
regulatory agencies. A list of the organisations is
given in Appendix 18.
Before contacting these organisations directly, as
much of the survey proforma as possible was
completed using information from their websites.
The proforma was sent to each organisation,
addressed to a named individual where possible.
The request was either for checking or for
additional information in the case of organisations
that provided some information on their websites,
or for completion by organisations that did not
provide website information. The covering letter
(Appendix 19) explaining the study and a short
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any relevant policy documents were requested.
Follow-up consisted of one postal reminder where
necessary, and resolution of queries by telephone
or e-mail.
Results
Work on the survey began in December 2001 and
was completed by May 2002. Some information
was available from the websites of 19 of 25
organisations identified; this varied from minimal
to very detailed information. Some response to the
letter and follow-up was received from all the
organisations (25/25), although several e-mail or
telephone reminders were needed for 19/25 (76%)
of the organisations.
Responses for each of the 25 organisations surveyed
are given in Appendix 18. These responses are
summarised below for each of the questions asked.
The categories are not mutually exclusive in the
following tables, as some of the respondents gave
more than one answer to each question.
As shown in Table 28, only one of the organisations
had no policy about DMCs although it was
considering developing a policy. A further six did
not have formal policies, but provided information
on their approaches to data monitoring (four of
these six reported that the situation was under
review). Five organisations had no formal policy
but referred to ICH guidelines, and two had no
formal policy but stated that they followed the
MRC guidelines (which are based on the ICH
1996 guidelines). Eleven had formal policies (five
referred also to NIH or ICH guidelines). Of the
seven organisations without formal policies that
did not refer to established guidelines, six stated
that this was because they were small organisations
and/or did not fund trials (although some of the
organisations that did have policies did not fund
trials either). 
Plans to change data monitoring policies
Ten organisations were in the process of reviewing,
or had plans to review, their policies on data
monitoring. This included three of the
organisations without formal data monitoring
policies that expected to formulate policies in the
future.
For the remainder of this section no distinction 
is made between formal and de facto policies. 
If a policy was described as under review and 
the new version not yet finalised, the authors
referred to the version current at the time of
response. 
Which trials should have a DMC?
Nineteen of the organisations surveyed had a
policy about which trials should have a DMC;
details of their policies are given in Table 29.
Ten of the 19 organisations addressing this
question viewed the institution of a DMC as a
default position for all trials.
Terms of reference for the DMC
Twenty of the organisations had terms of 
reference for DMCs (Table 30). As the categories 
in the table were not prespecified but simply
summarise the responses, the answers may
underestimate the number of organisations that
considered any of the categories to fall within 
the terms of reference. The most frequently
described objective or purpose of the DMC was to
consider data from interim analyses. The form
and content of the analysis were trial dependent,
but were usually unblinded. As a general rule, 
this information was used as the basis of a 
report recommending continuing or stopping 
the trial, or amendment of the trial protocol. 
In most cases (18/20 respondents) this report was
in the form of recommendations (i.e. advisory),
but for two organisations it was considered
binding.
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TABLE 28 Existence of DMC policies
DMC policy Number (n = 25)
No policy 0
No policy but policy under consideration 1
No formal policy but de facto policy 2
No formal policy but de facto policy and formal policy under consideration 4
No formal policy but refer to ICH guidelines 5
No formal policy but follow MRC guidelines 2
Formal policies (including five referring to NIH/ICH guidelines) 11
No information 0When the DMC should be initiated
All the organisations that had a policy about when
a DMC should be initiated stated that the DMC
should be set up at an early stage, in most cases
adding that this should be early enough to
comment on the trial protocol before recruitment
began (Table 31).
Size and composition of the DMC
Eighteen organisations had policies about the size
and composition of the DMC. The membership of
those based in the UK tended to be around three
or four people, whereas those based in the USA
were usually larger (six or more). 
Most of the respondents (n = 14) specified the
need for appropriate clinical and statistical
expertise; three USA-based organisations
supplemented this with bioethicists and one with a
patient advocate. Eight referred to the model of a
standing committee covering a portfolio of trials,
adding appropriate experts where necessary. In
nine organisations the policy was that DMC
members were nominated by the trial sponsor, and
in six nomination was by the investigators and
their research institution, with or subject to the
approval of the sponsor. In the remaining three
organisations with policies, the sponsor nominated
the chair, who then chose the rest of the members. 
Position of the DMC with respect to the sponsor,
trialists and participants
All 19 organisations with DMC policies said that
the DMCs should be independent. It was not
always clear what ‘independence’ meant in
practice. Two referred to independence from the
trial, and 11 specified that this meant
independence from the clinical investigators and
trial participants. Four also specified
independence from the host institution, three
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Terms of reference Number (n = 20)
To protect patients in the trial 3
To consider trial protocol  3
To consider which data should be provided/request additional data 4
To consider outcome data from interim analyses 16
To consider data about safety/adverse events from interim analyses  18
To consider data about recruitment (including that from individual centres) 8
To consider ‘performance’ (e.g. compliance, data quality) in trial (including that from individual centres) 3
To establish/agree stopping rules 2
To apply stopping rules 7
To consider extension/progression from Phase II to Phase III 2
To consider implications of external information 7
To report on continuation/stopping/amendment 11
Resources/funding issues  4
To consider requests for interim information 4
To comment on any part of the trial 1
No policy  5
TABLE 29 Trials that should have a DMC
Type of trial Number (n = 19)a
All trials as default 10
Large/multicentre/long-running  8
With public health impact 5
High risk/more than minimal risk/potentially toxic regimens/vulnerable populations 5
Phase III 4
Phase II, especially if going on to Phase III 2
For registration  1
Blinded/masked 1
Decisions made on a case-by-case basis 1
No policy  6
a The number in parentheses in this table and in Tables 30–32 refers to the total number of respondents. Some respondents
gave more than one category of response and therefore the totals may sum to more than the total number of
respondents.from the TSC and one from the sponsor. Note
that there is some overlap in these responses,
which were not predefined in the proforma sent to
the respondents.
Payment for DMC members
Fifteen of the respondents had no policy about
payment for DMC members. Of the remainder,
one paid an honorarium for face-to-face meetings
(not teleconferences). A further nine paid
expenses (usually travel and accommodation if
necessary). One of these nine organisations also
paid compensation for members’ time and
another for members’ services.
Dealing with conflicts of interest
Only 11 of the organisations had policies for
addressing conflicts of interest, all involving a
declaration of potential conflicts. In addition, one
of the 11 specified that this documentation should
be regularly updated, and another that a person
with a conflict of interest should leave the room
during relevant discussions, if this was acceptable
to the rest of the DMC. 
Open, closed or mixed meetings (are non-
members of the DMC allowed to attend)?
Thirteen of the organisations did not have a
policy. Of the 12 that did, one respondent
reported that DMC meetings were completely
closed. The other 11 had a policy of mixed
meetings in which unblinded data were seen in
closed session, but others (e.g. investigators and/or
sponsor) could be invited to attend an open
session. In five of these 11, there was a provision
to invite the trial statistician to the closed session if
deemed appropriate.
Who has access to accumulating data during the
trial (in addition to DMC members)?
For three of the 17 respondents with a policy, only
the trial statistician and the DMC had access to
the accumulating data. One allowed data centre
personnel access to the interim data; seven
respondents stated only that participants in the
trial should not have access. The six NIH
organisations had a provision for access by key
institute staff involved in the trial. One of these
organisations said that there was also provision for
the data to be seen occasionally on a confidential
basis by others, usually the DMC of another trial.
Who receives the report from the DMC?
The policy for ten of the organisations was that
the report should be given to the sponsor. In
addition, nine organisations specified that the
TSC and/or investigators also receive a copy of the
report (Table 32).
Disposal of the DMC’s meeting papers after the
meeting
Seventeen of the organisations did not have a
policy about the disposal of the DMC’s meeting
papers after the meeting. For three, the DMC kept
the papers. The question did not specify which
papers (i.e. with or without unblinded information),
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TABLE 31 When should a DMC be initiated?
Initiation of DMC Number (n = 17)
Before the trial begins 10
As soon as the trial begins 2
At the first meeting of TSC 3
Standing committee for a group of trials already established 2
No policy 8
TABLE 32 Who receives the report from the DMC?
Recipient of the DMC report Number (n = 25)
Sponsor 10
TSC 5
PIs 4
IRB 5
Others involved in the coordination and running of the triala 3
No policy  7
a Comprising personnel at the data centre, the study coordinator and the chair of the clinical group of the sponsor
organisation responsible for general oversight of the trial.so this information was unavailable. Two
respondents stated that papers were destroyed at
the end of the meeting. One respondent stated
that the papers would be collected, but was not
specific about arrangements for archiving them.
Two did not have a policy about disposing of the
DMC’s papers, but stated that DMC minutes
would be forwarded to the trial sponsor. They did
not discuss whether and to what extent the
minutes would contain discussion of confidential
interim data.
Timing and frequency of the DMC meetings 
Seventeen organisations had a policy about the
timing and frequency of meetings. Eleven stated
that this depended on each individual trial and
would be specified in the trial protocol, although
one stated that meetings should take place at least
once a year. A further four organisations reported
that meetings should be at least annual, and two
that meetings should be at least 6-monthly.
Means of communication used (personal contact,
teleconference, e-mail, etc.)
Twenty organisations had no policy on the way in
which meetings should be held. Two had policies
that face-to-face meetings were preferable, but
teleconferences would be acceptable if necessary.
Another two stated that either medium was equally
acceptable. One organisation replied that
meetings were usually conducted by e-mail, but
could be supplemented by teleconferences as
required; no mention was made of holding face-to-
face meetings. This organisation had a standing
DMC to review all of its trials.
Training the DMC members for their role
Twenty-three organisations had no policy about
training members of the DMC. One respondent
said that the organisation had no formal policy
about training members, but that the first meeting
of each DMC was used to orientate the members
to their task and the trial. Another recommended
that potentially interested participants attend
DMC meetings as observers to encourage capacity
building in data monitoring. This would depend
on the observers maintaining independence of the
trial in question. 
Who produces the data considered by the DMC?
Seventeen organisations had no policy about who
produces the data. Six expected the trial
statistician to perform the interim analysis and
prepare the DMC reports. For a further two
organisations, this function was to be carried out
by the DCC without an explicit statement that the
report would be prepared by a statistician. 
Information provided to the DMC (including
whether relevant information external to the trial
is included in DMC meeting discussions)
Sixteen organisations had no policy on what
information would be included; nine organisations
had some policy in this respect. Four stated that
this would depend on the type of trial. Another
three stated that the information would be
unblinded, but gave no further details. Examples
given of the type of information to be included in
the DMC report were adverse events (n = 1),
efficacy data (n = 2), information on data quality
(n = 1), information on protocol violations (n = 1)
and toxicity data (n = 1). One organisation had
guidelines as to the information to be included in
the report, but these were not made available to
the research team. Five of the nine expected that
external information (such as new data from other
trials) would be considered, while another stated
that consideration of external data would be
unusual. 
The decision-making process within the DMC
Only two organisations had a policy about how a
DMC should arrive at its recommendations. Both
expected decisions to be made by voting; one of
these added that ex officio members of the DMC
and observers were not permitted to vote.
Policy about addressing issues of safety and
efficacy differently (e.g. giving separate guidelines
for stopping)
Sixteen respondents did not address the issue of
whether safety and efficacy data should be treated
differently. The policy of eight organisations, all of
whom referred to the ICH guidelines, was that
stopping rules for efficacy should be more
conservative than for safety, and that the rules for
both should be specified in the trial protocol. The
remaining organisation stated that these rules
should be drafted on a case-by-case basis for each
trial.
Are issues of patient recruitment discussed by the
DMC as a matter of policy?
Fifteen organisations had no policy about whether
or not patient recruitment should be considered
by a DMC. The policies of the other ten varied
from an unwillingness for this to be part of the
discussions (n = 1) to an important part of the
discussions (n = 3).
Discussion of ethical issues
Seventeen organisations did not respond to a
question about policies for the discussion of
ethical issues. Of the eight that did, six said that
the safety and well-being of patients in the trial
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addressed by the DMC (n = 1). Four respondents,
all from the USA, referred to bioethicists as
members of the DMC, and one of these also
mentioned the need for feedback to be given to
the IRB.
How long have the policies been in place?
Of the nine organisations reporting how long
policies had been in place, one said it had had its
DMC policies for 7 years. The other respondents’
policies were more recent, with three implemented
in 1998, two in 1999, two in 2001 and one
currently under development.
Discussion of survey of DMC policies of
key organisations involved with RCTs
In the context of this survey, some organisations
reported no formal policy, but proposed ways in
which they might meet the needs of investigators
or trials requiring input about data monitoring
procedures – these were referred to as de facto or
informal policies. Other organisations have written
procedures to provide guidance on data
monitoring, which are referred to as formal
policies. In many cases the demarcation between
formal and informal policies was not clear from
the responses received; therefore, no distinction
was made between the different types of policy
when reporting the findings of the survey. In
many cases, even the formal policies were not very
detailed, some referring to guidelines from other
bodies, and some to little more than a
requirement that provision for data monitoring
should exist. Some of the guidelines produced by
the organisations seemed to be intended for
investigators’ information, rather than for
enforcement by the organisation.
Whereas many issues were common across
organisations, some showed differences especially
between North America and the UK. The NIH
and its constituent organisations had some of the
most detailed policies, with differences between
the policies reflecting the different nature of the
trials they fund. In the UK, the MRC guidelines
were the most detailed, explicitly addressing most
of the issues raised. Two other UK organisations
referred to these guidelines. Recently established
or smaller organisations, such as charities or
governmental coordination bodies, often either
did not have fixed policies or referred to
guidelines such as the ICH GCP guidelines. For
those organisations adopting ICH or MRC
guidelines, however, it was not always clear to what
extent the full details of these guidelines were
observed. In addition, the ICH guidelines were
not detailed in several areas. 
The sample for the survey does not represent a
comprehensive or representative sample of all
organisations involved with RCTs, and as such the
results should be seen as indicative only of the
state of policies among these organisations at the
time of the survey. In addition, the survey covered
different types of organisation, including those
that conducted trials, those that funded trials and
those that had responsibility for overseeing the
conduct of trials (see Appendix 18). Many
respondents indicated that the issue was under
discussion, pointing to changes such as the EU
Directive and Research Governance in the UK. It
is also possible that for some organisations the
survey acted as a stimulus for the organisations to
rethink or revisit their policies.
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Background
The constitution and working practices of DMCs
can vary considerably between trials, and the
impact of these factors on the quality of their
decision-making is currently unclear. For example,
the size and balance of groups vary, the procedures
for choosing the chair and membership are rarely
specified and there is varying participation of the
trialists in DMC meetings. There is also debate
about the frequency and timing of meetings, the
optimum communication medium, the role of the
chair, what data should be presented, how
decisions are made, and how decisions are
communicated to collaborators and participants.
These issues may have a significant influence on
DMC decision-making. 
It is against this background that qualitative
methods were used to explore decision-making
processes in DMCs that made ‘difficult’ decisions.
These components of the project are described in
this chapter. Data were derived from a
combination of general interviews with
experienced DMC members regarding their
experience across a range of trials and in-depth
case studies of trials where the decision-making
had been ‘difficult’. For the purpose of this study,
a ‘difficult’ decision included trials that stopped
early for a number of reasons (futility, efficacy,
safety, toxicity) and trials that had continued
despite circumstances where early stopping might
have been considered. To maintain confidentiality,
names and specific details relating to trials have
been removed.
Part I: General interviews with
experienced DMC members
Methods
For the general interviews, a purposive sample of
DMC members was identified from the knowledge
and experience of the DAMOCLES project team.
Potential interviewees were selected because of
their extensive experience across a range of trials,
and included statisticians and clinicians, in
addition to some consumer representatives. In
total, 15 potential interviewees were contacted by
letter or e-mail (Appendix 21), of whom 14 agreed
to be interviewed.
A semistructured interview schedule (Appendix
22) was used to interview DMC participants;
questions focused on the interviewee’s experiences
of DMC decision-making and general conduct
across a range of trials. Interviews were conducted
face-to-face (n = 13) or by telephone (n = 1), and
lasted for between 25 minutes and 1 hour and 
15 minutes. All interviews were audio-recorded
and transcribed verbatim, with the interviewer
verifying the accuracy of the transcript.
Nvivo software (version 1.3) was used to code the
data, organise similar topics into categories and
continually compare these topics with earlier data.
The interviewer carried out the analysis; another
member of the research team separately analysed
a selection of transcripts to compare coding and
emerging themes.
Findings
Structure and organisation of DMCs
Size of DMC
For more complex trials, interviewees felt that a
broader range of perspectives was needed to
ensure that the right level of expertise and
experience is provided. Although experiences of
DMC size varied, it was generally felt that ideally
committees should be limited to five or six
members, and should be no fewer than three.
However, most importantly, it was felt a DMC
should be large enough to provide a diversity of
perspectives and full representation at the level of
expertise required. For trials that are particularly
complex, it was agreed that consideration should
be given to a larger DMC:
Health Technology Assessment 2005; Vol. 9: No. 7
101
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.
Chapter 6
General interviews with experienced 
data monitoring committee members and 
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data monitoring decisions“I would say specifically from three to five people for
a DMC. I find that with more than five you begin to
get too many people who are not really concentrating
on what the study is about. If you go to less than three
I don’t think you are getting a big enough range of
experience and balance.”
“My feeling is that the more important the trial is,
there is a case for having a bigger group of people
with a wider range of backgrounds, but maybe that is
wrong ….”
Selection of DMC members
The importance of selecting the right people to
serve on DMCs was seen as crucial, particularly in
small DMCs: 
“Certainly we found three to work reasonably well,
although it is not so great if you have chosen wrongly
on your DMC and you have a bit of a maverick and
you get into a bit of trouble because they have quite a
lot of influence. One of three has more influence than
one of five.” 
“… People have been appointed as being the great
and the good, and have not a clue about data analysis
and even the function of DMCs. So, if I am
formulating a DMC, I would certainly want to be
extremely careful to select wisely.” 
“In my experience, it is more important who you have
got on the DMC rather than any rules or guidelines
you might like to put down.” 
Although all interviewees generally felt that DMC
members should be relatively experienced and
well-respected in their field, one interviewee felt
strongly that the selection criteria should be
exclusively for senior individuals:
“… only very senior people should be on DMCs, who
have cut their teeth on clinical trials, because it is an
awesome responsibility and I really think there is no
place for tokenism. I think you really need very, very
experienced, very senior people who carry authority
and who are respected through their scholarship in
the subject.” 
The selection of DMC members appears to
happen largely by word of mouth through the
relevant networks, and it was suggested that the
demand for DMC members is exceeding current
supply:
“There are not enough people that are either asked
or have acquired the interest or are interested in
participating. A lot of the same people are involved
on many DMCs.” 
“You need to have people who are well-respected in
the general area. That actually narrows down the field
quite a lot. Increasingly we find, as we did with [trial
name removed], going across to the continent of
Europe to get members on to the DMC.”
In terms of who does the selecting, interviewees
reported that (in the UK) it is typically the trial
organisers and PIs who make suggestions to the
TSC, which approves and ensures that the
suggested candidates are appropriate choices. This
practice was perceived to work quite well, ensuring
confidence among the PIs, TSC and trial
organisers. However, as it would seem that many
of the same people are selected to serve on DMCs,
greater consideration may need to be given to the
selection process and how best to increase the pool
of potential members.
Selection of DMC statistician
Specific expertise in the clinical field is an obvious
prerequisite for any DMC, in addition to an
experienced statistician. Although it was
collectively felt that all members have an
important role to play in a DMC, it was suggested
that the statistician has a particularly important
role:
“… the statistician is probably the most important
person at the end of the day; this is not because I
myself am a statistician, but I think by virtue of their
training they can grasp the data, grasp the issues
much faster, and can be extremely influential.” 
“I would expect the statistician to have the most
leverage in any decision to stop the trial because
stopping the trial would simply be based on numbers,
as well as clinical aspects of the depth of adversity as
it were, but as a statistician I would expect to be
among the most important inputters if not the most.” 
Such views appear to be based on the assumption
that the statistician is closest to understanding and
interpreting the data. Often the presentation of
data by the trial statistician will be quite complex,
requiring them to interpret and explain it,
especially to the less statistically minded committee
members. 
In terms of the role of the statistician, it was
summarised as advising on stopping rules,
weighing up external evidence where appropriate,
and assisting with decisions about whether a trial
should continue or not. 
Selection of DMC chair
The selection of the DMC chair was also
considered very important to the conduct of the
committee, yet the chair was commonly described
as being the most difficult post to fill. Specifically,
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directing discussions and framing the decision-
making:
“From the trials I have been involved in, it is a pretty
critical role. If they are a good chair, they can usually
direct the discussion in the direction that they feel
appropriate and have a major influence on the
recommendations; it’s pretty critical actually, the chair.” 
As to who should select the chair, it was widely
agreed that responsibility should lie with the TSC
or trial organisers. From the collective experience
of the interviewees, the chair was typically a
clinician. However, concern was expressed as to
whether this should always be the case, and
whether the chair needs to be an expert on the
clinical area under discussion:
“I think it is very important for the chair to be
somebody who is really an expert in clinical trial
methodology and also very familiar with how perverse
the play of chance can be … I think for the chair it is
less important that they should have expertise in the
clinical area under discussion. It’s more important
they should have a really good understanding of
clinical trials and also of stopping rules of clinical
trials, methodology and dangers being brought about
by easily suggested unconvincing evidence.”
More generally, it was felt that the selection
criteria for the chair should focus on their
experience of chairing meetings, preferably
DMCs, their ability to understand the complexity
of issues, to facilitate effective group interaction,
and overall to protect the validity and credibility
of the trial:
“They have to embody and always keep in mind the
primary responsibility of a DMC, to protect and serve
the study patient and to assist and advise the
principal investigators with the ultimate objective of
protecting the validity of the trial, but also very
importantly its credibility … you would like them to
have a track record of doing it before, you would want
them to be articulate and pretty even tempered. I
would always want them to have a sense of humour.”
“I think probably the most important thing is to make
certain that everybody on the committee has the
chance to express themselves, and is not dominated
by one of the members.” 
In this collective experience, these interviewees
felt that the role and responsibility of the DMC
chair is based on the assumption that everyone
knows what the job entails:
“Nothing was explained to me …. I had no direct
contact with the funders but it would seem to me, this
is a good question as to who should specify the role of
the chair. I don’t remember discussing it within the
committee. I think it was assumed that everyone knew
what the role was.” 
None of the interviewees who had served as a
DMC chair reported having any kind of remit
explained to or discussed with them. Nevertheless,
it was widely agreed that the role and
responsibilities of the chair fall broadly into two
categories. First, it is their responsibility to chair
meetings and provide everyone with the
opportunity to express their points of view.
Second, they are expected to communicate and
accurately reflect the decisions and opinions of the
group to the TSC.
Although the chair is recognised as being very
important in the conduct of DMCs, it was
emphasised that the chair should not be totally in
charge of proceedings, but rather encourage open
discussion, without forcing their own opinions or
views upon the committee. 
Consumer representatives and ethicists
In terms of other areas of expertise to be included
on a DMC, consideration may be given to the
potential input of consumer representatives and
ethicists. However, when interviewees were asked
their thoughts on this, there were very mixed
feelings not only about their possible presence on
a DMC, but also what is meant by the terms
‘consumer’ and ‘ethicist’.
The perceived benefit of having a consumer
representative on a DMC is the added patient
perspective that they are able to bring to
proceedings, which may otherwise be overlooked.
However, opinions were mixed and, in general,
tended not to be very supportive of consumer
input on a DMC. In contrast, the contribution of
consumers at the trial design stage was considered
more favourably.
“Consumers don’t represent anybody any more than I
do, they are just another person who maybe has the
diseases of interest. Certainly on TSCs and when you
design a trial I am very in favour of consumers, if for
no other reason than to protect you against the
maniac consumers who criticise.” 
“My view is that the person who is the consumer is
the person who is offered entry into a clinical trial
and not some do-gooder standing in as a surrogate
…” 
“It doesn’t make sense to me. If you are saying you
are bringing in people who are there because they
understand the biology and they understand the
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don’t have any of those.” 
The most frequently described reason for not
having a consumer representative on a DMC was
because of the perceived difficulties faced by
consumers in understanding complex data:
“Most people are only content to sit and look at the
data, and just believe it. In the event I think you have
to be able to look at it extremely carefully in detail. It
is a very highly specialised task, and I think the
chances of any consumer representative having those
very skills are quite small.” 
Further concern was raised in relation to the
potential emotional involvement of a consumer
representative, and the potential stress it would
place them under, particularly if there were a
decision about whether to release a result that had
an impact on patient care:
“If you are trying to make quite a difficult decision
about whether to release a result which will then have
an impact on people’s care, I think it must be quite
hard to disassociate yourself from that emotional type
of involvement.” 
Related to this issue, it was felt by some interviewees
that consumer representatives would have a
tendency possibly to over-interpret interim data;
this could potentially lead to some trials stopping
prematurely.
Other interviewees opposed to consumer input on
DMCs stated:
“You’ll find that the efficiency of the DMC would go
down and therefore it just gets dragged out.” 
“It’s not quite as easy as people might think. Whereas
I can get up to speed very rapidly … I think it is
asking an awful lot of a lay person to achieve that
level of sophistication and although it is not politically
correct, I would oppose it. I think it would be just out
of political correctitude and it would be absurd to
expect a lay person can just be taken off the street to
do that.” 
Such views were opposed by those who felt
consumer representatives have a potentially
positive and important role to play on DMCs:
“It is almost to be expected that professionals will
dismiss the probability that uneducated people, in
their terms, have a contribution to make. That may be
excusably paternalistic, but it is also a bit arrogant.” 
“I think the idea is good. If nothing else, it makes
people who sit on the committee feel more
accountable, I would have thought. I think it would be
great to have a consumer on a DMC, but again you
have to have the right consumer. Someone who is
knowledgeable in the area and is thoughtful.”
In contrast to the ambiguity regarding consumer
representatives on DMCs, the same could not be
said for ethicists, as their potential input on a
DMC was viewed very negatively:
“I have a personal prejudice against the word ethicist,
simply because I think it implies as if somehow their
views on ethics are more valid than others, and I do
not accept that. That doesn’t necessarily mean they
couldn’t contribute to the DMC, but I would not be in
favour.” 
“I have sat on data monitoring committees with an
ethicist, which has not been a good experience … I
think ethicists mix up everything. The only rationale I
can find is trying to create an issue of medical ethics
by making things more complicated than they need to
be.” 
Practical arrangements and procedures for 
DMC meetings
Role and responsibilities of the DMC
On the whole, it was felt that DMCs perform a
variety of tasks in meeting their prime
responsibility of safeguarding trial participants.
Descriptions of their role and responsibilities were
very broad in terms of monitoring incoming data,
identifying adverse events and acting in an
advisory capacity to the TSC on whether the trial
should continue or not. It was also felt that the
DMC should generally assist and advise the PI and
TSC, in protecting the validity and credibility of
the trial.
In terms of specific tasks for the DMC, it was
widely felt that they should not be involved in
writing trial protocols, but they should have a role
before and after trial recruitment. Specifically, it
was felt that the DMC should review and agree
protocol contents, particularly if there are
concerns with any of the primary goals of the trial
or proposed monitoring boundaries.
In a broader sense, it was suggested that the DMC
has a responsibility in ensuring that the trial stays
on track and possibly should even be involved in
the deliberations for the final published report.
Indeed, it was suggested by one interviewee that in
some situations, the DMC should arbitrate
between the TSC and journal editors where there
may be some controversy.
In respect of to whom the DMC reports, there was
no ambiguity that this should be the TSC.
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capacity, accepting that, ultimately, it is the study
investigators who retain the final responsibility for
trial progress and conduct. 
Although interviewees were able to provide a good,
broad overview of the role and responsibilities of a
DMC, it was suggested that new or inexperienced
DMC members were not always clear on such
issues. This was particularly well highlighted by an
interviewee who described how they struggled to
obtain much material or background information
before their first meeting:
“When I was invited, I enquired of [name removed] as
to what a statistician does on a DMC, but they had
nothing to give me to read, and despite them wanting
to help, I was a little bemused as to what it was I was
going to be doing. I felt I was very lucky that [name
removed] was the trial statistician and they attended
all the meetings and prepared all the analysis for the
meeting. They were telling me what I ought to be
deciding.” 
Terms of reference documents
Most of the interviewees were able to recall a
terms of reference document at some stage during
the life of a DMC, and although there were
variations, they were generally described as useful
documents outlining the broad role and
responsibilities of the DMC. However, when asked
about how and to what extent the document was
used in practice, it became evident that it was
commonly sidelined: 
“We tend not to spend a great amount of time [on the
terms of reference] or go into a great amount of
detail. I don’t know whether that is because people
are experienced … they don’t worry too much and it
is rare that we have to turn to it, but every now and
again we do when things get a bit difficult. When
things get difficult, process is really quite important,
and this is what it is, process, but typically it’s not a
big issue.”
For new or inexperienced committee members,
some concern was raised that they did not always
fully understand the terms of reference document.
Therefore, it was considered vital that more time
should be given to discussing the document and
its implications, especially at initial DMC
meetings.
Meeting format
Although there is a variety of approaches to DMC
meeting formats, there was strong agreement
among interviewees that the initial meeting of a
DMC is very important for discussing not only the
terms of reference, but also the protocol and
general procedures for the conduct of future DMC
meetings. As the DMC constitutes a very
important component of a trial, it was considered
essential that more emphasis be given to ensuring
that all DMC members, particularly new members,
fully understand the role and responsibilities of
the DMC and agree on what guidelines and
procedures to adopt. Many interviewees even felt
that where possible, DMCs should be appointed
before the trial has started recruiting, so that
members have an opportunity to meet before any
data are available to learn about the trial and
become familiar with the protocol.
After any initial meetings have taken place, the
format described by most interviewees for
subsequent meetings was open sessions attended
by the DMC members, study investigators, trial
statisticians and perhaps representatives of the
sponsor, funder or regulator with a closed session
to discuss trial efficacy and safety data.
Interviewees felt that an open session was a very
useful forum for reviewing trial progress and
exchanging information, with all members
benefiting from such participation and
involvement. Subsequent closed meetings are
usually limited to the DMC members and possibly
the trial statistician responsible for conducting the
analyses. 
Timing of DMC meetings
It would seem that the timing of DMC meetings
varies. The collective experience of interviewees
was usually an annual meeting, but often more
frequently, subject to the nature and requirements
of the specific trial. However, it was suggested that
perhaps more consideration should be given to
the timing of future meetings.
Communication media for DMC meetings
There was near unanimity among interviewees
that for DMC meetings, face-to-face
communication is preferable to telephone
conference calls, as this is perceived to facilitate
more effective group interaction. However, it was
accepted that the use of telephone conference calls
is inevitable, mainly because of the heavy demand
on those who serve on DMCs, which makes it
logistically unreasonable to expect members to
attend all meetings in person:
“All meetings in the perfect world would be best using
face-to-face communications, but you just can’t do it,
flying everyone around the world … so I think
providing you do have some meetings face-to-face,
then some teleconferencing is acceptable. But I think
if any major concern arises, then a meeting is pretty
important.” 
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people don’t like phone conferences, they just put up
with them.” 
Nevertheless, it was strongly felt that at least the
initial DMC meeting should take place face-to-
face, particularly when members do not know each
other. It was also suggested that a face-to-face
meeting should be arranged if possible where a
DMC reaches a key decision-making stage: 
“I think it would be very important not to have a key
decision-making DMC by teleconference. So if you
could predict that you might have to make a really
difficult decision about a trial, I think it is quite
difficult to have to do it by teleconference.” 
Although conference calls are easier to arrange,
and appear to be more efficient, interviewees did
raise serious concerns about using this medium for
DMC meetings. In particular, where members do
not know each other it was felt conference calls do
not facilitate effective communication at the same
level as a face-to-face meeting. Further, some
members also acknowledged that they probably
participate less in a conference call and are more
easily distracted, and less focused than they would
be in a face-to-face situation:
“In my office I am distracted by other things,
watching e-mails coming in and all that kind of stuff.
Once people get together they can focus better … I
suspect that you get a more thorough discussion in a
face-to-face meeting and you would be less likely to
feel uncomfortable at the end of it. I really don’t
know. What matters, of course, is what is decided and
how comfortable people are about it.” 
“If everyone is having a meeting by teleconference,
you just happen to be talking to a machine in the
middle of the table, which makes it very hard to pick
up all the conversations and comments. It sounds like
a good idea because it saves people flying across the
place, but I think it’s got problems.” 
Concern was also raised with regard to using
conference calls when not all DMC members
speak the same first language. While on the whole
it was not reported as a serious problem, some
interviewees were able to recall occasions when it
had led to misunderstandings and difficulties in
the group, which might have been avoidable in a
face-to-face meeting.
Information presented to DMCs
The general experience of interviewees on the
level and quality of data provided to DMCs had
been satisfactory, with no reported cases of a DMC
being unable to make a decision owing to
inaccurate or incomplete data. Nevertheless, a
couple of interviewees did express their concern
that this is an area that has been neglected, and
requires greater attention:
“It seems to me that there should be dialogue
between the trial statistician and the DMC prior to
the first interim analysis relating to what proposed
information is provided. In my experience what
happens is the trial statistician writes the report and
they decide what’s in it … and sometimes they attach
their own interpretation of what it is saying …. I
think there is a debate to be had about what
information does the DMC want, as its very common
that the committee find there are things it wants that
aren’t there, very common especially at the first one.” 
“The quality of statistical reports for DMCs is a
subject that requires greater attention than it has
received; although some reports lack essential details,
others often contain an excess of unnecessarily
detailed tables of minor issues not pertinent to the
focused ethical and scientific monitoring functions of
a DMC.” 
“Some of the poorer reports are vast because no-one
is focused on what a DMC really needs to know and
they waste a lot of paper and time, and they don’t
necessarily focus on the issues of inference and ethics
that a DMC needs to keep an eye on. A good report
can be much shorter and written nearer to the style
that you would put in a publication.” 
Interviewees who had experience of DMCs liaising
at the outset of a trial directly with the trial
statistician on the contents of the data to be
presented, felt that it was extremely helpful in
ensuring the provision of an acceptable level of
data for the DMC to work with. The practice of
sending out information to the DMC in advance
of meetings was also considered very helpful by
providing committee members with an
opportunity to digest the data fully, and to identify
issues for discussion at the forthcoming meeting. 
Decision-making procedures
The interviews suggested that one of the most
commonly neglected issues with regard to DMCs is
the decision-making process. Apart from stopping
rules/guidelines that may be incorporated in some
trials, no formal procedures or methods of
decision-making are traditionally used. This was
demonstrated by the fact that on only one occasion
was an interviewee able to recall a DMC using a
voting technique to facilitate its decision-making.
Although the use of formal statistical stopping
rules is incorporated into many trial designs, they
serve only as guidelines to the DMC’s decision
about continued accrual to the trial, and even
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addition to considering p-values, DMCs consider
many other aspects of trials, such as toxicity/safety,
number of patients and events observed, external
information and ethical concerns. No general
guidelines or procedures are commonly used to
assist with such issues. Instead, the collective
experience of interviewees was for a general
consensus to be reached by way of open-ended
discussion. Usually, the chair will engage the
committee in discussion of the most pertinent
findings to develop opinions, and then seek to
formulate a consensus that is acceptable to the
group. 
In terms of ways to assist and improve the
decision-making process in DMCs, interviewees
did not appear convinced that any procedures
other than what they already used could be
successfully adopted. Instead, interviewees
emphasised the importance of retaining flexibility
in the DMC decision-making process owing to the
unique features of individual trials and scenarios
faced by committees: 
“A DMC would be destroying itself if you made it
absolutely perfect. The essence of it is you fully
respect each other and work together. That is why I
like to keep it small so that you can have this feeling
of unity you don’t get in a much larger group.” 
“If you have to have a vote to stop or not, I think you
should probably not, because if on a DMC you are not
certain about whether to stop or not then the world is
not going to be certain and you had better keep
going. I would say you would be better to keep going
until you have got a unanimous agreement.” 
Reporting of DMC recommendations
Once a DMC has reached a decision, the standard
practice common to all interviewees was for the
DMC chair to formulate a written summary,
reflecting the opinion and recommendation of the
committee, to be addressed to the chair of the
TSC and or study coordinators. 
Minutes of meetings
Although the majority of interviewees felt that it
was beneficial to record minutes from closed DMC
meetings, there were some variations:
“Absolutely not for closed sessions. Real minutes tell
you who says what on all the major issues and this is a
confidential meeting and I don’t think that should be
documented as it leaves the DMC open to exposure.” 
“ I’m not sure what I think about minutes. I suppose
it’s how likely you think it is that the DMC may have
to justify decisions they have made, and remember
why they reached that decision at that time.… most
of the DMCs I’ve been involved with have always left
it to the DMC to decide if they want minutes.” 
Although all interviewees were concerned to a
certain degree on issues of confidentiality, it was
accepted that it is not necessary to provide a
verbatim account of meetings, so long as there is
sufficient detail of the key issues discussed and,
most importantly, the rationale for the DMC’s
recommendations. There was, however, unanimous
agreement that when minutes are recorded,
individual DMC member names should not be
attributed to any specific details in the minutes.
Typically, the DMC chair is responsible for
drafting the minutes of meetings, although there
were some examples of other members of the
DMC or the trial statistician recording minutes. 
Although there were mixed feelings on the level of
detail that should be recorded, it was widely
agreed that it is important to record some record
of meetings, particularly where meetings may only
be annual, and members needed prompting of
previous discussions and the rationale for
decisions reached. Another but less frequently
mentioned reason for recording and keeping
minutes was to provide protection against
potential future litigation claims that may arise. 
To a lesser degree, some interviewees felt it useful
to record minutes or at least to summarise
discussions from open sessions with the study
investigators.
Training for prospective members
As it is becoming more commonplace for trials to
incorporate DMCs, there is an increasing demand
for members to serve on these committees.
However, concern has been raised that this
demand has led to members being appointed to
DMCs without sufficient experience or training:
“There is a total absence of any training or
enlightenment for people who are going on DMCs,
what their role is and indeed what the role of the
committee is.” 
“There are people coming on to DMCs who seem to
me to know very little about trials. Ideally you need
people on DMCs who know about trials, who know
about the content, what the treatment is, what the
disease is, and some knowledge of statistics.” 
However, there were mixed feelings on how best to
prepare prospective DMC members:
“Well I wouldn’t want to set up a DMC where
everybody sort of knew the game. I think new
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more experience than them. I am not sure I see any
value in setting up formal training, as you might go
on one of these courses and never be asked to be on a
DMC ….” 
“I think first of all there actually needs to be a wider
discussion as much in public as possible, as to what
the role of the DMC is. If there [are no] agreed
objectives, then knowing what training to offer the
role of a consumer doesn’t make a great deal of
sense.” 
Essentially, two approaches have been broadly
advocated: first, formal training, by way of
seminars and/or training packs, and second,
adopting an observational approach. Although it
was widely agreed that it is not possible formally to
train up prospective DMC members, there was a
strong feeling that there needs to be at least an
improvement in the provision of background
information on DMCs, combined with the use of
short training seminars:
“I think apprenticeship is good, but I think we need
to think more seriously about training, because it is
not widespread enough. For those people who come
into it, it is often very different from what they would
otherwise be doing in the normal part of their
research life. So I think there is a need for much
clearer training than takes place at the moment.” 
“I would love to have had more insight into what was
expected of me. It was a steep learning curve for 
me …. I think that it would have been good to have
attended a short course or something which told me
exactly what these committees can and can’t do, and
how we should weigh things up. I think I would have
been more confident. As it was, I felt daunted by the
seniority of the people around me, so I think more
training is an excellent idea.” 
Those interviewees who suggested more
information combined with training seminars
acknowledged that the provision of such training
should be limited to either a couple of half-days or
one full day. In terms of who is best placed to offer
such training, it was suggested that experienced
DMC members would be preferable, but perhaps
consideration could also be given to incorporating
professional societies involved with clinical trials.
It was also suggested that any such training should
aim to include case-study examples of difficult
DMC decisions to provide prospective members
with a feeling for what they might be faced with:
“I suppose those who have got the T-shirts could do a
seminar sort of thing using worked examples …. I
think people can handle this type of training much
more effectively if it is populated by worked examples
with the sorts of issues that might come up.” 
The other main training approach advocated was
based on the premise that the optimal way to
provide any type of training for prospective new
members is by engaging them as an observer in a
real DMC. For example, the candidate would be
invited to shadow a senior member of the
committee for a couple of meetings, so they could
be exposed to the workings of a DMC, and gain
an insight into their expected role and
responsibilities on the DMC:
“My own view is to have someone sit in as an
observer. Maybe not for the whole series of meetings,
but at least one or two to see how they function and
see what people’s roles are. I think that sort of
practical experience would be particularly helpful. I
am sure [that] to have some more structured guidance
for members would also be helpful. The trouble is, no
matter how thorough that information was, you would
still leave gaps because you can’t foresee every
situation in every study, so laying down general
principles would be fine, but actually having members
who are sufficiently confident in their area and have
experience of seeing how DMCs work would be very
helpful.” 
Although it was generally accepted that some form
of training should be provided for prospective
DMC members, there was a contrary minority view
that no form of training was appropriate. This was
largely based on the view that such a position is
essentially an ‘apprenticeship-type’ role, and
therefore members can only learn from their
actual experience of serving as a member of a
committee. 
Part II: Case studies of trials with
difficult data monitoring decisions
Methods
A purposive sample of trials was identified from
the knowledge and experience of the DAMOCLES
project team and experienced DMC members
interviewed about their general experiences of
DMCs. A sampling frame of 15 potential case-
study trials was drawn up and five trials were
selected for inclusion. However, owing to
difficulties contacting DMC members from one of
the trials, only four case studies have been actually
described. 
The trials selected were chosen to reflect a range
of difficult DMC decision-making situations, across
different clinical areas. For the purposes of
recruitment, the PIs were considered the
gatekeepers and so they were contacted initially by
letter or e-mail (Appendix 23) to seek their
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for permission to contact the trial DMC members.
Once consent has been received from the PI(s),
DMC members were contacted by a letter or e-mail
(Appendix 24) outlining the project and inviting
them to participate. For each individual trial the
aim was to interview as many of the DMC members
as possible in addition to the PI(s). Across the five
trials, a total of 26 DMC members were identified
and contacted. Of the 26 contacted, 23 agreed to
be interviewed. The remaining three were not
interviewed owing to non-response or unavailability.
A semistructured interview schedule (Appendix 22)
was developed to interview informants about the
general conduct of DMC meetings and explore
what made the decision-making difficult. Because
of time restrictions, the majority of interviews were
conducted by telephone. All interviews were
audiotape-recorded and transcribed verbatim for
analysis; the interviewer verified accuracy. Any
relevant documents such as reports, letters and
journal articles were included to supplement
analysis of interviews.
Nvivo software (version 1.3) was used to assist with
coding the data, organising topics into categories
and facilitating comparison of topics with earlier
data. The interviewer carried out analysis; another
member of the project team separately analysed a
selection of transcripts to compare coding and
emerging themes.
Case study A
Issues under consideration by the DMC
The trial was evaluating an expensive and invasive
treatment for critically ill patients. It was set up to
assess whether a new treatment had a beneficial
effect on survival to 1 year without severe disability
in comparison with conventional management.
The main difficulty for the DMC was the two-part
outcome variable: effects on mortality emerged
before effects on long-term disability could be
assessed.
DMC membership
All five people serving on the DMC were
interviewed:
  chairperson (clinician)
  two clinicians
  one epidemiologist
  one statistician.
One of the PIs was also interviewed as they were in
attendance at closed meetings.
Background and experience of DMC members
Most of the DMC members knew one another
fairly well and perceived it to be a well-chosen
committee with a good range of experience and
expertise. However, one member occasionally
raised some doubts about their ability to serve on
the committee, as they were not a clinician
involved in the clinical trial area:
“The only one I felt slightly worried about was myself,
otherwise it was absolutely the right mix I think …. I
don’t remember being dissatisfied with anything
except myself … my particular weakness was that I am
not a clinician and I don’t do this [disease treatment]
area.. I think that put me in slight difficulty, but then
this was also true of two of the others.” 
With the exception of one DMC member, the
committee had a considerable amount of previous
experience serving on DMCs. In particular, the
chair was an extremely well-respected and
experienced DMC chair, although without any
clinical expertise in this particular field. 
Rather unusually, both the PIs were invited by the
chair to attend DMC meetings as they were not
directly involved in entering participants into the
trial. Although it is not common practice to have
the PIs in attendance at DMC meetings, no DMC
members expressed unease with this arrangement. 
Structure and organisation of meetings
There was a total of four DMC meetings, which
took place over a 2-year period. All the meetings
took place face-to-face, with the first meeting used
to discuss the terms of reference, protocol and
dummy table structures for future reports and
tables of results. At each meeting, a report was
prepared by the trial statistician that was used to
guide DMC meetings. At the end of each meeting,
agreement was sought regarding the DMC report
to be communicated to the steering committee.
DMC members recalled being presented with
good-quality trial information, which provided
sufficient trial background information for the
committee:
“I do think the documentation was exceptionally
good. We had an enormous folder of stuff, which
described what the trial was about, and what it was
trying to do in great detail and how it had been put
together. And we had all the documentation that the
trial participants would have had and so on. So that
was put together extremely well, I wasn’t wanting for
any of that.” 
However, as the trial progressed and data were
presented to the DMC, one interviewee expressed
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procedures were not always of a high standard: 
“I did have slight trouble where the data didn’t come
in as rapidly as it should have done, and when it
came in, it wasn’t always checked as carefully as it
should have been done. But that is a technical
problem and certainly we put it right in the end, but
especially if they are very big trials, it is absolutely
essential that the administration in the data
processing and checking is impeccable.”
DMC deliberations and decision to recommend
termination of trial
It would seem that, from the first meeting, there
was quite a strong suggestion that there were
differences in mortality rates. However, there 
were few data available early on, and they were
difficult to interpret at this stage. Indeed, the use
of such long-term outcome variables for future
trials was questioned by one of the DMC
members: 
“I would think very carefully in designing a future
study using a complex long-term variable like that,
when the stopping time is so crucial.” 
As the trial progressed, statistical issues became
less important because the difference in mortality
was apparent without the need for statistical
testing. Instead, the focus of deliberations was with
regard to ethical questions:
“… almost all we ever discussed was who are we
disadvantaging by continuing the study?” 
Indeed, interviewees described how issues were
tossed backwards and forwards between the
statistician and clinicians:
“… the thing divided really into the statisticians and
clinicians. The clinicians turned up for meetings
thinking the statisticians would have the answers. The
statisticians said it was not really a statistical question
at all, it is a clinical question, so it’s over to you guys;
it batted backwards and forwards.” 
“I don’t think you can make formal rules for DMC
where you are trying to balance information about
different end-points with different importance. How
on earth can you balance one death against another
death?” 
All the interviewees considered the role of the
chair as crucial during DMC deliberations.
Although to a certain extent the chair was
described as taking the lead, their experience and
guidance was considered very important in
guiding and framing the decision-making:
“… [name of chair removed] is a very pleasant person
to work with, and is a brilliant mind, and very
carefully brought everybody together, and got us to
understand very quickly what we really had to look
at.” 
“I think the chairperson took a lead role but it was
definitely a group decision, but the chair certainly did
take the lead in respect of conduct of the meetings
and in framing the decision-making.” 
In terms of the time taken to discuss issues, all of
the interviewees felt their meetings were very
thorough, and issues were explored
comprehensively:
“People were generally asking lots of questions and
trying to work out what an extra 6, or 12 months
would produce. And in the end, we all realised it
wasn’t going to produce anything. I think we got our
views logically. There were no terribly strong contra
feelings being expressed. It was just that people were
trying to turn over every stone we hadn’t considered.” 
Despite the fact that the interviewees were
comfortable that they had discussed the issues as
thoroughly as possible, one DMC member felt that
the input of a lay person may have been useful:
“ I think even though we weren’t directly involved in
it, we were too close to the study to be really able to
balance that as a member of the general public
would. And I would like to have known, I wouldn’t
want to have been overrun, but I really would have
liked to have had a feel from somebody who wasn’t
involved in the study, as to what the value of that
balance was, or where that balance should lie.”
As the trial progressed and more data became
available, it became clearer that the intervention
was saving lives; however, it was less certain for
how long the trial should continue:
“ … we knew it was saving lives, and the question is
how far do we keep going before we are convinced
that there is a net benefit .… one had to take a longer
term view of the importance of getting the right
information.”
However, this member felt comfortable that the
committee made the right decision to recommend
continuing the trial for as long as it did:
“ I think in that situation my feeling is, in terms of
overall balance of benefits to the greatest good to the
greatest number of people, yes some people will have
missed out, but I still think it was right to carry on.” 
Undoubtedly the decision-making was complex
and difficult, particularly owing to the nature of
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DMC was looking. Although no formal methods of
consensus were adopted, interviewees felt that the
chair played an important role in terms of helping
them to focus on the most important issues.
Although towards the end the clinicians were
reported as being very keen to continue the trial,
the statistician convinced them that they wouldn’t
be gaining what they expected by continuing:
“Although the clinicians were keener to carry on than
the statistician, I think they were able to demonstrate
to us that really we wouldn’t be gaining what we
thought we might be gaining and I think that was
useful. In the end there was a lot of discussion, but we
certainly all agreed without any difficulty in the end,
we talked ourselves to a consensus.” 
By the end of the final meeting, the DMC judged
that there were enough data to conclude there was
an absolute clear effect on the combined end-
point. It was 2 months before recruitment was due
to end formally:
“The DMC recommended to the steering committee
that they look at the data with a view to stopping the
trial. And the trial stopped early, 2 months before
formal recruitment was due to stop.”
With regard to satisfaction with the decision
reached, interviewees felt they did the best they
could under the circumstances. However, it had
been a difficult process, which is perhaps best
summarised by one of the interviewees:
“I guess this is a trial where the difficulty lies with the
data to be monitored rather than the difficulties
within the committee. This is a situation where
another committee could have come against a very
stormy time whereas that didn’t happen … that is
what we were worried about and that is why we chose
this group so carefully, unusually highly respected and
experienced.”
Case study B
Issues under consideration by the DMC
The key concerns of this DMC centred on their
early misgivings about numbers recruited to one
of the treatment options and the adverse effects
resulting from dosage levels. It was intended that
patients would opt for either option A or option
B. Option A would randomise them between a
placebo and two treatments, and option B would
randomise between the two treatments with no
placebo arm. The DMC anticipated that, in such a
situation, few patients would opt for A, when B
assured them of at least some treatment. These
concerns came to fruition as the trial progressed. 
DMC membership
Owing to the international nature of the trial, the
DMC was comprised of three members from two
countries: two joint chairpersons, two medical
specialist and two statisticians. Of the six DMC
members, four agreed to be interviewed, in
addition to one of the PIs. The remaining two
DMC members were unable to be interviewed.
Background and experience of DMC members
In terms of previous experience, all of the
members had served on an earlier DMC and had
experience of the trial area. Prior to that, only two
members had previous knowledge or experience
of serving on a DMC. 
Interviewees felt comfortable with the group’s mix
of experience; it was also felt that an equal balance
in the international composition, including the
chairs, worked well, and provided a well-balanced
model for the DMC:
“They were a mix of quite different skills and I think
they had a particularly effective way of working as a
result of monitoring [trial name removed], which they
navigated very successfully. It was felt this was a very
good model for a DMC.” 
“They were balanced by a person with the same
expertise from the other country, and I think that was
an added benefit.” 
In particular, interviewees felt that the background
and experience of the joint chairs was valuable to
the group, and provided a balanced perspective to
meetings. The fact that one of the chairs did not
have a clinical or statistical background did not
appear to be problematic to the committee:
“These were people who had substantial experience in
committee work and in ethics and law. The way I saw
their role was they provided a lay and ethical oversight,
and the opportunity to represent a common-sense view
that stood aside from the professional input from the
clinical side and the detailed analysis of numbers from
the statisticians … maintaining a proper balance
between the risks that the trial participants are
undergoing against the benefit for the greater good of
patients to come, and people of the future.” 
Structure and organisation of DMC meetings
The DMC had preliminary sessions with senior
investigators before the trial started, which
interviewees felt had been very valuable in
allowing them to discuss how they were going to
proceed in future meetings. In addition, senior
investigators met with the DMC before meetings
on an informal basis to provide an up-to-date
summary of progress and problems.
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English (not the first language of three members),
and meeting venues alternated between the two
countries represented. It was apparent from the
interviewees, however, that difficulties with
language made some discussions problematic.
All the relevant documentation was produced in
English, but not circulated to members in advance
of meetings. With the exception of one
interviewee, it was felt that the interim analysis
should have been sent out in advance of meetings
to allow members more time to study the data:
“The arrangements for presentation of data at the
routine meetings of the DSMC were satisfactory and
ensured confidentiality. At the meetings for the
interim analysis, where much more extensive data
were provided, there would have been some
advantage if the data sheets to DSMC members had
been securely mailed a few days in advance of the
meeting.” 
However, as mentioned previously, owing to the
particular circumstances of this trial running
parallel to another major trial, some interviewees
felt that sending out the interim analysis in
advance of meetings would have imposed too
much of a logistical burden on the coordinating
centre.
The trial protocol planned for an interim analysis
after 15 months, and the DMC in the early stages
saw no reason to recommend any change to this.
The DMC met to review the data on four separate
occasions. For various reasons interviewees
recalled how the provision of accurate and timely
data was difficult:
“… the only problems were the ones of availability
and accuracy and their presentation … I think that
really gives the dilemma about the timing which
would be appropriate to make decisions and the
timing in which you got the maximum material, and I
think really, that is a judgement call.” 
Members were provided with a terms of reference
that clearly laid out the role and responsibilities of
the DMC; however, interviewees did not recall this
as being a particularly important or prominent
document at meetings.
The general format for meetings constituted an
open session between the DMC and senior
investigators, followed by a confidential closed
session for committee members. These open
sessions with the investigators were described as
being very informative especially in learning about
other relevant studies. Despite this, a couple of
interviewees described feeling quite anxious about
similar ongoing trials, and their possible impact
on the decision-making of this DMC:
“I do think there is one thing which I think was
missing which worried me from time to time. I was
worried about whether at each meeting we knew
about what else was going on in the world … which
could be relevant to the decision-making of that DMC
meeting.… I think that would be the thing I
remember worrying about all the time, I kept
thinking there is a lot going on the world out there …
is there something which would change our decision?”
This was supported further by one of the
interviewees, who stated:
“The impact of other trials on this trial concerned us
greatly. We were very interested in what was going on
in the outside world."
It was suggested that it might have been useful if
the DMC and coordinating committee had
discussed in more detail at the outset the types of
problems and complexities that might arise and
how they should be handled. However, it was
acknowledged that in reality this might not have
made any difference:
“… I think it would be very hard at the beginning of a
very complicated process when other stuff is coming
through all the time to have made any predictions. It
might be right, but I don’t feel that it would
necessarily solve it.” 
DMC discussions and recommendation to stop
the trial
From the outset, members had expressed concerns
about the trial, particularly in relation to the
treatment options:
“We had misgivings about the trial. We were going to
be dealing with people in an advanced stage [of
disease], and the one thing we were constantly being
reminded of was that we never really knew at what
point these people developed the disease.. For all we
knew, we could be looking at 3-year-old cases or 3-
month-old cases …. It came as no surprise to us when
we found we were seriously beginning to question
whether the trial was really worth continuing. We did,
of course, eventually reach the stage where we
thought the trial should stop, and we knew this was
going to cause some discussion.” 
During deliberations, it would seem that statistical
issues were paramount as things progressed, with
one of the statisticians reported as taking a
prominent role. There were no formal rules for
the early termination of the trial, but the DMC
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discussion with some of the PIs before their formal
meeting to discuss possible scenarios under which
the trial might be terminated.
The DMC came to their final meeting with the
realisation that it was unlikely to recommend
termination of the trial on grounds of a clear
advantage to either group; the results presented at
earlier meetings had shown only moderate
differences in crucial end-points, which were not
consistent in direction. However, the absence of
marked differences in efficacy might justify an
early termination of the trial, on the grounds that
continuation was unlikely to affect the picture to
any important extent. 
Interviewees recollected how discussions had been
relaxed, and after much discussion (at the closed
DMC meeting) committee members became
satisfied that there was no suggestion of consistent
trends becoming clearly established with longer
follow-up:
“We took the view that although consideration of the
sequential nature of the analysis is important, the
whole set-up in this trial was so complicated that you
couldn’t easily define the conditions under which you
would want to stop … I think we took the view that a
purely significant difference by itself isn’t enough. You
really need to be fairly clear that the difference is big
enough to make people change their practice.” 
The DMC took the view that the expectations of
further clarification were not high, and the case
for continuing the trial had to be measured
against the disadvantages of doing so. A clear
consensus was reached with no members reporting
feelings of unease about their recommendation to
the coordinating committee, that the trial should
be terminated; however, the coordinating
committee did not accept this recommendation.
Although the DMC members accepted that their
role was advisory, there were feelings of surprise
among them when the steering committee did not
accept their recommendation:
“The co-ordinating committee, of course, was entitled
to reject the advice of the DMC and future
deliberations by the two bodies led to a general if, on
the part of the DMC, reluctant agreement to continue
the trial ….” 
“I don’t think there was any particular row about it. I
suppose we might have been a bit surprised and a bit
disappointed. I don’t think we felt they were wrong to
do that, because there was no particular ethical
argument against continuing to randomise. After all,
if there wasn’t much of a difference in these
treatments you didn’t do anyone any harm by
continuing to give one half of them one, and the
other half the other. It was a different sort of problem
to one that would arise if there was a big difference
and you felt there was a real ethical problem in
continuing at that stage.” 
The coordinating committee asked the DMC to
accept that the trial should continue for a further
short period, and that the DMC should then
review whatever information emerged. Although
the DMC accepted that the coordinating
committee was entitled to reject the advice of the
DMC, future deliberations between the two bodies
led to a general if, on the part of the DMC,
reluctant agreement to continue the trial for a
short period. 
In the end, the trial continued for another 
7 months, at the end of which the coordinating
committee reported that:
“The suggestion of a longer survival with the
[removed] at our previous analysis had disappeared.”
Although it was suggested that it might have been
more useful if some issues had been considered
more fully before discussion, it was acknowledged
that, in practice, this would probably have been
very difficult:
“In hindsight it might have been useful if the DSMC
and coordinating committee had discussed more fully,
at the outset of the trial, the types of circumstances
that might lead to crucial recommendations about
termination. It is likely, though, that the relevant
circumstances would not have been clearly envisaged
at that stage and in any case the views of members of
both committees might well have changed with the
passage of time.” 
Case study C
Issues under consideration by the DMC
A crucial feature of this DMC was the fact the
committee had access to an earlier similar dose-
ranging trial looking at the effects of different
dosage regimens. Results from this previous trial
had not been available before this trial was
initiated; therefore, the DMC was very concerned
at the lack of evidence relating to dosage levels
being used in this trial. 
DMC membership
Of the four people serving on the DMC, three
were interviewed: 
  chair (clinician)
  clinician
  statistician.
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to be contacted for an interview. Two of the PIs
were interviewed, although they were not in
attendance at any DMC closed meetings.
Background and experience of members
All committee members had a good knowledge
and understanding of clinical trials, and were
experienced DMC members; the chair had
previously served on a DMC as an ordinary
member; however, this was only their second
experience as a DMC chair. 
Although it was generally felt that the DMC
composition was satisfactory, one interviewee felt
quite strongly from the outset that the committee
would have been better placed with additional
clinical expertise:
“I felt the composition was incorrect. [Removed] was a
clinician, but I was the only hands-on clinician who
understood this drug. [Removed] and the [removed]
were statisticians and knew nothing about it …. I
realised I was the only one from the DMC who knew
anything about the drug or anything really about the
active clinical area at this time … the composition was
wrong.” 
Structure and organisation of DMC meetings
There does not appear to have been any
preliminary briefing session before trial
recruitment began to discuss stopping rules or
how they were going to proceed generally in
meetings. However, a document similar to a terms
of reference was prepared by the DMC that
outlined some guidance for managing the trial. It
would seem that this document was not shared
with the TSC and never formally approved. This
was a source of frustration and concern for one
interviewee:
“… that document had never been shared with the
steering committee and was never formally approved.
That was a clear gap in the management of the study
that the document was not even viewed by the
steering committee and therefore they were not aware
what rules the DMC were following.… they were
making a judgement that was not supported by any
kind of document that was available to everyone.” 
In general, most of the DMC meetings were
conducted face-to-face, except when an urgent
meeting was called and a teleconference was
arranged. Meetings were a mixture of open and
closed sessions, usually with the sponsors in
attendance at the open sessions. These meetings
were described as ‘interactive sessions’ in which
the DMC reported to the sponsor, thus providing
an opportunity to discuss issues of concern.
Meetings followed the structure of the statistician’s
report to the committee, and members liaised
directly with the contract research organisation
(CRO), which was responsible for presenting the
data. This arrangement appeared to work very
well, and ensured that the quality and style of
reports were acceptable to the DMC. 
DMC deliberations and decision to recommend
termination of trial
Before any major deliberations were underway,
one of the DMC members indicated that they were
very unhappy with the DMC composition, and felt
strongly from the initial meeting they were the
only member who fully understood the
complexities of the treatment being assessed.
As discussions progressed and more data became
available, this DMC member continued to feel that
they were the only one who understood how
serious the implications of this new treatment
could be. In particular, concern centred on its
withdrawal effects:
“… I don’t think they understood how serious the
issues were. My problem was that the other DMC
members didn’t understand the importance of the
dose and the dose interval here.”
Approximately 4 months after the first patient was
randomised, weekly updates were being produced
that led to growing concerns in the pattern of
excess mortality. At this point a DMC
teleconference was convened, followed by a face-
to-face meeting. Although interviewees were
unable to recall exact details from those meetings,
it was clear that members were very concerned by
the emerging data and for the safety of trial
participants. At this stage, some criticism was
directed at the chair:
“[name removed] was afraid to be courageous and the
whole time they were trying to explore what would
people think if they did this, or did that. [Name
removed] was very concerned with that.” 
In comparison, one of the statisticians was
described as being braver, yet perhaps too focused
on the numbers:
“They were extremely courageous, but totally focused
on the numbers and he didn’t have a feel for what
were the consequences of what we were about to
do.… we were picking up that this drug was killing
people like flies and I think they were very wary about
this, and this is what DMCs are all about, they are
about protecting patients and this trial was not doing
that.”
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face meetings the crucial DMC meeting took
place, which was to lead to its recommendation of
stopping the trial. From the clinical perspective,
there was concern that terminating the trial would
have serious implications for this promising type
of treatment in the future. For the others, concern
rested on the numbers and the rate of excess
mortality. 
From one member’s perspective, it was clearly felt
unethical to continue, as patients were being
exposed to a drug where there had been little
prior evidence of its effects. Also, in the earlier
Phase II trial there had been a slight indication
that the mortality rate was going the wrong way:
“I felt the phase II trial that had been done earlier,
also had a hint of mortality trending the wrong way,
but it was obviously far too small to carry a lot of
weight on its own …. I felt that based on this early
mortality … the chances of the drug actually seeing
benefit for the primary outcome were extremely low
… there was no prior evidence of this drug from
other sources … I felt it was unethical to continue.” 
So, after much discussion, the DMC chair
concluded that the trial should be stopped, based
on the apparent significant adverse effects of the
drug compared with the placebo. This had also
been suggested in the small amount of data in the
earlier study. However, even though the chair
described the final decision as “clear-cut”, others
felt that there were differences in the strengths of
agreement, with one DMC member expressing
their dissatisfaction with the decision reached:
“Basically it was not my view, basically I thought I was
a single dissenter to this and I thought we should
make every effort to modify the protocol based on
what we knew about the drug and not try to stop
something because I knew what the consequences of
this would be.” 
However, when asked to describe how strongly the
recommendation being made to the steering
committee was resisted, the interviewee was unable
to recall. In addition, none of the other
interviewed DMC members recalled any
disagreement in the decision reached. However,
one committee member acknowledged that there
were different strengths in the decision reached:
“… there were graduations of strength of stopping …
and some were more strongly for stopping than
others. But there was no-one really against the
recommendation, so it was a unanimous
recommendation.” 
Once the written recommendation had been made
to the TSC, a joint meeting was held with the
DMC to reveal the data behind the decision. With
suggested differences in the opinions within the
DMC, there were feelings among the senior
investigators that the most outspoken individual
on the committee drove the DMC decision: 
“… there was one of the members who was
particularly outspoken on the DMC, and felt very
definitely that the trial should be terminated. So they
were not necessarily all of the same mind, but I
believe that viewpoint determined the committee’s
final decision.” 
After the TSC had studied the data, one DMC
member described how at least one of the steering
committee members remained unconvinced:
“The representatives of the trial steering committee,
or at least one of them, didn’t get convinced by the
results we had, and wanted to continue the trial. We
were convinced that we should not do that, so we
tried to reach some type of consensus here, but it was
not possible to do that because the steering
committee member didn’t want to stop the trial …” 
“… there was a considerable discussion about whether
or not [name removed] was willing to continue as a
member of the DMC …. I felt very strongly that once
a DMC member dropped out, especially someone of
[name removed] stature, it had to be the end. I would
not have participated if they had dropped out. I
would not have continued, I would have felt I was
doing something wrong and so we had to convince
[name removed] that these modifications actually
were solving the problem and it was the design that
was wrong ….” 
During this crucial meeting, the DMC and TSC
were joined by representatives from the
sponsoring company, who announced that they
were no longer going to fund the trial. Members
of the steering committee and DMC members
were surprised at this announcement; however, for
those members who had advocated for the trial to
stop, it was considered to be the right decision. 
Undoubtedly, it had been a difficult decision-
making process, and some interviewees made
suggestions for future trials, especially with regard
to safety reviews for future new drugs. For
example, although the safety stopping guidelines
taken from a data monitoring wallchart stated that
there would be a safety review every 6 months,
they tended to be held more frequently:
“I think for a new drug in hindsight there should
have been safety reviews more often than that,
although in practice we did it more often.”
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this data monitoring experience was the fact that
the DMC oversaw and had access to data from a
previous unpublished dose-ranging trial:
“When I look back at it in retrospective, I should have
refused to participate in the DMC if they were going
to do these two trials in parallel, … you can’t do two
trials simultaneously trying to find out what the
appropriate dose is in a mortality trial.” 
“The problem was, the dose levels were not well
known at the time … the best way would have been if
they had closed the first dose-finding study to see
what doses they should recommend, and then started
the other one, but that was not done.” 
Case study D
Issues under consideration by the DMC
The key issue under consideration by the DMC
was to do with new external evidence that came to
light from a number of sources. Details of the
external evidence were provided to the DMC by
the PIs along with analysis of the first couple of
hundred patients recruited to the trial; an urgent
DMC meeting was then convened to discuss the
data. As there were so few data from this particular
trial, almost the same information was available to
the DMC, PIs and TSC members.
DMC membership
All four DMC people who served on the DMC
agreed to be interviewed: 
  chair
  statistician
  two clinicians.
In addition, one of the PIs was interviewed, as he
serviced the committee and attended all DMC
meetings.
Background and experience of DMC members
In terms of previous experience, only one
interviewee had not served on a DMC before.
However, all the committee members appeared to
have a good knowledge and understanding of,
and practical experience with, clinical trials.
Although none of the committee members had
worked together before or was familiar with each
other’s expertise, this was generally not regarded
as being very significant:
“… the calibre of the DMC member is far more
important than whether you know them or not. I am
on quite a few DMCs and have no problem at all
working with people I don’t know.”
All the interviewees collectively agreed that the
role of the chair was extremely important for the
quality of group functioning. In this case, the chair
was a well-respected clinician with extensive
experience and knowledge of multicentre clinical
trials. However, they had no knowledge of this
particular field and little previous experience of
serving on a DMC. This was also their first
experience as chair of a DMC.
Despite this lack of clinical expertise and DMC
experience, the chair felt very clear and confident
about their role and responsibilities:
“I was to work closely with the chairman of the trial
steering committee to monitor the data on an interim
basis so that the trial would not continue longer than
was necessary … and to be kept appraised of the
science of the subject and any data that existed prior
to the trial, or that appeared during the trial, bearing
in mind that I knew nothing about the subject itself.” 
When asked whether they felt it was a disadvantage
in not having the specialist clinical knowledge
under discussion, they described feeling:
“Entirely comfortable because the principles of
clinical trials and the statistics of clinical trials can be
generalised across all subject areas.” 
With limited knowledge of the workings of DMCs
and no previous experience of chairing such
committees, there was no discussion of their role
and responsibilities as chair:
“It wasn’t explicitly described, but the assumption was
a fair assumption that I know about the workings of a
DMC.”
Structure and organisation of meetings
The DMC had had no preliminary briefing session
or introductory meeting before trial recruitment
had begun, and so their first meeting was called
(by teleconference) with the specific remit to
discuss the emerging external evidence. All the
relevant information had been circulated to
committee members at least a week in advance of
the meeting. Members were also provided with
terms of reference which broadly outlined the role
and responsibilities of the committee.
It was strongly felt by almost all the committee
members that it would have been beneficial if
there had been an opportunity to meet before the
trial began, to discuss how they were going to
proceed and handle issues for future meetings.
Added to this, concern was raised about the use of
teleconferencing for their first meeting:
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trial had been funded and agreed, if we had met then
we would have been better prepared for what
followed, because our first contact wouldn’t have been
in relation to some crisis … having a chance to meet
and decide how as a group we were going to deal with
the terms of reference I think would have been very
helpful.”
“ I think looking back it would have been easier if
there had been some communication, at least from
the chair of the committee. The only communication
I had had was with the trial group. Face-to-face
meetings in advance, or at the time would have been
good, but I recognised that it is awkward when people
are long distance. But having never even spoken with
the chair before that meeting made it a bit difficult to
know what the plan was for the meeting to proceed.”
In terms of how the teleconference was handled,
there was general dissatisfaction regarding its
conduct and how the final decision was reached.
In particular, criticism has focused on the role of
the chair, with descriptions of it being a rushed
meeting with no initial discussion about how best
to proceed:
“The chairperson was certainly the most dominant
figure, there is no doubt about it. I seem to remember
we all assembled and the chairperson’s secretary was
there and they came on the phone to sort this out
and it was all a very brisk affair. That was my only
lasting memory of the individuals involved.”
“As I recall … the chair took a fairly strong view and
very much took the lead, probably more so than they
would have done in a face-to-face meeting because I
think there has to be a fairly disciplined approach to
a teleconference. There was a perception that this had
to be done very quickly. I am not sure why that was,
but it was done by teleconference and it did move
very quickly, but I think the chair was certainly very
much in the lead.”
“The shortest DMC meeting I have ever had is that
one about the [removed] … half an hour, I would
have thought.”
DMC deliberations and decision-making
It would appear that the main tensions in the
DMC deliberations and decision-making process
were between the clinical interpretation and the
methodology: 
“There was a methodologist who knew nothing about
the topic area arguing that the trial must continue.
Yet the two people who were involved in the topic
area were much more uncertain about it.”
The general feeling from the interviewees was
recollections of shared confusion about whether it
was even relevant for the DMC to be considering
external evidence, and what weighting to give it.
None of the committee members had been in a
similar situation before and they felt very unsure
on how best to make a decision and
recommendation to the TSC:
“There was confusion about what they should or
should not recommend and to what extent they
should or should not take note of external evidence.
They felt they should take note of external evidence,
but they didn’t know how much weight to give it,
whether it was of relevance to them, and if so, how it
was relevant to them and what they should do with
that information. There was quite widespread
confusion and I shared that confusion because I had
no idea. It was all new to all of us.” 
During the discussion the chair was described as
taking a dominant role, yet as they did not have
any expert knowledge in this clinical area it was
felt that they had to rely quite heavily on the PI in
attendance:
“… Suddenly faced with this very difficult decision
about the trial, they had no idea at all about the topic
area, and it made it extremely difficult for them to be
an effective chair. There was one other person on the
committee who had no experience of this field, so
there was a lack of knowledge about the topic area
which made it quite difficult for them to make
judgements.”
“The chairperson didn’t say they were vulnerable in
any way, but they did keep asking for input into the
clinical relevance of this.”
In terms of discussing the issues and engaging in
the decision-making process, it seems that, in
addition to the chair, there was one other
individual who played quite a dominant role which
resulted in other members participating less:
“I think a lot of the committee felt very under-
empowered to contribute very much. The two people
who contributed the most were the chair … who
needed to because it was a teleconference … and
[name withheld], who again is extremely experienced.
Those were the two most vocal members and those
were the two who knew nothing about the area.”
“When you are talking against two trialists, its very
difficult to argue with them …. [Name withheld] was
extremely strong in saying the trial must continue,
which was extremely reassuring for the other DMC
members, even though they couldn’t quite necessarily
understand the logic behind it …. I think it was a
very good demonstration of group dynamics where
one person can almost force everybody else into
agreeing with them when that isn’t their instinct and
wasn’t their instinct when they first went into the
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happen.”
This was further supported by another
interviewee, who felt that it was difficult to
contribute and fully participate in the meeting
owing to the telephone conference situation:
“I believe that I made my views known on that
conference call, but I didn’t find it easy to do so. I
would have found it easier face-to-face, but whether
there would have been more interest in my
perspective if I had been face-to-face and a difference
in the end result, I don’t know.”
In reaching a consensus for the recommendation
to the TSC, there appear to have been mixed
feelings about the strength of decision reached:
“I don’t recall there being a good consensus reached
… I recall a more middle of the road kind of result at
the meeting … I don’t recall it being a strong
recommendation.”
In the end, the chair concluded that, based on
what had been discussed, the DMC should
recommend that the trial continue, subject to the
trial protocol being amended. Although no one
was reported as disagreeing with the chair’s
conclusion, some members clearly had been very
dissatisfied with the decision reached:
“I don’t think people were happy with that decision
necessarily, and the inability to express their
unhappiness was because of the situation, the
telephone conference. If it had been face-to-face, it
would certainly have been easier to pick up that they
were unhappy because it would have shown. The
whole thing could have been explored more.”
After lengthy discussions, the TSC decided that
continuing with the trial could not be justified,
and recruitment was stopped. The decision of the
TSC led to mixed feelings from DMC members:
“I actually was supportive of stopping the trial. I was
relieved to hear they had stopped it.”
“… It was a pragmatic decision that they thought they
would not get the recruitment they had projected
because people would be unwilling to take part in it. I
think scientifically that was a poor decision.”
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The DAMOCLES project used a range of
approaches to consider behavioural, procedural
and organisational aspects of data monitoring in
RCTs, and these have been described in earlier
chapters of this report. The project aimed to
develop guidance for future practice. Structured
around the 23 prespecified questions (Box 1), this
chapter compares and contrasts the findings of the
different approaches and discusses their
implications for future DMCs. Where clear views
have emerged and are endorsed by members of
the DAMOCLES group, these have been
highlighted as recommendations in Chapter 8.
Which trials need an independent
DMC? (Question 1)
The sample survey of published reports of RCTs
showed that the proportion with DMCs mentioned
among those reported in general medical journals
more than doubled between 1990 and 2000.
DMCs were more likely if trials had larger sample
sizes, were multicentre and/or multicountry, had
survival as a primary outcome measure, or were
likely to take a relatively long time to complete. 
Nevertheless, in only 26% of trial reports in the
general journals was it stated that there was a
DMC, the percentage ranging from 3 to 35%
across the six journals sampled. The overall rate
in the general journals was higher than that found
in specialist journals, among which there was also
wide variation in reported usage. DMCs were
relatively commonly described in trials reported in
cardiology and infection journals, but none of the
76 trial reports identified in psychiatry journals
mentioned a DMC. 
The survey of policies about DMCs of major
organisations involved in trials (such as funders
and regulatory agencies) is likely to provide a
pointer to the role of DMCs in future trials. This
showed that funders are increasingly prescriptive
about the need for DMCs in trials that they
support. Nineteen of the 25 organisations had a
policy about which trials need a DMC. For ten, the
policy was for trials to have a DMC ‘as default’,
whereas for the others the policy was more
selective (see Table 29). 
The review of the literature on DMCs found broad
agreement that nearly all trials need some form of
formal data monitoring. Common models for
DMCs vary in their degree of independence (see
Table 2). However, independent DMCs are
increasingly accepted components of RCTs.
Suggested characteristics of trials that need a
DMC (see Box 2) include definitive trials likely to
have a profound effect on practice, trials with vital
status or irreversible serious morbidity as primary
outcome, trials of long duration, blinded (masked)
as opposed to open trials, trials that require
complex monitoring (e.g. to assess the balance of
risks and benefits) and trials in vulnerable groups
of patients. 
A further suggested category was trials where there
is a strong reason for independent evaluation
because of concerns about likely vested interests.
In principle, there are potential vested interests in
any trial that may jeopardise the trial’s integrity.
For this reason, it may be more appropriate to
assume that in general a DMC is required, and
rather to reverse the question and to ask which
trials do not need a DMC. There appear to be
three broad scenarios where this may apply. The
first is where it is not possible for a DMC to make
a contribution to a trial. For example, a trial may
be of such short duration as to make a DMC
infeasible. This is also likely to apply to many
cross-over trials. The second scenario is where any
observed differences between trial groups,
however extreme, would not prompt any change
in the trial’s protocol (such as early stopping). It
has been suggested that this could, for example,
apply to small trials with outcomes that are
‘minor’. The third scenario is where there is no
reason for thinking that an independent DMC
would reach any conclusions that significantly
differed from decisions that would be reached
after internal monitoring. This latter criterion
appears to be behind the suggestions that open
trials, and specifically trials testing a behavioural
or an administrative intervention, do not require a
DMC (see Box 3). This does not, however, seem
appropriate as a general rule. Participants in these
sorts of trials need protection from the vested
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Chapter 7
Discussioninterests of investigators and sponsors in just the
same way as participants in other trials, and open
trials can, and arguably should, have blinded
interim analyses. 
A plethora of different names has been used to
describe groups responsible for data monitoring in
trials (see Chapter 4, Table 16), and this is
potentially confusing. A standard term would be
desirable and the DAMOCLES study group
favours ‘data monitoring committee’ (DMC).
Who should decide the details of
how a DMC operates? 
(Question 2)
The DAMOCLES project has explored in detail
many aspects of DMC operation and showed wide
variation between trials in many of these.
Differences among DMC members (and others
involved in the trial) in their understanding of
these could lead to difficulties within the
committee (or between the committee and those
to whom it is responsible). For this reason there is
a general view that all parties (DMC, investigators
and sponsors/funders) can beneficially agree many
of the details of how a DMC operates in advance.
This could be in the form of standard operating
procedures, or a charter. It is, however, implicit in
the independent nature of a DMC that it has some
flexibility (such as in requesting extra analyses or
meetings as it sees fit, or in choosing to modify
the criteria upon which it makes
recommendations).
A template for a DMC charter was developed
within this project and is presented as Table 33. 
It aims to cover the range of operational issues
that are relevant to DMCs in a systematic way,
adaptable for individual trials.
What should the DMC’s terms of
reference cover? (Question 3)
One aspect that would be covered in such a
charter is often called the terms of reference: a
description of what the DMC should do. Terms of
reference have varied between trials, although
there has been little direct disagreement. The
surveys of recently completed trials showed that
terms of reference tend to be of two types: specific
guidance about monitoring interim data, or a
description of the purposes of DMCs in more
general terms. The terms of reference identified in
the review of funders tend to be of the latter type,
outlining the core tasks that funders expected to
be covered by a DMC (see Chapter 5, Table 30);
the three most commonly mentioned were
‘consider outcome data from interim analyses’,
‘consider data about safety and adverse events’,
and ‘report on continuation/stopping/amendment’.
When the experienced DMC members were
interviewed, they mentioned how important terms
of reference can be when there are difficult
decisions to be made. They thought that it was
very important that time was put aside to agree
these at the beginning of a trial. However, their
experience of DMCs had been that often little
attention had been given to this at the times when
DMCs were being established.
In the review of the literature on DMCs, terms of
reference were explored in more detail. The
DMCs’ roles (what DMCs do) were distinguished
from their responsibilities (to whom DMCs are
responsible). Roles have been divided between
major and ancillary (see Chapter 2, Table 3). The
major roles could all be relevant to an individual
trial, although not all are essential and the
emphasis may vary. This table therefore provides a
useful checklist when a DMC is established as a
basis for agreeing in advance what it will or will
not do (and indeed these are all covered in the
template for a DMC charter; see Table 33). 
In its deliberations, a DMC should take into
account the interests and concerns of a number of
groups (see Chapter 2, Box 4): trial participants,
future patients to be enrolled in the trial, patients
with the target condition who will be treated after
the trial, society in general, the investigators, the
TSC and the sponsor. Explicit recognition of this
in a DMC’s terms of reference should clarify later
deliberations, particularly at times when the
interests of the various groups seem to conflict.
Does the DMC have a role before
the trial recruitment phase?
(Question 4)
The main roles suggested for DMCs before trial
recruitment starts are: to agree how the DMC will
operate (e.g. through a charter), to agree what it
will do (terms of reference), and to review the trial
protocol and procedures, including guidelines for
stopping early and the analysis plan. There was
wide agreement among the experienced DMC
members who were interviewed of the value of an
early meeting to address these issues.
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terms of reference have been outlined above.
Consideration of interim data by a DMC without
such structures in place risks less effective
functioning by the DMC and hence poor decision-
making. In addition, if it postpones such decisions
until later on, knowledge of interim analyses could
adversely affect a DMC’s ability to agree its
working arrangements.
People invited to become members of a DMC
should only do so on the basis that the trial’s
protocol is acceptable to them. Some aspects of a
trial’s protocol have a major bearing on the DMC.
These include the choice of primary outcome, the
analysis plan, the size of difference between trial
groups that is thought to be clinically important,
and what statistical approach will be used to
monitor data. It is difficult to see how a DMC could
function if it was unhappy about any of these; the
deliberations of a DMC before the start of the trial
may therefore reasonably lead to changes in any of
these aspects of a protocol, although these are likely
to be in detail only. A wider role for the DMC in
protocol development is questionable as this is
primarily the responsibility of the investigators. 
An early meeting before any trial data are
available may also provide an easier atmosphere
for members to get to know each other. One
suggestion has been that an early meeting may
also be used to discuss hypothetical scenarios and
how the committee may respond if these situations
actually occurred in the trial. It is not clear,
however, whether this has ever been tried.
How should regulatory issues
impact on the DMC? (Question 5)
The commercial sensitivity of a trial performed for
drug licensing purposes may make a company
reluctant to establish an independent DMC. Both
the ICH57 and FDA36 encourage independent
DMCs. They argue that this benefits the sponsor
as well as the participants and enhances the
credibility of the trial. In particular, the sponsor is
protected from pressure to disclose results
prematurely for commercial reasons. 
The survey of recent reports of trials showed that
around 25% of those with pharmaceutical company
involvement explicitly mentioned a DMC and
there was some evidence that this rate was higher
than for other trials. It was not possible to
distinguish trials mounted for regulatory purposes
from other trials supported by pharmaceutical
companies. It proved particularly difficult to
obtain information about pharmaceutical company
trials in the survey of ongoing trials; the four trials
for which information was incomplete were all in
this category. Of the three pharmaceutical trials
with DMCs for which there is information, one
DMC was independent, one had independent
‘voting’ members but with additional non-voting
company members, and the third had a DMC
drawn from within the company. 
There are aspects of trials performed for regulatory
purposes that have important implications for
independent DMCs. The need to report to the
regulatory authorities brings extra responsibilities.
Some authorities expect to see in advance a copy of
the protocol, which would include details of how a
DMC will function. ICH E9 and draft FDA guidance
state that all DMC meeting records should be
submitted to the regulatory body, although they do
not expect to see interim analyses and do not want
to be an “observer … or member …” of a DMC.
Significant protocol changes recommended by a
DMC have to be notified to the FDA.
Any decision by the DMC in a pharmaceutical trial
could have major regulatory consequences. Early
stopping of a trial before there is sufficient
information to meet regulatory requirements
could mean that a useful drug is not licensed or its
licence is delayed, and the company would be
penalised commercially. Where a DMC is thinking
of recommending that a pivotal trial (on which
regulatory approval will depend) closes
recruitment early, consultation with the FDA may
clarify the implications, although the FDA would
“rarely, if ever”, advise a sponsor on whether or
not to stop a trial.36
The commercial sensitivity of a regulatory trial
enhances the need for confidentiality in all
dealings of the DMC. There may be pressure from
the sponsor to allow access to interim analyses.
The FDA expects to be notified if this occurs, and
ICH E9 says that the role of any sponsor
representative on the DMC must be clearly
defined. In these circumstances, it is not unusual
for analyses to be performed by a statistician who
is independent of the company to ensure complete
confidentiality and objectivity of interpretation.
What should the membership of a
DMC be? (Question 6)
The size of DMCs varies considerably: the median
size identified in the survey of published reports
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the review of the literature found suggestions
ranging from three to more than 20, although
these could include people attending who were
not members. There was evidence from the review
of organisations’ policies that DMCs in the USA
tend to be larger than those in the UK. The
conclusion of the review of the literature on small
group processes was that size is likely to have little
impact on the decision made, but may affect the
quality of the decision-making. Very small groups
(e.g. three or four members) are less likely to
represent the full range of opinion and individuals
are more likely to dominate, hence poorer quality
decisions are more likely. In larger groups (e.g. 12
or more members) there may be reluctance to
express views, conflicts may appear and there may
be a bias towards riskier decisions. On the basis of
this literature a size of six to 12 members appears
optimum. There are practical difficulties
associated with larger committees, such as finding
people who are qualified and willing (given the
small pool available), arranging meeting dates,
ensuring confidentiality and covering the costs
(especially if international). The experienced
DMC members in their interviews thought that
the size should be limited to six or fewer, while
recognising that DMCs should be large enough to
provide appropriate diversity of perspectives with
the right level of expertise and experience.
Choosing an odd number has been suggested if
voting is to be used (see below).
The review of the literature identified three
models for DMCs. In the first model, all members
(defined in this report as those who are fully
involved in the decision-making process) are
completely independent of the trial and an
independent statistician conducts the analyses.
This model is less commonly used than the others,
principally because of concerns about the ability of
independent statisticians to do appropriate
analyses when they are not intimately involved in a
trial; there are also practical difficulties finding an
independent statistician prepared to undertake
what are often complex analyses. In the second
model, people involved in the trial attend the
meeting but decision-making is limited to
members, who are all independent. A common
approach is for the trial’s statistician to prepare
and present interim analyses to the DMC. The
trial’s statistician may sit in on the DMC’s
discussions or be asked to leave once the report
has been presented. If others associated with the
trial attend, such as representatives of the
investigators or the sponsor, the meeting is often
split into open and closed sessions, with
confidential information only discussed in closed
sessions after these people have left the meeting.
In the third model, people involved in the trial,
particularly the study investigators, are involved in
decision-making and hence, by definition, are
members of the DMC. Often the majority of the
DMC members are independent, although
sometimes independents are in the minority. The
potential advantage of involving study
investigators in the decision-making is that the
deeper knowledge of the trial that an investigator
brings to the meetings should increase its
competence, while the involvement of
independent members should protect against
biased decision-making. Knowledge of interim
analyses may, however, jeopardise the impartiality
of the investigator, affecting his or her ability to
lead the trial. The view of the DAMOCLES group
is that a member of the trial group who is not
involved in patient recruitment, such as the trial
statistician or another non-clinician, should attend
the DMC, but the formal members should all be
independent. Others involved in the trial, such as
investigators recruiting to the trial and the
sponsor, may usefully be involved in open sessions
(see below) where confidential information is not
discussed, but then leave the meeting when trial
analyses are considered. 
As discussed above, an appropriate range of
membership is needed while keeping the size of
the group manageable. Statistical and clinical
input is clearly essential. More than one clinician
may be needed to give the range of input required
and to avoid over-dependence (or perceived over-
dependence) on a single individual, as illustrated
in Case Study C (see Chapter 6). The review of the
literature on small groups suggested that diversity
is likely to improve decision-making, provided that
any conflict is handled appropriately. Involvement
of a consumer representative may improve the
quality of decision-making, provided that they are
able to participate fully. Some of the experienced
DMC members when interviewed were sceptical
about whether such a person could participate
fully given the technical nature and complexity of
the process, and questioned whether they could be
fully independent. There was no support from
experienced DMC members for an ethicist to be a
member of DMCs. The policies of three of the US
organisations surveyed were to supplement
membership of their DMCs with an ethicist,
although none of the current trials surveyed
included an ethicist. Experienced DMC members
when interviewed expressed strongly held views
about the importance of selecting ‘the right
people’ to serve on DMCs, arguing that they
Discussion
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concerned about the effect that a ‘maverick’
member could have on the functioning of a DMC.
These uncertainties suggest that extension of
DMC membership beyond clinicians, trialists and
statisticians should be formally evaluated. 
The ways in which DMCs are chosen also vary. A
common approach is for the investigators or TSC
to suggest members, subject to approval by the
sponsor. In two of the three ongoing
pharmaceutical company trials surveyed, the DMC
was chosen by the company. In four of the other
ongoing trials the DMC was a standing entity
responsible for a number of trials and the
investigators had no influence on this. The
important requirement is that the DMC is truly
independent, with the necessary range of
expertise. It is also important, however, that both
the sponsor and investigators have confidence in
the DMC; it therefore seems reasonable for them
both to agree membership before it is finalised.
Experienced DMC members who were interviewed
saw the appointment of the chair of the DMC as
crucial. They thought that the chair should have
an understanding of both clinical and statistical
issues, and should have had experience of
chairing meetings, with the ability to facilitate
effective interaction in the group. The findings in
the small group processes review were that chairs
have a big impact on decision outcome and the
quality of decision-making. The review suggested
that sound decision-making was more likely if the
chair was facilitating (rather than directive) and
impartial (in the sense of being open to others’
opinions and not expressing their own views until
after a full discussion). 
How is independence to be
maintained? (Question 7)
Table 4 (Chapter 2) lists characteristics of
independence and lays out the arguments for and
against inclusion of potential types of DMC
members. As discussed earlier, a common
approach is to limit the DMC to people who have
no link with, or apparent vested interest in, the
trial and its results. It therefore seems reasonable
for there to be a formal check for potential
conflicts of interests before or when the DMC first
meets. Arguably, these characteristics should be
monitored to ensure that independence is
maintained. The review of decision fiascos
underlined the importance of small groups being
clearly accountable for their decisions. The
process by which DMC decisions are made should
be explicit and transparent. In respect of
payments, it appears to be generally accepted that
reimbursement of travel, accommodation and
communication expenses is appropriate, and that
any other payments should be so modest as to
have no likely effect on decision-making.
Nevertheless, consideration should be given to
providing some recompense for the time involved.
Should the DMC deliberations be
open or closed? (Question 8)
As a general rule interim trial data are kept
confidential and restricted to the DMC and
selected people such as the statistician who
performs the interim analyses. The basis for this is
that trends in the data, which may well be due to
chance, could lead to false conclusions. Current or
potential trial participants, or the clinicians
involved in recruitment, would then leave the trial,
and the trial would fail to provide a clear and
reliable answer to the question being addressed. In
addition, others with a vested interest in the
results, such as a sponsoring company, may
withdraw support, leading to (inappropriate) early
termination. Deliberations of a DMC are therefore
usually closed, although it is not uncommon to
have an open session with the trial investigators
and/or sponsors to discuss general issues such as
recruitment rates. This widely held view has been
challenged, as outlined in Chapter 2 (Question 8).
The argument for totally open data monitoring
reflects a different view of what is in the best
interests of trial participants, future participants
and society. More experience is needed of this
approach to clarify its effects. 
One of the three common models for DMCs is for
people involved in the trial, such as the trial’s
statistician, to attend the DMC meetings, but not
as formal members. The reviews of small group
processes concluded that the implications of
having non-members at a meeting were unclear: it
may be inhibitory such that members would be
more inclined to vote with the majority, or it may
increase the DMC’s sense of accountability.
What are the optimal practical
arrangements for interim analysis
and data monitoring? (Question 9)
The view of the experienced DMC members was
that the optimal timing for meetings varies from
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flexible and at the discretion of the DMC or its
chair. Most DMCs build in a minimum frequency.
In the survey of ongoing trials, this was generally
6-monthly or annually, or after a given number of
outcome ‘events’. The effects of such practical
arrangements on other types of small decision-
making groups do not appear to have been
studied.
The review of small group processes did, however,
suggest that face-to-face meetings are likely to be a
more effective way of facilitating communication
between DMC members. This was the preferred
option of both the experienced DMC members
and the respondents to the survey of ongoing
trials, particularly for the first meeting, for any
meeting where a major decision is made, or for
multinational DMCs who do not share the same
first language. Respondents considered that
teleconference was a less satisfactory medium,
because it can inhibit communication and hence
decision-making. However, they thought that it
had a place because of the practical difficulties in
bringing some DMCs together. To the authors’
knowledge, anonymous electronic discussions have
not been tried. These can allow anonymity, which
can enhance quality of decision-making in small
groups. Future DMCs should consider using these
and building in an evaluation of their usefulness.
What sort of training or
preparation should DMC
members have? (Question 10)
In their interviews, experienced DMC members
expressed concerns that increasing demand for
DMCs may have led to the appointment of
members who have insufficient experience or
expertise. Some thought that formal training
would help, although others were sceptical about
its value. The findings in this project show that
training and preparation of DMC members have
hitherto received little attention. In none of the
recently completed trials had members received
any formal training (partly because many had
previous experience) and 24 of the 25
organisations surveyed had no policy about
training. Most commonly, new members learn
from more experienced members ‘on the job’, with
the first meeting providing orientation. It is widely
accepted that all DMCs should include members
with DMC experience, although what represents
the minimum is not clear. The introduction of
inexperienced members is easier in larger
committees and this is one attraction of the
approach used by North American cooperative
groups, which is to have a large DMC covering a
number of trials. Other models are for
inexperienced people to attend DMC meetings as
observers, or to be mentored by more experienced
members of the DMC that they join. Other
suggested approaches to training are through
informal study of published case studies and by
formal training courses. The review of decision-
making in small groups suggested that chairs of
DMCs may benefit from training to develop
facilitation, conflict management and impartial
chairing skills. All members would need training if
formal decision-making approaches (such as
devil’s advocacy) were used. The DAMOCLES
group discussed the value of training in ethics to
provide a framework for DMC discussions. No
examples of this were found, and the experienced
DMC members held strong views that involvement
of ethicists in DMC deliberations had not been
helpful in their experience. Nevertheless,
opportunities to participate in discussions about
ethical dilemmas in advance of DMC meetings may
help some inexperienced DMC members. The view
of the DAMOCLES group is that development of
training for DMC membership should be pursued
further, but initiatives should include evaluation so
that their value can be assessed.
What material should be available
to a DMC? (Question 11)
Table 5 (Chapter 2) lists the areas of a trial that a
DMC may consider and the specific aspects where
they may wish to have information. This could
provide a useful checklist when a DMC is
considering what materials it wishes to receive. It
is likely to be useful for the DMC to agree the
template of the report in advance, including the
detailed structure and content of the tables. This
should ensure that the committee receives what it
requires, but not more detail than it needs. If the
meeting is to have both open and closed sessions,
two reports (or two formats) will be necessary. The
analysis plan should be outlined in the protocol,
but should be agreed with the DMC. In their
interviews, the experienced DMC members
emphasised the value of early discussions with
whoever will write the reports to the DMC
(describing the interim analyses) and the
importance of being given the right amount of
information; their experience was that too much
detail can be overwhelming. The review of small
group decision-making suggested that too much
detail could increase the likelihood of making a
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may cloud the quality of the evidence. The surveys
suggested that the information provided to DMCs
varies (see Table 26 in Chapter 5 for examples),
although this may be in emphasis rather than
content. The survey of ongoing trials suggested
that there is more emphasis on safety data in trials
funded by pharmaceutical companies than in
other trials. The small group processes review,
however, suggested that DMCs should be given all
the information about benefits and risks in a
balanced way, on the basis that partial disclosure
may affect decision-making. This review also
suggested that excessive publicity related to the
trial should be avoided if possible, as this can
cause significant bias in small group decision-
making. This could happen, for example, because
of the commercial importance of a major
pharmaceutical trial.
One area of controversy is whether the treatment
groups should be masked in DMC reports.
Although some respondents argued in favour of
this on the basis that it may prevent inappropriate
premature decisions, most commentators felt that
masking hampers the DMC from doing its job
properly because aspects of data monitoring
require knowledge of the allocation. Either way,
the format should be agreed with the DMC in
advance. 
The general feeling from the review of the
literature on DMCs was that receiving the report
in advance of each DMC meeting is of value
because it allows members to have a chance to
read it thoroughly; the experienced DMC
members endorsed this. There is also wide
agreement that DMCs should routinely consider
evidence from other similar studies that have been
reported. Marshalling this information can involve
a large amount of work and so it is unrealistic to
expect the DMC to do this; commonly, the
investigators provide a systematic review, which is
updated for each report. Again, the DAMOCLES
group recommend that arrangements are agreed
in advance of the DMC seeing any interim trial
analyses. As described in Chapter 2 (Question 11;
Should there be interaction with other DMCs?),
the issues around sharing information with
another DMC of a similar trial being mounted by
other investigators are more complex because of
the confidential nature of the committees’
deliberations and the fact that both DMCs are
considering accumulating data. It is not clear what
is best in these circumstances. There are merits in
the committee chairs making contact and agreeing
to consult each other if their committee is faced
by, or has decided to make, a decision that would
change that trial’s protocol (including an early end
to recruitment). 
It is widely agreed that DMCs should see analyses
that are as up to date as possible. It has been
argued that this should include unchecked data,
but that efforts should be made to assess the
extent to which these data may change after they
have been cleaned. 
Who should own the interim data
and analyses? (Question 12)
Little information about the ownership of interim
data and analyses was found in any of the
components of this project. While it seems fair to
assume that the owners of the overall dataset also
own the interim data, the ownership of interim
analyses is more problematical (see Chapter 2,
Question 12). It may be more appropriate to see
the DMC as guardians (rather than owners) of the
interim analyses and in that role the DMC would
decide who, if anyone, outside the DMC could see
them. Once the trial has been completed and the
full dataset analysed the DMC’s guardianship role
of interim analyses would have been discharged. 
Should non-comparative analyses
(which are administrative and not
separated by treatment arm) be
carried out? (Question 13)
Administrative analyses are usually considered to
be those that assess factors important to the
integrity of a trial without the need to reveal
comparative outcome data. They cover aspects of
the trial such as recruitment, treatment
compliance, randomisation, data quality and data
completeness that affect data monitoring but are
the prime responsibility of the trial organisers and
TSC. It is these aspects that are commonly
discussed at open sessions with those involved in
running the trial. Non-comparative analyses of
outcome data are sometimes considered or
requested, for example for reassessing the
assumptions behind the original sample size
calculations, or for presenting to participating
clinicians to encourage their continued
participation. These can be based on control data
only, experimental arm data only or pooled overall
data. As discussed in Chapter 2 (Question 13),
there are potential dangers in these analyses. The
choice of analysis, the people to whom the analysis
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should all be thought through carefully in
advance.
Is the DMC advisory (to make
recommendations) or executive
(to make decisions)? (Question 14)
An advisory rather than executive function for
DMCs was favoured in all parts of the project. A
common approach described in the surveys and
the interviews with the experienced DMC
members was for the chair to report the
recommendations of a DMC to the PI or TSC, on
the basis that it is the trial organisers who are
ultimately responsible for the conduct of the trial.
The survey of organisations involved in trials,
however, showed that the majority with a policy
expected the DMC’s report to go to the sponsor.
Although it is usual for the trial organisers to
accept a DMC’s recommendations, they can still
choose not to, as for example happened in Case
Study B (see Chapter 6). The two organisations
whose policies were that DMC decisions were
binding (i.e. executive) were both North American.
What decisions and
recommendations should be open
to the DMC? (Question 15)
Although the surveys of DMCs in current and
completed trials (described in Chapter 5) suggested
variation in the types of recommendation that a
DMC could make, this probably reflects differences
in emphasis rather than true disagreement. The
range of options open to a DMC is described in
detail in Chapter 2 (Question 15).
Recommendations can be made about changes to
the trial’s protocol before a trial starts. Once the
trial has started, the most common
recommendation is that a trial should continue
without modification. Other options are stopping
the trial completely or partially, or continuing the
trial with modifications. The implications of any
decision depend on the stage that the trial has
reached. If recruitment is continuing, recruitment
can stop early, usually with early reporting; if
recruitment is complete but trial treatment
continuing, the less effective treatment can be
stopped early, again usually with early reporting; if
the trial is in the follow-up stage, just early reporting
can be recommended. At the outset, a DMC should
understand the range of options open to it and the
implications that these would have for the trial.
However, it is reasonable for a DMC to make any
suggestions (which may or may not be acted on)
that it thinks will enhance the conduct of the trial.
How should the decisions or
recommendations be reached
within the DMC? (Question 16)
Only two of the 25 organisations surveyed had a
policy about the way in which DMCs should reach
their decisions and recommendations. The
experienced DMC members who were interviewed
saw this as a neglected area. In their experience
there had been no pre-agreed procedure, apart
from stopping guidelines, and the use of voting
had been rare, as had other formal procedures for
decision-making. Discussion within the DMC had
led to the development of opinions and then
unanimous agreement had been reached. The
experienced DMC members generally favoured
this approach. Where information was available in
the trials surveyed, unanimous agreement had
been the approach most commonly used. In other
trials the decision-making approach had been left
to the DMC or its chair to decide the method to
be used, while others used voting. An odd number
of members has been recommended if voting is to
be used. The review of small group processes
suggested that standards of proof should be
explicit in DMCs. Decisions should be unanimous
where possible, with voting encouraged, but only
after a full discussion. This review also suggested
that formal decision-making tools (e.g. devil’s
advocacy, electronic discussions which avoid one
person dominating) may be useful for DMCs,
especially where the information is complex.
These warrant further exploration.
What should be the role of formal
statistical methods in DMCs?
(Question 17)
Monitoring of clinical trials always involves some
form of statistical analysis. It is widely accepted,
however, that statistics are only one of a number of
considerations that a DMC needs to take into
account when monitoring accumulating data.
Others include the balance of risk and benefit, the
internal consistency of results, the consistency with
any external evidence and the likelihood that the
results would influence clinical practice. Statistical
criteria should therefore be considered guidelines
rather than rules. The various approaches to
statistical monitoring of accumulating trial data
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the DMC to understand the statistical approach
chosen and the meaning of any statistical
guidelines derived from this. It is essential that
both the DMC statistician and the trial statistician
are competent to apply them to the interim
analyses.
Should specific trial designs
influence the proceedings?
(Question 18)
The review of the literature on DMCs identified
situations where the design of a trial would affect
its data monitoring. For example, standard data-
dependent stopping guidelines generally assume
individual randomisation and these would not be
appropriate for cluster randomised trials.
Difficulties are presented to DMCs by trials with
composite outcomes, particularly if the outcomes
become known at different times, as in Case Study
A (see Chapter 6), and by trials where the relative
effect on an outcome may change over time, such
that there is a disproportionate difference early in
the trial. Data monitoring in equivalence trials
must take into account compliance levels if a
misleading claim of equivalence is to be avoided.
Some commentators have suggested that
asymmetric statistical boundaries should be used
in circumstances where the interest is only in
establishing superiority (or greater toxicity) of one
arm of a trial. However, data monitoring usually
involves weighing benefits and risks with no
assumption of direction of effect, in which case
symmetrical boundaries would be more
appropriate.
How should ethical issues be
handled in DMCs? (Question 19)
The primary purpose of a DMC may be seen as
ensuring that continuing a trial according to its
protocol is ethical. RECs will have agreed the
ethical basis for that protocol, and the DMC
should approach their role from that starting
point rather than their own personal perspectives.
Ethical dilemmas for a DMC are often characterised
as balancing the interests of participants against
the interests of future patients. The authors are
inclined to agree with Armitage55 that this is too
simplistic; rather, it is a question of when the
evidence is sufficiently persuasive that it is clear
what is in the best interests of both current
participants and future patients. The degree of
conservatism or radicalism in the decision-making
of a DMC is reflected in its terms of reference and
monitoring plans, which include the statistical
guidelines. Evidence from the small group
processes review suggests that DMC members,
especially the chair, should have some experience
of discussing this type of issue. Whether the DMC
has a broader remit in respect of ethical issues is
more controversial, and this was reflected in
responses in the survey of recently completed
trials. While some felt that the DMC should
restrict itself to ethical issues related to whether or
not the trial should continue, others saw no reason
why the DMC should not comment on other
ethical issues. Some of these respondents felt that
wider ethical issues were the responsibility of the
TSC or RECs. The different views of what ethical
issues are the responsibility of a DMC are reflected
in the fact that some US organisations recommend
that a bioethicist should be a member of DMCs,
whereas some hostility to this was identified in the
interviews with experienced DMC members.
What should DMCs do with their
decisions or recommendations?
(Question 20)
As discussed above and described in Chapter 2
(Question 20), DMCs usually report to the sponsor
or the investigators (in the form of a
representative executive committee). To avoid any
conflict between the two it may be better if the
DMC reports to both at the same time and
involves both in subsequent discussions.
Sometimes the sponsor makes the final decision
and sometimes it is a joint decision between the
sponsor and investigators. Appropriate regulatory
authorities and RECs should also be kept
informed, and this is the responsibility of the
organisers rather than the DMC.
If there are no concerns about the trial, it is likely
that only a brief, but carefully worded, statement
from the DMC chair is needed, encouraging
progress in the trial while avoiding any mention of
the content of any confidential interim analyses. If
a change to the protocol is being recommended by
a DMC a much fuller report is likely to be needed.
Alternatively, a meeting may be arranged with the
investigators where the interim analyses are
shared. In contrast, it has been argued that no
data should be released if the DMC is executive,
on the basis that the final analyses will then be
conducted without knowledge of what the interim
analyses showed; the rationale and feasibility of
this are questionable, however. 
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document indicate that minuting of DMC
meetings is expected, and state that in regulatory
trials all minutes should be submitted, possibly in
a blinded form, to the regulatory authorities. The
review of the literature on DMCs suggested almost
unanimous agreement that a formal record should
be made for both closed and open meetings, and
some funders (including the UK HTA programme)
now require this. The record should document the
major points of discussion, any decisions and
actions and their reasons, and any additional
information required for future meetings. It was
suggested that attribution of names should be
limited to members with a specific expertise or a
particular view. A useful checklist of the areas that
may be covered was given in Chapter 2 (Question
20; Are minutes of the meetings or notes of
decisions made?). The experienced DMC
members who were interviewed favoured keeping
a record of each meeting that described the key
issues discussed and the rationale for any decisions
taken. They thought that a summary of open
sessions would also be useful; such a record acts as
a reminder and aids future decision-making when
meetings are some time apart. Some also thought
that the record could be important if there was
any future litigation about the trial, albeit that this
is an unlikely event. The experienced DMC
members when interviewed thought that minutes
would be too detailed and they were not
comfortable about naming individuals in any
report of a meeting. Commentators recognised
that keeping a record can involve a significant
amount of work. If a representative of the data
management centre attends the DMC, this person
is often asked to keep a record (for later approval
by the chair). Otherwise, a member of the DMC
will have to do this. This should be agreed in
advance.
What should be done in ‘difficult’
situations? (Question 21)
In their interviews, the experienced DMC
members emphasised that having terms of
reference and standard procedures in place is
particularly valuable when data monitoring
becomes difficult. The proposed charter (Table 33)
provides a template for defining these. While the
agreed procedures may include a set of
prearranged meetings, the DMC should build in
flexibility to call meetings at short notice if a
difficult issue arises. A problem may be due to a
development within the trial or to pressure
coming from outside the trial, such as from the
sponsor or mass media. Closed sessions restricted
to DMC members provide the best forum for
formulating a response. The review of small group
processes suggested that increasing conflict caused
by difficult situations may actually improve
decision quality and outcome, provided that all
members express their views. This review
identified the importance of making sufficient
time available. Factors that make it more difficult
for members to participate (e.g. short notice,
telephone conference call) could reduce the
quality of decision-making and this appears to
have occurred in Case Study D (see Chapter 6).
Formal decision support techniques may be
helpful, particularly where unforeseen
circumstances increase the complexity of the
information to be considered.
Should some DMC decisions be
considered to be ‘errors’?
(Question 22)
It is difficult to judge whether a DMC has made a
good or poor decision. At the time of the decision,
it incorporates a subjective element and later
judgement has the benefit of hindsight. In other
settings, errors are identified by post hoc
assessment by public opinion, or where the
consequences of a decision were not those
intended (see section ‘Error and bias in small
group decision-making’, p. 52). Scenarios where
an erroneous DMC decision is likely or possible
are listed in Chapter 2 (Question 22). There are
examples of trials that have stopped early for a
benefit that has disappeared or is no longer
clinically significant in the final analysis (e.g. Case
Study 1 in Chapter 279). A decision to continue a
trial in the hope that a benefit will emerge, despite
evidence of harm, can be criticised if no benefit
emerges, but the decision may still have been
correct at the time.
Where a DMC has an advisory rather than an
executive role, it is not the DMC that has the final
decision and so arguably the DMC is not
responsible for the decision. It is rare, however, for
a DMC recommendation not to be accepted.
Nevertheless, the group that receives the
recommendation may not be independent: an
investigator may wish the trial to continue to
provide an even clearer result, while the sponsor,
such as a pharmaceutical company, may wish to
stop the trial for other reasons, such as
commercial considerations. Where the decision-
making body, such as a TSC, does not agree with a
Discussion
128DMC’s recommendation, it has been suggested
that a third committee (based on an ‘escalation’
clause in the terms of reference) be established.
This group may include representatives of both
the DMC and TSC, as well as independents.
One of the principal arguments for including a
representative of the trial within the DMC
deliberations, irrespective of whether or not as a
member who can vote, is that the investigators’
perspectives can be incorporated in the decision-
making. Building a consensus that includes the
investigators is likely to reduce the chances of later
disagreement when a DMC makes a
recommendation.
Concerns have been expressed about who would be
deemed liable in a legal challenge about decisions
made during the conduct of a trial. Although
hitherto this does not appear to have been an
issue, it would be reasonable for DMCs to seek
clarification of this when they are first 
established. 
The review of small group processes suggested
ways to reduce the chances of a decision error:
thorough review of evidence, accurate
comprehension of instructions, active 
participation by all group members, resolution of
differences through discussion, and systematic
matching of case facts to the criteria for various
decision options. The review suggested that
absence of these increases the likelihood of an
error.
What should the DMC’s role be
concerning publications?
(Question 23)
The possible involvement of the DMC in
publication of the trial results has received little
attention. There are good reasons for the DMC at
least being able to comment on a draft of the trial
report. Members of the DMC may have a useful
contribution to make in the interpretation of the
results because of their knowledge of the trial
data. (They should not be authors of the report as
this would be contrary to their independent
status.) Members can also voice any difference of
opinion, so that disagreement after publication is
avoided if possible. The report should also
describe the DMC and the data monitoring
process, and it is reasonable for the DMC to have
the chance to check this.
Failure to report a trial is a form of scientific
misconduct. Some commentators have suggested
that it is the DMC’s responsibility to ensure that
reporting occurs, even by writing the report
themselves if the investigators fail to do so. It is,
however, questionable how feasible this would be.
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TABLE 33 Charter for DMCs. (Also reported in the Lancet: DAMOCLES Study Group. A proposed charter for clinical trial data
monitoring committees: helping them to do their job well. Lancet 2005;365:711–22.)
Content Comments from DAMOCLES and illustrative examples
1. Introduction
Name (and sponsor’s ID) of trial  Insert name (and sponsor’s ID) of trial and registration number (e.g. ISRCTN and/or 
plus ISRCTN and/or EUDRACT  EUDRACT number)
number
Objectives of trial, including  Insert objectives of trial, including interventions being investigated from protocol. 
interventions being investigated Suggest including a flowchart of the trial design (insert as Figure 1)
Outline of scope of charter Summary of the purpose and content of this document
Illustrative example:
The purpose of this document is to describe the roles and responsibilities of the
independent DMC for the [– give name –] trial, including the timing of meetings, methods
of providing information to and from the DMC, frequency and format of meetings,
statistical issues and relationships with other committees
2. Roles and responsibilities
A broad statement of the aims of  Illustrative example:a
the committee “To protect and serve [trial] patients (especially re: safety) and to assist and advise
principal investigators so as to protect the validity and credibility of the trial.”
“To safeguard the interests of trial participants, assess the safety and efficacy of the
interventions during the trial, and monitor the overall conduct of the clinical trial.”
Terms of reference Illustrative example:a
“The DMC should receive and review the progress and accruing data of this trial and
provide advice on the conduct of the trial to the TSC.
The DMC should inform the chair of the TSC if, in their view: 
(i) the results are likely to convince a broad range of clinicians, including those supporting
the trial and the general clinical community, that on balance one trial arm is clearly
indicated or contraindicated for all participants or a particular category of participants,
and there was a reasonable expectation that this new evidence would materially
influence patient management; or
(ii) it becomes evident that no clear outcome would be obtained.”
Specific roles of DMC Interim review of the trial’s progress including updated figures on recruitment, data
quality, and main outcomes and safety data. 
A selection of specific aspects could be compiled from the following list:
  assess data quality, including completeness (and by so doing encourage collection of
high-quality data)
  monitor recruitment figures and losses to follow-up
  monitor compliance with the protocol by participants and investigators
  monitor organisation and implementation of trial protocol (the DMC should only
perform this role in the absence of other trial oversight committees) 
  monitor evidence for treatment differences in the main efficacy outcome measures 
  monitor evidence for treatment harm (e.g. toxicity data, SAEs, deaths)
  decide whether to recommend that the trial continues to recruit participants or
whether recruitment should be terminated, either for everyone or for some
treatment groups and/or some participant subgroups 
  suggest additional data analyses
  advise on protocol modifications suggested by investigators or sponsors (e.g. to
inclusion criteria, trial end-points or sample size)
  monitor planned sample size assumptions
  monitor continuing appropriateness of patient information
  monitor compliance with previous DMC recommendations
  consider the ethical implications of any recommendations made by the DMC 
  assess the impact and relevance of external evidence 
continuedHealth Technology Assessment 2005; Vol. 9: No. 7
131
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.
TABLE 33 Charter for DMCs (cont’d)
Content Comments from DAMOCLES and illustrative examples
3. Before or early in the trial
Whether the DMC will have input  All potential DMC members should have sight of the protocol/outline before agreeing 
into the protocol to join the committee. Before recruitment begins the trial will have undergone review
by the funder/sponsor (e.g. peer review for public sector trials), scrutiny by other trial
committees and a research ethics committee. Therefore, if a potential DMC member
has major reservations about the trial (e.g. the protocol or the logistics) they should
report these to the trial office and may decide not to accept the invitation to join.
DMC members should be independent and constructively critical of the ongoing trial,
but also supportive of aims and methods of the trial. 
Whether the DMC will meet  It is recommended that, if possible, the DMC meets before the trial starts or early in 
before the start of the trial the course of the trial, to discuss the protocol, the trial, any analysis plan, future
meetings, and to have the opportunity to clarify any aspects with the PIs. The DMC
should meet within one year of recruitment commencing.
Consideration should be given to an initial ‘dummy’ report, including the use of shell
(empty) tables, to familiarise the DMC members with the format that will be used in
the reports.
Any issues specific to the disease  Issues specific to the disease under study should be described.
under study
Any specific regulatory issues The DMC should be aware of any regulatory implications of their recommendations.
Any other issues specific to the  Issues specific to the treatment under study should be described.
treatment under study
Whether members of the DMC  Members of a DMC, particularly for a commercially sponsored trial, may be advised to 
will have a contract have a contract making clear the need for confidentiality and the liability status of the
DMC members. When there is no such contract, DMC members could formally
register their assent by confirming (1) that they agree to be on the DMC and (2) that
they agree with the contents of this charter.
4. Composition
Membership and size of the DMC  Membership should consist of a small number of members (perhaps four to five), who
include at least one clinician experienced in the clinical area and at least one
statistician. Additional members experienced in clinical trials should reflect the other
specialities involved in the trial. Consideration may be given to consumer
representation. In the case of intergroup trials or trials with international collaboration
consideration should be given to broad representation. 
The members should be independent of the trial (e.g. should not be involved with the
trial in any other way or have some competing interest that could impact on the trial).
Any competing interests, both real and potential, should be declared. A short
competing interest form should be completed and returned by the DMC members to
the trial coordinating centre (Annex 1). 
The members of the DMC for this trial are: 
(1) [give name]
(2) [give name]
(3) [give name]
It may be helpful to provide the trial coordinating centre with brief personal details
(say, one paragraph) of all DMC members, especially relating to experience relevant to
the trial and to the operation of DMCs (such information need not be contained
within the charter). 
The chair, how they are chosen  The chair should have previous experience of serving on DMCs and experience of 
and the chair’s role (likewise,  chairing meetings, and should be able to facilitate and summarise discussions. The 
if relevant, the vice-chair) chair is sometimes chosen by the sponsor or the investigators running the trial and
sometimes by the DMC members themselves. The chair is expected to facilitate and
summarise discussions.
The responsibilities of the DMC  The DMC membership will include a statistician to provide independent statistical 
statistician expertise.
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TABLE 33 Charter for DMCs (cont’d)
Content Comments from DAMOCLES and illustrative examples
The responsibilities of the trial  The trial statistician, [give name], will produce (or oversee the production of) the 
statistician report to the DMC and will participate in DMC meetings, guiding the DMC through
the report, participating in DMC discussions and, on some occasions, taking notes.
The responsibilities of the trial  The trial office team (e.g. trial manager, etc.) usually only inputs to the production of 
office team the non-confidential sections of the DMC report.
The responsibilities of the PI and  The PI may be asked, and should be available, to attend open sessions of the DMC 
other members of the trial  meeting. The other members of the trial management group will not usually be 
management group expected to attend but can attend open sessions when necessary (see Organisation of
DMC meetings).
5. Relationships
Relationships with PIs, other trial  A diagram can help to clarify relationships when there are several interrelated 
committees (e.g. TSC or  committees. A short statement of the responsibilities of the other committees should 
executive committee), sponsor and  be given if these are not provided in the protocol.
regulatory bodies
Clarification of whether the DMC  It is customary that the DMC does not make decisions about the trial, but rather 
is advisory (make  makes recommendations to an appropriate executive committee or its chair.
recommendations) or executive 
(make decisions)
Payments to DMC members Members should be reimbursed for travel and accommodation. Any other payments
or rewards should be specified. 
The need for DMC members to  Competing interests should be disclosed. These are not restricted to financial matters 
disclose information about any  involvement in other trials or intellectual investment could be relevant. Although 
competing interests members may well be able to act objectively despite such connections, complete
disclosure enhances credibility (see Annex 1). 
DMC members should not use interim results to inform trading in pharmaceutical
shares, and careful consideration should be given to trading in stock of companies with
competing products. 
6. Organisation of DMC meetings
Expected frequency of DMC  The exact frequency of meetings will depend on any statistical plans specified, and 
meetings otherwise on trial events. The wishes of the DMC and needs of the trial office will be
considered when planning each meeting. It is recommended that the DMC meet at
least yearly.
Whether meetings will be  The first meeting should ideally be face-to-face to facilitate full discussion and allow 
face-to-face or by teleconference members to get to know each other. It is recommended that all subsequent meetings
should be face-to-face if possible, with teleconference as a second option.
How DMC meetings will be  A mixture of open and closed sessions is recommended. Closed and open sessions 
organised, especially regarding  should be defined. Commonly, only DMC members and others whom they specifically 
open and closed sessions, including  invite, e.g. the trial statistician, are present in closed sessions. In open sessions, all 
who will be present in each session those attending the closed session are joined by the PI(s) and/or the head of the trials
office, and sometimes also representatives of the sponsor, funder or regulator, as relevant.
The format of the meetings should be described.
Illustrative example:
1. Open session: introduction and any ‘open’ parts of the report
2. Closed session: DMC discussion of ‘closed’ parts of the report
and, if necessary,
3. Open session: discussion with other attendees on any matters arising from the previous
session(s)
4. Closed session: extra closed session
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TABLE 33 Charter for DMCs (cont’d)
Content Comments from DAMOCLES and illustrative examples
7. Trial documentation and procedures to ensure confidentiality and proper communication
Intended content of material to be  Illustrative example:
available in open sessions  Open sessions: accumulating information relating to recruitment and data quality (e.g.
data return rates, treatment compliance) will be presented. Toxicity details based on
pooled data will be presented and total numbers of events for the primary outcome
measure and other outcome measures may be presented, at the discretion of the DMC.
Intended content of material to be  Illustrative example:
available in closed sessions Closed sessions: in addition to all the material available in the open session, the closed
session material will include efficacy and safety data by treatment group.
Whether or not the DMC be   Blinding is generally not recommended for DMC members, although opinions vary.
blinded to the treatment allocation
The people who will see the  These should be specified
accumulating data and interim 
analysis
DMC members do not have the right to share confidential information with anyone
outside the DMC, including the PI.
Responsibility for identifying and  Identification and circulation of external evidence (e.g. from other trials and systematic 
circulating external evidence  reviews) is not the responsibility of the DMC members. The PI or the trials office 
(e.g. from other trials/ team will usually collate any such information.
systematic reviews)
To whom the DMC will  The DMC usually reports its recommendations in writing to the TSC or sponsor’s 
communicate the decisions/ representative. This should be copied to the trial statistician (or trial manager) and if 
recommendations that are reached possible should be sent via the trials office in time for consideration at a TSC meeting. If
the trial is to continue largely unchanged then it is often useful for the report from the
DMC to include a summary paragraph suitable for trial promotion purposes (see Annex 2). 
Whether reports to the DMC be  It is usually helpful for the DMC to receive the report at least 2 weeks before any 
available before the meeting or  meetings. Depending on the trial, it may sometimes be preferable for all papers to be 
only at/during the meeting brought to face-to-face meetings by the trial statistician; time would then be needed
for DMC members to assimilate the report.
What will happen to the  Illustrative examples:
confidential papers after the  1. The DMC members should destroy their reports after each meeting. Fresh copies of 
meeting previous reports will be circulated with the newest report before each meeting. 
2. The DMC members should store the papers safely after each meeting so they may
check the next report against them. After the trial is reported, the DMC members
should destroy all interim reports. 
8. Decision-making
What decisions/recommendations  Possible recommendations could include:
will be open to the DMC   no action needed, trial continues as planned 
  early stopping due, for example, to clear benefit or harm of a treatment, futility, or
external evidence 
  stopping recruitment within a subgroup 
  extending recruitment (based on actual control arm response rates being different
to predicted, rather than on emerging differences) or extending follow-up
  stopping a single arm of a multiarm trial
  sanctioning and/or proposing protocol changes
The role of formal statistical  This charter should include or provide reference to the planned interim analyses and 
methods, specifically which  statistical guidelines, i.e. the DMC should review and agree any interim analysis plan.
methods will be used and whether  Formal statistical methods are more generally used as guidelines rather than absolute 
they will be used as guidelines or  rules. This is because they generally only consider one dimension of the trial. Reasons 
rules should be recorded for disregarding a stopping guideline.
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TABLE 33 Charter for DMCs (cont’d)
Content Comments from DAMOCLES and illustrative examples
How decisions or  Issues to be specified can include:
recommendations will be reached    The decision-making methods and criteria that will be adopted for guiding 
within the DMC deliberations.
  The process of decision-making, including whether there will be voting or other
formal methods of achieving consensus. The method of deliberation should not be
revealed to the overseeing committee as this may reveal information about the
status of the trial’s data.
  The role of the chair: to summarise discussions and encourage consensus; it may be
best for the chair to give their own opinion last.
It is recommended that every effort should be made for the DMC to reach a
unanimous decision. If the DMC cannot achieve this, a vote may be taken, although
details of the vote should not be routinely included in the report to the TSC as these
may inappropriately convey information about the state of the trial data.
It is important that the implications (e.g. ethical, statisticial, practical, financial) for the
trial be considered before any recommendation is made.
When the DMC is quorate for  There should be a minimum number of attendees before the DMC is quorate for 
decision-making decision-making; this should be specified.
Illustrative example:a
“Effort should be made for all members to attend. The trials office team will try to ensure
that a date is chosen to enable this. Members who cannot attend in person should be
encouraged to attend by teleconference. If, at short notice, any DMC members cannot
attend at all then the DMC may still meet if at least one statistician and one clinician,
including the chair (unless otherwise agreed), will be present. If the DMC is considering
recommending major action after such a meeting the DMC chair should talk with the
absent members as soon after the meeting as possible to check they agree. If they do not,
a further teleconference should be arranged with the full DMC.”
Can DMC members who cannot  If the report is circulated before the meeting, DMC members who will not be able to 
attend the meeting make an input attend the meeting may pass comments to the DMC chair for consideration during
the discussions.
What happens to members who  Illustrative example:
do not attend meetings If a member does not attend a meeting, it should be ensured that the member is available
for the next meeting. If a member does not attend a second meeting, they should be asked
if they wish to remain part of the DMC. If a member does not attend a third meeting, they
should be replaced.
Whether different weight will be  This should be specified and will depend on the trial.
given to different end-points 
(e.g. safety/efficacy)
Any specific issues relating to the  This should be specified and will depend on the trial.
trial design that might influence the 
proceedings (e.g. cluster trials, 
equivalence trials, multiarm trials)
9. Reporting
To whom will the DMC report  Usually, this will be a letter to the TSC or sponsor’s representative. A timescale 
their recommendations/decisions,  should be specified, e.g. usually within 3 weeks. It is helpful if a copy of this is lodged 
and in what form with the trial office. 
Whether minutes of the meeting  These details should be specified (separate records may be required for open and 
be made and, if so, by whom and  closed sessions). The DMC chair should sign off any minutes or notes.
where they will be kept
What will be done if there is  Specify which committee has primacy or how disagreement will be resolved, 
disagreement between the DMC  e.g. a further committee may be convened to adjudicate.
and the body to which it reports
Illustrative example:
“If the DMC has serious problems or concerns with the TSC decision a meeting of these
groups should be held. The information to be shown would depend upon the action
proposed and the DMC’s concerns. Depending on the reason for the disagreement
confidential data will often have to be revealed to all those attending such a meeting. The
meeting should be chaired by a senior member of the trials office staff or an external
expert who is not directly involved with the trial.”
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TABLE 33 Charter for DMCs (cont’d)
Content Comments from DAMOCLES and illustrative examples
10. After the trial
Publication of results  At the end of the trial there may be a meeting to allow the DMC to discuss the final
data with principal trial investigators/sponsors and give advice about data
interpretation.
The DMC may wish to see a statement that the trial results will be published in a
correct and timely manner.
The information about the DMC  DMC members should be named and their affiliations listed in the main report, unless 
that will be included in published  they explicitly request otherwise. A brief summary of the timings and conclusions of 
trial reports DMC meetings should be included in the body of this paper.
Whether the DMC will have the  The DMC may wish to be given the opportunity to read and comment on any 
opportunity to approve publications,  publications before submission.
especially with respect to reporting 
of any DMC recommendation 
regarding termination of a trial
Any constraints on DMC members  It should be specified when the DMC may discuss issues from their involvement in the 
divulging information about their  trial, e.g. 12 months after the primary trial results have been published, or when 
deliberations after the trial has  permission is agreed with the overseeing committee. 
been published
Illustrative examples are shown in italic text.
a Based on real trial protocols.
– Insert figures and appendices:
– Figure summarising trial
– Figure showing relationship of trial committees, including DMC
– List of abbreviations and glossary
– Annex 1: Competing interest form
– Annex 2: Illustrative letter from DMC to TSC
– Annex 3: Details of interim analysis plan (if not in protocol)Annex 1 Suggested competing interests form
Potential competing interests of Data Monitoring Committee members for [Insert trial name (and
sponsor’s ID)]
The avoidance of any perception that members of a DMC may be biased in some fashion is important for
the credibility of the decisions made by the DMC and for the integrity of the trial.
Possible competing interest should be disclosed via the trials office. In many cases simple disclosure up
front should be sufficient. Otherwise, the (potential) DMC member should remove the conflict or stop
participating in the DMC. Table 1 lists potential competing interests.
TABLE 1 Potential competing interests
Please complete the following section and return to the trials office.
No, I have no competing interests to declare
Yes, I have competing interests to declare (please detail below)
Please provide details of any competing interests:
Name:
Signed: Date:
  Stock ownership in any commercial companies involved
  Stock transaction in any commercial company involved (if previously holding stock)
  Consulting arrangements with the sponsor
  Frequent speaking engagements on behalf of the intervention 
  Career tied up in a product or technique assessed by trial
  Hands-on participation in the trial
  Involvement in the running of the trial
  Emotional involvement in the trial
  Intellectual conflict, e.g. strong prior belief in the trial’s experimental arm
  Involvement in regulatory issues relevant to the trial procedures
  Investment (financial or intellectual) in competing products
  Involvement in the publication
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Annex 2 Illustrative report from DMC to TSC where recommendation is to continue the trial according to the protocol 
[Insert date]
To: Chair of Trial Steering Committee
Dear [Chair of Trial Steering Committee]
The Data Monitoring Committee (DMC) for the [insert trial name] trial met on [meeting date] to
review its progress and interim accumulating data. [List members] attended the meeting and
reviewed the report.
The trial question remains important and, on the basis of the data reviewed at this stage, we
recommend continuation of the trial according to the current version of the protocol [specify protocol
version number and date] with no changes. 
We shall next review the progress and data [provide approximate timing].
Yours sincerely,
[Name of meeting chair]
Chair of Data Monitoring Committee 
On behalf of the DMC (all members listed below)
DMC members: 
(1) [Insert name and role]
(2) [Insert name and role]
(3) [Insert name and role]For the conduct of data
monitoring in RCTs
Which trials need an independent
DMC? (Question 1)
Criteria derived from this project for those RCTs
that do not need an independent DMC are: where
it is not possible for a DMC to make a
contribution to a trial, where any observed
differences between trial groups, however extreme,
would not prompt a change in the trial’s protocol
(such as early stopping), and where there is no
reason for thinking that an independent DMC
would reach a conclusion that differed significantly
from decisions that would be reached after
internal monitoring. 
Recommendation
Some form of data monitoring should be
considered for all RCTs, with an explicit reason
given where there is a decision either to have no
DMC or to include members in a DMC who are
not independent. 
Who should decide the details of how a
DMC operates? (Question 2)
The evidence reviewed suggested that clarifying
and agreeing in advance a DMC’s roles and
responsibilities decreases the chances of later
difficulties. This may be considered most easily
within a structured charter, and a template for this
with potential issues listed as a checklist was
developed within this project for this purpose (see
Table 33).
Recommendation
At the start of a trial, DMCs, investigators and
sponsors/funders draw up a charter describing a
DMC’s planned operations. 
What should the DMC’s terms of
reference cover? (Question 3)
A range of roles has been suggested for DMCs.
Central is monitoring accumulating evidence
related to treatment benefit and toxicity, but other
aspects of trial conduct will usually be considered.
Variation in the emphasis of a DMC’s roles has
been reflected in a plethora of names and this can
be confusing. A DMC is responsible to a number
of groups or parties (including current
participants, future participants, future patients,
investigators and sponsors) and needs to take
account of these potentially conflicting
perspectives.
Recommendation
A DMC pre-agrees its roles and responsibilities
(and the proposed charter in Table 33 provides a
template for this). The DAMOCLES group
recommend that groups responsible for data
monitoring be given the standard name ‘data
monitoring committee’ (DMC). 
Does the DMC have a role before 
the trial recruitment phase? 
(Question 4)
It has been argued that, if as recommended above,
a DMC pre-agrees how it will operate, it is best if
this is done before the DMC sees any trial data. A
meeting before recruitment starts also allows a
DMC to review and agree relevant aspects of the
trial protocol and procedures, including guidelines
for stopping early and the analysis plan; in
addition, it allows members to get to know each
other in advance of any decision-making about the
trial.
Recommendation
A DMC meets early before any outcome data 
have accrued, ideally before recruitment 
starts.
How should regulatory issues impact on
the DMC? (Question 5)
Both the ICH and FDA encourage independent
DMCs. This study found no reason why DMCs of
trials performed for regulatory purposes should
differ significantly from other DMCs, although
they should be aware of any special requirements
that this entails and should take into account the
regulatory consequences of any decisions that they
take. 
Recommendation
Similar principles are used for DMCs of regulatory
trials as for other trials, although committees
should take the regulatory consequences into
account when making decisions.
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Chapter 8
Conclusions and recommendationsWhat should the membership of a 
DMC be? (Question 6)
Advantages were identified for both larger sized
DMCs (full range of specialist skills without over-
dependence on individuals, low risk of dominance
and a wider range of opinion) and smaller sized
committees (fewer practical difficulties finding
appropriately qualified people and of arranging
meetings, less reluctance of members to express
views, less risk of conflict and less potential for a
bias towards riskier decisions). The optimal size
will reflect a balance of these considerations and is
likely to be between three and eight. There is
general agreement that a DMC should be
independent and multidisciplinary, with at least
one member being a statistician and another a
clinician with appropriate specialist knowledge.
The involvement of consumer representatives in
DMCs is controversial and should be explored.
While there was recognition that DMC members
would be likely to benefit from introduction to the
ethical considerations in data monitoring, little
support was found for ethicists being members of
DMCs and their involvement should also be
researched. The chair is recognised as being
particularly influential, and likely to be most
effective if experienced in both data monitoring
and chairing small groups, having an
understanding of both statistical and clinical
issues, being facilitating in style and impartial. It is
common practice for the investigators to agree the
DMC membership with the trial sponsors. 
Recommendation
The size of a DMC is chosen to optimise
performance, members are independent and from
an appropriate range of backgrounds, and the
chair is experienced and facilitating. Although
they would not be members of the DMC, it is
appropriate if selected trial personnel conduct the
confidential analyses and attend DMC meetings.
(The model in which all members are completely
independent of the trial and an independent
statistician conducts the analyses has considerable
drawbacks, whereas the model in which people
involved in the trial are DMC members runs the
risk of biased decision-making.)
How is independence to be maintained?
(Question 7)
Characteristics of independence have been
described (see Chapter 2, Box 5), and include no
commercial, clinical or intellectual conflict of
interest. It is generally accepted that potential
competing interests should be formally identified,
with active consideration of whether they
jeopardise independence and credibility such as to
make a person ineligible for membership. The
review suggested that rewards must be so minimal
as to have no effect on decision-making.
Nevertheless, costs such as travel and
communication should be covered and
consideration should be given to providing some
recompense for time involved.
Recommendation
DMC members are screened for potential 
conflicts of interest at the start of a trial, with 
later checks to ensure that independence is
maintained.
Should the DMC deliberations be open
or closed? (Question 8)
It is common practice to have open and closed
sessions at DMC meetings. At open sessions,
general trial issues, such as recruitment, are
discussed with investigators; at closed sessions,
there is discussion of confidential information,
such as interim analyses.
Recommendation
DMC meetings have both open and closed
sessions, but with the closed sessions limited to
those for whom access to confidential interim
analyses has been pre-agreed by the DMC.
What are the optimal practical
arrangements for interim analysis and
data monitoring? (Question 9)
Optimal timing of DMC meetings depends on 
the particular trial. It is usual to have a minimum
frequency, with the committee able to meet at
shorter notice if a reason arises. There is 
evidence that face-to-face meetings should be 
the preferred method of communication,
especially for the first meeting or when difficult
decisions are predictable, although a chair may
elect to use teleconferencing when the discussion
appears straightforward or when there are
practical difficulties in bringing the committee
together.
Recommendation
A minimum frequency of meetings is agreed, with
flexibility for more frequent meetings if a reason
arises. Meetings should be held face-to-face, if
possible and practicable.
What sort of training or preparation
should DMC members have? 
(Question 10)
It is widely accepted that some members at least,
including the chair, should have previous
experience of trials and serving on DMCs. There
Conclusions and recommendations
140is no evidence on which to judge the value of
suggested approaches to training and preparation.
These include apprenticeship training, possibly
enhanced by more formal mentoring by an
experienced member of the DMC, attendance at
other DMCs as observers and formal courses. The
value of basic instruction in relevant ethical
principles and experiential training in discussing
ethical dilemmas is also unclear. The special
training requirements of chairs of DMCs should
also be addressed. 
Recommendation
Some members of a DMC should have prior
experience. Approaches to training members of
DMCs should be developed and evaluated. 
What material should be available to 
a DMC? (Question 11)
The materials required by a DMC depend on the
areas of the trial that will be monitored. 
(Potential areas are summarised in Chapter 2,
Table 5.) The general view is that information to 
be included in a report to a DMC and its format
should be agreed in advance with the DMC.
Information about benefits and risks should be
given in a balanced way, summarised so as to be
accessible, avoiding too much detail, and as up to
date as possible. While there is a theoretical
argument that DMCs should consider blinded
analyses, this may not be possible in practice, 
and anyway many DMCs need to know the 
group allocation to perform their monitoring
functions fully. The report should also include
information about comparable studies and be
available in advance of the meeting. Interaction
with DMCs of other similar trials is controversial.
The issues and potential implications are complex
and some commentators have recommended
caution.
Recommendation
The information to be included in a report to a
DMC and its format are agreed in advance with
the DMC.
Who should own the interim data and
analyses? (Question 12)
Little was found in this project about the issue of
ownership of interim data and analyses.
Recommendation
A DMC should be seen as having a guardianship
role in respect of deciding who outside the DMC,
if anyone, could be allowed to see confidential
interim analyses. This role would be discharged
once final analyses have been completed. 
Should non-comparative analyses
(which are administrative and not
separated by treatment arm) be
carried out? (Question 13)
Information about ‘administrative’ factors, such as
recruitment, compliance and data quality, which
are important to the integrity of a trial, are
commonly considered by DMCs and shared with
the trial’s investigators. Non-comparative analyses
of outcome data may occasionally be indicated,
but should only be conducted with caution, and in
a way that ensures the confidentiality of the
interim trial analyses.
Recommendation
Administrative analyses are usefully discussed at
open sessions of a DMC. Non-comparative
outcome analyses should only be performed for a
specific purpose and in a way that does not
jeopardise the integrity of the trial.
Is the function of the DMC advisory (to
make recommendations) or executive
(to make decisions)? (Question 14)
The general, but not unanimous, view is that
DMCs should have an advisory rather than
executive role on the basis that it is the trial
organisers who are ultimately responsible for the
conduct of the trial. The organisers then choose
whether or not to accept the DMC’s
recommendations (although it is unusual for them
not to do so).
Recommendation
DMCs are given an advisory role, with the trial
organisers taking ultimate responsibility for any
decisions.
What decisions and recommendations
should be open to the DMC? 
(Question 15)
Variation between trials in the decision options
open to DMCs seems to reflect differences in
emphasis rather than disagreement. The
implications of potential decisions depend on the
stage that the trial has reached. Before a trial starts
recommendations can be made about changes to
the trial’s protocol. Once the trial has started, the
DMC can recommend that a trial should continue
without modification, or stop completely or
partially, or continue with modifications. 
Recommendation
Members of a DMC should understand the range
of recommendations or decisions that is open to
them and the implications that these could have
for the trial. 
Health Technology Assessment 2005; Vol. 9: No. 7
141
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.How should the decisions or
recommendations be reached within
the DMC? (Question 16)
The ways in which DMCs reach decisions vary.
Usually, this is by consensus, but other approaches
are sometimes used, including voting, in which
case an odd number of members has been
recommended. The evidence suggests that
decisions should be unanimous where possible,
with voting encouraged only after a full discussion.
There is general agreement that the process by
which the DMC makes decisions should be explicit
and transparent. 
Recommendation
A DMC agrees in advance how it will reach a
decision. A record should be kept of each DMC
meeting that describes the key issues discussed
and the rationale for any decisions taken. 
What should be the role of formal
statistical methods in DMCs? 
(Question 17)
A range of formal statistical approaches can be
used in interim analyses of trials (the principles
behind these are outlined in Appendix 1 of this
report). However, this is only one of a number of
considerations that a DMC would take into account
and statistical criteria should be considered
guidelines for stopping rather than rules.
Recommendation
A DMC should understand and agree the
statistical approach (and guidelines) chosen for a
trial. Both the DMC statistician and the trial
statistician should be competent to apply this
method to the trial’s interim analyses. 
Should specific trial designs influence
the proceedings? (Question 18)
Unusual trial designs have implications for data
monitoring. These designs include cluster trials,
equivalence trials, and trials with a composite
outcome or where the difference in outcome is
disproportionately larger soon after entry. These
circumstances are unusual, but should be
identified and taken into account in advance of
any data monitoring.
Recommendation
DMCs should recognise in advance the implications
of any unusual aspects of a trial’s design and take
these into account in their deliberations. 
How should ethical issues be handled 
in DMCs? (Question 19)
The aim of a DMC should be to decide when the
evidence is sufficiently persuasive that it is clear
what is in the best interests of both current
participants and future patients. The degree of
conservatism or radicalism to be adopted in
making this decision should be reflected in the
DMC’s terms of reference and the trial’s
monitoring plans, which include the statistical
criteria chosen as guidelines. RECs will have
agreed the ethical basis for the trial’s protocol,
and the DMC should approach its role from that
starting point. 
Recommendation
The primary purpose of a DMC is to ensure that
continuing a trial according to its protocol is
ethical, taking account of both individual and
collective ethics. Whether the DMC has a broader
remit in respect of wider ethical issues is
controversial; the view of the DAMOCLES group
is that these are primarily the responsibility of
RECs, TSCs and investigators. 
What should DMCs do with their
decisions or recommendations?
(Question 20)
DMCs usually report to the sponsor or the
investigators (in the form of a representative
committee) and there can be advantages in
reporting to both at the same time. If there are no
concerns about the trial, it is likely that only a
brief, but carefully worded, statement from the
DMC chair is required. A much fuller report is
needed if a change to the protocol is being
recommended by a DMC. 
Recommendation
It should be agreed in advance to whom a DMC
reports, how it does this and what record-keeping
is required.
What should be done in ‘difficult’
situations? (Question 21)
There is wide agreement that a DMC must have
the flexibility to call meetings at short notice if a
difficult issue arises. The importance of these
meetings having sufficient time available is also
recognised. Closed sessions restricted to DMC
members provide the best forum for formulating a
response. Factors that could make it more difficult
for members to participate (such as calling a
meeting at short notice or using a telephone
conference call rather than an in-person meeting)
should be avoided if possible. 
Recommendation
A DMC should agree in advance how it would
respond to difficult circumstances. This is likely to
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at short notice. A trial’s decision-making body
(such as the TSC or sponsor) and its DMC should
also consider planning in advance to allow a third
group to arbitrate if they were later to disagree
when the DMC recommends a change in protocol.
Should some DMC decisions be
considered to be ‘errors’? (Question 22)
While it is difficult to judge whether a DMC has
made a good or poor decision, there is evidence of
ways to minimise the chances of a poor decision.
Concerns have been expressed about who would
be deemed liable for an erroneous decision if a
legal challenge were to be mounted, and this
needs clarification. 
Recommendation
DMCs should recognise that the chances of a
decision error are likely to be reduced if they make
a thorough review of the evidence, they have a
clear understanding of how they should function,
there is active participation by all group members,
resolution of differences is through discussion, and
there is systematic matching of the facts to the
criteria for the various decision options. 
What should the DMC’s role be
concerning publications? (Question 23)
The question of what role, if any, the DMC should
play once interim analyses have been completed
has received little attention. There are, however,
good reasons for the DMC at least commenting on
the draft trial report. 
Recommendation
DMCs should be encouraged to comment on draft
trial reports and this should be agreed at an early
DMC meeting. Trial reports should include
information about the data monitoring procedures
and processes, and about the DMC membership.
For further research on
behavioural and organisational
aspects of data monitoring in
RCTs
  Widening of DMC membership beyond
clinicians, trialists and statisticians (e.g. to
include consumer representatives or ethicists)
should be formally evaluated. 
  Initiatives to train members of DMCs should be
evaluated as they are introduced. 
  Research is needed on methods of decision-
making in DMCs, in particular the role of
voting and of formal decision-making tools. 
  The role of ‘open’ data monitoring requires
further research.
  The advantages and disadvantages of DMCs
covering a portfolio of trials (rather than single
trials) should be clarified.
  There was inconsistency between the
components of this study about what constituted
the optimal size of a DMC. This warrants
further study, incorporating issues of group
dynamics.
  The generalisability of findings related to other
small decision-making groups, such as juries, is
questionable; this could be addressed by
empirical research of DMCs and their decision-
making.
  The question of which trials should or should
not have a DMC remains controversial and
further research could clarify this.
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It is universally accepted that monitoring of
clinical trials will involve some form of statistical
analysis, although the underlying statistical
philosophy and the precise methods to be used
remain controversial subjects. This appendix
reviews the approaches of the main schools of
statistical ‘ideology’, and summarises how they can
be applied to the range of problems facing a
DMC. No attempt is made to review
comprehensively the large literature on statistical
aspects of monitoring clinical trials, and the
reader may refer to books by Whitehead112 and
Jennison and Turnbull,192 and less technical
chapters such as that provided by Piantadosi.80 In
particular, Ellenberg and colleagues19 provide a
range of worked examples, and the special issue of
Statistics in Medicine in 1994193 also contains a
range of relevant papers to ‘stopping rules’. Other
review articles6,7,194–196 mainly focus on frequentist
methods, although alternatives are increasingly
being mentioned. In contrast, this brief review
attempts to consider all potential methods without
regard to their current popularity.
Statistical approaches
Four major statistical paradigms can be identified,
and this section will first consider how each one
tackles the issue of early stopping in the face of
apparent benefit of an active intervention; their
approach to other situations will be considered
afterwards. Only a minimum of notation is
required: at the ith interim analysis, it is assumed
that the evidence is adequately summarised by a
standardised test statistic zi, typically based on the
current estimate of the treatment effect divided by
its standard error. Traditional values of interest
include zi = 3, corresponding to a two-sided 
p-value of around 0.001, and zi = 2,
corresponding to a two-sided p-value of around
0.05. However, these ‘naive’ p-values ignore the
influence of the repeated analyses typically carried
out when data monitoring, and such issues
emphasise the careful attention paid to statistical
methodology in this context.
Frequentist
This Neyman–Pearson approach is rooted in a
theory of ‘inductive behaviour’, seeking
procedures of hypothesis testing and estimation
with guaranteed properties under repeated use.
Specifically, clinical trials are generally designed to
have fixed size (the chance of incorrectly rejecting
the null hypothesis, or ‘Type I’ error), often taken
as 5% or 1%, and fixed power (the chance of not
detecting the alternative hypothesis, or one minus
the ‘Type II’ error), often taken to be 80% or 90%. 
The option of early termination of trials presents
frequentist methods with a strong challenge, since
all potential actions must be considered when
establishing their repeated sample properties.
Suggested protocols for early stopping can be well
visualised as ‘stopping boundaries’ which describe,
for example, critical values of the test statistic zi
that would be considered sufficient evidence for
stopping and concluding efficacy. For example, a
naive boundary would stop a trial for efficacy of 
zi > 1.96: while this would provide a test with
fixed Type I error of 0.025 for a fixed sample size,
it is clear that the chance of crossing such a
boundary at some point during the course of a
trial can considerably exceed this nominal figure,
owing to the well-known problems associated with
repeated significance tests.
Stopping boundaries will generally be designed to
have fixed Type I error over the planned
maximum lifetime of the trial; open-ended
schemes with no preset maximum sample size will
not generally be considered practical. Within this
class of boundaries there are many options that
can be compared, for example, on the basis of
their power to detect plausible alternatives or their
expected sample size. 
Major recommendations for frequentist schemes
can be divided into two main classes: group
sequential and continuous procedures.
Group sequential procedures assume a limited
number of interim analyses at preset times. It is
useful to focus on two of the most widely discussed
proposals: the Pocock model in which a common
Health Technology Assessment 2005; Vol. 9: No. 7
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Summary of statistical approaches to 
data monitoringboundary for zi is used at all interim analyses, with
the boundary chosen to have the appropriate 
Type I error, and the O’Brien and Fleming
boundary, which is much more conservative at the
start of the trial, but comes near to the nominal
level at the final analysis. O’Brien and Fleming
boundaries are perhaps more popular in the USA.
The boundaries for five interim analyses are
shown in Figure 7.
Continuous procedures allow inspection of the
data and therefore stopping to occur at any stage
of a trial. Two approaches have been used in
practice. First, the triangular test has linear
boundaries on a plot relating estimated effect with
information gained. Whitehead112,197 emphasises
the generality of this approach and indicates
adjustments for sampling at fixed times, over-
running (in which information is received after
having crossed the boundary198) and so on. The
alpha spending approach199,200 specifies a
‘spending function’, which is a smooth increasing
function of information gained ranging from 0 to
the overall Type I error, say 0.05. At any point in
the trial, the boundary is set so that the probability
of falsely rejecting the null hypothesis before that
point is equal to the spending function. This
increased flexibility carries with it a substantial
computational burden.
The repeated confidence interval method201 does
not use an explicit boundary, but monitors
whether an interval estimate (adjusted for
repeated analyses) excludes the null hypothesis.
An important issue is the estimation of the
treatment effect after early stopping in a
sequential design. The naive estimate will be
biased if the trial stops and publishes; informally,
a contributory reason for crossing a boundary is
likely to be a run of good or bad luck.202
Techniques for producing unbiased estimates have
been researched,112 but they are complex and
appear to have rarely been used in practice.
Likelihood approach
This Fisherian approach bases inference on the
true underlying treatment effect solely on the
likelihood function, which expresses the relative
support given by the observed data to different
values of the true underlying treatment effect. It
would be possible to draw conclusions based solely
on the relative support for null and alternative
values of the true underlying treatment
effect.203,204 If carried out after each observation
this leads to the sequential probability ratio test,
although Piantadosi80 points out that this test
becomes a frequentist procedure once its
boundaries start being set on the grounds of its
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FIGURE 7 Haybittle–Peto, O’Brien and Fleming, Pocock and sceptical Bayesian stopping boundaries for five interim analysessampling properties. Fisher suggested that the
evidence against a null hypothesis be summarised
by a p-value (unadjusted for multiple looks at the
data), which is the chance of observing such
extreme data under the null hypothesis. 
When monitoring trials, this somewhat informal
approach is perhaps best exemplified by trials
influenced by the Oxford school under Richard
Peto,205 in which protocols generally state that the
DMC should only alert the TSC to stop the trial
on efficacy grounds if there is “both (a) ‘proof
beyond reasonable doubt’ that for all, or for some,
types of patient one particular treatment is clearly
indicated …, and (b) evidence that might
reasonably be expected to influence the patient
management of many clinicians who are already
aware of the results of other main studies”. There
is no formal expression of what evidence is
required to establish ‘proof beyond reasonable
doubt’, although |zi| > 3 and p < 0.001 have
been mentioned as possible criteria. Also note the
explicit, though again informal, appeal to the idea
that the results should be convincing to a broad
spectrum of opinion (see next section). 
Although this approach is not intended as a
formal stopping boundary, it may be considered as
an informal continuous monitoring scheme, and is
often termed the Haybittle–Peto rule: its form is
displayed in Figure 7. Its precise frequentist
properties are not explored, so it cannot be
considered a formal frequentist method. It is
perhaps more popular among UK trialists. 
Bayesian approach
Bayesian methods extend the likelihood approach
inference by including a ‘prior distribution’, which
is intended to summarise evidence concerning the
true underlying treatment effect arising externally
from the trial. This is then combined with the
likelihood using Bayes’ theorem to produce a
posterior distribution, which expresses an updated
belief having taken into account evidence from the
study, and on which all inferences are based.
Monitoring of the clinical trial is based on
posterior distribution and hence Bayesian
monitoring procedures explicitly use external
evidence or judgement and are not solely based
on data from the trial. The Bayesian approach to
trials has been reviewed in detail by Spiegelhalter
and colleagues.206 (See also reviews by
Spiegelhalter,207 Berry,208,209 Freedman210 and
Fayers.211)
There is no formal necessity to preset stopping
boundaries within the Bayesian approach, but
criteria such as ‘stop if the posterior probability
that the treatment is beneficial is greater than
97.5%’ have been investigated. The following
three issues immediately arise.
What prior to use? 
Although the ideal Bayesian view is that the trial
evidence revises one’s personal subjective beliefs,
in practice it is generally accepted that a
community of priors should be considered. This
formalises the idea that “the purpose of a trial is
to collect data that bring to conclusive consensus
at termination opinions that had been diverse and
indecisive at the outset”.212 Priors may include the
opinions of enthusiasts for the new innovation or a
sample of clinicians, or be based on a formal
meta-analysis. In particular, before concluding
efficacy, it has been argued that the data should be
sufficient to overcome the handicap of a ‘sceptical
prior’ centred on the null hypothesis. One
suggestion is that such a prior reflect the opinion
that the targeted alternative hypothesis is
unlikely.211 Such a sceptical prior will tend to draw
the estimated treatment effect towards the null
hypothesis, inducing a degree of conservatism
similar to that of frequentist stopping procedures.
This is demonstrated in Figure 7, which shows a
practical example of monitoring using a sceptical
prior, reported by Parmar.213 Other prior
distributions may be appropriate in different
circumstances (see below). 
What are the sampling properties?
Repeated sampling properties are, officially, of no
interest within the Bayesian paradigm, but it is
inevitable that comparison is drawn with
frequentist procedures. It has been shown that
group-sequential schemes based on posterior tail
areas and sceptical prior can have good sampling
properties,214 but there can be considerable
sensitivity to the prior distribution.215
What about null hypotheses?
Within the Bayesian paradigm there is no need for
null hypotheses to remain fixed throughout the
trial: the goalposts may move. Thus, it may be
reasonable to specify a point of clinical
equivalence, which may change as the trial
progresses, and monitor the posterior probability
that the true effect exceeds this. 
Decision-theoretic approach
The decision-theoretic approach requires a
specification of a formal loss or utility function
which quantifies the desirability or otherwise of
different outcomes, such as treating a patient with
an inferior treatment or spending resources on
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even to start) a trial are based on the potential
losses (or gains) under the different options: both
Bayesian (e.g. take the decision that minimises the
expected loss) and non-Bayesian (e.g. take the
decision that minimises the maximum potential
loss) alternatives are available.216 In support of
this approach, Berry217 states that “deciding
whether to stop a trial requires considering why we
are running it in the first place, and this means
assessing utilities”, while Healy218 considers that
“in my view the main objective of almost all trials
on human subjects is (or should be) a decision
concerning the treatment of patients in the
future”.
Although there has been substantial theoretical
work in this area (see, for example, Berry and
Pearson219), the DAMOCLES group is unaware of
any reported examples of prospective use.
Critical comparison of approaches
It is easy to emphasise the differences between the
approaches outlined above, but Piantadosi80 points
out similarities such as the need for clearly stated
objectives, proper design and conduct of the trial,
and acknowledgement of additional context
beyond the raw observed data, as well as the
qualitative similarity of the various options, in that
they all exhibit conservatism in protecting against
a trial stopping inappropriately early. In addition,
in spite of the technical formalism of the
approaches, there is a general consensus that these
statistical techniques should only be used as
guidelines rather than as rules, and that a strong
element of contextual judgement is always
required. Nevertheless, there are some clear
ideological differences between the paradigms.
Frequentist
Particularly strong attacks have been made against
the (most commonly adopted) frequentist
approach:
  The investigators may disobey the likelihood
principle,220 in that the inference is based on
the intentions of the investigator rather than
simply the data observed. Hence, exactly the
same data could lead to rejection or no
rejection of a null hypothesis depending on
what the investigator would have done had
different data been observed earlier in the
study.203,221 Meier222 considers that “provided
the investigator has faithfully presented his
methods and all of his results, it seems hard
indeed to accept the notion that I should be
influenced in my judgement by how frequently
he peeked at the data while he was collecting
it”.
  Cornfield220 points out that “the entire basis for
sequential analysis depends upon nothing more
profound than a preference for minimising  
for given   rather than minimising their linear
combination. Rarely has so mighty a structure,
and one so surprising to scientific common
sense, rested on so frail a distinction and so
delicate a preference”.
  Anscombe223 says, “the concept of error
probabilities of the first and second kinds …
has no direct relevance to experimentation”.
  Frequentist approaches have difficulty adapting
to changes in the trial, for example a shift in
null hypothesis brought about by findings of
toxicity.
  Naive estimates following early termination are
biased, since the data are more likely to be
subject to a transient random extreme.6,7,202
This fact appears to be almost universally
ignored when reporting results following early
termination. 
In response, it can be argued that when treatments
are being recommended for general use or passed
by regulatory authorities there is a need for quality
control, and procedures that pre-specify rates of
inappropriate conclusion provide a simple and
communicable framework, with protection against
inappropriate early stopping of a trial.
Likelihood 
Objections include:
  the lack of formal assessment of possible Type I
error
  the associated informality of the monitoring
procedure.
Bayesian
Objections to the Bayesian approach include those
associated with the likelihood approach, and in
addition:
  Conclusions may depend strongly on the prior,
and this necessarily involves a subjective
judgement. Even with extensive sensitivity
analysis, such input may be considered
unacceptable to, for example, regulatory bodies.
  The techniques are generally more complex
than frequentist and likelihood approaches, and
may be seen as less transparent.
  There are generally no established sampling
properties.
Appendix 1
160  There is little experience in their use, and
limited understanding of their basis. 
Decision-theoretic
Objections include: 
  This approach is generally complex for
monitoring trials owing to the difficulty in
specifying an agreed loss function, particularly
for the post-trial consequences of stopping a
trial. For example, Peto,224 in the discussion of
Bather,216 states that “Bather, however, merely
assumes … ‘it is implicit that the preferred
treatment will then be used for all remaining
patients’ and gives the problem no further
attention! This is utterly unrealistic, and leads
to potentially misleading mathematical
conclusions.”
  There are strong computational demands in
calculating potential losses under all possible
future actions. This ‘backwards induction’
requires dynamic programming techniques in
all but the simplest circumstances. Nevertheless,
advances are being made.225
Questions under consideration by
a DMC
This section considers the different questions that
could be asked by the DMC, using the same
structure as for question 15 in the systematic
review of published literatures on DMCs (see
Chapter 2). Emphasis is placed both on frequentist
and Bayesian methods.
The study should stop completely or
partially
Apparent benefit of active treatment on primary
outcome
The different approaches have already been
outlined above.
Apparent benefit of control on primary outcome
Frequentist schemes require a lower boundary,
which may well be asymmetric with the efficacy
boundary because of the wish to detect quickly a
potentially inferior active treatment. From a
Bayesian perspective it may be reasonable to
monitor with an ‘enthusiastic’ prior centred on the
alternative hypothesis. Evidence against the active
treatment could then be assessed on the basis of
its capacity to convince an enthusiast that the
treatment is ineffective, interpreted as a very low
posterior probability that   exceeds a clinically
important effect. When investigating non-
inferiority or equivalence, non-zero null
hypotheses will generally need to be specified 
(see below).
Safety concerns with secondary outcomes
These may be too rare or too diffuse to have
formal stopping rules, although combinations of
events could be used. Formal bivariate monitoring
schemes have been explored.226
Small chance of eventually showing benefit
Futility calculations, also known as stochastic
curtailment, can be carried out within a frequentist
framework, by calculating the conditional
probability of an eventual significant result, given
the data so far and the null or alternative
hypothesis.227,228 From a Bayesian perspective it
makes more sense to average such conditional
probabilities with respect to the current posterior
distribution, which then produces an overall
predictive assessment of the chance of eventual
success.84,229 It is possible to make such
predictions based on the current data alone and
without using a prior distribution,230 and in this
context there is essentially no difference between
the frequentist and non-informative Bayesian
approach. 
Convincing evidence of equivalence or 
non-inferiority, in a trial with this objective
In this context it will be necessary to specify an
effect demarcating non-inferiority or a range
indicating equivalence. Frequentist designs that
simultaneously monitor efficacy and non-
inferiority have been suggested.231 From a
Bayesian perspective no special considerations are
necessary, since at any time the posterior
probability of lying in any region can be obtained
and used for monitoring. However, as with looking
for control benefit, one may want to be assured
that the findings were convincing to an enthusiast
for the new treatment. 
Part of the study should stop
Stopping randomisation in a subgroup for one of
the reasons given above
Frequentist approaches would require
prespecification of tests of treatment by subgroup
interaction, designed to have appropriate
sequential properties, although these are likely 
to have low power. From a Bayesian perspective, 
it is standard to adopt a sceptical prior for
between-subgroup differences, leading to
shrinkage of estimates towards the overall effect 
to a degree decided by the empirical between-
subgroup heterogeneity.232 Individual 
subgroups can then be monitored using 
posterior tail areas.
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for one of the reasons given above
Frequentist techniques exist for terminating one
arm in a multiarm trial, 106,233,234 which may be
particularly appropriate in factorial designs.73
Again, Bayesian analysis is unaffected by other
arms unless the treatment effects are assumed to
be correlated.
Factors that may be taken into account in statistical
analysis include the following.
External evidence
This is clearly important,19 but formal meta-
analysis is not recommended as a basis for
monitoring within a frequentist framework.235,236
Thus, there is a strong element of subjectivity as to
how external evidence is considered. Within the
Bayesian paradigm it is natural to incorporate
external evidence, possibly discounted, into one of
the prior opinions being considered.
Need to influence clinical opinion
This can be handled informally within a likelihood
approach (as noted by the Peto stopping rule) and
the frequentist approach by making more stringent
stopping criteria. The Bayesian paradigm can
require data to overwhelm the handicap of a
sceptical prior opinion. Both approaches can shift
the null hypothesis in response to substantial
clinical demands for efficacy. 
The study should continue with
modifications
Basic statistical analysis may be involved in many
suggestions for improvement to a study, but the
following are of particular interest.
Additional interim analyses
Group-sequential designs will have their
properties changed by such a request, 
whereas continuing monitoring schemes,
likelihood (Peto) and Bayesian methods will be
unaffected. 
Extending recruitment or follow-up time
Many factors may lead to wanting to change the
planned sample size: slow recruitment, low event
rate, change in alternative hypothesis, and so on.
The effect of revising sample size calculations at
an interim stage has been studied for frequentist
designs.237–239 There is no effect on Bayesian
procedures.
Conclusions
Currently, there is no single approach that can be
considered both theoretically and practically ideal.
The frequentist approach is currently the
dominant philosophy, strongly influenced by the
quality-control framework set up by the regulatory
bodies. Bayesian approaches are rare in practice,
but they are becoming increasingly discussed.
Focus on cost-effectiveness and health policy is
bringing decision-theoretic ideas away from purely
theoretical constructs. Novel studies, such as
complex adaptive dose-finding designs, are
demanding increasingly flexible monitoring
procedures. However, while it is likely that a
somewhat wider range of statistical approaches 
will be used in future, the nature of their role is
likely to make DMCs rather cautious and
conservative in their use of experimental statistical
techniques. 
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162Search terms used in MEDLINE,
PREMEDLINE, EMBASE, 
CINAHL and HealthSTAR 
(all on OVID) for the systematic
review of the published literature
on DMCs
1. (data adj3 (committee$ or board$)).tw.
2. (interim adj2 analy$).tw.
3. dmsb.tw.
4. (trial$ adj2 monitor$).tw.
5. (monitor$ adj2 (committee$ or board$)).tw.
6. interim data.tw.
7. trial$ adj1 halt$.tw.
8. revis$ adj2 recruit$.tw.
9. or/1-8
10. safety committee$.tw.
11. (dilemma$ adj1 resol$).tw.
12. (earl$ adj1 stop$).tw. 
13. (stop$ adj1 rule$).tw.
14. or/10-13
15. controlled clinical trial.pt.
16. randomized controlled trial.pt.
17. randomized controlled trials/
18. random allocation/
19. double blind method/
20. single blind method/
21. clinical trial.pt.
22. exp clinical trials/
23. placebos/
24. placebo$.tw.
25. random$.tw.
26. research design/
27. volunteer$.tw.
28. (clin$ adj25 trial$).tw.
29. ((singl$ or doubl$ or trebl$ or tripl$) adj25
(blind$ or mask$)).tw.
30. factorial.tw.
31. cross-over studies/
32. crossover.tw.
33. latin square.tw.
34. (balance$ adj2 block$).tw.
35. (animal not human).sh.
36. or/15-34
37. 36 not 35
38. 37 and 14
39. 38 or 9
Key: .tw., textword search (i.e. searching in titles
and abstracts); $, wildcard; adjn, within n words
either side; /, MeSH term all subheadings; 
sh, MeSH term; .pt., publication type.
Four of the terms (line 14) were combined, using
the Boolean operator ‘AND’, with a set of terms to
locate RCTs based on the Cochrane Highly
Sensitive Search Strategy (line 37) 
[Appendix 5c.2, The Cochrane Handbook. In The
Cochrane Library (Issue 2). Oxford: Update
Software; 2002].
Date last search performed: 26 June 2001. 
Years/dates covered by search: MEDLINE 1966 to
Week 2 June 2001: PREMEDLINE 25 June 2001;
EMBASE 1980 to Week 24 2001; CINAHL 1982 to
May 2001; HealthSTAR 1975 to December 2000.
Search terms used in the
Cochrane Library for review of
literature relevant to DMCs
The following search terms were used for
searching the Cochrane Controlled Trials Register
and the Cochrane Methodology Register:
1. (DATA near COMMITTEE*)
2. (DATA near BOARD*)
3. (INTERIM near ANALY*)
4. DMSB
5. (TRIAL* near MONITOR*)
6. (MONITOR* near COMMITTEE*)
7. (MONITOR* near BOARD*)
8. (INTERIM next DATA)
9. (TRIAL* near HALT*)
10. (REVIS* near RECRUIT*)
11. (SAFETY next COMMITTEE*)
12. (DILEMMA* near RESOL*)
13. (STOP* near RULE*)
14. (EARL* near STOP*)
15. (((((((((((((#1 or #2) or #3) or #4) or #5) or
#6) or #7) or #8) or #9) or #10) or #11) or
#12) or #13) or #14)
Key: *, wildcard.
Date of last search: 26 June 2001, Issue 2, 2001,
(on CD-ROM) Update Software, Oxford.
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Search terms used for the systematic review of
published literature on data monitoring committeesRejected terms for review of
literature relevant to DMCs
The following terms were tested in MEDLINE but
rejected as no (or very few) additional relevant
articles were retrieved.
These terms were not combined with other 
terms:
(trial$ adj25 futil$).tw. 
(trial$ adj1 effic$).tw. 
(trial$ adj25 oversight).tw. 
(trial$ adj25 oversee$).tw. 
scientific integrity review.pt. 
(trial$ adj1 (dilemma$ or fiasco$)).tw. 
equipoise.tw. 
Data adj1 monitor$
DMEC
DMEB
DMSC 
DSMC
DSMB
DMB
DMC
TMC
TMB
ID
AMC
Independent adj1 review
Data adj1 (policy or policies) AND RCT terms
Monitor$ adj1 safety.tw.
Trial$ safety.tw.
Oversight adj1 committee$.tw.
Institutional review board 
IRB
Professional staff committees/
Drug monitoring/
Adverse drug reaction reporting systems/
Utilization review/
Trial$ adj1 extend$.tw.
Extens$ adj1 recruit$.tw.
Trial$ adj3 stop$.tw.
Sn.fs. (ie statistical and numerical data as a
floating subheading) AND RCT terms AND review
terms
(Trial$ adj1 fail$) not (heart failure$).tw.
The terms below were combined, using the
Boolean operator ‘AND’, with a set of review terms
based on the Centre for Reviews and
Dissemination’s (CRDs) strategy for locating
systematic and other reviews (short version)
1. review, academic.pt. 
2. review tutorial.pt. 
3. review literature.pt. 
4. review multicase.pt. 
5. review of reported cases.pt. 
6. review.pt. 
7. bibliography.pt. 
8. (meta-analysis or review literature).sh. 
9. meta-analy$.tw. 
10. metaanal$.tw. 
11. (systematic$ adj4 (review or overview$)).tw. 
12. meta-analysis.pt. 
13. case report.sh. 
14. historical article.pt. 
15. meta-analysis.ti. 
16. or/1-15 
17. (stop$ adj1 rule$).tw. – when combined with
review, reject, useful when combined with
RCT terms
18. (earl$ adj1 stop$).tw. – when combined with
review, reject, useful when combined with
RCT terms
19. (trial$ adj3 stop$).tw. – not useful when used
alone either
20. (trial$ adj1 discontinu$).tw. – not useful when
used alone either
21. (stop$ adj1 recruit$).tw. – not useful when
used alone either
22. (stop$ adj2 recruit$).tw. – not useful when
used alone either
23. (stop$ adj3 recruit$).tw. – not useful when
used alone either
24. (revised$ adj1 recruit$).tw. – not useful when
used alone either
25. (revis$ adj2 recruit$).tw. – not useful when
used alone either
26. (extens$ adj2 recruit$).tw. – not useful when
used alone either
27. earl$ adj1 terminat$.tw. – not useful when
used alone either
28. trial$ adj25 terminat$.tw. – not useful when
used alone either
29. trial$ adj1 continu$.tw. 
This term below was combined, using the Boolean
operator ‘AND’, with a set of RCT terms based on
the Cochrane Highly Sensitive Search Strategy to
locate RCTs (see the MEDLINE search above for
these RCT terms):
(stop$ adj3 enroll$).tw.
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164Since the number of quotes does not take into account the length of the quotes highlighted, the eventual
plain ASCII text file size is displayed as a measure of overall length. Relevant quotes may have been
included under more than one question.
Question No. of quotes  File size (kb)
1 279 444
2 56 106
3 135 230
43 6 6 3
5 94 171
6 199 289
7 165 209
8 143 226
9 70 103
10 14 38
11 305 497
12 13 38
13 12 40
14 26 51
15 89 145
16 118 185
17 143 214
18 9 35
19 32 70
20 112 162
21 8 32
22 34 101
23 32 67
Total 2124 3516
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170PsycINFO (on WebSPIRS, the Web interface of
SilverPlatter)
Years searched: 1887 to April 2001. Date of
search: June 2001. 
Some terms only (indicated on list of search terms)
1996 to August 2001. Date of search: November
2001. 
ASSIA PLUS (Applied Social Sciences Index and
Abstracts Plus) (on Bowker Saur on A&I Plus 
CD-ROM, now published and distributed by
Cambridge Scientific Abstracts, E. Grinstead,
UK)
Years searched: spring 2001 (covers 1987 to
present). Date of search: August/September and
November 2001.
SSCI (Social Science Citation Index) (Institute for
Scientific Information, Philadelphia, PA, USA)
(on ISI Web of Science on MIMAS)
Years searched: 1996 to 11 November 2001. Date
of search: 12 November 2001.
MEDLINE (on OVID on Digital Island, web
interface)
Years searched: 1966 to week 2 May 2001. Date of
search: May 2001.
PREMEDLINE (on OVID on Digital Island, web
interface)
Search covered: 24 May 2001. Date of search: 
29 May 2001.
EMBASE (on OVID on Digital Island, web
interface)
Years searched: 1980 to week 22 2001. Date of
search: May/June 2001.
CINAHL (on OVID on Digital Island, web
interface) 
Years searched: 1982 to April 2001. Date of
search: May 2001.
HealthSTAR (on OVID on Digital Island, web
interface)
Years searched: 1975 to December 2000. Date of
search: May 2001.
HMIC (Health Management Information
Consortium database) (on WinSPIRS) 
Years searched: DHdata and Kings Fund Database
1979 to current; HELMIS 1984 to current. Date
of search: 20 November 2001.
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Summary of databases searched for the review of 
small group processesPsycINFO
Years searched: 1887 to April 2001 for reviews
(some terms only 1996 to August 2001, indicated
beside individual term). Date of last search:
November 2001.
All terms limited to publication type = Literature
review – research review, unless otherwise stated;
all fields searched unless otherwise stated.
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2001)
Small NEAR group* NEAR research*
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3630 in CC (ie Personnel Evaluation and job
performance) 
exp Interpersonal interaction in DE
Individual differences in DE
Groupthink (dates searched: 1996 to August 2001)
Decision* NEAR disaster* (dates searched: 1996
to August 2001)
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(dates searched: 1996 to August 2001)
leadership NEAR decision* (dates searched: 1996
to August 2001)
Decision* NEAR strateg* (dates searched: 1996 to
August 2001)
Decision* NEAR technique* (dates searched: 1996
to August 2001)
Decision* NEAR process* (dates searched: 1996 to
August 2001)
(Decision* OR  task*) AND committee* (dates
searched: 1996 to August 2001)
complex* NEAR task* (dates searched: 1996 to
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Exp Group decision making in DE (dates
searched: 1999 to April 2001)
Exp Group dynamics in DE (dates searched: 1999
to April 2001)
Group problem-solving in DE (dates searched:
1999 to April 2001)
Key: *, wildcard; DE, descriptor; CC, concept
code; exp, exploded search; AG, age group field.
ASSIA PLUS (on Bowker Saur on
A&I Plus CD-ROM)
Spring 2001 (goes back to 1987). Date of search:
August/September and November 2001.
Review terms, all combined with review$ in
keyword field (words in any order):
1. Group$ Task$
2. Group$ AND Decision$
3. Group$ dynamic$ 
4. Groupthink
5. Groupwork$
6. Leadership AND decision$
7. Leadership AND task$
8. Decision$ AND disaster$
9. Task$ AND disaster$
10. Child protection AND decision$
11. Team$ AND process$
12. Team$ AND task$
13. Team$ AND decision$
14. Complex$ AND decision$
15. Decision$ AND (error$ OR bias$)
16. (Team$ OR group$) AND error$
17. Decision$ AND strateg$
18. Decision$ AND technique$
19. Decision$ AND process$
20. (Decision$ OR task$) AND committee$
21. Complex$ AND task$
Key: $, wildcard.
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Appendix 6
Electronic databases with search terms used
for the review of small group processesMEDLINE, CINAHL, HealthSTAR
Years searched: MEDLINE (1966 to April/week 2/3
May 2001), CINAHL (1982 to April 2001),
HealthSTAR (1975 to December 2000). Dates of
searches: May 2001
All terms combined with review terms, given
below, unless otherwise stated:
Team$ adj2 process$. tw 
Complex$ adj1 decision$.tw 
Conflict$ adj1 resolv$.tw. 
Group processes/
Groupthink.tw (not combined with review terms)
(majority or minority) adj1 influence$.tw. (not
combined with review terms)
Terms tested in MEDLINE and rejected, not run
in CINAHL and HealthSTAR (dates searched: mid
1998 to April/week 2/3 May 2001).
All combined with review terms, given below,
unless otherwise stated:
(team adj25 (task$ or decision$)).tw. 
Group processes/
Group structure/
Committee$ and (decision$ or task$).tw
(Group$ adj1 process$).tw. 
Expert$ adj1 panel$) and process$).tw. 
Group$ adj25 decision$.tw. 
Group$ adj25 task$.tw. 
Group$ adj1 task$.tw. 
Group$ adj1 dynamic$. tw 
Leadership/ 
Decision$ adj2 strateg$.tw.
Task performance and analysis/ 
Decision support techniques/
Complex$ adj1 task$ tw. 
Task$ adj1 perform$.tw. 
Decision$ adj1 technique$.tw.
Decision adj1 making.tw. 
((Decision adj1 making) AND complex$).tw
Interprofessional relationships/ 
Interprofessional relationships/AND decision
making/ 
Communications/ AND interprofessional relations/ 
Decision$ adj1 process$.tw.
Dilemma$ adj1 resolv$.tw.
Decision$ adj1(bias$ or error$) 
Decision making/
Critical adj1 incident$.tw.
EMBASE
Years searched: 1980 to week 22 2001. Dates of
searches: May/June 2001.
All combined with review terms, given below,
unless otherwise stated:
Group dynamics/
Teamwork/ AND (decision$ or task$)
Psychodynamics/
Group psychology/
Team$ adj2 process$. tw 
(team$ and (task$ or decision$))tw. 
Complex$ adj1 decision$.tw 
Conflict$ adj1 resolv$.tw.
Interpersonal Communication/ AND (group$ or
team$).tw.
Group processes/
(majority or minority) adj1 influence$.tw. (not
combined with review terms)
Groupthink.tw (not combined with review terms)
CRD
Search Strategy for Systematic and Other Reviews
(Short Version) Terms used for searching for
reviews in MEDLINE, CINAHL, EMBASE and
HealthSTAR: 
1. Review, academic.pt.
2. Review tutorial.pt.
3. Review literature.pt.
4. Review multicase.pt.
5. Review of reported cases.pt.
6. Review.pt.
7. Bibliography.pt.
8. (meta-analysis or review literature).sh.
9. meta-analy$.tw.
10. metaanal$.tw.
11. (systematic$ adj4 (review or overview$).tw.
12. meta-analysis.pt.
13. (case report).sh.
14. historical article.pt.
15. meta-analysis.ti.
16. or/1-15
Key: ti, term in title; tw, textword, i.e. term in title
or abstract; pt, publication type; sh or /, MeSH
(medical subject heading) (with all subheadings); 
$, wildcard; adj(n), word within n words either side
of another word.
SSCI (on Web of Science)
Years searched: 1996 to 11 November 2001. Date
of search: 12 November 2001.
All in textword (i.e. title, abstract and author
assigned keywords):
Appendix 6
174(Decision* AND disaster*) AND review*
(Decision* SAME group*) AND review*
HMIC (on WinSPIRS) 
Years searched: DHdata and Kings Fund Database
1979 to current; HELMIS 1984 to current. Date of
search: 20 November 2001. 
Search terms used:
((decision* or task*) NEAR (group* or team*))
AND review*
(leadership NEAR (decision* or task*)) AND
review*
PREMEDLINE
Year searched: 24 May 2001. Date of search: 
29 May 2001.
All terms rejected, no review terms used:
Team$ adj2 process$. tw 
(team$ and (task$ or decision$))tw. 
Complex$ adj1 decision$.tw 
Groupthink.tw.
Conflict$ adj1 resolv$.tw.
(majority or minority) adj1 influence$.tw. 
group$ adj1 process$.tw.
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Appendix 7
Number of review papers identified at each stage 
of the review of small group processes
Source Field No. of  No. of  Reassessment  No. of full  No. of 
abstracts abstracts  of  abstracts  papers  papers 
assessed potentially (2nd  assessment) assessed included  in 
relevant the  review
(1st assessment)
Electronic sources
PsycINFO Psychology 810 117 67 62 36
ASSIA PLUS Social sciences 482 64 42 40 9
SSCI Social sciences 112 14 10 10 4
MEDLINE Clinical 1230 17 13 13 1
PREMEDLINE Clinical 58 0 0 0 0
EMBASE Clinical 302 0 0 0 0
CINAHL Nursing and allied  50 1 1 1 0
health professions
HealthSTAR Health services  9 0 0 0 0
research and health 
management
HMIC Health management 134 0 0 0 0
Electronic sources: total 3187 213 133 126 50
Other sources
Experts 7 7 7 7 7
Total 3194 220 140 133 57Health Technology Assessment 2005; Vol. 9: No. 7
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Appendix 8
Summary of review articles included in the review 
of small group processes
Authors and year Focus Type of studies Description of review
Aldag and Fuller,  Reappraisal of groupthink and a new model of  Laboratory and field Narrative review and 
1993163 group decision processes conceptual integration/
new model
BarNir, 1998141 Meta-analysis of research on group decisions  Laboratory research  Search strategy and 
about life dilemmas (group polarisation/choice  (14 studies),  eligibility criteria 
shift). Aim to identify moderators of choice shift 1974–1994 specified. Meta-
analytical review
Bettenhausen, 1991240 Primary purpose, to review the literature on  Laboratory research  Search strategy and 
groups published in the past 5 years. Second goal  and case studies,  eligibility criteria 
is to provide insight into the dynamics of group  all types (n = 250),  specified. Narrative 
behaviour for academics and practitioners 1986–1989 review
Blumberg, 1994145 Reviews studies on group discussion and decision- Laboratory research,  Narrative review
making: predominantly choice shift and simulated  1973–1988
juries
Bonito and  Studies on participation in small groups Laboratory and field Specified inclusion 
Hollingshead, 1997180 criteria. Narrative
review
Chemers, 2002241 Effects of leadership  Laboratory and field Conceptual review
Chertkoff and Mesch,  Effects of contingent reward systems on task  Experimental studies,  Strict methodological 
1997173 performance in groups laboratory only quality criteria for
inclusion. Narrative
review
Davies, 1994182 Review of research on personality and  Laboratory and field  Search strategy 
interpersonal/group behaviour studies specified
De Dreu, 1999183 Relationship between conflict and performance  Laboratory and field Narrative and 
in groups conceptual review
Devine et al., 2001140 Reviews empirical research on jury  Laboratory and field  Tabulated data. 
decision-making (206 studies),  Narrative review
1955–1999
Dukerich et al., 1990151 Investigation into how groups reason about moral  Laboratory research,  Narrative review driven 
dilemmas 4 members per  by theories of moral 
group in empirical  reasoning plus two 
studies experimental studies
testing theoretically
based hypotheses
Esser, 1998157 Summary of empirical research on groupthink  Case studies  Tabulated data and 
theory (17  articles,  narrative  review
16 cases), laboratory 
tests (11 articles, 
13 experiments), 
1971–1996
Frey, 1996176 History of research on communication and small  Laboratory and field,  Historical narrative 
group decision-making  1920–1990 review
George and Jessup,  Studies of groups using group support systems  Laboratory (7),  Tabulated data 
1997242 technology and working over time on  quasi-laboratory (3)  (12 studies)
common tasks and field (2)
continuedAppendix 8
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Authors and year Focus Type of studies Description of review
Gill et al., 1984175 Reviews member characteristics and conditions  Laboratory and field Narrative review
that increase the likelihood of participation in 
small groups
Gigone and Hastie,  Methodology in research on group judgement  Laboratory and field  Tabulated data and 
1997136 accuracy conceptual integration
Gist et al., 1987129 Review of role of groups in organisations Field Narrative
Griffith and Vaitkus,  Develops a framework for organising variables  Field (military  Narrative review and 
1999243 related to group cohesion and task performance  settings) conceptual integration
in military groups
Guerin, 1986174 Review of literature on social facilitation (mere  Experimental,  Search strategy and 
presence effects) laboratory research eligibility criteria 
(85 studies) specified. Tabulated
data. Narrative review
and vote counting
Gully et al., 1995244 Investigates the hypothesis that task  Laboratory and field,  Search strategy and 
interdependence moderates the relationship  (46 studies,  eligibility criteria 
between cohesion and performance in groups 51 effect sizes) specified. Meta-analysis
Guzzo and Dickson,  Reviews recent research investigating factors that  Studies conducted  Narrative review
1996188a influence the effectiveness of teams at work in  in organisational 
organisations settings in 1990s
Hartman and Nelson,  Studies on group decisions in the negative domain  Not clear,  Tabulated data/vote-
1996143 (prospect theory/framing)  1961–1993 counting based
narrative review
Hollingshead, 2002245 Communication technologies and group  Laboratory and field Narrative
performance
Honeywell-Johnson  Effects of small group incentives on performance Experimental studies  Tabulated data
and Dickinson, 1999172 in laboratory (9) and 
field (3), 1952–1997
Isenberg, 1986142a Review of group polarisation studies. Comparison  21 studies (33 effect  Meta-analysis
of two major explanatory hypotheses sizes), 1974–1982
Jones and Roelofsma,  Critical review of social contextual and group  Laboratory and field Narrative review
2000131 biases relevant to team decision making in 
command and control situations
Kagehiro, 1990246 Reviews literature on jury comprehension of  Laboratory Narrative review and 
instructions and standard of proof summary of five
experiments
Larson, 1997247 Studies on sharing of information in  Laboratory research Narrative review and 
decision-making groups new model
Levine and Moreland,  Comprehensive overview of research on small  Laboratory research  Narrative review
1990126 groups and natural groups
Levine and Moreland,  Updates Levine and Moreland (1990)126 Laboratory research  Narrative review
1998127 and natural groups 
(672 refs)
Maass and Clark,  Reviews and evaluates literature on minority  Laboratory Narrative review and 
1984150a influences in small groups conceptual integration
MacCoun, 1989167 Reviews experimental research on jury  Laboratory Narrative review
decision-making
Martin and Hewstone,  Reviews literature on majority and minority  Laboratory,  Narrative review and 
2002149 influence. Updates Maass and Clark (1984)150 predominantly conceptual  integration
1980–2000
Matsatsinis and  Effects of group decision support systems Laboratory and field Narrative review
Samaras, 2001139
McLeod, 1992179 Relationship between electronic group support  Experimental studies  Search strategy and 
systems and group processes and outcomes (13) 1980–1990 eligibility criteria
specified
Meta-analytical review
continuedHealth Technology Assessment 2005; Vol. 9: No. 7
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Authors and year Focus Type of studies Description of review
Miranda, 1994171 Explores the potential role of group support  Empirical studies of  Tabulated data
systems in avoiding groupthink groupthink and  Narrative review
decision quality, 
empirical studies of 
group support systems
Mohamed and Wiebe,  Aims to identify the theoretical nature of  Case studies and  Conceptual and 
1996248 groupthink theory and consider how it should be  experimental studies methodological review
tested
Moorhead et al.,  Application of groupthink theory to self-managing  Laboratory research  Narrative review
2002165 teams: does groupthink have relevance to  and case studies
organisations in the twenty-first century?
Mullen et al., 1994162 Effects of group cohesiveness on quality of  Experimental studies,  Search strategy and 
decision-making laboratory or field  eligibility criteria 
(9 papers, 17 effect  specified. Meta-analysis
sizes, 1382 
participants), 
1960–1992
Murphy et al., 1998128 To identify factors that affect the decisions that  Empirical articles  Search strategy and 
emerge from consensus development methods  and reviews, with  inclusion criteria 
and make recommendations for groups  emphasis on studies  specified. Narrative 
developing clinical guidelines undertaken in the  review driven by key 
health sector  questions
(n = 177), 
1966/1974–1996
Neck and Moorhead,  Reviews research on groupthink and effects of  Case studies  Tabulated data. 
1995156 time pressure on group decision-making (4 articles, 4 cases),  Narrative review. 
experimental studies  Conceptual integration
(11 articles), 
1977–1992
Park, 1990159 Review of empirical studies on groupthink Laboratory research  Narrative and vote 
(7) and natural  counting
groups case studies 
(9), 1974–1990
Pavitt, 1993184a Do formal group discussion procedures result in  Laboratory research Narrative and vote 
better quality decisions? counting
Phills, 1998170 Review of literature on group composition with  Laboratory research  Narrative review and 
respect to relevance to real-life groups and case study of  qualitative case study
theatre group
Postmes and Lea,  Evaluation of group decision support systems Quasi-experimental  Search strategy and 
2000186 field studies and  criteria for eligibility 
experimental specified
laboratory studies  Meta-analytical review
(12 independent 
studies, 1432 
participants in 332 
groups)
Postmes et al., 1998249 Studies of impact of characteristics of computer- Laboratory research Narrative review
mediated communication on social influence
Raven, 1998155 Reanalysis of groupthink case studies (Bay of Pigs  Case studies Qualitative analysis and 
and Watergate)  conceptual review
Robertson and  Personality factors in work performance (including  Field Narrative review
Callinan, 1998250 group performance)
Salazar, 1995177 Development of theory on effects of  Unclear Theoretical 
communication on group outputs (including  development
decision quality)
continuedAppendix 8
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Authors and year Focus Type of studies Description of review
Shelly, 1995251 Reviews one theory of interaction with respect to  Not clear Narrative review
task groups
Stasser and  Reviews studies of collective choice, judgement  Laboratory Narrative review
Dietz-Uhler, 2002144 and problem solving in cooperative groups
Tindale et al., 2002168 Reviews literature on socially shared cognitions in  Laboratory Conceptual review
groups and effects on process and performance
Tindale et al., 2002252 Reviews studies of procedural mechanisms and 
jury behaviour
Turner and Horvitz,  Overview of literature relevant to understanding  Laboratory research  Narrative
2001166 how groups perform under external threat and natural groups, 
1952–1998
Wekselberg, 1996160 Critical review of groupthink theory Laboratory research  Theoretical critique
and case studies, 
analysis of social 
psychology textbooks, 
1973–1995
Whyte, 1998164 Develops a non-groupthink framework for  Laboratory research  Conceptual review
explaining decision fiascos and case studies of 
decision fiascos
Zander, 1979253 General overview of group processes, including  Laboratory and field Narrative review
decision-making
a Reviews included in the Murphy et al. (1998) Health Technology Assessment report.128Review of Empirical Studies
Review Type Yes No Unclear, with details 
Review Inclusion Criteria Yes No Unclear, with details
QUALITY OF REVIEW YES NO  UNCLEAR, WITH DETAILS
RESULTS OF REVIEW
What are the main results of 
the review?
Can the results be applied to 
DMCs?
Did the review address a clearly 
focused research question?
Did the review try to identify all 
relevant studies?
Did the reviewers assess the 
quality of the included studies?
Review of empirical studies 
(published between 1950–2001)
Review of group processes & 
decision making in small 
task-orientated groups 
Laboratory setting
Naturally occurring groups 
(e.g. juries, committees)
Systematic
First author & date
Refman number
Extracted by
Publication
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Appendix 9
Data extraction form (review of small 
group processes)Health Technology Assessment 2005; Vol. 9: No. 7
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Appendix 10
Data extraction form (cross-sectional review of 
reported use of data monitoring committees in main
published reports of randomised controlled trials)Appendix 10
186Mention of DMC in the article Total
Yes No
Single-centre trials 0 15 15
Multicentre trials 7 23 30
Total 7 38 45
Disease area Total
Cancer Cardiovascular/respiratory Other
Single-centre trials 1 5 9 15
Multicentre trials 8 10 12 30
Total 9 15 21 45
In addition, there were 15 trials from the UK, 15 from North America (i.e. the USA and Canada) and 
15 from the rest of the world.
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Appendix 11
Sampling strategy for completed trials in surveys of 
policies and practiceDear Sir or Madam
Data Monitoring Committees: Lessons, Ethics and Statistics (DAMOCLES)
I am writing to you in relation to a survey we are conducting on data monitoring committees in the
context of randomised controlled trials (RCTs) which we are conducting with colleagues at the MRC
Clinical Trials Unit and the Health Services Research Unit in Aberdeen. An outline of the project is
attached. This letter relates to part C ii), practices relating to data monitoring committees in recently
completed trials.
We have selected your trial, ref from a list of trials published during 2000. We are aware that editorial
constraints often do not allow space for many details. If you would like to take part, we would be most
grateful if you would be kind enough to send us a copy of the trial protocol in the envelope provided. If
you would prefer to attach the protocol to an e-mail response, the e-mail address is given on the
letterhead.
Please would you also tell us whether the trial data were monitored as detailed in the protocol, or
whether there were any circumstances which necessitated a change from those plans. If so, would you be
willing to answer a few questions about this by telephone? Please include your telephone and e-mail
contact details on the attached sheet. If you are not able to help, please let us know who would be the
most appropriate person to contact.
All information will be treated in confidence, and any publications will be based on aggregated data
(unless you specifically request that your contribution be acknowledged by name). If you have any
questions about this survey in the meantime, please feel free to contact us.
Thank you for your help.
Yours sincerely
Ms Felicity Clemens, Prof. Diana Elbourne, Prof. Stuart Pocock, London School of Hygiene and Tropical
Medicine; Prof. Janet Darbyshire, MRC Clinical Trials Unit
On behalf of the DAMOCLES group
Encl. Summary of the DAMOCLES study
Return envelope
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Appendix 12
Letter to principal investigator(s) for the survey of 
data monitoring in recently completed trialsDMC policies in recent trials
This information on the role of DMCs in a recent trial will be collated mainly from the trial protocol, with
some extra space for feedback following a telephone interview with PIs if they are happy to give one
(their contact details should be returned with the protocol)
If there was a DMC, how many times did it meet over the course of the study?
Health Technology Assessment 2005; Vol. 9: No. 7
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Appendix 13
Proforma for recent trials identified (part III) in 
surveys of policies and practice
Trial name and reference
Area of clinical interest (delete two) Cardiovascular or respiratory/Cancer/Other
Number of centres Single/Multi
Contact Name of PI
Address/phone/e-mailAppendix 13
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Appendix 14
Sampling strategy for survey of ongoing trials in 
surveys of policies and practiceAppendix 14
196
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.Dear Sir or Madam
Data Monitoring Committees: Lessons, Ethics and Statistics (DAMOCLES)
I am writing to you in relation to a survey we are conducting on data monitoring committees in the
context of randomised controlled trials (RCTs) in conjunction with colleagues at the MRC Clinical Trials
Unit and the Health Services Research Unit in Aberdeen. An outline of the project is attached. This letter
relates to part C ii), practices relating to data monitoring committees in ongoing trials.
We have selected your current trial, name, from a database made available to us by collaborators at the HTA/from
the register of MRC-funded trials publicly available on the Internet. We would be most grateful if you would be
kind enough to send us a copy of the trial protocol in the envelope provided/by mail to the address
below or as an e-mail attachment to the address below. 
Please would you also tell us whether the data monitoring is working in practice as detailed in the
protocol, or whether circumstances have necessitated a change from these plans. If so, would you be
willing to answer a few questions about this by telephone? Please include your telephone and e-mail
contact details on the attached sheet. If you are not able to help, please let us know who would be the
most appropriate person in the trial for us to contact.
All information will be treated in confidence, and any publications will be based on aggregated data
(unless you specifically request that your contribution be acknowledged by name). If you have any
questions about this survey in the meantime, please feel free to contact us.
Thank you for your help.
Yours sincerely
Ms Felicity Clemens, Prof. Diana Elbourne, Prof. Stuart Pocock, London School of Hygiene and Tropical
Medicine; Prof. Janet Darbyshire, MRC Clinical Trials Unit
On behalf of the DAMOCLES group
Encl. Summary of the DAMOCLES study
Sheet for contact details
Return envelope
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Appendix 15
Letter to principal investigator(s) for the survey of 
current data monitoring practicesAre the data being monitored as detailed in the protocol?
Yes
No (circumstances necessitated a change)
If you would be willing to provide a brief outline of how the monitoring process has changed over the
course of the study, please do so in the box below:
If you would prefer to be interviewed about this briefly by telephone, please provide contact details
below:
E-mail address  Telephone contact details
Name of principal  Title of trial HTA reference number 
investigator where applicable
Appendix 15
198DMC policies in current trials
This information on the role of DMCs in a current trial will be collated mainly from the trial protocol,
with some extra space for feedback following a telephone interview with PIs if they are happy to give one
(their contact details should be returned with the protocol)
For trials that have a DMC, has it met yet? If so, how many times?
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Appendix 16
Proforma for data extraction from the studies 
sampled (part II) in surveys of policies and practice
Trial name and ref. number if applicable
Area of clinical interest (delete two) Cardiovascular or respiratory/Cancer/Other
Sponsor (delete two) MRC/HTA/MREC/LREC
Contact Name
Address/phone/e-mailAppendix 16
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The questions on the following pages ask about whether your organisation has a policy about particular
issues to do with Data Monitoring Committees (DMCs), and if so, what this policy is. 
If there are policy documents available, please attach them. 
If there is no policy, who makes decisions regarding data monitoring? 
Note: to save your time, we have already completed some sections from the website(s) cited above, but
please amend these details if we have interpreted them incorrectly This line is omitted for those organisations
for which we don’t have any information
This form contains five columns. Column 1 contains each policy question. Column 2 asks if there is a
policy in place dealing with each question; if Y, go to columns 3 and 4; if N, go to column 5.
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Appendix 17
Proforma used to gather policy information from 
funding organisations in surveys of policies and
practice
Organisation
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nDear Sir or Madam
Data Monitoring Committees: Lessons, Ethics, and Statistics (DAMOCLES)
We are writing to you in relation to a research project on data monitoring committees in the context of
randomised controlled trials (RCTs) which we are conducting with colleagues at the MRC Clinical Trials
Unit and the Health Services Research Unit in Aberdeen. The project is funded by the HTA. Brief details
of the different components of the project are given on the attached summary sheet. We are responsible
for component C (i), surveys of the policies about data monitoring committees from major organisations
(such as organisation name) that support RCTs.
We have consulted your website to see if we can obtain the information we need for your organisation,
but not all the details were available from this source. We are therefore attaching a partially completed
proforma, and would be very grateful if you would:
(a) check that the information we have included is correct, and 
(b) add the details which are currently missing. If all this information is already available in written
policy statements, please send us these instead if this would be easier for you.
Please return the checked and completed proforma (and policy statements, if available) in the envelope
provided. If you would prefer to complete the form electronically, please e-mail us and we can send it to
you as a word or rtf attachment. If you are not able to help, please let us know who would be the most
appropriate person for us to contact within your organisation, or forward the proforma to them. We
would be very grateful if you could reply within the next 10 days.
We will send you a copy of the findings of the study when completed but if you have any questions about
the survey in the meantime, please feel free to contact us.
Thank you very much for your help.
Yours sincerely
Ms Felicity Clemens, Prof. Diana Elbourne, Prof. Stuart Pocock, London School of Hygiene and Tropical
Medicine; Prof. Janet Darbyshire, MRC Clinical Trials Unit
On behalf of the DAMOCLES group
Enc. Summary of the DAMOCLES study; Proforma; Return envelope
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Appendix 19
Letter to key organisations involved with 
randomised controlled trialsRandomised controlled trials (RCTs) are a major component in the
evaluation of interventions in health care. RCTs are essential to identify
the best way to manage a particular health condition, but they can be
costly and can raise difficult ethical issues. RCTs are only worthwhile if
their findings are sufficiently robust to enhance future health care; and
they are only ethical if the possibility of being harmed as a result of
being in the trial is minimised. To ensure that this is the case, most RCTs
incorporate a data monitoring (or safety) committee to assess the data as
they accumulate and decide whether or not a trial should continue. The
quality of the decision made by a data monitoring committee is crucial,
and concern has been raised that ‘wrong’ decisions may occur because of
the ways in which data monitoring committees are conducted. 
To develop recommendations for the conduct of data monitoring
committees in RCTs in order to minimise the risk that ‘wrong’ decisions
will occur.
The proposed study will have four components: 
(A) A systematic review of available information about the conduct of
data monitoring committees
(B) A review of the relevant literature on decision-making processes in
other types of task-orientated small groups
(C) Surveys of (i) the policies about data monitoring committees from
major agencies which support RCTs, and (ii) practices relating to
data monitoring committees in recently completed and ongoing
trials
(D) Case studies of particular trials drawn from the sample survey and
experiences of members of the study group
Two of these pieces of work (A & C) will be conducted by London
members of the research team based in the London School of Hygiene
and Tropical Medicine and the MRC Clinical Trials Unit. A team at the
Health Services Research Unit, Aberdeen, will undertake components B
& D.
Start date: 1 February 2001
Completion date: 31 July 2002
NHS R&D Health Technology Assessment Programme
FUNDING
TIMETABLE
PLAN OF
INVESTIGATION
AIM
BACKGROUND
Data Monitoring Committees: Lessons, Ethics and Statistics (DAMOCLES)
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Appendix 20
Summary of the DAMOCLES study in surveys of 
policies and practiceDear 
NHS R&D FUNDED PROJECT ON DATA MONITORING COMMITTEES: LESSONS, ETHICS &
STATISTICS (DAMOCLES)
The NHS R&D HTA programme have funded a project to explore practical issues related to monitoring
accumulating data in randomised controlled trials. An outline of the project is attached. 
As part of the project we hope to interview a number of experienced DMC members with a view to
identifying possible advantages and disadvantages of alternative models of working. Given that you have
served on a number of DMCs the DAMOCLES team (see below) suggested you as a key person in this
regard.
If you were agreeable, it would involve a relatively short telephone interview, to discuss your experience of
DMCs. It is hoped interviewing would take place towards the beginning of May. 
I look forward to hearing from you, however if you require any further information please do not hesitate
to contact me directly on 01224 551100 or e-mail skm@hsru.abdn.ac.uk
Yours sincerely
Sharon McLeer 
(on behalf of the DAMOCLES group)
Enc. Summary of the DAMOCLES study
The DAMOCLES group:
Prof. Stuart Pocock, Prof. Diana Elbourne, Prof. Janet Darbyshire, Prof. Adrian Grant, Prof. Doug Altman,
Dr David Spiegelhalter, Dr Mahesh Parmar, Dr Abdel Babiker, Dr Anne Walker, Marion Campbell,
Matthew Sydes, Felicity Clemens, Sharon McLeer, Sheila Wallace
Health Technology Assessment 2005; Vol. 9: No. 7
217
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.
Appendix 21
Letter to experienced data monitoring committee 
members requesting a general interview1. Membership of DMC
(a) Can you begin by telling me about the
members of the DMC?
(lead into discussion about group size, how they
were chosen, range of expertise, status,
familiarity, etc.)
(b) Was there a chairperson and, if so, how
were they selected?
(probe into committee satisfaction with
chairperson selection)
(c) What was the role of the chairperson (and
statistician)?
(probe into opinions about responsibilities,
influence, abilities)
2. Training and expertise
(a) Did you or any of the other members have
any prior training or experience of DMCs?
(probe familiarity with standard DMC
procedures and small group decision-making. If
training provided, by whom?)
3. Accountability and role of DMC
(a) What position did the DMC have with
respect to sponsor, trialist and participant?
(probe independence, payment, incentives)
(b) Were the DMC deliberations open or
closed?
(lead into discussion about who was present
during discussions, who outside the committee
saw the interim analysis, and who was informed
about the decisions reached)
(c) Was a terms of reference available for the
DMC?
(probe scope and value of terms of reference,
perceived role and responsibilities of the DMC)
(d) What recommendations were open to the
DMC?
(probe decision versus recommendation, early
stopping, extending subgroups, trial
organisation)
(e) Did the DMC have any role before or after
the trial recruitment phase?
(probe input to protocol, e.g. changing outcome
measures and sanctioning changes)
4. Practical arrangements
(a) How frequent were the meetings?
(probe timing of meetings, attendees, format of
meetings, etc.)
(b) What communication media were used? 
(c) What material was available to the DMC?
(probe what was produced, who produced it and
what was available before and during the
meeting)
(d) Was any external evidence included; if so,
how?
(probe when and who circulated external
evidence, e.g. systematic reviews, other trials)
5. Decision-making
Issues relating to decision-making in the DMC
(a) What were the main issues under
consideration by the DMC?
(lead into discussion to clarify events leading up
to the decision)
(b) Was the DMC decision difficult to reach,
and if so, why?
(probe task complexity)
(c) In your opinion, what factors impacted on
the decision-making process?
(e.g. probe for group composition and size,
leadership, communication, time constraints,
external influence/accountability, trial design,
formal statistical methods)
(d) How was the decision reached in the DMC?
(probe for methods and criteria for guiding
deliberations e.g. role of the chairperson, 
formal statistical methods versus 
guidelines)
(e) Was there any formal method of achieving
consensus?
(probe member satisfaction with outcome)
(f) What factors impacted on the decision-
making process?
(e.g. probe for group composition and size,
leadership, communication, time constraints,
external influence/accountability, trial design,
formal statistical methods)
(g) Was there a role for consumer members on
the DMC?
Health Technology Assessment 2005; Vol. 9: No. 7
219
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.
Appendix 22
Semistructured interview schedule used for general 
interviews and case studies6. Ethical issues
(a) Were ethical issues made explicit in the
handling of the DMC deliberations?
(probe the nature of issues and who raised 
them)
(b) How were these issues handled?
(probe general principles underlying decision,
weights given to different end-points)
7. DMC recommendations and reporting
(a) How did the DMC make its
recommendations?
(probe who it reported to, advisory or executive,
and whether form or report)
(b) Did the DMC approve any publications,
especially in relation to reporting any DMC
recommendations regarding the
termination of the trial?
(probe what information was included in
published trial reports in light of the CONSORT
report)
Appendix 22
220Dear 
NHS R&D FUNDED PROJECT ON DATA MONITORING COMMITTEES: LESSONS, ETHICS &
STATISTICS (DAMOCLES)
The NHS R&D HTA programme have funded a project to explore practical issues related to monitoring
accumulating data in randomised controlled trials. An outline of the project is attached. 
To facilitate this study, members of the project team (see below) have identified a number of trials that
faced difficult DMC monitoring decisions about whether the trial should continue or not. The [name of
trial] has been suggested as one such possible case study. As the principal investigator, we would like to
ask for your permission to include this trial in our study.
If you were agreeable this would involve a telephone interview with you, and with members of the data
monitoring committee. It is hoped interviewing could take place in the next couple of weeks.
I look forward to hearing from you, however if you require any further information please do not hesitate
to contact me directly on +44 1224 551100 or e-mail skm@hsru.abdn.ac.uk
Kind regards
Sharon McLeer 
(on behalf of the DAMOCLES group)
The DAMOCLES group:
Prof. Stuart Pocock, Prof. Diana Elbourne, Prof. Janet Darbyshire, Prof. Adrian Grant, Prof. Doug Altman,
Prof. David Spiegelhalter, Prof. Mahesh Parmar, Dr Abdel Babiker, Dr Anne Walker, Marion Campbell,
Matthew Sydes, Felicity Clemens, Sharon McLeer, Sheila Wallace
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Appendix 23
Letter to principal investigator(s) requesting 
permission to include a trial in case-study interviewsDear 
NHS R&D FUNDED PROJECT ON DATA MONITORING COMMITTEES: LESSONS, ETHICS &
STATISTICS (DAMOCLES)
The NHS R&D HTA programme have funded a project to explore practical issues related to monitoring
accumulating data in randomised controlled trials. An outline of the project is attached. 
To facilitate this study, members of the project team (see below) have identified a number of trials that
faced difficult data monitoring decisions about whether the trial should continue or not. The [name of
trial] has been suggested as one such possible case study. 
I have already spoken to [name of PI(s)] as one of the principal investigators, who has kindly given his
permission for me to contact you as one of the DMC members involved in this trial.  If you were
agreeable, I would like to interview you to discuss your experience as a DMC member. It is hoped that a
telephone interview would take place in the next couple of weeks.
I look forward to hearing from you, however if you require any further information please do not hesitate
to contact me directly on 01224 551100 or e-mail skm@hsru.abdn.ac.uk
Yours sincerely
Sharon McLeer 
(on behalf of the DAMOCLES group)
Enc. Summary of the DAMOCLES study
The DAMOCLES group:
Prof. Stuart Pocock, Prof. Diana Elbourne, Prof. Janet Darbyshire, Prof. Adrian Grant, Prof. Doug Altman,
Prof. David Spiegelhalter, Prof. Mahesh Parmar, Dr Abdel Babiker, Dr Anne Walker, Marion Campbell,
Matthew Sydes, Felicity Clemens, Sharon McLeer, Sheila Wallace
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Letter to data monitoring committee members 
requesting an interview for case studiesHealth Technology Assessment 2005; Vol. 9: No. 7
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